

000169183-24-00006110-Q AXON ENTERPRISE, INC. 202110720241107204532204532204532 0 0001069183-24-000061 10-Q 108 20240930 20241108 20241107 AXON ENTERPRISE, INC. 0001069183 3480 860741227 DE 1231 10-Q 34-001-16391 241437716 17800 N. 85TH ST. SCOTTSDALE AZ 85255 480-991-0797 17800 N. 85TH ST. SCOTTSDALE AZ 85255 TASER INTERNATIONAL INC 20012212 10-Q 1 axon-20240930.htm 10-Q axon-20240930false2024Q30000106918312-31http://fasb.org/us-gaap/2024/SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember502498xbri:sharesiso4217:USDiso4217:USDxbri:sharesxbri:pureaxon:trancheaxon:instrumentaxon:securityiso 01-012024-09-3000010691832024-11-0100010691832024-09-3000010691832023-12-310001069183us-gaap:ProductMember2024-07-012024-09-300001069183us-gaap:ProductMember2023-07-012023-09-300001069183us-gaap:ProductMember2024-01-012024-09-300001069183us-gaap:ProductMember2023-01-012023-09-300001069183us-gaap:ServiceMember2024-07-012024-09-300001069183us-gaap:ServiceMember2023-07-012023-09-300001069183us-gaap:ServiceMember2024-01-012024-09-300001069183us-gaap:ServiceMember2023-01-012023-09-300001069183us-gaap:CommonStockMember2023-12-310001069183us-gaap:AdditionalPaidInCapitalMember2023-12-310001069183us-gaap:TreasuryStockCommonMember2023-12-310001069183us-gaap:RetainedEarningsMember2023-12-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001069183us-gaap:CommonStockMember2024-01-012024-03-310001069183us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100010691832024-01-012024-03-310001069183us-gaap:RetainedEarningsMember2024-01-012024-03-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001069183us-gaap:CommonStockMember2024-03-310001069183us-gaap:AdditionalPaidInCapitalMember2024-03-310001069183us-gaap:TreasuryStockCommonMember2024-03-310001069183us-gaap:RetainedEarningsMember2024-03-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100010691832024-03-310001069183us-gaap:CommonStockMember2024-04-012024-06-300001069183us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001069183us-gaap:RetainedEarningsMember2024-04-012024-06-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001069183us-gaap:CommonStockMember2024-06-300001069183us-gaap:AdditionalPaidInCapitalMember2024-06-300001069183us-gaap:TreasuryStockCommonMember2024-06-300001069183us-gaap:RetainedEarningsMember2024-06-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000010691832024-06-300001069183us-gaap:CommonStockMember2024-07-012024-09-300001069183us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001069183us-gaap:RetainedEarningsMember2024-07-012024-09-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001069183us-gaap:CommonStockMember2024-09-300001069183us-gaap:AdditionalPaidInCapitalMember2024-09-300001069183us-gaap:TreasuryStockCommonMember2024-09-300001069183us-gaap:RetainedEarningsMember2024-09-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001069183us-gaap:CommonStockMember2022-12-310001069183us-gaap:AdditionalPaidInCapitalMember2022-12-310001069183us-gaap:TreasuryStockCommonMember2022-12-310001069183us-gaap:RetainedEarningsMember2022-12-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100010691832022-12-310001069183us-gaap:CommonStockMember2023-01-012023-03-310001069183us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100010691832023-01-012023-03-3100010691832023-01-012023-03-310001069183us-gaap:RetainedEarningsMember2023-01-012023-03-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001069183us-gaap:CommonStockMember2023-01-012023-03-310001069183us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001069183us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001069183us-gaap:RetainedEarningsMember2023-03-310001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100010691832023-03-310001069183us-gaap:CommonStockMember2023-04-012023-06-300001069183us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000010691832023-04-012023-06-300001069183us-gaap:RetainedEarningsMember2023-04-012023-06-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001069183us-gaap:CommonStockMember2023-06-300001069183us-gaap:AdditionalPaidInCapitalMember2023-06-300001069183us-gaap:TreasuryStockCommonMember2023-06-300001069183us-gaap:RetainedEarningsMember2023-06-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000010691832023-06-300001069183us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001069183us-gaap:CommonStockMember2023-07-012023-09-300001069183us-gaap:RetainedEarningsMember2023-07-012023-09-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001069183us-gaap:CommonStockMember2023-09-300001069183us-gaap:AdditionalPaidInCapitalMember2023-09-300001069183us-gaap:TreasuryStockCommonMember2023-09-300001069183us-gaap:RetainedEarningsMember2023-09-300001069183us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000010691832023-09-300001069183axon:ConvertibleSeniorNotesDue2027Member2024-09-300001069183us-gaap:StockCompensationPlanMember2024-07-012024-09-300001069183us-gaap:StockCompensationPlanMember2023-07-012023-09-300001069183us-gaap:StockCompensationPlanMember2024-01-012024-09-300001069183us-gaap:StockCompensationPlanMember2023-01-012023-09-300001069183axon:TwoThousandTwentySevenNotesMember2024-07-012024-09-300001069183axon:TwoThousandTwentySevenNotesMember2023-07-012023-09-300001069183axon:TwoThousandTwentySevenNotesMember2024-01-012024-09-300001069183axon:TwoThousandTwentySevenNotesMember2023-01-012023-09-300001069183axon:TwoThousandTwentySevenWarrantsMember2024-07-012024-09-300001069183axon:TwoThousandTwentySevenWarrantsMember2023-07-012023-09-300001069183axon:TwoThousandTwentySevenWarrantsMember2024-01-012024-09-300001069183axon:TwoThousandTwentySevenWarrantsMember2023-01-012023-09-300001069183axon:PerformanceBasedRestrictedStockUnitMemberaxon:ExponentialStockPlan2024Member2024-05-102024-05-100001069183axon:TaserDevicesProfessionalMemberaxon:TaserSegmentMember2024-07-012024-09-300001069183axon:TaserDevicesProfessionalMember2024-07-012024-09-300001069183axon:TaserDevicesProfessionalMemberaxon:SoftwareAndSensorsSegmentMember2024-07-012024-09-300001069183axon:TaserDevicesProfessionalMember2023-07-012023-09-300001069183axon:TaserDevicesProfessionalMemberaxon:SoftwareAndSensorsSegmentMember2023-07-012023-09-300001069183axon:TaserDevicesProfessionalMember2023-07-012023-09-300001069183axon:TaserDevicesProfessionalMember2023-07-012023-09-300001069183axon:CartridgesMemberaxon:TaserSegmentMember2024-07-

[illegible]

gaap:ResearchAndDevelopmentExpenseMember2023-07-01-2023-09-300001069183us-gaap:ResearchAndDevelopmentExpenseMember2024-01-01-2024-09-300001069183us-gaap:ResearchAndDevelopmentExpenseMember2023-01-01-2023-09-300001069183axson:A2022StockIncentivePlanMember2024-05-3100001069183axson:A2022StockIncentivePlanMember2024-09-300001069183axson:AtMarketOfferingMember2024-01-01-2024-09-300001069183axson:SeniorUnsecuredMultiCurrencyRevolvingCreditFacilityMember2022-12-3100001069183us-gaap:LineOfCreditMember2022-12-3100001069183axson:ConvertibleSeniorNotesDue2027Memberus-gaap:LetterOfCreditMember2022-12-01-2022-12-3100001069183us-gaap:LineOfCreditMember2024-09-300001069183srt:MinimumMemberus-gaap:LineOfCreditMember2024-01-01-2024-09-300001069183srt:MaximumMemberus-gaap:LineOfCreditMember2024-01-01-2024-09-300001069183us-gaap:PendingLitigationMember2024-09-300001069183axson:ExpiringInTwoThousandTwentyFourMemberus-gaap:SuretyBondMember2024-01-300001069183axson:AnotherCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001069183us-gaap:SuredyBondMember2024-09-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-3100001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-12-3100001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-01-2024-03-310001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-01-01-2024-03-310001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-01-2024-06-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-04-01-2024-06-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-01-2024-09-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-07-01-2024-09-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-3100001069183us-gaap:AccumulatedTranslationAdjustmentMember2022-12-3100001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-01-2023-03-310001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-01-01-2023-03-310001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-01-2023-06-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-04-01-2023-06-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-01-2023-09-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-07-01-2023-09-300001069183us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001069183us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001069183axson:FususIncMember2024-01-310001069183axson:FususIncMember2024-01-01-2024-01-3100010691832024-01-310001069183us-gaap:SeriesOffnallyImmateralBusinessAcquisitionsMember2024-01-310001069183axson:DedroneHoldingsInc.Memberus-gaap:SubsequentEventMember2024-01-01-2024-10-310001069183axson:DedroneHoldingsInc.Memberus-gaap:SubsequentEventMember2024-10-310001069183srt:ScenarioPreviouslyReportedMember2023-12-310001069183srt:RestatementAdjustmentMember2023-12-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ProductMember2024-04-01-2024-06-300001069183us-gaap:ProductMember2024-04-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-04-01-2024-06-300001069183us-gaap:ServiceMember2024-04-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMember2024-04-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ProductMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-04-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-04-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMember2024-01-01-2024-06-300001069183srt:RestatementAdjustmentMember2024-01-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2024-01-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ProductMember2024-01-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-01-01-2024-06-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-01-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMember2024-01-01-2024-06-300001069183srt:RestatementAdjustmentMember2024-01-01-2024-06-3000010691832024-01-01-2024-06-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2024-01-01-2024-03-310001069183us-gaap:ProductMember2024-01-01-2024-03-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2024-01-01-2024-03-310001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2024-01-01-2024-03-310001069183srt:ScenarioPreviouslyReportedMember2024-01-01-2024-03-310001069183srt:RestatementAdjustmentMember2024-01-01-2024-03-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2023-10-01-2023-12-310001069183srt:RestatementAdjustmentMember2023-10-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-10-01-2023-12-310001069183srt:RestatementAdjustmentMember2023-10-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMember2023-10-01-2023-12-310001069183srt:RestatementAdjustmentMember2023-10-01-2023-12-3100010691832023-10-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2023-01-01-2023-12-310001069183srt:RestatementAdjustmentMemberus-gaap:ProductMember2023-01-01-2023-12-310001069183us-gaap:ProductMember2023-01-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-01-01-2023-12-310001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2023-01-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMember2023-01-01-2023-12-310001069183srt:RestatementAdjustmentMember2023-01-01-2023-12-3100010691832023-01-01-2023-12-310001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2023-07-01-2023-09-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-07-01-2023-09-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-07-01-2023-09-300001069183srt:ScenarioPreviouslyReportedMember2023-07-01-2023-09-300001069183srt:RestatementAdjustmentMember2023-07-01-2023-09-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ProductMember2023-01-01-2023-09-300001069183srt:RestatementAdjustmentMemberus-gaap:ProductMember2023-01-01-2023-09-300001069183srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-01-01-2023-09-300001069183srt:RestatementAdjustmentMemberus-gaap:ServiceMember2023

[illegible]

starting 78,080A 75,952A 77,614A 75,212A Net income per common share:Basic0.089A \$0.82A \$3.20A \$1.61A Diluted0.086A \$0.81A \$3.12A \$1.58A Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Stock-based awards4,574A 481A 4,620A 470A 2027 Notes2,002A 3,017A 2,244A 3,017A 2027 Warrants2,966A 3,017A 3,017A 3,017A Total potentially dilutive securities9,542A 6,515A 9,881A 6,504A For additional information regarding our 2027 Notes and 2027 Warrants, refer to Note 10.6Table of ContentsWarranty ReservesWe warranty our TASER® brand conducted energy devices (ã€œCEDsã€), Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. We estimate and record a liability for standard warranty at the time products are sold. The estimates are based on historical experience and reflect managementã€™s best estimates of costs to be incurred over the warranty period. Adjustments may be required when actual or projected costs differ. Variations in component failure rates, repair costs and the point of failure within the product life cycle are key drivers that impact our periodic re-assessment of the warranty liability.Revenue related to separately priced extended warranties is initially recorded as deferred revenue at its allocated amount and subsequently recognized as net sales on a straight-line basis over the warranty service period. Costs related to extended warranties are charged to cost of product and service sales when the costs become probable and can be reasonably estimated.Changes in our estimated product warranty liabilities were as follows (in thousands):Nine Months Ended September 30,20242023Balance, beginning of period\$7,374A \$811A Utilization of reserve(5,007)(901)Warranty expense4,860A 3,381A Balance, end of period\$7,227A \$3,291A Fair Value Measurements and Financial InstrumentsWe use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:ã€œLevel 1ã€ Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.ã€œLevel 2ã€ Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices from markets that are not active for assets or liabilities that are identical or similar to the assets or liabilities being measured. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.ã€œLevel 3ã€ Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability.We have cash equivalents and investments, which at Septemberã€ 30, 2024 comprised money market funds, U.S. government bonds, term deposits, U.S. Treasury bills, and agency bonds. Cash equivalents and investments at Decemberã€ 31, 2023 also included corporate bonds, commercial paper and U.S. Treasury inflation-protected securities. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Debt investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Included in the balance of other long-term assets as of Septemberã€ 30, 2024 and Decemberã€ 31, 2023 was \$8.6 million and \$7.6 million, respectively, related to corporate-owned life insurance policies, which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. 7Table of ContentsWe have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain (or loss) on marketable securities, which is included in other income (loss), net.We have strategic equity investments in various privately held companies as of Septemberã€ 30, 2024 and Decemberã€ 31, 2023. The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic equity investments in privately held companies, we utilize observable data available to us as discussed further in Note 7.The fair value of our 2027 Notes is determined based on the closing trading price per \$1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the 2027 Notes at Septemberã€ 30, 2024 and Decemberã€ 31, 2023 to be a Level 2 measurement based on the fair value hierarchy. The fair value is primarily affected by the trading price of our common stock and market interest rates.Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet.Restricted CashRestricted cash balances of \$2.3 million and \$2.1 million as of Septemberã€ 30, 2024 and Decemberã€ 31, 2023, respectively, primarily relate to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. As of Septemberã€ 30, 2024, approximately \$2.2 million was included in prepaid expenses and other current assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.Valuation of Goodwill, Intangibles and Long-lived AssetsWe evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such events and circumstances could include a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair values computed using discounted cash flows. Finite-lived intangible assets and other long-lived assets are amortized over their estimated useful lives. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We test goodwill and indefinite-lived intangible assets for impairment on an annual basis in the fourth quarter and on an interim basis when certain events and circumstances exist.Business CombinationsAcquired businesses are included in the consolidated financial statements from the date we gain control of the business. We recognize, separately from goodwill, the identifiable assets acquired and liabilities assumed at their estimated acquisition-date fair values. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record qualifying adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. In addition, uncertain tax positions, tax-related valuation allowances and pre-acquisition contingencies are initially recorded in connection with a business combination as of the acquisition date. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any qualifying adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our condensed consolidated statement of operations. In the event that we acquire an entity in which we previously held an existing minority ownership interest, the difference between the fair value of the interest as of the acquisition date and the carrying value of the interest is recorded as a gain or loss within other income (loss), net, in the condensed consolidated statement of operations. Preexisting relationships 8Table of ContentsSubject to termination as a result of consummating an acquisition may require the recognition of a gain or loss upon settlement, which is recognized within income from operations on the condensed consolidated statement of operations. All third-party transaction-related costs are recognized as expense in the period in which they are incurred.Stock-Based CompensationOn Mayã€ 10, 2024, our shareholders approved the Axon Enterprise, Inc. 2024 eXponential Stock Plan (the ã€œ2024 Employee XSPã€). The 2024 Employee XSP includes an approved pool of shares of common stock to be reserved for grants of awards of eXponential Stock Units (ã€œXSUsã€) to employees. The grants of XSUs (the ã€œ2024 XSUsã€) are grants of performance-based RSUs that vest in seven substantially equal tranches. The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions: (1) stock price goals; (2) operational goals; and (3) minimum service conditions.Additionally, shareholders approved the grant of the 2024 XSUs to our CEO, Patrick W. Smith (the ã€œ2024 CEO Performance Awardã€). The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Refer to Note 12 for further discussion regarding ongoing progress towards reaching the aforementioned goals.Recently Issued Accounting Guidance and Disclosure RulesStandards Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (ã€œFASBã€) issued Accounting Standards Update (ã€œASUã€) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for our Annual Report on Form 10-K for the year ending Decemberã€ 31, 2024, and subsequent interim periods, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In December 2023, the FASB issued ASUã€ 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax. The provisions of ASU 2023-09 are effective for our Annual Report on Form 10-K for the year ending December 31, 2025, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In March 2024, the SEC adopted final rules under SEC Release No. 34-99678 and No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (the ã€œFinal Rulesã€), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The financial statement disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules pending judicial review. We are currently evaluating the impact of the Final Rules on our consolidated financial statements.Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.9Table of ContentsNote 2 - RevenuesNature of Products and ServicesThe following tables present our revenues by primary product and service offering and reportable segment (in thousands):Three Months Ended September 30, 2024Three Months Ended September 30, 2023TASERSoftware and SensorsTotalTASERSoftware and SensorsTotalTASERDevices (Professional)\$130,515A \$ã€ 130,515A \$86,718A \$ã€ 86,718A Cartridges60,179A \$ã€ 60,179A \$4,279A \$ã€ 4,279A Axon Evidence and Cloud Services13,861A 203,481A 217,342A 8,975A 151,518A 160,493A Extended Warranties9,729A 17,306A 27,035A 8,078A 14,06A 22,124A Axon Body Cameras and Accessoriesã€ 70,363A 70,363A \$ã€ 52,488A 52,488A Axon Fleet Systemsã€ 23,239A 23,239A \$ã€ 27,336A 27,336A Other (1) (2)7,450A 8,151A 15,601A 4,520A 5,320A 9,840A Total\$221,734A \$322,540A \$544,274A \$162,570A \$250,708A \$413,278A Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023TASERSoftware and SensorsTotalTASERSoftware and SensorsTotalTASERDevices (Professional)\$333,815A \$ã€ 333,815A \$239,165A \$ã€ 239,165A Cartridges181,792A \$ã€ 181,792A 149,504A \$ã€ 149,504A Axon Evidence and Cloud Services40,297A 570,222A 610,519A 25,575A 401,281A 426,856A Extended Warranties27,164A 48,651A 75,815A 23,463A 40,194A 63,657A Axon Body Cameras and Accessoriesã€ 180,592A 180,592A \$ã€ 124,066A 124,066A Axon Fleet Systemsã€ 79,620A 79,620A \$ã€ 99,015A 99,015A Other (1) (2)14,373A 30,855A 45,228A 14,460A 13,600A 28,060A Total\$597,441A \$909,940A \$1,507,381A \$452,167A \$678,156A \$1,130,323A (1)TASER segment ã€œOtherã€ includes smaller categories, such as Virtual Reality (ã€œVRã€) hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales. (2)Software and Sensors segment ã€œOtherã€ includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment.The following table presents our revenues disaggregated by geography (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023United States\$482,596A 89A %\$341,767A 83A %\$1,298,775A 86A %\$954,023A 84A %Other countries61,678A 11A 71,511A 17A 208,606A 14A 176,300A

deposits128,205.05\$A 128,205.05\$A 128,205.05\$A 128,205.05\$A Corporate bonds80,646.88\$A (165)80,489.9\$A 80,489.9\$A Treasury inflation-protected securities2,635.65\$A (5)2,630.65\$A 2,630.65\$A Commercial paper14,456.65\$A 14,456.65\$A 14,456.65\$A Subtotal225,942.88\$A (170)225,780.45\$A 225,780.45\$A Total\$1,333,022.41\$158.81(12,641)\$1,320,539.4\$598,545.4\$77,940.4\$644,054.4\$A 12 months or longer, with total gross unrealized losses of \$0.3 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases.

Note 4 - Expected Credit LossesWe are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, contract assets, notes receivable and off-balance sheet exposures is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions. The following table provides a roll-forward of the allowance for expected credit losses for finance receivables and off-balance sheet exposures. The expected credit losses for receivables are deducted from the amortized cost basis of accounts receivable, contract assets and notes receivable to present the net amount expected to be collected (in thousands):

	Nine Months Ended September 30, 2024	United States	Other countries	Total
Balance, beginning of period	\$3,369.4	\$597.4	\$3,966.4	
Provision for expected credit losses	2,606.4	216.4	2,822.4	
Amounts written off charged against the allowance	(700.4)	(84.4)	(784.4)	
Other, including foreign currency translation	14.4	14.4		
Balance, end of period	\$5,275.4	\$743.4	\$6,018.4	

Table of ContentsAs of September 30, 2024 and December 31, 2023, the allowance for expected credit losses for each type of customer receivable and off-balance sheet exposures were as follows (in thousands):

	September 30, 2024	December 31, 2023
Accounts receivable and notes receivable, current	\$3,292.4	\$2,392.4
Contract assets, net	2,678.4	1,516.4
Long-term notes receivable, net of current portion	48.4	44.4
Other current liabilities	14.4	14.4

allowance for expected credit losses on customer receivables\$6,018.4\$3,966.4

Note 5 - InventoryInventories are stated at the lower of cost or realizable values. Cost of inventories is determined on the first-in, first-out basis. Additional provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value. These provisions are based on management's best estimate after considering historical demand, projected future demand, inventory purchase commitments, industry and market trends and conditions among other factors. We evaluate inventory costs for abnormal costs due to excess production capacity and treat such costs as period costs. Inventory consisted of the following at September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024	December 31, 2023
Raw materials	\$100,526.4	\$104,112.4
Finished goods	171,769.4	165,743.4
Total inventory	\$272,295.4	\$269,855.4

Note 6 - Goodwill and Intangible AssetsThe changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):

	September 30, 2024	December 31, 2023
Software and Sensors	\$2,984.5	\$4,961.5
Goodwill acquired	250,653.2	250,653.2
Purchase accounting adjustments	(364.4)	(364.4)
Foreign currency translation adjustments	14.2	23.8
Balance, end of period	\$2,970.3	\$502,308.4

Table of ContentsIntangible assets (other than goodwill) consisted of the following at September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024	December 31, 2023				
Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Amortizable (definite-lived)	intangible assets:	Developed technology	3.8	years	8.5	years
Customer relationships	4.1	years	18.6	years	4.9	years
Trademarks	3.6	years	3.3	years	1.9	years
Issued patents	5.1	years	3.0	years	0.9	years
Non-compete agreements	3.4	years	0.1	years	0.1	years
Non-amortizable (indefinite-lived)	intangible assets:	Trade names	1.1	years	0.4	years
Patents and trademarks pending	4.6	years	0.2	years	0.2	years
Total non-amortizable intangible assets	1.7	years	1.2	years	0.8	years

Amortization expense of intangible assets for the three and nine months ended September 30, 2024 was \$3.8 million and \$10.7 million, respectively. Amortization expense of intangible assets for the three and nine months ended September 30, 2023 was \$1.3 million and \$3.2 million, respectively. Estimated amortization for intangible assets with definite lives for the remaining three months of 2024, the next five years ended December 31, and thereafter, is as follows (in thousands):

	2024	2025	2026	2027	2028	2029	2030	Thereafter
Total	\$80,026.4	\$100,950.4	\$15,016.4	\$1,176.4	\$16,192.4	\$1,176.4	\$1,176.4	\$1,176.4

Note 7 - Strategic InvestmentsStrategic investments include equity and debt investments in a number of non-public technology driven companies. We account for strategic equity investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investments. The investments are measured at cost less impairment, adjusted for observable price changes and are assessed for impairment whenever events or changes in circumstances indicate that the fair value may be less than its carrying value. For the debt security strategic investment, we have elected to account for this investment and the associated embedded derivatives utilizing the fair value option. Unrealized changes in fair value for the entire hybrid instrument are recorded within 15Table of Contentsother income (loss), net in the condensed consolidated statement of operations. The debt security is recorded as a strategic investment within the long-term assets section of the condensed consolidated balance sheet. In conjunction with certain of our strategic investments, we have the ability to commit additional capital over time through warrants and call options; for some investments, the exercisability and exercise prices are conditional on the achievement of certain performance metrics. The following tables provide a roll-forward of the balance of strategic investments (in thousands):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)
Balance, end of period	\$215,945.4	\$459.4

Table of ContentsSeptember 30, 2024 and December 31, 2023

	September 30, 2024	December 31, 2023
Equity investments	\$13,033.4	\$13,033.4
Warrants	\$7,637.4	\$363.1
Debt investments	\$215,945.4	\$459.4
Total	\$215,945.4	\$459.4
Unrealized gains	449.4	449.4
Unrealized losses and impairments	(113.4)	(113.4)

18.6%. Before discrete adjustments, the estimated annual effective tax rate was 23.3%, which differs from the federal statutory rate due to the impact of state taxes net of federal benefit and executive compensation limitation under IRC Section 162(m) on projected pre-tax income for the year, partially offset by R&D tax credits and a net gain related to an investment transaction not recognized for tax. The effective tax rate was favorably impacted by a net \$13.0 million discrete tax benefit associated with net windfalls related to stock-based compensation for RSUs and PSUs that vested, in addition to non-qualified stock options that were exercised during the nine months ended September 30, 2024. 20Table of ContentsNote 12 - Stockholders' Equity2024 Employee XSP and 2024 CEO Performance AwardOn May 10, 2024, our shareholders approved the 2024 Employee XSP. The 2024 Employee XSP includes an approved pool of 4.5 million shares of common stock to be reserved for grants of XSU awards to employees under the 2024 Employee XSP. A total of approximately 3.8 million 2024 XSUs were granted in the nine months ended September 30, 2024. The 2024 XSUs are grants of performance-based RSUs that vest in seven substantially equal tranches. The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions, described in the following table:Operational Goals(1) (in millions)Stock PriceGoalMinimum Service RequirementTrancheRevenueAdj. EBITDAEmployee XSPCEO AwardGoal Expiration1\$1,834A or\$393A and\$247.40A andJune 2025December 2028December 31, 202622,293A or\$508A and\$309.25A andDecember 2025December 2028December 31, 202732,866A or\$655A and\$386.56A andJune 2026December 2029December 31, 202843,583A or\$714A and\$483.20A andDecember 2026December 2029December 31, 202954,479A or1,088A and\$604.00A andJune 2027December 2030December 31, 203065,599A or1,400A and\$755.00A andDecember 2027December 2030December 31, 203176,999A or1,750A and\$943.75A andJune 2028December 2030December 31, 2032(1) Operational goals are measured, as of any date, for the previous four consecutive fiscal quarters, beginning with the Company's first full fiscal quarter ending after the fiscal quarter in which the grant date occurred. Additionally, shareholders approved the 2024 CEO Performance Award to grant 679,102 shares of the 2024 XSUs to our CEO, Patrick W. Smith. The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Stock-based compensation expense associated with the 2024 XSU awards is recognized over the requisite service period, which is considered the longest explicit, implicit or derived service period for each respective tranche. We utilized Monte Carlo simulations to evaluate a range of possible future stock price goals over the term of the awards at each of the respective grant dates. The median of all iterations of the simulation was used as the basis for the derived service period for each tranche. We measured the grant date fair value of each tranche using a Monte Carlo simulation with the following assumptions: risk-free interest rate of 4.3% - 4.5%, expected volatility of 41.4% â€” 41.5%, expected term of 8.6 years, and dividend yield of 0.0%. We utilized a blended volatility assumption, equally weighting both historical volatility and implied volatility, resulting in a weighted-average expected volatility of 41.4%. An illiquidity discount is considered in our estimate of the fair value of shares during post-vesting holding periods. The mandatory post-vesting holding periods for 2024 XSU awards will lapse on the earlier of (i) December 31, 2030, or (ii) the date that a subsequent tranche vests and settles. Therefore, the illiquidity discount is dependent upon projected tranche vesting dates, determined via the Monte Carlo simulation. This simulation is based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis. Even though no tranche with respect to either the 2024 Employee XSP or the 2024 CEO Performance Award vests unless the stock price goal, operational goal and corresponding minimum service condition are achieved, stock-based compensation expense is recognized when an operational goal is considered probable of attainment regardless of the achievement of the stock price and minimum service conditions. As of September 30, 2024, we consider some of the tranches probable and will recognize the expense ratably over their respective expected vesting periods. This may result in volatility and higher upfront expense recognition and is subject to change based on periodic probability assessments. 21Table of ContentsRestricted Stock UnitsThe following table summarizes RSU activity for the nine months ended September 30, 2024 (number of units and aggregate intrinsic value in thousands):Number of UnitsWeighted Average Grant-Date Fair ValueAggregate Intrinsic ValueUnits outstanding, beginning of year1,615\$193.09A Granted595269.18A Released(488)185.33A Forfeited(128)202.01A Units outstanding, end of period1,594\$223.16A \$636,869A Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was \$399.60 per share, multiplied by the number of RSUs outstanding. As of September 30, 2024, there was \$252.7 million in unrecognized compensation costs related to RSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.2 years. RSUs are settled when vesting requirements are met. On January 2, 2024, we granted an aggregate of 0.4 million RSUs to employees whose compensation was under a specified threshold. The RSUs generally vest in five annual installments from March 2024 through March 2028. For the nine months ended September 30, 2024, there was \$38.3 million of stock compensation expense related to these RSUs that was primarily recorded within cost of product and service sales. Performance Stock UnitsThe following table summarizes PSU activity for the nine months ended September 30, 2024 (number of units and aggregate intrinsic value in thousands):Number of UnitsWeighted Average Grant-Date Fair ValueAggregate Intrinsic ValueUnits outstanding, beginning of year394\$201.61A Granted4,517240.07A Released(11)149.49A Forfeited(345)232.01A Units outstanding, end of period4,555\$237.57\$1,820,338Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was \$399.60 per share, multiplied by the number of PSUs outstanding. As of September 30, 2024, there was \$585.0 million in unrecognized compensation expense related to PSUs under our stock plans for awards that are expected to vest. Of the balance, there was \$579.5 million of total unrecognized stock-based compensation expense related to XSP for performance goals that were considered probable of achievement, which will be recognized over a weighted-average period of 3.7 years. 22Table of ContentsStock Option ActivityThe following table summarizes stock option activity for the nine months ended September 30, 2024 (number of options and aggregate intrinsic value in thousands):Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (years)Aggregate Intrinsic ValueOptions outstanding, beginning of year531\$28.58Granted46\$21.66A Exercised(350)28.58Expired / terminated46\$21.66A Options outstanding and exercisable, end of period181\$28.5831\$67,085Aggregate intrinsic value represents the difference between the exercise price of the underlying stock options and the closing stock price on the last trading day of the period ended September 30, 2024, which was \$399.60 per share. Of the total stock options exercised during the nine months ended September 30, 2024, 0.2 million shares were immediately sold to cover the exercise price and the option holder's tax obligation for the applicable income and other employment taxes. Stock-based Compensation ExpenseThe following table summarizes the composition of stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 (in thousands):Three Months Ended September 30, Nine Months Ended September 30, 2024202320242023Cost of product sales and service sales\$10,123A \$1,687A \$48,235A \$4,685A Sales, general and administrative expenses\$55,248A 12,886A 117,036A 43,232A Research and development expenses\$36,409A 15,414A 86,445A 48,311A Total stock-based compensation expenses\$101,780A \$29,987A \$251,716A \$96,228A Stock Incentive PlanIn May 2024, our shareholders approved the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan (the "Amended 2022 Plan") authorizing an additional 2.2 million shares, plus remaining available shares under prior plans, for issuance under the Amended 2022 Plan. Combined with the shares of our common stock available under our legacy stock incentive plans, there are 3.7 million shares of our common stock available for grant under the Amended 2022 Plan as of September 30, 2024. At-The-Market Equity OfferingWe participate in an "at-the-market" equity offering program (the "ATM"), pursuant to which we are authorized to sell up to a total of approximately 2.0 million shares of our common stock. As of September 30, 2024, there were approximately 2.0 million shares remaining. There were no issuances under the ATM during the nine months ended September 30, 2024. Note 13 - Line of CreditIn December 2022, we entered into a credit agreement that provides for a senior unsecured multi-currency revolving credit facility (the "Credit Agreement") in an aggregate principal amount of up to \$200.0 million, \$30.0 million of which is available for the issuance of letters of credit. The Credit Agreement will mature on the earlier of December 15, 2027 or the date that is six months prior to the stated maturity date of the 2027 Notes unless the Notes have been redeemed, repurchased, 23Table of Contentsconverted or defeased in full. Additionally, the Credit Agreement has an accordion feature which allows for an increase in the total line of credit up to \$300.0 million, in each lender's sole discretion. As of September 30, 2024, no amounts were drawn under the Credit Agreement and outstanding letters of credit totaled \$8.2 million. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest expense, taxes, depreciation and amortization ratio, which for the purposes of the Credit Agreement excludes investment interest income. "SOFR" is defined as a rate equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York or a successor administrator of the secured overnight financing rate. We are required to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, and a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense. As of September 30, 2024, we are in compliance with the associated covenants under the Credit Agreement. Note 14 - Commitments and ContingenciesProduct LitigationAs a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products. We are currently named as a defendant in one such lawsuit in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn. They seek compensatory and sometimes punitive damages, often in unspecified amounts. We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results of operations or cash flows. We are self-insured for the first \$5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products liability case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period. Other MattersDespite the FTC's dismissal of its administrative enforcement complaint against Axon without consent decree or other condition in October 2023, other parties continue to allege that Axon's May 2018 acquisition of an insolvent body-worn camera competitor, Viewu LLC ("Viewu"), was anticompetitive. Two purported antitrust lawsuits based largely on the FTC's unproven allegations are pending in the District of New Jersey (Case No. 3:23-cv-7182) and District of Arizona (Case No. 2:24-cv-01869-SMB). Axon denies all allegations of anticompetitive or other misconduct and is vigorously defending the cases. Axon has also received a request for information from the Pennsylvania Office of Attorney General regarding this same consummated Viewu transaction. Axon is cooperating with the investigation to resolve any concerns of the Commonwealth. GeneralFrom time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time. Based on our assessment of outstanding litigation and claims as of the date of these financial statements, we have determined that it is not reasonably possible that these losses, if any, from lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the 24Table of Contentsresolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows. Off-Balance Sheet ArrangementsUnder certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At September 30, 2024, we had outstanding letters of credit issued under our credit facility of \$8.2 million that are expected to expire through 2025. We also had outstanding letters of credit of \$0.1 million that do not draw against our credit facility. Additionally, we had \$13.6 million of outstanding surety bonds as of September 30, 2024, with expiration dates ranging through 2029. Note 15 "Accumulated Other Comprehensive Income (Loss)"The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands):Unrealized Gains (Losses) on Available-for-SaleInvestmentsForeign Currency TranslationTotalBalance, December 31, 2023\$(399)\$(10,280)\$(10,679)Other comprehensive loss(106)(801)(907)Balance, March 31, 2024\$(505)\$(11,081)\$(11,586)Other comprehensive income (loss)\$119(2,727)(2,608)Balance, June 30, 2024\$(386)\$(13,808)\$(14,194)Other comprehensive income\$434A 4,640A 5,074A Balance, September 30, 2024\$48A \$(9,168)\$(9,120)Unrealized Gains (Losses) on Available-for-SaleInvestmentsForeign Currency TranslationTotalBalance, December 31, 2022\$(1,251)\$(5,928)\$(7,179)Other comprehensive income184A 1,676A 1,860A Balance, March 31, 2023\$(1,067)\$(4,252)\$(5,319)Other comprehensive loss(850)(557)(1,407)Balance, June 30, 2023\$(1,917)\$(4,809)\$(6,726)Other comprehensive income (loss)\$65A (6,799)(6,143)Balance, September 30, 2023\$(1,261)\$(11,608)\$(12,869) 25Table of ContentsNote 16 - Segment DataOur operations comprise two reportable segments: the development, manufacture and sale of fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share and analyze video and other digital evidence (collectively, the "Software and Sensors" segment); and the manufacture and sale of our CEDs, batteries, accessories, extended warranties and other products and services (collectively, the "TASER" segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer, who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. During the nine months ended September 30, 2024, the segment measure of profit and loss used by the CODM was changed from gross margin to adjusted gross margin, defined as gross margin before stock-based compensation expense and amortization of acquired intangible assets. This change in segment measure allows the CODM to better assess operating results over time and is consistent with how the CODM evaluates our businesses. Accordingly, we have updated our segment disclosure for the three and nine months ended September 30, 2023 to conform to the new presentation. Information relative to our reportable segments was as follows (in thousands):Three Months Ended September 30, 20242023TASER segment net sales\$221,734A \$162,570A Software and Sensors segment net sales\$322,540A 250,708A Total consolidated net sales\$544,274A \$413,278A TASER adjusted gross margin\$139,632A \$102,151A Software and Sensors adjusted gross margin\$204,258A 157,147A Total segment adjusted gross margin\$343,890A \$259,298A Stock-based compensation expense\$10,123A 1,687A Amortization of acquired intangible assets\$3,020A 955A Gross margin\$330,747A \$256,656A Sales, general and administrative\$192,189A 122,357A Research and development\$114,477A 76,880A Interest income, net\$10,978A 10,458A Other income (loss), net\$4,510A 3,852A Income (loss) before provision for (benefit from) income taxes\$79,569A \$71,729A 26Table of ContentsNine Months Ended September 30, 20242023TASER segment net sales\$597,441A \$452,167A Software and Sensors segment net sales\$909,940A 678,156A Total consolidated net sales\$1,507,381A \$1,130,323A TASER adjusted gross margin\$374,072A \$280,875A Software and Sensors adjusted gross margin\$577,992A 417,460A Total segment adjusted gross margin\$952,064A \$698,335A Stock-based compensation expense\$48,235A 4,685A Amortization of acquired intangible assets\$8,298A 2,189A Gross margin\$895,531A \$691,461A Sales, general and administrative\$514,228A 357,611A Research and development\$307,008A 219,747A Interest income, net\$31,134A 29,787A Other income (loss), net\$191,510A (42,569)Income before provision for income taxes\$296,939A \$101,321A Note 17 "Business AcquisitionsFusus, LLC. On January 31, 2024, we acquired the remaining 79.7% interest in Fusus, LLC ("Fusus"), a global leader in real-time crime center technology, for total consideration transferred of approximately \$241.3 million, subject to customary adjustments (the "Fusus acquisition"). The acquisition expands our ability to aggregate live video, data and sensor feeds, which enhances situational awareness and investigative capabilities for our customers in public safety, education and enterprise. Total transaction costs related to the acquisition were \$0.3 million and \$4.6 million for the three and nine months ended September 30, 2024, respectively. These transaction costs were expensed as incurred in sales, general and administrative expenses ("SG&A") in our condensed consolidated statements of operations. Our existing 20.3% interest had a fair value at the acquisition date of \$63.3 million, which resulted in a non-taxable gain of \$42.3 million recorded in other

(oss) net in our condensed consolidated statement of operations. Prior to the step acquisition, the fair value of the previously held investment was determined using Level 3 valuation techniques, which include inputs to the valuation methodology that are considered unobservable and significant to the fair value measurement. The purchase price allocation is subject to revision during the measurement period, which is expected to be completed in the fourth quarter of 2024. Based on the purchase price allocation, we recorded \$250.1 million of goodwill, \$72.9 million of identifiable intangible assets, and other net liabilities assumed of \$7.8 million, excluding deferred taxes. We recorded a net deferred tax liability of \$10.5 million. With the assistance of third-party valuation experts, we calculated the fair values of intangible assets using the multi-period excess earnings method for the acquired developed technology and the with and without method for customer relationships. The weighted average amortization period of the acquired intangible assets was 7.5 years. The goodwill generated from the acquisition is primarily attributable to synergies that are expected to be achieved from the integration of the business and is not deductible for tax purposes. Following the acquisition, the consolidated results of Fusus are included in the Company's Software and Sensors operating segment. Note 18 - Subsequent Event In October 2024, we acquired the remaining outstanding stock of Dedrone Holdings, Inc. ("Dedrone"), a global leader in air space security, for approximately \$400A million, subject to customary purchase price adjustments. This acquisition will be recorded to our Software and Sensors segment, and it represents alignment to our mission and positions us to accelerate the next generation of drone and air space solutions. Prior to this transaction, we had an approximately 20% ownership interest in Dedrone. This transaction is considered a step acquisition under GAAP whereby our ownership interest in Dedrone held 27% of the equity before the acquisition is required to be remeasured to fair value at the date of the acquisition. We expect to recognize a gain on our previously held strategic equity investment as a result of this transaction in the fourth quarter of 2024. Due to the proximity of the closing date of the acquisition of the remaining interest in Dedrone to the date of this filing, the initial accounting for the acquisition is not yet complete. Transaction costs related to the acquisition were approximately \$7.5A million for the nine months ended September 30, 2024. These transaction costs were expensed as incurred in SG&A in our condensed consolidated statements of operations. Note 19 - Revision of Prior Period Financial Statements As discussed in Note 1, in preparing the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024, we identified errors in our previously issued financial statements related to our historical conclusions of principal vs. agent accounting of certain reseller arrangements under ASC 606 and concluded they were not material to any previously issued financial statements. The identified errors impacted our previously issued 2021 and 2022 annual financial statements, 2023 quarterly and annual financial statements, and 2024 quarterly financial statements through June 30, 2024. We have made adjustments to the prior period amounts presented in these financial statements accordingly. Additionally, we have made adjustments to correct for other previously identified immaterial errors. The following tables reflect the impact of the revision to the specific line items presented in our previously reported (a) consolidated balance sheet as of December 31, 2023; (b) consolidated statements of operations and comprehensive income for the years ended December 31, 2023, December 31, 2022, and December 31, 2021, and for the quarterly periods ended June 30, 2024, March 31, 2024, December 31, 2023, and September 30, 2023; (c) consolidated statements of cash flows for the years ended December 31, 2023 and December 31, 2022, and for the year to date periods ended June 30, 2024, March 31, 2024, September 30, 2023; and (d) consolidated statements of stockholder's equity for the quarterly periods ending December 31, 2022 through June 30, 2024. Consolidated Balance Sheet (in thousands) As of December 31, 2023As ReportedRevisionAs RevisedAccounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023\$417,690A \$(4,729)\$412,961A Contract assets, net\$275,779A 11,453A 287,232A Prepaid expenses and other current assets\$112,786A (9,731)\$103,055A Total current assets\$2,396,649A (3,007)\$2,393,642A Deferred tax assets, net\$229,513A (1,729)\$227,784A Long-term contract assets, net\$77,710A 6,672A 84,382A Other long-term assets\$220,638A (29,607)\$191,031A Total assets\$3,436,845A (27,671)\$3,409,174A Accounts payable\$88,326A (22,474)\$65,852A Accrued liabilities\$188,230A 5,320A 193,550A Current portion of deferred revenue\$491,691A (21,276)\$470,415A Total current liabilities\$799,969A (38,430)\$761,539A Deferred revenue, net of current portion\$281,852A (10,951)\$270,901A Other long-term liabilities\$2,936A 17,979A 20,915A Total liabilities\$1,824,811A (31,402)\$1,793,409A Retained earnings\$431,249A 3,731A 434,980A Total stockholders' equity\$1,612,034A 3,731A 1,615,765A Total liabilities and stockholders' equity\$3,436,845A (\$27,671)\$3,409,174A Table of Contents Consolidated Statements of Operations and Comprehensive Income (in thousands, except per share data) Three Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\$295,185A (2,422)\$292,763A Net sales from services\$208,914 1,559\$210,473A Net sales\$504,099(\$863)\$503,236A Cost of product sales\$451,154(2,527)\$448,627A Cost of service sales\$55,210(757)\$54,453A Cost of sales\$200,364(3,284)\$197,080A Gross margin\$303,735(2,413)\$301,322A General and administrative\$169,427\$170,964A Total operating expenses\$270,861\$327,272A Income from operations\$32,874\$84,333A 758A Income before provision for income taxes\$50,590A 884A 51,474A Provision for (benefit from) income taxes\$9,793A 208A 10,001A Net income\$40,797A \$676A \$41,473A Net income per common and common equivalent shares - Basic\$0.54A \$0.01A 0.55A Comprehensive income\$38,189A \$676A \$38,865A There was no impact on disclosed diluted income per common and common equivalent shares for the three months ended June 30, 2024. Six Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\$567,233A (4,046)\$563,187A Net sales from services\$397,602 3,183\$399,920A Net sales\$964,835(1,728)\$963,107A Cost of product sales\$296,852(2,065)\$294,787A Cost of service sales\$104,202(666)\$103,536A Cost of sales\$401,054(2,731)\$398,323A Gross margin\$563,781 1,003\$564,784A Sales, general and administrative\$232,096(57)\$231,519A Total operating expenses\$514,627(57)\$514,570A Income from operations\$49,154(60)\$49,094A Net income\$174,015A \$810A \$174,825A Net income per common and common equivalent shares - Basic\$2.31A \$0.01A 2.32A Net income per common and common equivalent shares - Diluted\$2.25A \$0.01A 2.26A Comprehensive income\$170,500A \$810A \$171,310A 29Table of Contents Three Months Ended March 31, 2024As ReportedRevisionAs RevisedNet sales from products\$272,048A (1,624)\$270,424A Net sales from services\$188,687\$191,847A Net sales\$460,736(865)\$459,871A Cost of product sales\$151,698(462)\$151,236A Cost of service sales\$48,992\$149,083A Cost of sales\$200,690\$532,021A 243A Gross margin\$260,046(1,418)\$258,628A Sales, general and administrative\$152,669(159)\$152,510A Total operating expenses\$243,766(1,594)\$242,172A Income from operations\$16,280\$176,156A Income before provision for income taxes\$165,720A 176A 165,896A Provision for (benefit from) income taxes\$32,502A 42A 32,544A Net income\$133,218A \$134A \$133,352A Comprehensive income\$132,311A \$134A \$132,445A There was no impact on disclosed basic and diluted income per common and common equivalent shares for the three months ended March 31, 2024. Three Months Ended December 31, 2023As ReportedRevisionAs RevisedNet sales from products\$258,405A (1,966)\$256,439A Net sales from services\$173,737\$200,173,937A Net sales\$432,142(1,766)\$430,376A Cost of product sales\$125,664(1,764)\$123,900A Cost of service sales\$42,591(107)\$42,484A Cost of sales\$168,255(1,871)\$166,384A Gross margin\$263,887\$105,263,992A Sales, general and administrative\$137,106\$171,37,273A Total operating expenses\$221,078\$167,221,245A Income from operations\$42,809(62)\$42,747A Income before provision for income taxes\$55,802A (62)\$55,740A Provision for (benefit from) income taxes\$1,469\$1,484A (1,321)A Net income\$57,271A (\$210)\$57,061A Comprehensive income\$59,461A (\$210)\$59,251A There was no impact on disclosed basic and diluted income per common and common equivalent shares for the three months ended December 31, 2023. 30Table of Contents Year Ended December 31, 2023As ReportedRevisionAs RevisedNet sales from products\$967,711A (3,709)\$964,002A Net sales from services\$595,680 1,017\$596,697A Net sales\$1,563,391(2,692)\$1,560,699A Cost of product sales\$450,718(3,010)\$447,708A Cost of service sales\$157,291\$247,515,538A Cost of sales\$608,009(2,763)\$605,246A Gross margin\$955,382\$1,955,453A Sales, general and administrative\$496,874(1,990)\$494,884A Total operating expenses\$800,593(1,990)\$798,603A Income from operations\$154,789\$2,061\$156,850A Income before provision for income taxes\$155,000A 2,061A 157,061A Provision for (benefit from) income taxes\$19,227\$505A (18,722)A Net income\$174,227A \$1,556A \$175,783A Net income per common and common equivalent shares - Basic\$2.35A \$0.02A 2.37A Net income per common and common equivalent shares - Diluted\$2.31A \$0.02A 2.33A Comprehensive income\$170,727A \$1,556A \$172,283A Three Months Ended September 30, 2023As ReportedRevisionAs RevisedNet sales from products\$256,443A (3,188)\$253,255A Net sales from services\$157,158 1,065\$158,223A Net sales\$413,601(323)\$413,278A Cost of product sales\$116,278(1,665)\$114,613A Cost of service sales\$42,051(42)\$41,630A Cost of sales\$158,329\$1,707\$156,622A Gross margin\$255,272 3,842\$258,656A Sales, general and administrative\$123,279(922)\$122,357A Total operating expenses\$200,159(922)\$199,237A Income from operations\$55,113\$2,306\$57,419A Income before provision for income taxes\$69,423A 2,306A 71,729A Provision for (benefit from) income taxes\$10,264\$394 10,420A Net income\$59,397A \$1,912A \$61,309A Net income per common and common equivalent shares - Basic\$0.79A \$0.03A 0.82A Net income per common and common equivalent shares - Diluted\$0.78A \$0.03A 0.81A Comprehensive income\$53,254A \$1,912A \$55,166A 31Table of Contents Nine Months Ended September 30, 2023As ReportedRevisionAs RevisedNet sales from products\$709,306A (1,74

same period in the prior year. Gross margin dollars increased \$204.1 million but decreased as a percentage of revenue to 59.4% from 61.2% compared to the nine months ended September 30, 2023. The decrease was primarily driven by higher stock-based compensation expense and related payroll taxes, as well as amortization of acquired intangibles. Excluding the impacts of stock-based compensation expense and intangibles amortization in the cost of goods sold, the gross margin increased to 63.2% for the nine months ended September 30, 2024, compared to 61.8% for the same period in the prior year, primarily due to an increased mix of high-margin Axon Cloud & Services revenue and investments in TASER automation and cost-reduction initiatives. Operating expenses increased \$243.9 million, reflecting an increase in salaries, benefits, and stock-based compensation expenses, as well as an increase in professional and consulting expenses related to transaction costs. For the nine months ended September 30, 2024, we recorded net income of \$241.9 million, which included realized and unrealized gains of \$192.2 million related to our acquisition of Fusus, strategic equity investment and marketable securities. Net income of \$118.7 million for the comparable period in the prior year reflected a noncash unrealized gain of \$29.6 million on our investment in marketable securities and a noncash unrealized impairment loss of \$71.9 million, net, related to a strategic investment and related warrants. Certain prior period amounts previously reported on our consolidated financial statements have been revised to correct for immaterial errors, as described in Note 1 and Note 19 to our condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q. 36Table of ContentsResults of OperationsThree Months Ended September 30, 2024 Compared to the Three Months Ended September 30, 2023The following table presents data from our condensed consolidated statements of operations as well as the percentage relationship to total net sales of items included in our statements of operations (dollars in thousands):Three Months Ended September 30, 20242023Net sales from products\$327,90060.2Å %\$255,0561.7Å %Net sales from services216,37439.8Å 158,22338.3Å Net sales544,274100.0Å 413,278100.0Å Cost of product sales156,16728.7Å 114,61327.7Å Cost of service sales57,36010.5Å 42,00910.2Å Cost of sales213,52739.2Å 156,62237.9Å Gross margin330,74760.8Å 256,65662.1Å Operating expenses:Sales, general and administrative192,18935.1Å 122,35729.6Å Research and development114,47721.0Å 76,88018.6Å Total operating expenses306,66656.3Å 199,23748.2Å Income from operations24,0814.5Å 57,41913.9Å Interest income, net10,9782.0Å 10,4582.5Å Other income (loss), net44,5108.1Å 3,8520.9Å Income (loss) before provision for income taxes79,56914.6Å 71,72917.3Å Provision for (benefit from) income taxes12,5442.3Å 10,4202.5Å Net income\$67,02512.3Å %\$61,30914.8Å %The following table presents our revenues disaggregated by geography (in thousands):Three Months Ended September 30, 20242023United States\$482,5968Å 89Å %\$341,7678Å 83Å %Other countries61,67811Å 71,51117Å 17Å Total\$544,274100Å %\$413,278100Å %International revenue decreased compared to the prior year comparable period, primarily driven by a large hardware deal in our Europe, Middle East and Africa (ÅœœEMEAÅœ) region during the third quarter of 2023.37Table of ContentsNet SalesNet sales by product line were as follows (dollars in thousands):Three Months Ended September 30, DollarChangePercentChange20242023TASER segment:TASER Devices (Professional)\$130,515Å 24.0Å %\$86,718Å 21.0Å %\$43,797Å 50.5Å %Cartridges60,179Å 11.1Å 54,279Å 13.1Å 5,900Å 10.9Å Axon Evidence and Cloud Services13,861Å 2.5Å 8,975Å 2.1Å 4,886Å 54.4Å Extended Warranties9,729Å 1.8Å 8,078Å 2.0Å 1,651Å 20.4Å Other (1),450Å 1.4Å 4,520Å 1.1Å 2,930Å 64.8Å Total TASER segment221,734Å 40.8Å 162,570Å 39.3Å 59,164Å 36.4Å Software and Sensors segment:Axon Body Cameras and Accessories70,363Å 12.9Å 52,488Å 12.7Å 17,875Å 34.1Å Axon Fleet Systems23,239Å 4.3Å 27,336Å 6.6Å (4,097)15.0ÅAxon Evidence and Cloud Services203,481Å 37.4Å 151,518Å 36.7Å 51,963Å 34.3Å Extended Warranties17,306Å 3.2Å 14,046Å 3.4Å 3,260Å 23.2Å Other (2),151Å 1.4Å 5,320Å 1.3Å 2,831Å 53.2Å Total Software and Sensors segment322,540Å 59.2Å 250,708Å 60.7Å 71,832Å 28.7Å Total net sales\$544,274Å 100.0Å %\$413,278Å 100.0Å %\$130,996Å 31.7Å % (1)TASER segment ÅœœOtherÅœ includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales. (2)Software and Sensors segment ÅœœOtherÅœ includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment. Net sales for the TASER segment increased 36.4% for the three months ended September 30, 2024 as compared to the prior-year quarter, primarily due to increases of \$43.8 million in TASER devices (professional) revenue and \$5.9 million of cartridge revenue. The increases are primarily related to increased TASER 10 device and cartridge volumes. Net sales for Axon Evidence and cloud services increased \$4.9 million in the three months ended September 30, 2024 due to an increase in the number of cloud-connected TASER devices in the field. Net sales for the Software and Sensors segment increased 28.7% for the three months ended September 30, 2024 as compared to the prior-year quarter as we continue to add users and associated devices to our network. The increase in the aggregate number of users and increasing adoption of our premium add-on features by our existing customers drove the majority of the increase in Axon Evidence and cloud services revenue of \$52.0 million. Net sales of Axon Body cameras and accessories increased \$17.9 million due to higher volume sales of Axon Body 4. The \$2.8 million increase in ÅœœOtherÅœ revenue was primarily driven by demand for smaller product offerings within the Software and Sensors segment. We consider total company future contracted revenues a forward-looking performance indicator. As of SeptemberÅ 30, 2024, we had approximately \$7.7 billion of total company future contracted revenue, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. We currently expect to recognize between 15% - 25% of this balance over the next 12 months and expect the remainder to be recognized over the following 10 years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses. Gross Margin As a percentage of net sales, gross margin for the TASER segment decreased to 60.8% from 62.5% for the three months ended September 30, 2024 and 2023, respectively. The decrease was primarily due to increased stock-based compensation expense. Excluding the impacts of stock-based compensation expense, gross margin for the TASER segment was 63.0% for the three months ended September 30, 2024, compared to 62.8% for the same period in 2023. The increase is primarily driven by investment in automation and cost reduction initiatives.38Table of ContentsAs a percentage of net sales, gross margin for the Software and Sensors segment decreased to 60.8% from 61.9% for the three months ended September 30, 2024 and 2023, respectively. Within the Software and Sensors segment, hardware gross margin decreased to 41.4% for the three months ended September 30, 2024 compared to 46.0% for the same period in 2023. Excluding the impacts of stock-based compensation expense and intangibles amortization, hardware gross margin decreased to 43.3% for the three months ended September 30, 2024, compared to 46.5% for the same period in 2023 due to manufacturing overhead reallocations made in the prior year. Service margin decreased to 72.3% for the three months ended September 30, 2024 from 72.7% for the same period in 2023. Excluding the impacts of stock-based compensation expense and intangibles amortization, service margin increased to 75.2% for the three months ended September 30, 2024, compared to 73.7% for the same period in 2023 due to higher mix of software revenue. Sales, General and Administrative ExpensesSG&A expenses were comprised as follows (dollars in thousands):Three Months Ended September 30, DollarChangePercentChange20242023Total sales, general and administrative expenses\$192,189Å 122,357Å \$69,832Å 57.1Å %As a percentage of net sales35.3%29.6%Å Å Stock-based compensation expense increased \$42.4 million in comparison to the prior-year comparable period, which was primarily related to the 2024 Employee XSP and the 2024 CEO Performance Award that were approved by shareholders in the 2024 Annual Meeting of Shareholders and increased headcount. As of SeptemberÅ 30, 2024, we consider some of the tranches probable and will recognize the expense ratably over their respective expected vesting periods. This may result in volatility and higher upfront expense recognition and is subject to change based on periodic probability assessments. Salaries, benefits and bonus expense increased \$10.9 million in comparison to the prior-year comparable period, which was primarily attributable to an increase in headcount and higher wages. Sales and marketing and travel expense increased \$3.8 million in comparison to the prior-year comparable period. The increase was partially attributable to an increase in travel expense of \$2.3 million due to higher seasonal travel for company events compared to the prior-year comparable period. Sales and marketing fees increased \$1.1 million as a result of in-person events. Research and Development ExpensesR&D expenses were comprised as follows (dollars in thousands):Three Months Ended September 30, DollarChangePercentChange20242023Total research and development expenses\$114,477Å \$76,880Å \$37,597Å 48.9Å %As a percentage of net sales21.0Å %18.6Å %Stock-based compensation expense increased \$20.9 million in comparison to the prior-year comparable period, which was primarily related to the 2024 Employee XSP that was approved by shareholders in the 2024 Annual Meeting of Shareholders and increased headcount. Salaries, benefits and bonus expense increased \$12.9 million in comparison to the prior-year comparable period, which was primarily attributable to an increase in headcount and higher wages. 39Table of ContentsInterest Income, NetInterest income, net, was as follows (dollars in thousands):Three Months Ended September 30, 20242023Interest income\$12,624Å \$12,220Å Interest expense(1,646)(1,762)Total interest income, net\$10,978Å 10,458Å Other Income, NetOther income, net, was as follows (dollars in thousands):Three Months Ended September 30, 20242023Realized and unrealized gain (loss) on fair value adjustments of strategic investments, net\$449Å \$(14)Unrealized gain on marketable securities, net44,010Å 4,050Å Loss on foreign currency transactions, net(233)(473)Other, net284Å 289Å Other income, net\$44,510Å \$3,852Å Provision for Income Taxes Our estimated annual effective income tax rate for 2024, before discrete period adjustments, is 23.3%, which differs from the federal statutory rate primarily due to the impact of state taxes net of federal benefit and executive compensation limitation under IRC Section 162(m) on projected pre-tax income for the year, partially offset by R&D tax credits and a net gain related to an investment transaction not recognized for tax. The effective tax rate was favorably impacted by a net \$5.5 million discrete tax benefit associated with net windfalls related to stock-based compensation for RSUs and PSUs that vested, in addition to non-qualified stock options that were exercised during the three months ended September 30, 2024. Provision for income taxes and effective tax rates were as follows (dollars in thousands):Three Months Ended September 30, 20242023ChangeProvision for income taxes\$12,544Å \$10,420Å Effective tax rate15.8Å 14.5Å %1.3Å %Net IncomeWe recorded net income of \$67.0 million for the three months ended September 30, 2024 compared to net income of \$61.3 million for the same period in 2023. Net income per basic share was \$0.89 for the three months ended September 30, 2024 compared to \$0.82 net income per basic share for the same period in 2023. Net income per diluted share was \$0.86 for the three months ended September 30, 2024 compared to \$0.81 net income per diluted share for the comparable period in 2023.40Table of ContentsThree Months Ended September 30, 2024 Compared to the Three Months Ended June 30, 2024Net SalesNet sales by product line were as follows (dollars in thousands):Three Months Ended September 30, 2024Three Months Ended June 30, 2024DollarChangePercentChangeTASER segment:TASER Devices (Professional)\$130,515Å 24.0Å %\$104,624Å 20.8Å %\$25,891Å 24.7Å %Cartridges60,179Å 11.1Å 65,415Å 13.0Å (5,236)(8.0)Å Axon Evidence and Cloud Services13,861Å 2.5Å 13,974Å 2.8Å (113)(0.8)Å Extended Warranties9,729Å 1.8Å 9,908Å 1.8Å 821Å 9.2Å Other (1),450Å 1.4Å 3,796Å 0.7Å 3,654Å 96.3Å Total TASER segment221,734Å 40.8Å 196,717Å 39.1Å 25,017Å 12.7Å Software and Sensors segment:Axon Body Cameras and Accessories70,363Å 12.9Å 59,024Å 11.7Å 11,339Å 19.2Å Axon Fleet Systems23,239Å 4.3Å 27,083Å 5.4Å (3,844)(14.2)ÅAxon Evidence and Cloud Services203,481Å 37.4Å 191,237Å 38.0Å 12,244Å 6.4Å Extended Warranties17,306Å 3.2Å 15,405Å 3.1Å 1,901Å 12.3Å Other (2),151Å 1.4Å 13,770Å 2.7Å (5,619)(40.8)ÅSoftware and Sensors segment322,540Å 59.2Å 306,519Å 60.9Å 16,021Å 5.2Å Total net sales\$544,274Å 100.0Å %\$503,236Å 100.0Å %\$41,038Å 8.2Å % (1)TASER segment ÅœœOtherÅœ includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales. (2)Software and Sensors segment ÅœœOtherÅœ includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment. Net sales within the TASER segment increased by approximately \$25.0 million, or 12.7%, during the three months ended September 30, 2024 compared to the prior quarter. The increase is primarily related to higher TASER 10 device volume. The \$5.2 million decrease in Cartridge revenue is due to lower international volume of legacy cartridges. Fluctuations in cartridge revenue are generally attributable to customers who are not on cartridge subscriptions plans and periodically purchase in bulk. Within the Software and Sensors segment, net sales increased \$16.0 million, or 5.2%, during the three months ended September 30, 2024 compared to the prior quarter. The increase in the aggregate number of users and increasing adoption of our premium add-on features by our existing customers drove the majority of the increase in Axon Evidence and cloud services revenue of \$12.2 million. Axon Body cameras and accessories revenue increased \$11.3 million on higher unit sales. Partially offsetting the increases in the Software and Sensors segment was a decrease of \$3.8 million in Axon Fleet revenue primarily reflecting lower unit volume.41Table of ContentsNine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023The following table presents data from our condensed consolidated statements of operations as well as the percentage relationship to total net sales of items included in our statements of operations (dollars in thousands):Nine Months Ended September 30, 20242023Net sales from products\$891,08759.1Å 1Å %\$707,56362.6Å %Net sales from services616,29440.9Å 422,76037.4Å Net sales1,507,381100.0Å 1,130,323100.0Å Cost of product sales450,95429.9Å 323,80828.6Å Cost of service sales160,89610.7Å 115,05410.3Å Cost of sales611,850Å 40.6Å 438,862Å 38.8Å Gross margin895,53159.4Å 691,461Å 61.2Å Operating expenses:Sales, general and administrative\$142,283Å 9.4Å 137,611Å 12.1Å Research and development\$130,707Å 8.7Å 107,000Å 9.5Å Total operating expenses\$273,990Å 18.1Å 244,611Å 21.6Å Income from operations\$1,231,541Å 81.3Å 886,751Å 78.4Å Interest income, net\$19,510Å 1.3Å 10,458Å 0.9Å Income (loss) before provision for income taxes\$1,251,051Å 82.6Å 897,209Å 79.3Å Provision for (benefit from) income taxes\$55,089Å 3.7Å (17,401)(1.5)ÅNet income\$1,195,962Å 78.9Å 914,610Å 80.8Å %The following table presents our revenues disaggregated by geography (in thousands):Nine Months Ended September 30, 20242023United States\$1,298,775Å 86Å %\$954,023Å 84Å %Other countries208,606Å 14Å 176,300Å 16Å Total\$1,507,381Å 100Å %\$1,130,323Å 100Å %International revenue increased compared to the prior year comparable period. The increase was primarily attributable to large hardware orders during the period in our EMEA and Americas regions.42Table of ContentsNet SalesNet sales by product line were as follows (dollars in thousands):Nine Months Ended September 30, DollarChangePercentChange20242023TASER segment:TASER Devices (Professional)\$333,815Å 22.1Å %\$239,165Å 21.2Å %\$94,650Å 39.6Å %Cartridges181,792Å 12.1Å 149,504Å 13.2Å 32,288Å 21.6Å Axon Evidence and Cloud Services40,297Å 2.7Å 25,575Å 2.3Å 14,722Å 57.6Å Extended Warranties27,164Å 1.8Å 23,463Å 2.1Å 3,701Å 15.8Å Other (1),437Å 1.0Å 14,460Å 1.2Å (87)(0.6)ÅTotal TASER segment597,441Å 39.7Å 452,167Å 40.0Å 145,274Å 32.1Å Software and Sensors segment:Axon Body Cameras and Accessories180,592Å 12.0Å 124,066Å 11.0Å 56,526Å 45.6Å Axon Fleet Systems79,620Å 5.3Å 99,015Å 8.8Å (19,395)(19.6)ÅAxon Evidence and Cloud Services570,222Å 37.8Å 401,281Å 35.5Å 168,941Å 42.1Å Extended Warranties48,651Å 3.2Å 40,194Å 3.6Å 8,457Å 21.0Å Other (2),30,855Å 2.0Å 13,600Å 1.1Å 17,255Å 126.9Å Total Software and Sensors segment909,940Å 60.3Å 678,156Å 60.0Å 231,784Å 34.2Å Total net sales\$1,507,381Å 100.0Å %\$1,130,323Å 100.0Å %\$377,058Å 33.4Å % (1)TASER segment ÅœœOtherÅœ includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales. (2)Software and Sensors segment ÅœœOtherÅœ includes revenue from items including Signal Sidearm, Interview Room and Axon Air. Net sales for the TASER segment increased \$145.3 million or 32.1% during the nine months ended SeptemberÅ 30, 2024, primarily due to an increase of \$94.7 million in TASER devices and \$32.3 million in cartridge revenue. The increase is primarily related to increased TASER 10 device and cartridge volumes. The increase in revenue from Axon Evidence and cloud services of \$14.7 million was driven by an increase in TASER software. An increase in TASER devices in the field drove the \$3.7 million increase in extended warranties, as most of those devices are sold with extended warranties. Net sales for the Software and Sensors segment increased \$231.8 million, or 34.2%, during the nine months ended SeptemberÅ 30, 2024, as we continued to add users and associated devices to our network. The increase in the aggregate number of users and the growing adoption of our premium add-on features by existing customers drove the majority of the increase in Axon Evidence revenue, totaling \$168.9 million, as well as increases in professional services revenue. Axon Body cameras and accessories revenue increased \$56.5 million due to higher unit sales. Partially offsetting the increase was a \$19.4 million decrease in Axon Fleet systems revenue primarily reflecting lower unit volumes on more normalized deployment timelines. An increase in cameras, docks and Fleet systems in the field drove the \$8.5 million increase in extended warranties, as most of those devices are sold with extended warranties. The \$17.3 million increase in ÅœœOtherÅœ revenue was primarily driven by demand for smaller product offerings within the Software and Sensors segment. Gross MarginAs a percentage of net sales, gross margin for the TASER segment decreased to 57.7% from 61.8% for the nine months ended SeptemberÅ 30, 2024 and 2023, respectively. The decrease was primarily due to increased stock-based compensation expense. Excluding the impacts of stock-based compensation expense, gross margin for the TASER segment is 62.6% for the nine months ended SeptemberÅ 30, 2024, compared to 62.1% for the same period in 2023. The increase is primarily due to the investments in automation and cost reduction initiatives. As a percentage of net sales, gross margin for the Software and Sensors segment decreased to 60.6% from 60.8% for the nine months ended SeptemberÅ 30, 2024 and 2023, respectively. Within the Software and Sensors segment, hardware gross margin was 39.6% for the nine months ended SeptemberÅ 30, 2024, compared to 45.4% for the same period in 2023. Excluding 43Table of Contentsthe impacts of stock-based compensation expense and intangibles amortization, hardware gross margin decreased to 43.3% for the nine months ended SeptemberÅ 30, 2024, compared to 45.7% for the same period in 2023 due to inventory reserve charges associated with legacy products in the second quarter of 2024. Service margin increased to 72.7% for the nine months ended SeptemberÅ 30, 2024 compared to 71.7% for the same period in 2023. Excluding the

Analysis of stock-based compensation expense and intangibles amortization, service margin increased to 75.2% for the nine months ended September 30, 2024, compared to 72.8% for the same period in 2023, due to higher software mix and cloud cost efficiencies. For the nine months ended September 30, 2024, we have seen an increase in stock-based compensation expense within our cost of goods sold as a result of RSUs granted in January 2024 that generally vest in five annual installments from March 2024 through March 2028. These RSUs were granted to employees whose compensation was under a specified threshold, including production-line employees. As previously disclosed in Note 15 to our consolidated financial statements included within our Annual Report on Form 10-K for the year ended December 31, 2023, Patrick W. Smith, our Chief Executive Officer, agreed to compensation in a lesser amount than the Compensation Committee of our Board of Directors was otherwise willing to provide so that the Company could instead provide enhanced compensation opportunities to other employees of the Company. If instead he had accepted higher compensation, it would have been reflected in SG&A expenses over a similar period. Sales, General and Administrative Expenses SG&A expenses were comprised as follows (dollars in thousands):

Nine Months Ended September 30, 2024	2023	Total sales, general and administrative expenses
\$514,228	\$357,611	\$1,556,617
43.8%	34.1%	31.6%

Stock-based compensation expense increased \$73.8 million in comparison to the prior-year comparable period, which was primarily related to the 2024 Employee XSP and the 2024 CEO Performance Award that were approved by shareholders in the 2024 Annual Meeting of Shareholders and increased headcount. Salaries, benefits, and bonus expense increased \$25.0 million in comparison to the prior-year comparable period, which was primarily attributable to an increase in headcount and higher wages. Sales and marketing and travel expenses increased \$18.9 million in comparison to the prior-year comparable period. The increase was partially attributable to an increase in travel expense of \$7.4 million due to higher seasonal travel for company events compared to the prior-year comparable period. Commissions increased \$7.9 million as a result of higher revenue. Professional and consulting expenses increased \$13.8 million in comparison to the prior-year comparable period, which was primarily attributable to transaction costs related to the acquisition of Fusus and expected acquisition of Dedrone. Other SG&A expenses increased \$21.7 million in comparison to the prior-year comparable period, which was attributable to an increase of \$4.7 million in computer license expenses and an increase of \$1.9 million for credit losses. Additionally, the prior-year comparable period had a \$3.3 million gain related to insurance proceeds received as a result of storm damages, which did not recur in the current year. Research and Development Expenses R&D expenses were comprised as follows (dollars in thousands):

Nine Months Ended September 30, 2024	2023	Total research and development expenses
\$307,008	\$219,747	\$87,261
39.7%	39.7%	39.7%

As a percentage of net sales 20.4% 19.4% 14.4% Table of Contents Salaries, benefits, and bonus expense increased \$40.8 million in comparison to the prior-year comparable period, which was primarily attributable to an increase in headcount and higher wages. Stock-based compensation expense increased \$38.0 million in comparison to the prior-year comparable period, which was primarily related to the 2024 Employee XSP that was approved by shareholders in the 2024 Annual Meeting of Shareholders and increased headcount. Interest Income, Net Interest income, net, was as follows (dollars in thousands):

Nine Months Ended September 30, 2024	2023	Interest income	Interest expense	Total interest income, net
\$36,407	\$35,010	(5,273)	(5,223)	\$31,134
\$29,787				

Other Income (Loss), Net Other income (loss), net, was as follows (dollars in thousands):

Nine Months Ended September 30, 2024	2023	Realized and unrealized gain (loss) on fair value adjustments of strategic investments	Unrealized gain on marketable securities	Loss on foreign currency transactions	Other
\$118,538	(71,916)				
\$72,620	\$29,610				

Other, net (468) 292 Other income (loss), net \$191,510 (\$42,569) Provision for Income Taxes Our estimated annual effective income tax rate for 2024, before discrete period adjustments, is 23.3%, which differs from the federal statutory rate primarily due to the impact of state taxes net of federal benefit and executive compensation limitation under IRC Section 162(m) on projected pre-tax income for the year, partially offset by R&D tax credits and a net gain related to an investment transaction not recognized for tax. The effective tax rate was favorably impacted by a net \$13.0 million discrete tax benefit associated with net windfalls related to stock-based compensation for RSUs and PSUs that vested, in addition to non-qualified stock options that were exercised during the nine months ended September 30, 2024. Provision for (benefit from) income taxes and effective tax rates were as follows (dollars in thousands):

Nine Months Ended September 30, 2024	2023	Change
\$55,089	(17,401)	\$72,490
18.6%	17.2%	35.8%

Net Income We recorded net income of \$241.9 million for the nine months ended September 30, 2024 compared to net income of \$118.7 million for the same period in 2023. Net income per basic share was \$3.20 for the nine months ended September 30, 2024 compared to net income per basic share of \$1.61 for the same period in 2023. Net income per diluted share was \$3.12 for the nine months ended September 30, 2024 compared to net income per diluted share of \$1.58 for the comparable period in 2023. 45 Table of Contents Non-GAAP Measures We utilize certain non-GAAP financial measures such as EBITDA, adjusted EBITDA, and adjusted gross margin as defined below to enhance understanding of our financial results and related measures. Beginning with our first fiscal quarter of 2024, we have added adjusted gross margin to our non-GAAP financial measures. We have adjusted for expenses that we believe are not indicative of our core operating results, including stock-based compensation expense and amortization of acquired intangible assets. To improve comparability, prior periods have been conformed to the current period presentation. Our management uses these non-GAAP financial measures in evaluating our operating performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented below.

EBITDA (most comparable GAAP measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation and amortization	Adjusted EBITDA (most comparable GAAP measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation, amortization, noncash stock-based compensation expense, fair value adjustments to strategic investments and marketable securities, transaction costs related to acquisitions and strategic investments, costs related to antitrust litigation and other unusual, non-recurring pre-tax items that are not considered representative of our underlying operating performance	Adjusted gross margin (most comparable GAAP measure: Gross margin) â€” Gross margin before noncash stock-based compensation expense and amortization of acquired intangible assets
101,780	29,987	251,716
96,228		

Unrealized (gain) loss on strategic investments and marketable securities, net (44,459) (4,036) (149,845) 42,306 A Realized gain on remeasurement of previously held minority interest, net (4,423) (313) (4,736) A Transaction costs related to strategic investments and acquisitions 2,652 A 495 A 13,145 A 1,793 A Loss on disposal, abandonment, and impairment of property, equipment and intangible assets, net (4,137) A 137 A (4,274) A Insurance recoveries (2,615) (4,304) Costs related to antitrust litigation (4,712) A 224 A 72 A Payroll taxes related to 2019 XSP vesting and 2018 CEO Performance Award option exercises 1,727 A 201 A 1,727 A 8,961 A Adjusted EBITDA \$145,053 A \$93,929 A \$379,785 A \$240,394 A Adjusted gross margin reconciles to gross margin as follows (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Net income
\$61,309	\$41,850	\$118,722
\$256,656	\$258,343	\$890,102
\$157,147	\$259,298	\$890,102

Gross margin 63.0% 63.3% 63.6% 2.6% 2.6% 7.6% Nine Months Ended September 30, 2024 Net income \$241.9 million Total Gross margin \$344,478 \$551,053 \$895,531 \$279,353 \$412,108 \$691,461 Stock-based compensation expense \$29,564 \$18,671 \$48,235 \$21,521 \$164,685 Amortization of acquired intangible assets \$308,268 \$298,122 \$881,189 Adjusted gross margin \$374,072 \$577,992 \$952,064 \$280,875 \$417,460 \$698,335 Gross margin 57.7% 60.6% 59.4% 61.8% 60.8% 61.2% Adjusted gross margin 62.6% 63.5% 63.2% 62.2% 61.6% 61.8% 64 Table of Contents Liquidity and Capital Resources Summary September 30, 2024 December 31, 2023 Dollar Change Cash and cash equivalents \$695,144 A \$598,545 A \$96,599 A Available-for-sale investments \$311,570 A \$44,054 A (\$32,484) A Total \$1,006,714 A \$1,242,599 A (\$235,885) A Our most significant source of liquidity continues to be funds generated by operating activities and available cash and cash equivalents and short-term investments. In addition, our Credit Agreement of \$200.0 million revolving credit facility is available for additional working capital needs or investment opportunities. We believe we have access to additional financing. However, there is no assurance that such funding will be available on terms acceptable to us, or at all. Refer to Note 13 for additional details related to our Credit Agreement and outstanding letters of credit. A We believe that our sources of funding will be sufficient to satisfy our currently anticipated cash requirements, including capital expenditures, working capital requirements, potential acquisitions or investments, income and payroll tax payments for net-settled stock awards, and other liquidity requirements through at least the next 12 months. We and our Board of Directors may consider repurchases of our common stock. Further repurchases of our common stock would take place on the open market, would be financed with available cash and are subject to authorization as well as market and business conditions. Cash Flows The following table summarizes our cash flows from operating, investing and financing activities (in thousands):

Nine Months Ended September 30, 2024	Dollar Change 2024 2023 A	Operating activities	Investing activities	Financing activities
\$158,146	\$49,225	\$108,921	(48,834)	(40,697)
\$96,779	\$52,459	\$44,320		

Effect of exchange rate changes on cash and cash equivalents 75 A (1,201) 1,276 A Net increase (decrease) in cash and cash equivalents and restricted cash \$96,779 A \$52,459 A \$44,320 A 48 Table of Contents Operating activities Net cash provided by operating activities was \$158.1 million for the first nine months of 2024, compared to \$49.2 million in the comparable period in the prior year. The \$108.9 million increase is due to changes in the following (in thousands):

Nine Months Ended September 30, 2024	Dollar Change 2024 2023 A	Net income
\$241,850	\$118,722	\$123,128
\$251,716	\$62,284	\$155,488
\$158,146	\$49,225	\$108,921

Deferred income taxes (27,061) (52,955) 25,894 A Inventory and accounts payable (1,386) (51,729) 50,343 A Receivables and contract assets (226,759) (186,614) (40,145) Deferred revenue \$6,720 A 103,386 A (46,66

to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the condensed consolidated statements of operations. Based on investment positions as of SeptemberÂ 30, 2024, a hypothetical 100 basis point increase in interest rates across all maturities would result in a \$0.4 million decline in the fair market value of the portfolio. Such losses would only be realized if we sold the investments prior to maturity.Additionally, we have access to a \$200.0 million line of credit borrowing facility which bears interest at SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net leverage ratio and consolidated interest coverage ratio. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit, which totaled \$8.2 million at SeptemberÂ 30, 2024. At SeptemberÂ 30, 2024, there was no amount outstanding under the line of credit, and the available borrowing under the line of credit was \$191.8 million. We have not borrowed any funds under the line of credit since its inception; however, should we need to do so in the future, such borrowings could be subject to adverse or favorable changes in the underlying interest rate.Exchange Rate RiskOur results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, in each case compared to the U.S. dollar, related to transactions by our foreign subsidiaries. The majority of our sales to international customers are transacted in foreign currencies and therefore are subject to exchange rate fluctuations on these transactions. The cost of our products to our customers increases when the U.S. dollar strengthens against their local currency, and we may have more sales and expenses denominated in foreign currencies in future years, which could increase our foreign exchange rate risk. Additionally, intercompany sales to our non-U.S. dollar functional currency international subsidiaries are transacted in U.S. dollars, which could increase our foreign exchange rate risk caused by foreign currency transaction gains and losses.To date, we have not engaged in any currency hedging activities. However, we may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, certain firmly committed transactions, forecasted future cash flows and net investments in foreign subsidiaries. However, we may choose not to hedge certain foreign exchange exposures for a variety of reasons, including, but not limited to, the prohibitive economic cost of hedging particular exposures. As such, fluctuations in currency exchange rates could harm our business in the future.Item 4. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresOur Chief Executive Officer and Chief Financial Officer are responsible for the evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of SeptemberÂ 30, 2024.51Table of ContentsThere was no change in our internal control over financial reporting during the quarter ended SeptemberÂ 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.PART II - OTHER INFORMATIONItem 1. Legal ProceedingsThe discussion in Note 14 to our condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q is incorporated by reference herein.Item 1A. Risk FactorsRisk Factor Summary The following is only a summary of the principal risks that may materially adversely affect our business, financial condition, results of operations and cash flows. The following should be read in conjunction with the more complete discussion of the risks we face, which are set forth more fully below. Strategic Risksâ€¢If law enforcement agencies do not continue to purchase and use our products and services, our growth prospects, operating results and financial condition will be materially adversely affected.â€¢If our CEDs do not continue to be widely accepted, our growth prospects, operating results and financial condition will be diminished.â€¢If we are unable to design, introduce, sell and deploy new products or new product features successfully, our business and financial results could be adversely affected.â€¢We face risks associated with rapid technological change and new competing products.â€¢Our future success is dependent on our ability to expand sales through direct sales and distributors and our inability to increase direct sales or recruit new distributors would negatively affect our sales.â€¢Negative publicity could adversely impact sales, which could cause our revenues or operating results to decline.â€¢Acquisitions of, or investments in, other products, technologies or businesses could disrupt our business, dilute shareholder value, and adversely affect our operating results.â€¢Our failure to retain executive officers, including Patrick W. Smith, could adversely impact our business.Operational Risksâ€¢Unavailability of materials or higher costs could adversely affect our financial results.â€¢Material adverse developments in domestic and global economic conditions, or the occurrence of other sufficiently disruptive world events, could materially adversely affect our revenue and results of operations.â€¢To the extent demand for our products increases, our future success will be dependent upon our ability to manage our growth and to increase manufacturing production capacity.â€¢Delays in product development schedules could adversely affect our revenues and cash flows.â€¢We expend significant resources in anticipation of a sale and may receive no revenue in return.â€¢Changes in civil forfeiture laws may affect our customersâ€™ ability to purchase our products.â€¢If our security measures or those of our third-party providers, including cloud storage providers, are breached and unauthorized access is obtained to customersâ€™ data or our data, our network, data centers and service may be perceived as not being secure, customers may curtail or stop using our products and services, and we may incur significant legal and financial exposure and liabilities.â€¢Catastrophic events could materially adversely affect our business, results of operations and/or financial condition.â€¢Uncertainty in the development, deployment and use of artificial intelligence (â€œAIâ€) in our products and services, as well as our business more broadly, could adversely affect our business and reputation.â€¢Defects or disruptions in our services could impact demand for our services and subject us to substantial liability.â€¢Defects in our products could reduce demand for our products or result in product recalls and result in a loss of sales, delay in market acceptance and damage to our reputation.â€¢Our international operations expose us to additional risks that could harm our business, operating results and financial condition.â€¢We depend on our ability to attract and retain our key management, sales and technical personnel.â€¢If we fail to comply with federal, state or local regulations applicable to TASER 10 CEDs, we may be subject to governmental actions or litigation that could materially harm our business.52Table of Contentsâ€¢Failure to maintain effective internal control over financial reporting, material weaknesses, or significant deficiencies may adversely affect our ability to accurately and timely report our financial condition and results of operations, which may cause investor confidence to diminish and the value of our common stock may decline.â€¢Our revision of previously issued consolidated financial statements may adversely affect investor confidence and could result in regulatory and litigation risks.Financial Risksâ€¢An increasing percentage of our revenue is derived from subscription billing arrangements that may result in delayed cash collections and may increase customer credit risk on receivables and contract assets.â€¢Our gross margin is dependent on a number of factors, including our product mix, cost structure and acquisitions we may make, any of which could cause our gross margin to decline.â€¢Revenue for our Software-as-a-Service (â€œSaaSâ€) products is recognized over the terms of the contracts, which may be several years, and, as such, trends in new business may not be immediately reflected in our operating results.â€¢Most of our end-user customers are subject to budgetary and political constraints that may delay or prevent sales.â€¢The open bidding process creates uncertainty in predicting future contract awards.â€¢We maintain most of our cash balances, some of which are not insured, at two depository institutions.â€¢Stock transactions may have a material, unpredictable impact on our results of operations and may result in dilution to existing shareholders.â€¢Our financial performance is subject to risks associated with changes in the value of the U.S. dollar versus local currencies.â€¢Unanticipated changes in our effective tax rate and additional tax liabilities may impact our results of operations and financial condition.â€¢Our revenues and operating results may fluctuate unexpectedly, which may cause our common stock price to decline.â€¢Our profitability could suffer from declines in fair value or impairment of our investments, including our strategic investments, and could fluctuate if the fair values of our investments increase.Legal and Compliance Risksâ€¢We may face personal injury, wrongful death, product liability and other liability claims that harm our reputation and adversely affect our sales and financial condition.â€¢Other litigation, government inquiries and regulatory actions may result in significant costs and judgments and divert management attention from our business.â€¢We have in the past and may in the future be subject to intellectual property infringement and other claims, which could incur substantial litigation costs, result in significant damages awards, inhibit our use of certain technologies, and divert management attention from our business.â€¢If we are unable to protect our intellectual property, the value of our brands and products may decrease and we may lose our competitive market advantage.â€¢We may be unable to enforce patent rights internationally, which may limit our ability to prevent our product features from being used by competitors in some foreign jurisdictions.â€¢The use of open-source software in our products, services and technologies may expose us to additional risks and harm our intellectual property rights.â€¢A variety of new and existing laws and/or interpretations could materially adversely affect our business.â€¢We are subject to evolving corporate governance and public disclosure regulations and expectations that could expose us to numerous risks.â€¢Our amended and restated bylaws include exclusive forum provisions that could increase costs to bring a claim, discourage claims or limit the ability of our shareholders to bring a claim in a judicial forum viewed by shareholders as more favorable for disputes.Risks Related to our Convertible Notesâ€¢Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow to pay our substantial debt.â€¢The conditional conversion feature of the Notes, if triggered, may adversely affect our operating results.â€¢Conversion of the Notes may dilute the ownership interest of our shareholders or may otherwise depress the price of our common stock.â€¢Changes in the accounting treatment for the Notes may have a material effect on our reported financial results.â€¢The 2027 Note Hedge and Warrant transactions may affect the value of the Notes and our common stock.â€¢We are subject to counterparty risk with respect to the convertible note hedge transactions.53Table of ContentsOur past financial performance may not be a reliable indicator of our future performance and historical trends should not be used to anticipate our results or trends in future periods because of the following factors and other variables affecting our operating results. You should carefully consider the trends, risks and uncertainties described below and other information in this Quarterly Report on Formâ€ 10-Q and subsequent reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of the following trends, risks or uncertainties actually occurs or continues, our business, financial condition, results of operations or cash flows could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.Strategic RisksWe are substantially dependent on acceptance of our products and services by law enforcement agencies throughout the world. If law enforcement agencies do not continue to purchase and use our products and services, our growth prospects, operating results and financial condition will be materially adversely affected.Our largest customer segment is U.S. state and local law enforcement. Axon has a customer relationship with a substantial number of state and local law enforcement agencies in the United States. At any point, whether or not related to the performance of our products and services, law enforcement agencies may elect to no longer purchase or use our CEDs or other products and services. For example, we believe that in the past our sales were adversely impacted by negative coverage and publicity surrounding our products and services and their use. If law enforcement agencies no longer purchase our products and services, or materially decrease their purchases, our growth prospects, operating results and financial condition will be materially adversely affected.We substantially depend on sales of our CEDs, and if these products do not continue to be widely accepted, our growth prospects, operating results and financial condition will be diminished.In each of the years ended DecemberÂ 31, 2023, 2022 and 2021, we derived a significant portion of our revenues from sales of CEDs and related products, whether on a standalone basis or as part of a bundled offering, and expect to depend on sales of these products for a significant portion of our revenue for the foreseeable future. The acceptance of these devices is critical to our growth prospects, operating results and financial condition. If we are unable to continue to meet customer demands or to achieve more widespread market acceptance of these products, our growth prospects, operating results and financial condition will be materially adversely affected. Demand for CED products is affected by several factors, many of which are beyond our control, including continued market acceptance of our products by our customers, technological change, and growth or contraction of the economy in general. Additionally, our CEDs and other offerings or products could fail to maintain or attain sufficient customer acceptance for many reasons, including:â€¢our failure to predict market demand accurately in terms of product functionality and to supply offerings that meet this demand;â€¢real or perceived defects, errors or failures;â€¢negative publicity about their performance or effectiveness;â€¢delays in releasing to the market our improved offerings or enhancements;â€¢introduction or anticipated introduction of competing products; andâ€¢budget constraints or other limitations for our customers.A decrease in the selling prices of or demand for these products, or their failure to maintain broad market acceptance, would significantly harm our competitive position, growth prospects, operating results and financial condition.If we are unable to design, introduce, sell and deploy new products or new product features successfully, our business and financial results could be adversely affected.Our future success will likely depend on our ability to develop new products or product features that achieve market acceptance in a timely and cost-effective manner. The development of new products and product features is complex, time-consuming and expensive, and we may experience delays in completing the development and introduction of new products. We may choose to carry higher levels of inventory to mitigate the risk of production delays, which may expose us to an increased risk of obsolescence. 54Table of ContentsWe have devoted, and continue to devote, significant resources to develop and deploy our cloud-based productivity and real-time operations SaaS solutions, which we continue to broadly deploy to a large number of customers. Customersâ€™ requirements for these products are complex and varied. If we cannot develop scalable solutions that can be consistently configured for customers with minimal effort or grow a professional services team that can consistently configure our products to meet the requirements of large numbers of customers in a timely and cost-effective manner, our ability to broadly scale our cloud-based productivity and real-time operations SaaS solutions could be negatively impacted, and our business prospects, operating results and financial condition could be negatively impacted.We cannot provide any assurance that products that we may develop in the future will achieve market acceptance. If we fail to develop new products or new product features on a timely basis that achieve market acceptance, our business, financial results and competitive position could be adversely affected.We face risks associated with rapid technological change and new competing products.The technology associated with law enforcement devices and software is receiving significant attention and is rapidly evolving. The introduction of products embodying new technologies (such as the use of AI and machine learning) and the emergence of new industry standards can render existing products obsolete and unmarketable. Additionally, our products are expected to meet and keep pace with evolving security standards and requirements of our industry and customers, including those of the U.S. federal government and international governments. While we have some patent protection in certain key areas of our Axon devices, CEDs and SaaS technology, new technology may result in competing products that operate outside our patents and could present significant competition for our products, which could adversely affect our business, financial results and competitive position. Additionally, our competitors may develop competing technologies or products that provide superior features or are less expensive than our products, or our competitors may respond more quickly to new or emerging technologies, undertake more extensive marketing campaigns, have greater financial, marketing, manufacturing and other resources than we do or may be more successful in attracting potential customers, employees and strategic partners. If we are not able to compete effectively, our business and financial results could be adversely affected.Our future success is dependent on our ability to expand sales through direct sales and distributors and our inability to increase direct sales or recruit new distributors would negatively affect our sales.Our distribution strategy is to pursue sales through multiple channels, which are principally direct sales and independent distributors. We are focusing on direct sales to larger agencies through our regional sales managers and our inability to grow sales to these agencies in this manner would materially adversely affect our business prospects, operating results and financial condition. In addition, our inability to establish relationships with and retain law enforcement equipment distributors who we believe can successfully sell our products would materially adversely affect our business prospects, operating results and financial condition. If we do not competitively price our products, meet the requirements of our distributors or end-users, provide adequate marketing support or comply with the terms of our distribution arrangements, our distributors may fail to aggressively market our products or may terminate their relationships with us. These developments would likely have a material adverse effect on our sales. Our reliance on the sales of our products by others also makes it more difficult to predict our revenues, cash flow and operating results.In certain states and foreign jurisdictions, we have decided to pursue sales directly with law enforcement customers, rather than working through established distribution channels. Our customers may have strong working relationships with distributors, and we may face resistance to this change. If we do not overcome this resistance and effectively build a direct relationship with our customers, sales may be adversely affected.Negative publicity could adversely impact sales, which could cause our revenues or operation results to decline.Our business is dependent upon the reputation of the Axon brand. If we are unable to maintain the position of the Axon brand, our business may be adversely affected by diminishing the appeal of the brand to our customer base. This could result in lower sales and earnings.In addition, unfavorable media or investor and analyst reports related to our industry, company, brand, marketing, personnel, operations, business performance or prospects may affect our common stock price and the performance of our business, regardless of accuracy. Furthermore, the speed at which negative publicity is disseminated has increased dramatically through the use of electronic communication, including social media

outlets, websites and other digital platforms. Our success in maintaining and enhancing our brand depends on our ability to adapt to this rapidly changing media environment. Adverse publicity or negative commentary from any media outlets could damage our reputation and reduce the demand for our products and services, which would adversely affect our business and financial results.

55Table of ContentsAcquisitions of, or investments in, other products, technologies or businesses could disrupt our business, dilute shareholder value, and adversely affect our operating results. Our business strategy has in the past and may in the future include acquiring or making investments in other complementary products, technologies or businesses. Identifying and negotiating these transactions can be time-consuming, difficult and expensive, and our ability to close these transactions has in the past and may in the future be subject to third-party approvals, such as government regulatory approvals and clearances, which are beyond our control. Consequently, we can make no assurance that these transactions once undertaken and announced, will close. These kinds of acquisitions or investments may result in unforeseen operating difficulties and expenditures. If we acquire businesses, technologies or products, we may not be able to integrate the acquired personnel, operations, technologies or products successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:

- inability to integrate or benefit from acquired products, technologies or businesses in a profitable manner;
- inability to correct or achieve regulatory approvals or certifications;
- exposure to new regulations related to the acquired products, technologies or business that are unexpectedly burdensome, negatively impact existing products, technologies or business or require significant investment in order to achieve compliance;
- unanticipated costs or liabilities associated with the acquisition, including potential liabilities due to litigation, government inquiries and regulatory actions relating to the acquired products, technologies or business and any non-compliance with applicable laws, regulations or contractual requirements;
- potential identified or unknown security vulnerabilities in acquired technologies that expose us to additional security risks or delay our ability to integrate the acquired products into our offerings or recognize the benefits of our investment;
- differences between our values and those of an acquired company, as well as potential disruptions to our workplace culture or how we are perceived by investors;
- incurrance of acquisition-related costs, including costs related to integration activities;
- difficulty integrating the accounting and information systems, operations and personnel of the acquired business;
- inability to augment the acquired technologies and platforms to the levels that are consistent with our brand and reputation;
- difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;
- challenges converting the acquired company's revenue recognition policies and forecasting the related revenues, including subscription-based revenues and software license revenues;
- potential write-offs of acquired assets or investments and potential financial and credit risks associated with acquired customers;
- difficulty converting the customers of the acquired business onto our platform and contract terms;
- diversion of management's attention and other company resources;
- harm to our existing business relationships with business partners and customers as a result of the acquisition;
- the potential loss of key employees;
- use of resources that are needed in other parts of our business; and
- use of substantial portions of our available cash to consummate the acquisition.

We cannot assure you that the anticipated benefits of any acquisition or investment will be realized, that projected synergies will materialize or that we will not be exposed to unknown liabilities or risks. Integrating an acquired technology, asset or business into our operations can be challenging, complex and costly and we cannot assure you that we will be successful or that the anticipated benefits of the acquisitions that we complete will outweigh their costs. If our integration and development efforts are unsuccessful and the anticipated benefits of the acquisitions we complete are not achieved, our business, operating results, financial condition and prospects could be adversely affected.

In connection with these types of transactions, we may issue additional equity securities that would dilute our shareholders, use cash that we may need in the future to operate our business, incur debt on terms unfavorable to us or that we are unable to repay, incur large charges or substantial liabilities, encounter difficulties integrating diverse business cultures and values or become subject to adverse tax consequences, substantial depreciation, or deferred compensation charges. These challenges could adversely affect our business, operating results, financial condition and prospects.

56Table of ContentsWe are highly dependent on the services of our executive officers, including Patrick W. Smith, our Chief Executive Officer. Our failure to retain executive officers could adversely impact our business. Our future success depends upon our ability to retain executive officers, including Patrick W. Smith, and any failure to do so could adversely impact our business, prospects, new product development, financial condition and operating results.

Among other qualifications, Patrick W. Smith is the founder of Axon and brings extensive executive leadership experience in the technology industry, including the management of worldwide operations, sales, service and support as well as technology innovation as an inventor listed on over 50 U.S. patents. Mr. Smith has been instrumental in building the public safety operating system of the future by integrating a suite of hardware devices and cloud-based software solutions that lead to modern policing and help save lives. From the early days of founding the organization to today as a market leader, Mr. Smith's expertise has brought forth entirely new product categories, including the less-lethal TASER de-escalation platform, body-worn cameras and cloud software that modernize public safety. The loss of any of our senior management, including Patrick W. Smith, could interrupt our ability to execute our business plan, as such individuals may be difficult to replace.

Operational RisksUnavailability of materials or higher costs could adversely affect our financial results. We depend on certain domestic and international suppliers for the delivery of components used in the assembly of our products. Our reliance on third-party suppliers creates risks related to our potential inability to obtain an adequate supply of components or sub-assemblies and reduced control over pricing and timing of delivery of components and sub-assemblies, including single or sole-source components used in the manufacture of our products. Specifically, we depend on suppliers of sub-assemblies, machined parts, injection molded plastic parts, printed circuit boards, custom wire fabrications and other miscellaneous customer and off-the-shelf parts for our products. Although we have and are implementing additional long-term agreements with strategic suppliers to mitigate the risk of supply continuity, there remains risk across our supply chain while we extend our supplier contract program, and there is no guarantee that supply will not be interrupted. Additionally, if our suppliers do not accurately forecast and effectively allocate production, if they are not willing to allocate sufficient production to us or if they decommit to us previously agreed-to supply levels, it may reduce our access to components and require us to search for new suppliers. As the scale of our hardware production increases, we will also need to accurately forecast, purchase, warehouse and transport components at high volumes to our manufacturing facilities. If we are unable to accurately match the timing and quantities of component purchases to our actual needs, we may incur unexpected production disruption, storage, transportation and write-off costs, which may harm our business and financial results.

Due to the unique requirements of TASER 10 CEDs, including the regulation of certain TASER 10 CED components for import into the United States and export from foreign sources, we purchase our raw materials from a limited number of suppliers. Some of the raw materials that are used in TASER 10 CEDs may be subject to fluctuations in market price, which we may be unable to pass through to our customers to offset market fluctuations. Because of the unique requirements of TASER 10 CEDs, we cannot change suppliers easily. We may be slower to establish alternative sources of supply for TASER 10 CED components as we continue to refine the design of the product. Any delay or interruption in the supply of the raw materials that are used in TASER 10 CEDs could impair our ability to manufacture and deliver TASER 10 CEDs, harm our reputation or cause a reduction in revenues.

A significant number of our raw materials or components comprise petroleum-based products or incur some form of landed cost associated with transporting the raw materials or components to our facility. Our freight and import costs and the timely delivery of our products could be adversely impacted by the materialization or re-emergence of a number of factors that could reduce the profitability of our operations, including: higher fuel costs (including increased petroleum prices as a result of, among other things, climate change-related regulations); potential port closures or shipping disruptions; customs clearance issues; increased government regulation or regulatory changes for imports of foreign products into the United States and exports from foreign sources; delays created by terrorist attacks or threats, public health issues, national disasters or work stoppages; and other matters. We are also subject to supply chain disruption should we learn that any of our suppliers is in violation of legislation that bans the import of goods based on their method of production, such as using forced labor or otherwise. This may also result in negative publicity regarding our production methods, and alleged unethical or illegal practices of any of our suppliers could adversely affect our reputation. Any interruption of supply for any material components of our products could significantly delay the shipment of our products and have a material adverse effect on our revenues, profitability and financial condition. For example, there have been and may continue to be disruptions in the semi-conductor supply chain that could negatively impact our ability to make our products.

57Table of ContentsDomestic or international geopolitical or other events, including the imposition of new or increased tariffs and/or quotas by the U.S. Government on any of these raw materials or components and other government trade policies, could adversely impact the supply and cost of these raw materials or components and could adversely impact our revenues, profitability and financial condition. In particular, the implementation of tariffs and trade restrictions as well as changes in trade policies between the United States and China have in the past led to some increases in our supply costs and have made it more difficult to obtain suppliers and may in the future have an adverse effect on our supply chain from a cost and sourcing perspective. We source certain raw materials from China, as do some of our suppliers. We may be unable to transition away from China to other jurisdictions or obtain secondary sources for raw materials, which could result in a material adverse effect on component availability and could result in a material adverse effect on our revenues, profitability and financial condition.

Material adverse developments in domestic and global economic conditions, or the occurrence of other sufficiently disruptive world events, could materially adversely affect our revenue and results of operations. Various factors contribute to the uncertain economic environment, including the ongoing conflicts in Gaza and Ukraine, the increase in, and volatility of, interest rates, high inflation, an actual recession or fears of a recession, trade policies and tariffs and geopolitical tensions. Our inability to offset price inflation in our materials, components, shipping or labor through increased prices to customers with long-term fixed-price contracts and formula-based or long-term fixed-price contracts with suppliers could adversely affect our business, financial condition and results of operations. Global supply chain and labor market challenges could also negatively affect our performance and our supplier's performance. Interest rate increases have also created financial market volatility and could further negatively impact financial markets, lead to an economic downturn or recession or have an adverse effect on our financial results. Economic slowdowns can also negatively impact municipal and state tax collections and put pressure on law enforcement budgets, which may increase the risk that our customers will be unable to appropriate funds for existing or future contracts with us. In addition, geopolitical risks could affect our customers' budgets and policies. These and other factors may adversely affect customer demand and ability to pay, cause decrease in sales, and negatively impact the realizability of our accounts and notes receivable and contract assets.

To the extent demand for our products increases, our future success will be dependent upon our ability to manage our growth and to increase manufacturing production capacity. To the extent demand for our products increases significantly in future periods, one of our key challenges will be to increase our production capacity to meet sales demand while maintaining product quality. Our primary strategies to accomplish this include introducing additional shifts, increasing the physical size of our assembly facilities, the hiring of additional production staff and the implementation of additional customized manufacturing automation equipment. As we develop additional products, we may need to bring new equipment online, implement new systems, technology, methods and processes and hire personnel with different qualifications. The costs associated with implementing new manufacturing technologies, methods and processes, including the purchase of new equipment, and any resulting delays, inefficiencies and loss of sales, could harm our financial results. The investments we make in equipment, technologies or personnel may not yield the anticipated labor and material efficiencies, and we may experience difficulty in attracting, integrating and retaining qualified personnel. Our inability to meet any future increase in sales demand or effectively manage our expansion could have a material adverse effect on our revenues, operating results and financial condition.

Delays in product development schedules may adversely affect our revenues and cash flows. The development of CEDs, devices, sensors and software is a complex and time-consuming process. To achieve market acceptance for our products, we must effectively anticipate customer requirements, and we must offer products that meet changing customer demands in a timely and cost-effective manner. Customers may require product features and capabilities that our current products do not have. If we fail to develop products that satisfy customer requirements, our ability to create or increase demand for our products will be harmed. Without the timely and cost-effective introduction of new products, services and enhancements, our offerings will likely become less competitive over time, in which case our competitive position and operating results could suffer. New products and services, as well as enhancements to existing products and services, can require long development and testing periods and may require significant investment, including substantial R&D, development of different engineering and manufacturing workflows, and adjustments to our data and analytics infrastructure. Our focus on our SaaS platform also presents complex development issues. Significant delays in new product or service releases or significant problems in creating new products or services could adversely affect our business, growth prospects, operating results, cash flows and competitive position.

58Table of ContentsWe expend significant resources in anticipation of a sale due to our lengthy sales cycle and may receive no revenue in return. Generally, our end-user customers consider a wide range of issues before committing to purchase our products, including product benefits, training costs, the cost to use our products in addition to, or in place of, other products, budget constraints and product reliability, safety and efficacy. Because we sell to various types of government entities of multiple sizes, including national agencies, state agencies, county agencies and municipal agencies, which can require varying levels of approvals followed by appropriations, the length of our sales cycle may range from a few weeks to as long as several years. Adverse publicity surrounding our products or the safety of such products has in the past, and could in the future, lengthen our sales cycle with customers. We believe that in the past our sales were adversely impacted by negative coverage and publicity surrounding our products or the use of our products. We may incur substantial selling costs and expend significant effort in connection with the evaluation of our products by potential customers before they place an order. If these potential customers do not purchase our products, we will have expended significant resources and received no revenue in return.

Changes in civil forfeiture laws may affect our customers' ability to purchase our products. Some of our customers use funds seized through civil forfeiture proceedings to fund the purchase of our products. From time to time, civil forfeiture proceedings have in the past received and may in the future receive media scrutiny and public criticism. Legislative changes could impact our customers' ability to seize funds or use seized funds to fund purchases. Changes in civil forfeiture statutes or regulations could limit the amount of funds available to our customers, which could adversely affect the sale of our products.

If our security measures or those of our third-party providers, including cloud storage providers, are breached and unauthorized access is obtained to customers' data or our data, our network, data centers and service may be perceived as not being secure, customers may curtail or stop using our products and services, and we may incur significant legal and financial exposure and liabilities.

Security breaches of Axon body-worn cameras, docks, Axon Fleet vehicle cameras, Axon Signal devices and Axon Evidence and other cloud services or products could result in the unauthorized release, gathering, monitoring, misuse, loss or destruction of our customers' data. Additionally, breaches of our network or data security measures or those of our third-party providers, including cloud storage providers, could disrupt the security of our internal systems and business applications, impair our ability to provide products and services to our customers and protect the privacy of their data, result in product development delays, result in theft or misuse of our intellectual property or other assets, require us to allocate more resources to improve technologies, or otherwise adversely affect our business. Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, grow more complex over time, and generally are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Moreover, our security measures and those of our third-party service providers or customers have not in the past and may not in the future immediately detect such security breaches if they occur. Although we have developed systems and processes that are designed to protect our data and user data, to prevent data loss, and to prevent or detect security breaches, we have been in the past and expect to continue to be a frequent target of third-party cybersecurity intrusion attempts and we cannot assure that such measures will provide absolute security. We may incur significant costs in protecting against or remediating cyber-attacks. We devote significant resources to engineer secure products and ensure security vulnerabilities are mitigated, and we require our third-party service providers to do so as well; however, security breaches that have not had a material effect on our business or our third-party service providers have occurred and will continue to occur, including as a result of third-party action, employee error, malfeasance or otherwise. Remote-work arrangements may also make our systems and employees more susceptible to attack. Breaches could occur during transfer of data to data centers or at any time, and result in unauthorized physical or electronic access to our data or our customers' data. Third parties may attempt to fraudulently induce employees or customers into disclosing sensitive information such as usernames, passwords or other information in order to gain access to our data or our customers' data. Additionally, hackers may develop and deploy viruses, worms and other malicious software programs that attack or gain access to our networks and data centers. Recent developments in the threat landscape include use of AI and machine learning, as well as an increased number of cyber extortion and ransomware attacks, with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques and methodology. Increasing socioeconomic and political instability in some countries has heightened these risks. In addition, retaliatory acts by foreign governments in response to Western sanctions could include cyber-attacks that could directly or indirectly impact our operations.

59Table of ContentsA security breach could expose us to a risk of loss or inappropriate use of

proprietary and sensitive data, or the denial of access to this data. A real or perceived security breach could also result in a loss of confidence in the security of our products and services, damage our reputation, disrupt our business, subject us to third-party lawsuits, regulatory fines or investigations or otherwise subject us to legal liability, negatively impact our future sales and significantly harm our growth prospects, operating results and financial condition. Even the perception of inadequate security may damage our reputation and negatively affect our ability to win new customers or retain existing customers. Catastrophic events could materially adversely affect our business, results of operations and/or financial condition. A disruption or failure of our systems or operations in the event of a major earthquake, weather event (including those caused or exacerbated by the effects of climate change), fire, explosion, failure to contain hazardous materials, industrial accident, utility failure, cyber-attack, terrorist attack, public health crisis, pandemic, or other catastrophic event could cause delays in completing sales, providing products and services, or performing other mission-critical functions. A catastrophic event that results in the destruction or disruption of any of our critical operations, or of the capacity, reliability or security of our information technology systems, could harm our ability to conduct normal business activities and our operating results, as well as expose us to claims, litigation and governmental investigations and fines. In addition, catastrophes may put pressure on federal, state and municipal government budgets, which may increase the risk that our customers will be unable to appropriate funds for existing or future contracts with us. These and other factors may adversely affect customer demand and ability to pay, cause decrease in sales, and negatively impact the realizability of our accounts receivable and contract assets. Public health emergencies have adversely affected workforces, economies and financial markets globally, and led to an economic downturn in the past and may do so again in the future. As an essential provider of products and services for law enforcement and other first responders, we remain focused on protecting the health and well-being of our employees while assuring the continuity of our business operations. If our backup and mitigation plans are not sufficient to minimize business disruption, our financial results could be adversely affected. We are continuously monitoring our operations and intend to take appropriate actions to mitigate the risks arising from catastrophic events, but there can be no assurances that we will be successful in doing so. Uncertainty in the development, deployment and use of AI in our products and services, as well as our business more broadly, could adversely affect our business and reputation. We are building and using systems and tools that incorporate AI-based technologies, including generative AI, for customers and our workforce. For example, Axon makes available a software product, Draft One, which leverages generative AI to draft police report narratives based on auto-transcribed body-worn camera audio. Additionally, beginning in the fourth quarter of 2024, we plan to introduce the Axon AI Era Plan, which will enable customers to subscribe to an expanding set of AI capabilities and features that further harness the power of our connected ecosystem as quickly as we can develop them. We also leverage and expect to continue to leverage AI-based technologies for internal use to drive efficiency in our business operations. As with many new and emerging technologies, AI presents numerous risks and challenges that could adversely affect our business. The development, adoption, integration and use of generative AI technology remains in early stages, and ineffective or inadequate AI or generative AI governance, development, use or deployment practices by us or third parties could result in unintended consequences. For example, AI algorithms that we use may be flawed or may be (or may be perceived to be) based on datasets that are biased or insufficient. In addition, any latency, disruption or failure in our AI systems or infrastructure could result in delays or errors in our offerings. Inadequate governance, testing or quality assurance processes could result in flawed deployments, producing erroneous or harmful outputs, which could damage our reputation and lead to legal liabilities. Thoroughly testing generative AI models is challenging due to their complexity and the unpredictability of their outputs. Developing, testing and deploying resource-intensive AI systems may require additional investment and increase our costs. There also may be real or perceived social harm, unfairness or other outcomes that undermine public confidence in the deployment and use of AI. Furthermore, third parties may deploy AI technologies in a manner that reduces customer demand for our products and services. Any of the foregoing may result in decreased demand for our products and services or harm to our business, financial results or reputation. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in relation to the areas of intellectual property, cybersecurity and privacy and data protection. For example, there is uncertainty around the validity and enforceability of intellectual property rights related to our development, deployment and use of AI. Additionally, third parties that license AI technologies to us may impose unfavorable licensing terms or terminate the licenses altogether which would require us to seek licenses from alternative sources to avoid disruptions in feature delivery. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant operational costs and may limit our ability to develop, deploy or use AI technologies. In part due to our global scope and law enforcement customer base, we may 60Table of Contentsface heightened scrutiny and regulatory requirements, which could further increase compliance costs and limit our ability to develop, deploy or use our AI solutions or other AI technologies. For example, President Biden’s recent Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence has potentially broad implications for the development and use of AI across agencies within the United States, the AI Act in the European Union imposes compliance requirements on a variety of AI uses by law enforcement, as well as on the companies that develop those products, including us. Other such laws are expected to be adopted in other jurisdictions in the coming months and years. Failure to appropriately respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm. Defects or disruptions in our services could impact demand for our services and subject us to substantial liability. We currently serve our Axon Evidence customers from third-party cloud storage providers based in the United States and other countries. The use of these cloud storage providers gives us greater flexibility in efficiently delivering a more tailored, scalable customer experience, but also exposes us to additional risks and vulnerabilities. Lack of availability of this infrastructure could be due to a number of potential causes, including technical failures, natural disasters, fraud or security attacks that we cannot predict or prevent. Interruptions in our service, or loss or corruption of digital evidence, may reduce our revenue, cause us to issue credits or pay penalties, cause customers to file litigation against us, cause customers to terminate their subscriptions and adversely affect our renewal rates and our ability to attract new customers. Our business will also be harmed if our customers and potential customers believe our service is unreliable. Since our customers use our services for important aspects of their operations, any errors, defects, disruptions in service or other performance problems could hurt our reputation and may damage our customers’ operations. As a result, customers could elect not to renew our services or to delay or withhold payment to us. We could also lose future sales or customers may make warranty or other claims against us, which could result in an increase in our warranty expense, an increase in collection cycles for and decline in the collectability of accounts receivable or in the convertibility of contract assets to cash, and an increase in the expense and risk of litigation. Defects in our products could reduce demand for our products or result in product recalls and result in a loss of sales, delay in market acceptance and damage to our reputation. Complex components and assemblies used in our products may contain undetected defects that could be subsequently discovered at any point in the life of the product. Errors or defects in our products may only be discovered after they have been tested, commercialized and deployed. If that is the case, we may incur significant additional development costs and product recall, repair or replacement costs, or liability for personal injury or property damage caused by such errors or defects. Our reputation or brand may be damaged as a result of these problems and may result in difficulty retaining current customers and securing new contracts. Defects in our products could result in a loss of sales, delay in market acceptance, damage to our reputation and increased warranty costs, which could adversely affect our business, financial results and competitive position. Additionally, we are subject to the U.S. Consumer Products Safety Act of 1972, as amended by the Consumer Product Safety Improvement Act of 2008, which empowers the Consumer Products Safety Commission to exclude from the market products that are found to be unsafe or hazardous, and similar laws under foreign jurisdictions. Under certain circumstances, the Consumer Products Safety Commission or comparable foreign agency could require us to repurchase or recall one or more of our products. If we were required to remove, or we voluntarily remove, our products from the market, our reputation could be tarnished, and we might have large quantities of finished products that we could not sell. Our international operations expose us to additional risks that could harm our business, operating results and financial condition. Our international operations are significant, and we plan to continue growing internationally by acquiring existing entities and/or setting up new legal entities in new markets. In certain international markets, we have limited operating experience and may not benefit from first-to-market advantages or otherwise succeed. Our international operations expose us to other risks, including: restrictions on foreign ownership and investments and stringent foreign exchange controls that might prevent us from repatriating cash earned in countries outside the United States; import and export requirements, tariffs, trade disputes and barriers, product certification requirements, sanctions and customs classifications that may prevent us from offering products or providing services in a particular country or obtaining necessary parts and components to manufacture products; longer payment cycles in some countries, increased credit risk and higher levels of payment fraud; 61Table of Contentsuncertainty regarding liability for our products and services, including uncertainty resulting from local laws and lack of legal precedent; and different labor laws and customs, existence of workers’ councils and labor unions, and other challenges caused by distance, language and cultural differences. In addition, our suite of CEDs is regulated by the U.S. Bureau of Industry and Security and require licenses for export abroad. Changes in U.S. foreign policy, foreign governmental status and evolving international human rights policy objectives may impact Axon’s ability to obtain licenses. Changes to foreign political, economic, regulatory, tax, social and labor conditions may adversely harm our business. Compliance with complex foreign and U.S. laws and regulations makes it harder to do business in certain jurisdictions, potentially decreases sales, and increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, environmental regulations, climate- and sustainability-related regulations, tax and statutory financial regulations, export and import controls, customs and duties regulations, internal control and disclosure rules, privacy and data protection requirements, anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act, and other local laws prohibiting corrupt payments to governmental officials, and competition regulations, among others. Violations of these laws and regulations could result in fines and penalties, criminal sanctions against us, our directors, officers or employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially adversely affect our brand, international growth efforts, ability to attract and retain employees, business and operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our directors, officers, employees, contractors or agents will not violate our policies. We depend on our ability to attract and retain our key management, sales and technical personnel. Our success depends upon the continued service of our key management personnel. Our success also depends on our ability to continue to attract, retain and motivate qualified technical employees. Our ability to compete effectively and our future success depends on our continuing to identify, hire, develop, motivate and retain highly skilled personnel. In addition, our compensation arrangements, such as our equity incentives, may not always be successful in attracting new employees and retaining and motivating our existing employees. Restrictive immigration policy and regulatory changes may also affect our ability to hire, mobilize or retain some of our global talent. Although we have employment agreements with our officers and other members of our executive management team, the employment of such persons is at-will and either we or the employee can terminate the employment relationship at any time, subject to the applicable terms of the employment agreements. In particular, we expect to continue to face significant challenges in hiring personnel, particularly for executive-level engineering talent, whether as a result of competition with other companies or other factors. We have had and expect to continue to have unique equity incentives designed to attract and retain long-term employees. We utilize these plans to align pay and performance and drive shareholder returns while reducing near-term cash expenditures. Our equity incentives and ongoing stock and option grants are subject to having sufficient shares under our stock plan and any new plans or increases in the number of shares available for grant under existing plans must be approved by our shareholders. If we are unable to obtain shareholder approval, we may be unable to attract and retain top talent, including senior executives. Our ability to attract, retain and motivate employees may also be adversely affected by common stock price volatility. The loss of the service of one or more of our key personnel could adversely impact our business, prospects, financial condition and operating results. If we fail to comply with federal, state or local regulations applicable to our firearm product, TASER 10 CED, we may be subject to governmental actions or litigation that could materially harm our business, operating results and financial condition. The TASER 10 CED is primarily regulated by the Bureau of Alcohol, Tobacco, Firearms and Explosives (the “ATF”), which licenses the manufacture, sale and import of firearms in the United States. The primary federal laws are the National Firearms Act of 1934, the Gun Control Act of 1968 (the “GCA”) and the Firearm Owners’ Protection Act of 1986, which have been amended from time to time. The ATF conducts periodic audits of our Arizona facilities that hold federal firearms licenses. If we fail to comply with ATF rules and regulations, the ATF may limit our activities or growth related to the TASER 10 CED, fine us, or, ultimately, suspend our ability to produce and sell the TASER 10 CED product line. There are also various state and local laws, regulations and ordinances relating to firearm characteristics, features and sales. Axon and local distributors must comply with 62Table of Contentsstate and local laws, regulations and ordinances pertaining to firearm and magazine sales in the jurisdictions where the TASER 10 CED is sold. Additionally, certain TASER 10 CED components are regulated for import into the United States by the ATF and are subject to ATF import permits that limit Axon’s ability to source from some suppliers leading to a potential decrease in supply chain agility. Supply chain constraints or an inability to source TASER 10 CED components could have a material adverse effect on our business, prospects, financial condition and operating results. 63Federal and state legislatures frequently consider legislation relating to the regulation of firearms, including the amendment or repeal of existing legislation. Existing laws may also be affected by future judicial rulings and interpretations. These possible changes to existing legislation or the enactment of new legislation may seek to restrict the makeup of a firearm, mandate the use of certain technologies in a firearm, remove existing legal defenses in lawsuits, set minimum age limits to purchase certain firearms, or ban the sale and, in some cases, the ownership of various types of firearms and accessories. Such restrictions or bans could have a material adverse effect on our business, prospects, financial condition and operating results. Failure to maintain effective internal control over financial reporting, material weaknesses, or significant deficiencies in our internal control over financial reporting may adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner, which may cause investor confidence in our company to diminish and the value of our common stock to decline. Preparing our consolidated financial statements involves a number of complex manual and automated processes, which are dependent upon individual data input or review and require significant management judgment. One or more of these processes may result in errors that may not be, and in the past have not been, immediately detected and could result in a material misstatement or other errors in our consolidated financial statements. Such errors may be more likely to occur when implementing new systems and processes, particularly when implementing evolving and complex accounting rules. The Sarbanes-Oxley Act of 2002 requires, among other things, that as a publicly traded company we disclose whether our internal control over financial reporting and disclosure controls and procedures are effective. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. While we continually undertake steps to improve our internal control over financial reporting as our business changes, we may not be successful in making the improvements and changes necessary to be able to identify and remediate control deficiencies or material weaknesses on a timely basis. For example, we have from time to time identified significant deficiencies in our internal controls and we identified a material weakness in our internal controls over revenue recognition and the reporting of deferred revenue for the year ended December 31, 2022 that has been remediated as further discussed in Item 9A. Controls and Procedures in our Annual Report on Form 10-K for the year ended December 31, 2023. If we are unable to successfully remediate control deficiencies, including any future material weaknesses in our internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected; our liquidity, access to capital markets and perceptions of our creditworthiness may be adversely affected; we may be unable to maintain compliance with securities laws, stock exchange listing requirements and debt instruments’ covenants regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; we may suffer defaults under our debt instruments; and our common stock price may decline. We are revising certain previously issued consolidated financial statements, which may adversely affect investor confidence and could result in stockholder litigation and regulatory actions. The revision of certain of our previously issued financial statements to correct errors related to our historical conclusions of principal vs. agent accounting under ASC 606 may have the effect of eroding investor confidence in the Company and our financial reporting and accounting practices and processes and may raise reputational issues for our business. Such revision may also result in stockholder litigation against us, or adverse regulatory consequences. Any such regulatory consequences, litigation, claim or dispute, whether successful or not, could subject us to additional costs, divert the attention of our management, or impair our reputation. Each of these consequences could have a material adverse effect on our business, results of operations and financial condition. Financial Risks An increasing percentage of our revenue is derived from subscription billing arrangements that may result in delayed cash collections and may increase customer credit risk on receivables and contract assets. Our strategy includes continuing to shift an increasing amount of our business to a subscription model, to better match the municipal budgeting process of our customers as well as to allow for multiple product offerings to be bundled into existing 63Table of Contentssubscriptions. This is in contrast to a traditional

CED sale in which the entire amount being charged for the hardware is invoiced upon shipment. This impacts liquidity in a commensurate fashion, with the cash for the subscription or installment purchase received in multiple installments rather than up front. While we record an estimate of expected credit losses and perform ongoing reviews of trade accounts receivables, if we become aware of information related to the creditworthiness of a major customer, or if future actual default rates on receivables in general differ from those currently anticipated, we may have to adjust our expected credit loss reserve, which could adversely affect our business, financial condition or operating results. Our gross margin is dependent on a number of factors, including our product mix, cost structure and acquisitions we may make, any of which could cause our gross margin to decline. Our gross margin could decline in future periods due to adverse impacts from various factors, including: changes in product mix; changes in shipment volume; increased warranty costs; sales discounts; entry into new markets or growth in lower margin markets, including markets with different pricing and cost structures, through acquisitions or internal development; our ability to reduce production costs; increases in material, labor or other manufacturing-related costs or higher supply chain logistics costs; excess inventory and obsolescence charges; increased amortization of purchased intangible assets, especially from acquisitions; and how well we execute on our strategy and operating plans. Any one of these factors or the cumulative effects of certain of these factors may result in significant fluctuations in our gross margin. This variability and unpredictability could result in our failure to meet internal expectations or those of securities analysts or investors for a particular period. Failure to meet or exceed such expectations for these or any other reasons may adversely affect the market price of our stock. Revenue for our SaaS products is recognized over the terms of the contracts, which may be several years, and, as such, trends in new business may not be immediately reflected in our operating results. Our SaaS revenue is generally recognized ratably over the terms of the contracts, which generally range from one to ten years. As a result, most of the SaaS revenue we report each quarter is the result of agreements entered into during previous quarters. Consequently, current trends, whether positive or negative, in this portion of our business may not be fully reflected in our revenue results for several periods, and a decline in new or renewed SaaS contracts in any period may not be immediately reflected in our reported financial results for that period, but may result in a decline in our revenue in future reporting periods. If any of our assumptions about revenue from our SaaS delivery model prove incorrect, our actual results may vary materially from those anticipated, estimated or projected. Most of our end-user customers are subject to budgetary and political constraints that may delay or prevent sales or result in cancellations or non-renewals of contracts. Most of our end-user customers are government agencies. These agencies often do not set their own budgets and therefore, have limited control over the amount of money they can spend. In addition, these agencies experience political pressure that may dictate the manner in which they spend money. As a result, even if an agency wants to acquire our products, it may be unable to purchase them due to budgetary or political constraints, particularly in challenging economic environments. There can be no assurance that the economic, budgeting or political issues will not worsen and adversely impact sales of our products. Some government agency orders may also be canceled or substantially delayed due to budgetary, political or other scheduling delays, which frequently occur in connection with the acquisition of products by such agencies, and such cancellations may accelerate or be more severe than we have experienced historically. Federal agencies may be particularly impacted by governmental impasse regarding continued government funding and debt limit constraints, which has previously resulted in shutdowns of the federal government in 2018 and 2019. Although we have entered into contracts for the delivery of products and services in the future and anticipate the contracts will be completed, if agencies fail to appropriate money in future year budgets, terminate contracts for convenience or if other cancellation clauses are invoked, revenue and cash associated with these bookings will not ultimately be recognized, and could result in a reduction to bookings and revenue. Termination without cause provisions generally allow agencies to terminate a contract at any time and enable us to recover only our costs incurred or committed and settlement expenses and 64Table of Contentsprofit, if any, on the work completed prior to termination. We may or may not be able to recover all the costs incurred during the start-up phase of a terminated contract. The unexpected termination of significant contracts could result in significant revenue shortfalls. If revenue shortfalls occur and are not offset by corresponding reductions in expenses, our business could be adversely affected. We cannot anticipate if, when, or to what extent our customers might terminate their contracts with us. The open bidding process creates uncertainty in predicting future contract awards. Many governmental agencies purchase products and services through an open bidding process. Generally, a governmental entity will publish an established list of requirements requesting potential vendors to propose solutions for the established requirements. To respond successfully to these requests for proposals, we must accurately estimate our cost structure for servicing a proposed contract, the time required to establish operations for the proposed customer, and the likely terms of any other third-party proposals submitted. We cannot guarantee that we will win any bids in the future through the request for proposal process, or that any winning bids will ultimately result in contracts on favorable terms. Our contracts typically run for a fixed number of years and may be extended for an additional specified number of years if the contracting entity or its agent elects to do so. When these contracts expire, they may be opened for bidding by competing bidders, and there is no guarantee that the contracts will be renewed or extended. Our customers may elect to open bidding processes up earlier than anticipated, resulting in increased competition prior to the anticipated end of contracts. Our failure to secure contracts through the open bidding process, or to secure such contracts on favorable terms, may adversely affect our revenues and gross margins. We maintain most of our cash balances, some of which are not insured, at two depository institutions. We maintain the majority of our cash and cash equivalents accounts at two depository institutions. As of September 30, 2024, the aggregate balances in such accounts at these two institutions were \$386.8 million. Our balances with these and other institutions regularly exceed Federal Deposit Insurance Corporation insured limits for domestic deposits and various foreign deposit insurance programs covering our deposits in Australia, Belgium, Canada, Finland, France, Germany, India, Italy, the Netherlands, Spain, the United Kingdom and Vietnam. We could suffer losses with respect to the uninsured balances if the depository institutions failed (such as the bank failures at several U.S. banks in spring 2023) and the institution's assets were insufficient to cover its deposits and/or the governments did not take actions to support deposits in excess of existing insurance limits. Any such losses or delays in access to funds as a result of such events could have a material adverse effect on our liquidity, financial condition and results of operations. Stock transactions may have a material, unpredictable impact on our results of operations and may result in dilution to existing shareholders. We have historically granted and expect to continue to grant stock-based compensation to employees and non-employee directors as a means of attracting and retaining highly qualified personnel. All stock-based awards are required to be recognized in our financial statements based on their grant date fair values. The amount recognized for stock compensation expense could vary depending on a number of assumptions or changes that may occur. Changes in the subjective and probability-based assumptions can materially affect the estimates of the fair value of the awards and timing of recognition of stock-based compensation expense and, consequently, the related amount recognized in our statements of operations and comprehensive income. As we continue to mature, the incentives to attract, retain and motivate employees provided by our equity awards or by future arrangements may not be as effective as in the past. We may also issue equity securities to pay for acquisitions and grant stock-based awards to retain the employees of acquired companies. If we issue significant equity to attract additional employees, to retain our existing employees or related to acquisitions, we could incur substantial additional stock-based compensation expense and the ownership of our existing shareholders would be further diluted, which could depress the market price of our stock. Our financial performance is subject to risks associated with changes in the value of the U.S. dollar versus local currencies. For current and potential international customers whose contracts are denominated in U.S. dollars, the relative change in local currency values creates relative fluctuations in our product pricing. These changes in international end-user costs may result in lost orders and reduce the competitiveness of our products in certain foreign markets. Additionally, intercompany sales 65Table of Contents to our non-U.S. dollar functional currency international subsidiaries are transacted in U.S. dollars, which could increase our foreign exchange rate risk caused by foreign currency transaction gains and losses. For non-U.S. dollar denominated sales, weakening of foreign currencies relative to the U.S. dollar generally leads us to raise international pricing, potentially reducing demand for our products. Should we decide not to raise local prices to fully offset the dollar's strengthening, the U.S. dollar value of our foreign currency denominated sales and earnings would be adversely affected. We do not currently engage in hedging activities related to fluctuations in foreign currency. Fluctuations in foreign currency could result in a change in the U.S. dollar value of our foreign denominated assets and liabilities, including accounts receivable. Therefore, the U.S. dollar equivalent collected on a given sale could be less than the amount invoiced causing the sale to be less profitable than contemplated. We also import selected components that are used in the manufacturing of some of our products. Although our purchase orders are generally in U.S. dollars, weakness in the U.S. dollar could lead to price increases for the components. Unanticipated changes in our effective tax rate and additional tax liabilities may impact our operating results and financial condition. We are subject to income taxes in the United States and various jurisdictions outside of the United States. Our effective tax rate could fluctuate due to changes in the mix of earnings and losses in countries with differing statutory tax rates. Our tax expense could also be impacted by changes in non-deductible expenses, changes in excess tax benefits related to exercises of stock options and vesting of RSUs, changes in the valuation of deferred tax assets and liabilities and our ability to utilize them, the applicability of withholding taxes, and changes in our liability for unrecognized tax benefits. We are subject to potential tax examinations in multiple jurisdictions. While we regularly evaluate new information that may change our judgment resulting in recognition, derecognition or change in measurement of a tax position taken, there can be no assurance that the final determination of any examinations will not have an adverse effect on our operating results and financial condition. Our tax provision could also be impacted by changes in U.S. federal, state and local or foreign tax laws, including fundamental tax law changes applicable to corporate multinationals, and proposals by the current U.S. President or Congress. Additionally, we may be subject to additional tax liabilities due to changes in non-income-based taxes resulting from changes in U.S. federal, state and local or foreign tax laws, changes in taxing jurisdictions' administrative interpretations, decisions, policies and positions, results of tax examinations, settlements or judicial decisions, changes in accounting principles, changes to our business operations, including acquisitions, as well as the evaluation of new information that results in a change to a tax position taken in a prior period. Further, recommendations from the OECD regarding a global minimum income tax and other changes are being considered and/or implemented in jurisdictions where we operate. We believe enactment of the recommended framework in jurisdictions where we operate will result in minimal impacts to our financial results in the near term. See Management's Discussion and Analysis of Financial Condition and Results of Operations' Provision for Income Taxes and in Part I, Item 2 of this Quarterly Report on Form 10-Q for additional information. The impact of any new tax legislation may differ materially from our estimates due to future regulatory guidance or changes in our interpretations or assumptions we have made. Our revenues and operating results may fluctuate unexpectedly from quarter-to-quarter, which may cause our common stock price to decline. Our revenues and operating results have varied significantly in the past and may vary significantly in the future due to various factors, including: budgetary cycles of municipal, state and federal law enforcement and corrections agencies; market acceptance of our products and services; the timing of large domestic and international orders; the outcome of any existing or future litigation; adverse publicity surrounding our products, the safety of our products, or the use of our products; changes in our sales mix; new product introduction costs; increased raw material expenses; changes in our operating expenses, including stock-based compensation expense; 66Table of Contents changes in foreign currency exchange rates, inflation and interest rates; inventory obsolescence; changes in warranty reserve; existing or future tariffs; and regulatory changes that may affect the marketability of our products and services. As a result of these and other factors, we believe that period-to-period comparisons of our operating results may not be meaningful in the short term, and our performance in a particular period may not be indicative of our performance in any future period. Fluctuations in our revenues and operating results may also cause our common stock price to decline. Our profitability could suffer from declines in fair value or impairment of our investments, including our strategic investments, and could fluctuate if the fair values of our investments increase. We invest a portion of available funds in a portfolio consisting of equity securities of various types. Our equity investments consist of investments in both marketable and non-marketable securities. Investments in marketable securities are measured at fair value on a recurring basis. We have elected to apply the measurement alternative for non-marketable securities. Under the alternative, we measure investments without readily determinable fair values at cost, less impairment, adjusted by observable price changes and we assess for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Our future investment income may fall short of expectations due to changes in interest rates, or due to certain inherent risks involved in investments in early-stage privately held companies. For example, we have recognized and may in the future recognize an unrealized loss on an investment if we determine that our carrying amount for an investment without a readily determinable fair value is not expected to be fully recovered, which would cause our earnings performance to suffer from such losses. By contrast, we have recorded and may in the future record an unrealized gain on an investment if we determine the fair value exceeds the carrying amount, which would benefit our earnings performance. Legal and Compliance Risks We may face personal injury, wrongful death, product liability and other liability claims that harm our reputation and adversely affect our sales and financial condition. Our CED products are often used in aggressive confrontations that may result in serious, permanent bodily injury or death to those involved. Our CED products may be associated with these injuries. A person, or the family members of a person, injured or killed in a confrontation or otherwise in connection with the use of our products, may bring legal action against us to recover damages on the basis of a number of theories, including wrongful death, personal injury, negligent design, defective product, product performance issues, or inadequate warnings or training. We are currently subject to a number of such lawsuits and have been and may be in the future subject to significant adverse judgments and settlements. We may also be subject to lawsuits involving allegations of criminal misuse of our products. We have no control over how our products are used by our customers or other end-users and cannot assure they are used consistent with our specifications, design and warnings. While our products are designed to be non-lethal, we cannot guarantee they will be used in a manner consistent with their intended use and any misuse exposes us to litigation, reputational harm and controversy. Although we maintain product liability insurance in amounts that we believe are reasonable, we may not be able to maintain such insurance on acceptable terms, if at all, and product liability claims could result in a potential award of monetary damages in excess of the amount of insurance coverage available to us. Because we manufacture and sell CEDs, insurance carriers may decide not to insure our products or our company in the future. Similar to product liability claims, we face exposure to class action lawsuits related to the design, performance, safety, pricing or advertising of our products. Such class action lawsuits could also result in substantial monetary judgments, defense costs, business distraction, reallocation of internal resources, injunctions related to the sale of products, and potentially harm our reputation. If successful, wrongful death, personal injury, misuse and other claims could result in adverse judgments or unfavorable settlements. We incur significant legal expenses in defending these cases, and significant litigation could result in a diversion of management's attention and resources and could also result in negative publicity about our products. The outcome of any litigation is inherently uncertain and there can be no assurance that our existing or any future litigation will not have a material adverse effect on our business, financial condition or operating results. 67Table of Contents Other litigation, government inquiries and regulatory actions may subject us to significant costs and judgments and divert management attention from our business. We have been and could in the future be involved in numerous other litigation, government inquiries and regulatory matters relating to our products, contracts, employees and business relationships, including litigation against persons or entities we believe have infringed on our intellectual property, infringement litigation filed against us, litigation against a competitor, antitrust litigation, and enforcement actions filed against us. See discussion of litigation in Note 13 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Such matters have resulted, and are expected to continue to result in, substantial costs to us, including in the form of attorneys' fees and costs, damages, fines or other penalties, whether pursuant to an adverse judgment or settlement, and diversion of our management's attention, which could adversely affect our business, financial condition or operating results. We have in the past and may in the future be subject to intellectual property infringement and other claims, which could incur substantial litigation costs, result in significant damages awards, inhibit our use of certain technologies, and divert management attention from our business. Many companies own intellectual property rights that are directly or indirectly related to public safety technologies. These companies periodically demand licensing agreements or engage in litigation based on allegations of infringement or other violations of their patents, trademarks, copyrights or trade secrets. These companies may also allege that their patents protect features essential to implementations of particular technical standards. Non-practicing entities also have patents they have been granted or otherwise acquired, including patents that are directly or indirectly related to public safety technologies. These entities may seek compensation for perceived infringement of their patents, including by filing claims against us, independent of the merit of any such claims. As we enter new markets, expand into new product categories, and otherwise offer new products, services and technologies, additional intellectual property claims may be filed against us by these companies, entities and other third parties. Additionally, our use of AI tools in our business may increase the likelihood that third parties will claim that we infringe their intellectual property rights. Intellectual property claims may also be filed against us as our current products, services and technologies gain additional market share. If our products, services or technologies were found to infringe a third-party's proprietary rights, we could be forced to discontinue use of the protected technology or enter

into costly royalty or licensing agreements in order to be able to sell our products, services or technologies. Such royalty and licensing agreements may not be available on terms acceptable to us or at all. We could also be required to pay substantial¹⁶ damages, fines or other penalties, indemnify customers or distributors, cease the manufacture, use or sale of infringing products or processes, make proprietary source code publicly available, and/or expend significant resources to develop or acquire non-infringing technologies. Our suppliers may not provide, or we may not be able to obtain, intellectual property indemnification sufficient to offset all damages, fines or other penalties resulting from any claims of intellectual property infringement brought against us or our customers. There is no guarantee that our use of conventional technology searching and brand clearance searching will identify all potential rights holders. Rights holders may demand payment for past infringements and/or force us to accept costly license terms or discontinue use of protected technology and/or works of authorship that may include, for example, photos, videos and software. Our development and sale of software-based products, including that which is related to AI or VR, increases this risk.If we are unable to protect our intellectual property, the value of our brands and products may decrease and we may lose our competitive market advantage.Our future success depends upon our proprietary technology. Our protective measures for this proprietary technology include patents, trademarks, copyrights and trade secret protection. However, these protective measures, as well as our efforts to pursue such protective measures, may prove inadequate. For example, the value of intellectual property protection in certain countries may not be apparent until after such protection can no longer be pursued. As such, our intellectual property protection may not extend to all countries in which our products are distributed or will be distributed in the future. Though we work to protect our innovations, we may not be able to obtain protection for certain innovations. For example, we may be unable to patent some software-based products. Furthermore, any use of AI tools to create content or code that may be incorporated into our products or services may also impact our ability to obtain or successfully defend certain intellectual property rights. The scope of any patent protection we have obtained, or may obtain, may not prevent others from developing and selling competing products. Despite our efforts, any intellectual property protection we obtain may be later determined to be insufficient or ineffective.Our protective measures may prove inadequate for reasons outside of our control. Varying intellectual property laws across countries may lead to differences in protection between such countries. In certain countries in which our products are 68Table of Contentsdistributed, the ability to effectively enforce intellectual property rights may not exist. Patent requirements differ by country and certain domestic or international laws may prohibit us from satisfying these requirements, creating a risk that some of our international patents may become unenforceable. Patents for older technologies, such as those first introduced in our TASER M26 CED and TASER X26 CED, have expired or will expire due to statutory limits on patent term. Despite policies and efforts to maintain secrecy of trade secrets and other confidential information, such information could be compromised by employees, partners or other third parties.Once established, there is no guarantee that our intellectual property rights will remain in force. Issued patents may be re-examined and subsequently ruled invalid or unenforceable. Our registered trademarks may also be diminished or lost. For example, there is a risk that our “TASER” trademark could become synonymous with the general product category of “conducted energy devices” resulting in claims of genericness that could interfere with our enforcement efforts and create customer confusion as to product source. The right to stop others from misusing our trademarks and service marks in commerce depends, to some extent, on our ability to show evidence of enforcement of our rights against such misuse in commerce. Our efforts to stop improper use, if ineffective, may lead to loss of trademark and service mark rights, brand loyalty and notoriety among our customers and prospective customers.Inability to protect our intellectual property could negatively impact our commercial efforts and competitive market advantage. Regardless of outcome, the prosecution of patent and other intellectual property claims is both costly and time-consuming. Unauthorized use of our proprietary technology could divert our management’s attention from our business and could result in a material adverse effect on our business, financial position and operating results.We may be unable to enforce patent rights internationally, which may limit our ability to prevent our product features from being used by competitors in some foreign jurisdictions.Our U.S. patents protect us from imported infringing products coming into the United States from abroad. We have filed applications for patents in foreign countries; however, these may be inadequate to protect markets for our products in these foreign countries. Each patent is examined and granted according to the law of the country where it was filed independent of whether a U.S. patent on similar technology was granted. Certain foreign countries have patent working requirements that require a patent owner to practice a patented invention within the respective country. A patent in a foreign country may be subject to cancellation, forfeiture, compulsory license or other penalty if the claimed invention has not been worked in that country. Meeting the requirements of working an invention differs by country and ranges from sales in the country to manufacturing in the country. U.S. export law, or the laws of some foreign countries, may prohibit us from satisfying the requirements for working the invention, creating a risk that some of our international patents may become unenforceable. In a country in which we do not have a patent or a country in which our patent in that country is unenforceable or unenforced, other companies and makers of similar products may be able to copy our products or features of our products without consequence, thus limiting our ability to capture market share or protect our technology, which could materially harm our growth prospects and operating results.The use of open source software in our products, services and technologies may expose us to additional risks and harm our intellectual property.Open source software is typically freely accessible, usable and modifiable. Certain open source software licenses require a user who intends to distribute the open source software as a component of the user’s software to disclose publicly part or all of the source code to the user’s software or require the user of such software to make any derivative works of the open source code available to others on potentially unfavorable terms or at no cost. The terms of many open source licenses have not been interpreted by courts, and there is a risk that those licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to commercialize our products, services and technologies. In that event, we could be required to seek licenses from third parties in order to continue offering our products, to re-develop our products, to discontinue sales of our products or to release our proprietary software code under the terms of an open source license, any of which could harm our business. Although we aim to avoid any use of open source software in our products, services and technologies, and otherwise only use open source software available under permissive open source licenses, it is possible that other manners of use, including those that a third party may allege to be in breach of a corresponding open source license, may have inadvertently occurred in deploying our products, services and technologies. If a third-party software provider has incorporated certain types of open source software into software we license from such third party for our products, services and technologies without our knowledge, we could be required to disclose the source code to our products, services and technologies. This could harm our intellectual property position as well as our business, financial condition, cash flows and results of operations. 69Table of ContentsA variety of new and existing laws and/or interpretations could materially and adversely affect our business.As detailed in “Item 1. Business” Government Regulation in our Annual Report on Form 10-K for the year ended December 31, 2023, we are subject to a variety of laws and regulations in the United States and abroad that involve matters central to our business, including laws and regulations related to: privacy, data protection, security, retention and deletion; rights of publicity; content; intellectual property; regulation of certain of our CEDs as firearms; advertising; marketing; distribution; electronic contracts and other communications; competition; consumer protection; telecommunications; product liability; taxation; labor and employment; sustainability; economic or other trade prohibitions or sanctions; securities; and online payment services. The introduction of new products and expansion of our activities in certain jurisdictions, including through acquisitions, or other actions that we may take may subject us to additional laws, regulations or other government scrutiny. There are a number of legislative proposals in the United States, at both the federal and state level, that could impose new obligations in areas affecting our business. In addition, foreign privacy, data protection, content, competition, sustainability and other laws and regulations can impose different obligations or be more restrictive than those in the United States.These U.S. federal and state and foreign laws and regulations, which in some cases can be enforced by private parties in addition to government entities, are constantly evolving and can be subject to significant change. As a result, the application, interpretation, and enforcement of these laws and regulations are often uncertain and may be interpreted and applied inconsistently from country to country and inconsistently with our current policies and practices. New laws and regulations (or new interpretations of existing laws and regulations) could materially and adversely affect our business.The cost of compliance with these laws and regulations is high and is likely to increase in the future. Additionally, these laws and regulations, or any associated inquiries or investigations or other government actions, have in the past and may in the future delay or impede the development of new products, result in negative publicity, cause customers to delay purchases, require significant management time and attention, cause us to change our business practices, and subject us to remedies that may harm our business, including civil or criminal liability, such as fines, demands or orders that we modify or cease existing business practices.Radio Spectrum and Unmanned Aerial and Ground-Based Robotic DevicesCertain of our products utilize radio spectrum to provide wireless voice, data and video communications services. The allocation of spectrum is regulated in the United States and other countries and limited spectrum space is allocated to wireless services and specifically to public safety users. We manufacture and market products in spectrum bands already made available by regulatory bodies. If current products do not comply with the regulations set forth by these regulatory bodies, we may be unable to sell our products or could incur penalties. Our results could be negatively affected by the rules and regulations adopted from time to time by the U.S. Federal Communications Commission (“FCC”), Innovation, Science and Economic Development Canada, the European Union Directorate-General for Environment or regulatory bodies in other countries. Regulatory changes in current spectrum bands may also require modifications to some of our products so they can continue to be manufactured and marketed.Axon body-worn cameras, docks, Axon Fleet vehicle cameras and Axon Signal devices are subject to the FCC’s rules and regulations in the United States, as well as rules and regulations as applicable outside of the United States. These regulations affect our CEDs with Axon Signal technology, including the TASER 7 CED, Signal Performance Power Magazine (“SPPM”), TASER 10 CED, and future CEDs implementing wireless technology. Compliance with government regulations could increase our operations and product costs and impact our future financial results.Additionally, some of our products depend on drones or other unmanned aerial and ground-based systems that operate on the radio spectrum. We have also recently completed the acquisition of the remaining outstanding stock of DEDrone, a market leader in airspace security combining hardware sensors with software to detect, identify, track and mitigate drones. The FCC, the Federal Aviation Administration and other agencies at the federal, state and local levels (as well as in foreign jurisdictions) are beginning to address some of the numerous certification, regulatory and legal challenges associated with drones, but a comprehensive set of standards and enforcement procedures has yet to be developed. Changes to the regulation of drones or other unmanned aerial systems may impact our future financial results.Axon and CEDsFor our CED products, we rely on the opinions of the ATF, including the determination that a device that does not expel projectiles by the action of an explosive is not classified as a firearm. Changes in laws, regulations and interpretations outside of our control may result in our products being classified or reclassified as firearms. If this were to occur, our private 70Table of Contentscitizen demand could be substantially reduced because consumers would be required to comply with federal, state or local firearm transfer requirements prior to purchasing our products.Federal regulation of sales in the United States: The majority of our currently offered CEDs are not classified as firearms regulated by the ATF. However, the ATF regulates the TASER 10 CED as a firearm under the GCA due to a technological advancement specific to the propulsion design of the propulsion design of TASER 10 CED cartridges. The implications of such classification on use-of-force standards and regulations could impact our ability to sell TASER 10 CEDs to law enforcement and government entities. Because Axon must maintain a federal firearms license to manufacture and sell TASER 10 CEDs, we are subject to periodic compliance inspections by the ATF. License violations discovered by the ATF can result in fines, penalties, warning letters or license revocation, leading to disruptions in operations. Further, we are required to administer, track and remit firearm excise taxes as applicable. Our CED products are also subject to testing, safety and other standards by organizations such as the American National Standards Institute, the International Electrotechnical Commission, the National Institute of Standards and Technology, and Underwriters Laboratories. These regulations also affect CEDs with Axon Signal technology, including SPPM technology, and TASER 7 CED and TASER 10 CED battery packs.Federal regulation of international sales: Our CEDs are considered a “crime control” product by the U.S. Department of Commerce (“DOC”) for export directly from the United States which requires us to obtain an export license from the DOC for the export of our CED devices from the United States to any country other than Canada. Future products and services may require classifications from the DOC before they may be shipped internationally. Our inability to obtain DOC export licenses or classifications on a timely basis for sales of our products and services to our international customers could significantly and adversely affect our international sales. Although the TASER 10 CED is regulated by the ATF for domestic sales, the DOC has ruled that the product’s unique propulsion design has no impact on its export classification and that the TASER 10 CED’s export classification remains consistent with all other Axon CED models.Federal regulation of foreign national employees: Our CED development and production is also considered controlled technology by the DOC and is categorized as a “deemed export” for any foreign national employees exposed to the technology within the United States. Consequently, we must obtain export licenses from the DOC for any deemed export within the United States made to a foreign national employee exposed to the controlled technology. Deemed export licenses are subject to DOC approvals and issued licenses require annual status reports for the stated employees. Inability to obtain proper licensing could curtail the Company’s ability to execute R&D and production related to CED technology.State and local regulation: Our CEDs are controlled, restricted or, less frequently, prohibited by some state and local governments. Other jurisdictions may ban or restrict the sale of our TASER-branded devices or restrict their use through changes to use-of-force laws or regulations, and our product sales may be significantly affected by additional state, county and city governmental regulation. The change in TASER 10 CED’s propulsion design may impact how TASER 10 CED is regulated at the state and/or local level depending on each state’s firearm laws.International regulation of foreign imports and sales: Certain jurisdictions prohibit, restrict, or require a permit for the importation, sale, possession or use of our CEDs (and other select Axon products), including in some countries by law enforcement agencies, impacting our international sales opportunities.U.S. and international regulation of component movements globally: We rely on a global supply chain of components across our product lines with most final assembly occurring in the United States. Export of these components is subject to a shifting regulatory landscape imposed by both foreign and U.S. authorities. Abrupt changes to these regulations can result in delays or interruptions to final product supplies. Additionally, ATF regulation of certain imports of TASER 10 CED components may impact Axon’s supply chain agility.International regulation of foreign-based operations: We maintain foreign operations in several countries globally for purposes of logistics, SG&A services and R&D support. Depending on these activities, applicable regulations may include business activity licensing and registration, import permits and recordkeeping, warehousing and storage security and permitting, and government reporting. Any failure to comply with these requirements could impact our ability to sell, support or develop our products and services both internationally and in the United States.Axon offers products and services that some jurisdictions determine to be “prohibited” or “controlled” weapons under applicable local arms brokering regulations. Consequently, jurisdictions with such regulations, particularly those that are signatories to the Arms Trade Treaty, can require certain covered groups and Axon employees to receive weapons brokering licenses. Brokering license issuance and approval is not always guaranteed and is subject to the applicable policy of the 71Table of Contentsapproving jurisdiction. Denial or limitations on brokering activity can impact the ability of individual employees to proceed with weapons brokering activity in certain instances.Federal Procurement RegulationsOur U.S. government business is subject to specific procurement regulations, such as the Federal Acquisition Regulation, and a variety of socioeconomic and other requirements imposed by executive order and statute. These requirements, although customary in U.S. government contracts, increase our performance and compliance costs. These costs might increase in the future, thereby reducing our margins, which could have an adverse effect on our business, financial condition, results of operations and cash flows. In addition, the U.S. government will likely continue to implement new requirements focused on initiatives to drive efficiencies, affordability and cost savings and other changes to its procurement practices to meet governmental interests. These initiatives and changes to procurement practices may change the way U.S. government contracts are solicited, negotiated and managed, which may affect whether and how we pursue opportunities to provide our products and services to the U.S. government, including the terms and conditions under which we do so, which may have an adverse impact on our business, financial condition, results of operations, and cash flows.Failure to comply with applicable regulations and requirements could lead to contractual, civil, criminal, and administrative remedies such as termination, fines, penalties, repayments or compensatory or treble damages, or suspension or debarment from U.S. government contracting or subcontracting for a period of time or indefinitely. Among the causes for suspension or debarment are violations of various laws and regulations, including those related to procurement integrity, export control, U.S. government security, employment practices, protection of the environment, accuracy of records, proper recording of costs and foreign corruption. The termination of a U.S. government contract or relationship as a result of any of these violations would have an adverse impact on our operations and could have an adverse effect on our standing and eligibility for future U.S. government contracts.Privacy RegulationsWe are subject to various U.S. and foreign laws and regulations associated with the collection, processing, storage and transmission of personally identifiable information and other sensitive and confidential information. This data is wide ranging and relates to our employees, customers and other third parties, including the subjects of law

enforcement. Our compliance obligations include those prescribed under laws and regulations that dictate whether, how and under what circumstances we can receive, control, process, hold and/or transfer certain data that is critical to our operations, including data shared between countries or regions in which we operate and data shared among our products and services. If one or more of the legal mechanisms for transferring data from other countries to the United States is invalidated, if we are unable to transfer data between and among countries and regions in which we operate, or if we are prohibited from sharing data among our products and services, it could affect the manner in which we provide our products and services or adversely affect our financial results. Countries may also pass legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our products and services and expose us to significant penalties for non-compliance. For example, the European Parliament adopted the General Data Protection Regulation, effective May 2018, that extended the scope of European privacy laws to any entity that controls or processes personal data of E.U. residents in connection with the offer of goods or services or the monitoring of behavior and imposes compliance obligations concerning the handling of personal data. Further, Vietnam’s Personal Data Protection Decree, which entered into force July 1, 2023, applies to organizations (wherever based) so long as they participate in personal data processing in Vietnam. We are also subject to U.S. laws and regulations, including the California Privacy Rights Act, which provides for enhanced consumer protections for California residents, a private right of action for data breaches and statutory i–nes and damages for data breaches or other California Consumer Privacy Act violations, as well as a requirement of reasonable cybersecurity, which could subject us to additional compliance costs as well as potential fines, individual claims, class actions and commercial liabilities. Any inability, or perceived inability, by us to adequately address privacy concerns, or comply with applicable laws, regulations, policies, industry standards and guidance, contractual obligations or other legal obligations, even if unfounded, could result in significant regulatory and third-party liability, increased costs, disruption of our business and operations, and a loss of confidence and other reputational damage. Furthermore, as new privacy laws and regulations are implemented, the time and resources needed for us to comply with such laws and regulations continues to increase and become a significant compliance workload.

Table of Contents

Environmental Regulations

We are subject to various U.S. federal, state, local and foreign laws and regulations governing the environment, including restricting the presence of certain substances in our products and making us financially responsible for the collection, treatment, recycling and disposal of such products. The European Union has published Directives on the restriction of certain hazardous substances in electronic and electrical equipment (the RoHS Directive) and on electronic and electrical waste management (the WEEE Directive). The RoHS Directive restricts the use of a number of substances, including lead. The WEEE Directive directs members of the European Union to enact laws, regulations and administrative provisions to ensure that producers of electric and electronic equipment are financially responsible for the collection, recycling, treatment and environmentally responsible disposal of certain products sold into the European Union. In addition, similar environmental legislation has been enacted in other jurisdictions, including the United States (under federal and state laws) and other countries. In addition, the European Union has defined a regulation for the registration, evaluation, authorization and restriction of chemicals that places responsibility on companies to manage the risks from chemicals contained in products and to provide safety information about such substances. Manufacturers and importers are required to gather information on the properties of the chemical substances in their products and provide for their safe handling. As of January 5, 2021, companies supplying products in the European Union containing substances of very high concern as identified by the European Union have to submit information on these products to the European Chemicals Agency. The information in their database is then made available to waste operators and consumers. Other countries have adopted chemical restrictions regulations, including the United States, Canada and Australia. For example, U.S. governmental authorities are increasingly focused on preventing environmental contamination from per- and polyfluoroalkyl substances (PFASs), which may be contained in certain Axon products. Federal and state governments and agencies are in various stages of considering and/or implementing laws and regulations requiring the reporting, restriction and/or phase-out of PFAS in products. In addition, further environmental or climate change disclosure legislation may be enacted in the jurisdictions in which we operate, including the United States (under federal and state laws) and other countries, the cumulative impact of which could be significant. For example, the European Union’s Corporate Sustainability Reporting Directive and the United Kingdom’s Streamlined Energy and Carbon Reporting will introduce additional due diligence and disclosure requirements addressing sustainability that will apply or we expect will apply, as applicable, to us in the coming years. Further, in September 2023, California passed the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act, requiring increased climate-related reporting. While currently stayed, the SEC’s recently adopted climate-related reporting requirements, to the extent they become effective, will also require extensive additional due diligence and disclosure regarding sustainability. These requirements will, and new, or changes in, environmental or climate change disclosure laws, regulations or rules could, lead to increased costs of compliance, including remediations of any discovered issues, and changes to our operations, including our manufacturing practices and/or product designs, which may be significant and could negatively impact our business, results of operations, financial condition and competitive position. Any failures to comply could result in governmental action, including the imposition of fines, or demands or orders that we modify or cease existing business practices, which could adversely affect our financial results. Our business is subject to evolving corporate governance and public disclosure regulations and expectations, including with respect to environmental, social and governance (ESG) matters, that could expose us to numerous risks. We are subject to changing rules and regulations promulgated by several governmental and self-regulatory organizations, including the SEC, the Nasdaq Stock Market and the FASB. These rules and regulations continue to evolve in scope and complexity and many new requirements have been created in response to laws enacted by Congress, making compliance more difficult and uncertain. In addition, increasingly regulators, customers, investors, employees and other stakeholders are focusing on ESG matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. For example, developing and acting on initiatives within the scope of ESG, and collecting, measuring and reporting ESG-related information and metrics can be costly, difficult and time-consuming and is subject to evolving reporting standards, including the SEC’s recently adopted and stayed climate-related reporting requirements, and similar proposals by other domestic or international regulatory bodies. Foreign governments have also enacted legislation to address ESG issues, such as the UK Modern Slavery Act. Table of Contents

Additionally, unfavorable perception regarding our social initiatives, governance practices, diversity initiatives, the perceived or actual impacts of our products and services, environmental policies or other growing concerns of our stakeholders, could adversely affect our reputation. Any negative effect on our reputation could have an adverse effect on the size of our customer base, which could adversely affect our business and financial results. We have been, and may be in the future, subject to informal private or public inquiries and formal proxy proposals by activists urging us to take certain corporate actions related to ESG matters, which may not be aligned with our best interests. These activities may adversely affect our business in a number of ways, since responding to inquiries or proposals can be costly, time-consuming, and disruptive to our operations and could meaningfully divert our resources, including the attention of our management team and our employees. We may also communicate certain initiatives and goals, regarding environmental matters, diversity, responsible sourcing and social investments and other ESG-related matters, in our SEC filings or in other public disclosures. These initiatives and goals within the scope of ESG could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Further, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals or for any revisions to these goals. Given the dynamic nature of ESG expectations, standards and regulations, which may change over time, we may from time to time need to update or otherwise revise our current practices, initiatives and goals, including in response to legislative or legal developments. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals within the scope of ESG on a timely basis, or at all, we may be exposed to potential liability or litigation, and our reputation, business, financial performance and growth could be adversely affected. Our amended and restated bylaws include exclusive forum provisions that could increase costs to bring a claim, discourage claims or limit the ability of our shareholders to bring a claim in a judicial forum viewed by shareholders as more favorable for disputes. Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Chancery Court of the State of Delaware will be, to the fullest extent permitted by law, the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or shareholders; (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or of our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv) any action asserting a claim against us or any of our directors or officers governed by the internal affairs doctrine. In addition, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any claim arising under the Securities Act. The exclusive forum provision in our amended and restated bylaws does not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. The choice of forum provision may increase costs to bring a claim, discourage claims or limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with Axon or Axon’s directors, officers or other employees, which may discourage such lawsuits against Axon or Axon’s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. Risks Related to our Convertible Notes

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow to pay our substantial debt. As of December 31, 2023, we had outstanding an aggregate principal amount of \$690.0 million of our 2027 Notes. Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Notes. Table of Contents

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results. In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert their Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, we would be required to settle any converted principal amount of such Notes through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current, rather than long-term, liability, which would result in a material reduction of our net working capital. Conversion of the Notes may dilute the ownership interest of our shareholders or may otherwise depress the price of our common stock. The conversion of some or all of the Notes may dilute the ownership interests of our shareholders. Upon conversion of the Notes, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock in respect of the remainder, if any, of our conversion obligation in excess of the aggregate principal amount of the Notes being converted. If we elect to settle the remainder, if any, of our conversion obligation in excess of the aggregate principal amount of the Notes being converted in shares of our common stock or a combination of cash and shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the market price of our common stock. Changes in the accounting treatment for the Notes could have a material effect on our reported financial results. We have adopted ASU 2020-06 as of January 1, 2022. Accordingly, we do not bifurcate the liability and equity components of the Notes on our balance sheet and we use the if-converted method of calculating diluted earnings per share. Under the if-converted method, diluted earnings per share will generally be calculated assuming that all the Notes were converted solely into shares of common stock at the beginning of the reporting period, unless the result would be anti-dilutive, which could adversely affect our diluted earnings per share. Because the principal amount of the Notes upon conversion is required to be paid in cash, and only the excess is permitted to be settled in shares, the application of the if-converted method will produce a similar result as the treasury stock method prior to the adoption of ASU 2020-06. The effect of the treasury stock method is that the shares issuable upon conversion of such Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of such Notes exceeds their principal amount. In accordance with ASU 2020-06, the Notes are reflected as a liability on our consolidated balance sheets, with the initial carrying amount equal to the principal amount of the Notes, net of issuance costs. The issuance costs have been treated as a debt discount for accounting purposes, which is and will be amortized into interest expense over the term of the Notes. As a result of this amortization, the interest expense that we recognize for the Notes for accounting purposes is greater than the cash interest payments payable on the Notes, resulting in lower reported income. We cannot be sure whether future changes made to the current accounting standards related to the Notes will not have a material effect on our reported financial results. The 2027 Note Hedge and Warrant transactions may affect the value of the Notes and our common stock. In connection with the pricing of the Notes, we have entered into 2027 Note Hedge transactions with the option counterparties. We have also entered into Warrant transactions with the option counterparties. The Note Hedge transactions are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be. However, the Warrant transactions could have a dilutive effect on our common stock to the extent that the market price per share of our common stock exceeds the strike price of the Warrants. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so in connection with any conversion of the Notes or redemption or repurchase of the Notes). This activity could cause or avert an increase or a decrease in the market price of our common stock. Table of Contents

In addition, if any of the Note Hedge and Warrant transactions fail to become effective, the option counterparties or their respective affiliates may unwind their hedge positions with respect to our common stock, which could adversely affect the value of our common stock. The potential effect, if any, of these transactions and activities on the market price of our common stock will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of our common stock. We are subject to counterparty risk with respect to the 2027 Note Hedge transactions. The option counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the 2027 Note Hedge transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral. If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the 2027 Note Hedge transactions with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the option counterparties. Item 2. A. A. Unregistered Sales of Equity Securities and Use of Proceeds

None. Item 3. A. A. Defaults Upon Senior Securities

None. Item 4. A. A. Mine Safety Disclosures

None. Item 5. A. A. Other Information

The table below describes the contracts, instructions or written plans for the purchase or sale of securities adopted by our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) during the three months ended September 30, 2024, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Name and Title Adoption Date Expiration Date Aggregate Number of Securities to be Sold

Brittany Bagley, Chief Operating Officer and Chief Financial Officer August 16, 2024 December 31, 2025 325 Caitlin Kalinowski, Director August 20, 2024 December 31, 2025 450

In addition, certain of our officers or directors have made, and may from time to time make, elections to have shares withheld or sold to cover withholding taxes or pay the exercise price of options, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K). No other Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (as defined by S-K Item 408(c)) were entered into, modified, or

terminated by our directors or officers during such period. 76Table of ContentsItem 6. Exhibits3.1Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q, filed August 9, 2022) 3.2Bylaws, as amended and restated (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed December 21, 2023)31.1*Principal Executive Officer Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a)31.2*Principal Financial Officer Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a)32**Principal Executive Officer and Principal Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema Document101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document104*The cover page from the Companyâs Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL

+Management contract or compensatory plan or arrangement*Filed herewith**Furnished herewith77Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.AXON ENTERPRISE, INC.Date:NovemberÂ 7, 2024By:/s/ PATRICK W. SMITHChief Executive Officer(Principal Executive Officer)Date:NovemberÂ 7, 2024By:/s/ BRITTANY BAGLEYChief Operating Officer and Chief Financial Officer(Principal Financial andAccounting Officer)78 EX-31.1 2 axon-20243009xexx311.htm EX-31.1 DocumentEXHIBIT 31.1CERTIFICATION PURSUANT TORULE 13a-14(a) or RULE 15d-14(a)SECURITIES EXCHANGE ACT OF 1934l, Patrick W. Smith, certify that:1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024 of Axon Enterprise, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâs other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâs disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâs internal control over financial reporting that occurred during the registrantâs most recent fiscal quarter (the registrantâs fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâs internal control over financial reporting; and5.The registrantâs other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâs auditors and the audit committee of the registrantâs board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâs ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâs internal control over financial reporting.Date:NovemberÂ 7, 2024By:/s/ Patrick W. SmithPatrick W. SmithChief Executive Officer EX-31.2 3 axon-20243009xexx312.htm EX-31.2 DocumentEXHIBIT 31.2CERTIFICATION PURSUANT TORULE 13a-14(a) or RULE 15d-14(a)SECURITIES EXCHANGE ACT OF 1934l, Brittany Bagley, certify that:1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024 of Axon Enterprise, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâs other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâs disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâs internal control over financial reporting that occurred during the registrantâs most recent fiscal quarter (the registrantâs fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâs internal control over financial reporting; and5.The registrantâs other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâs auditors and the audit committee of the registrantâs board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâs ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâs internal control over financial reporting.Date:NovemberÂ 7, 2024By:/s/ Brittany BagleyBrittany BagleyChief Operating Officer and Chief Financial Officer EX-32 4 axon-20243009xexx32.htm EX-32 DocumentEXHIBIT 32CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Axon Enterprise, Inc. (the âCompanyâ) for the quarterly period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the âReportâ), I, Patrick W. Smith, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Patrick W. SmithPatrick W. SmithChief Executive OfficerNovemberÂ 7, 2024In connection with the Quarterly Report on Form 10-Q of Axon Enterprise, Inc. (the âCompanyâ) for the quarterly period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the âReportâ), I, Brittany Bagley, Chief Operating Officer and Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Brittany BagleyBrittany BagleyChief Operating Officer and Chief Financial OfficerNovemberÂ 7, 2024 EX-101.SCH 5 axon-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Cash, Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Expected Credit Losses link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Strategic Investments link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Line of Credit link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Segment Data link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Revision of Prior Period Financial Statements link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Cash, Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Expected Credit Losses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Segment Data (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revision of Prior Period Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Warranty Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Revenues - Revenues by Products and Service Offerings (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Revenues - Revenues By Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Revenues - Contract Assets, Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Revenues - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Revenues - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Revenues - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Cash, Cash Equivalents and Investments - Schedule Of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Expected Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Expected Credit Losses - Type Of Customer Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Goodwill and Intangible Assets - Definite-Lived Intangible Assets Other than Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Strategic Investments - Schedule Of Roll-Forward Of Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Strategic Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Strategic Investments - Schedule Of Debt Security Strategic Investment (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Convertible Senior Notes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Convertible Senior Notes - Net carrying amount (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Convertible Senior Notes - Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Convertible Senior Notes - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Convertible Senior Notes - Hedge (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Convertible Senior Notes - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Stockholders' Equity - 2024 eXponential Stock Plan and 2024 CEO Performance Award (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Stockholders' Equity - Operational Goals (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Stockholders' Equity - Summary of RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Stockholders' Equity - RSU, PSU and Stock Option Activity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Stockholders' Equity - Reported Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Stockholders' Equity - At-the-Market equity offering - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Line of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Segment Data (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Subsequent

link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954531 - Disclosure - Revision of Prior Period Financial Statements - Statements of Operations and Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954532 - Disclosure - Revision of Prior Period Financial Statements - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954533 - Disclosure - Revision of Prior Period Financial Statements - Cash Flow Statement (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink EX-101.CAL 6 axon-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 axon-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 axon-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eXponential Stock Units eXponential Stock Units eXponential Stock Units [Member] Strategic investments and warrants Strategic Investments And Warrants Represents information pertaining to strategic investments and warrants. Reclassification [Line Items] Reclassification [Line Items] Proceeds Proceeds from Issuance of Warrants Performance Based Restricted Stock Unit Performance Based Restricted Stock Unit Performance based restricted stock unit. Goodwill acquired Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Expiring In Two Thousand Twenty Four Expiring In Two Thousand Twenty Four [Member] Expiring In Two Thousand Twenty Four Contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Current Summary of cash, cash equivalents, marketable securities, and available-for-sale investments Cash, Cash Equivalents and Investments [Table Text Block] Cover [Abstract] Cover [Abstract] Another Credit Facility Another Credit Facility [Member] Another Credit Facility Debt investments Debt Securities [Member] Convertible Notes Payable [Abstract] Convertible Notes Payable [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Intangible Asset, Indefinite-Lived [Table] Intangible Asset, Indefinite-Lived [Table] Other current liabilities Other Liabilities, Current Remaining interest acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of weighted average number of shares outstanding and earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accrued inventory in transit Accrued Inventory In Transit, Current Carrying value as of the balance sheet date of accrued inventory in transit. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cash paid for income taxes, net of refunds Income Taxes Paid, Net Sales Equity Securities Without Readily Determinable Fair Value Sales Amount of sales of equity securities without readily determinable fair value. Allowance on accounts receivable Accounts receivable and notes receivable, current Accounts Receivable, Allowance for Credit Loss, Current Purchase accounting adjustments Goodwill, Measurement Period Adjustment 2027 Note Hedge Convertible Note Hedge 2027 It represents the information pertaining to convertible note hedge transaction (the "Note Hedge" or "2027 Note Hedge") with certain investment banks, with respect to the Company's common stock concurrently with the issuance of the 2027 Notes. Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Strike Price (in dollars per share) Derivative, Price Risk Option Strike Price Short-Term Investments Short-Term Investments [Member] Restricted cash including prepaid expenses and current assets Restricted Cash Including Prepaid Expenses and Other Assets Amount of restricted cash included in prepaid expenses and other assets. Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Income per Common Share Earnings Per Share, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Proceeds from options exercised Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Performance Stock Units Performance Stock Units (PSUs) Share instrument which is convertible to stock or an equivalent amount of cash, after specified performance conditions are met. Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Proceeds from call, maturity, and sale of investments Proceeds from Sale and Maturity of Marketable Securities Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Long-term lease liabilities Operating Lease, Liability, Noncurrent Number of lawsuits against Company Loss Contingency, Pending Claims, Number Extended Warranty Warranty Warranty [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Current portion of deferred revenue Current Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] United States UNITED STATES Continuous unrealized loss position of available-for-sale investments, gross unrealized losses Available-for-Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Gross Unrealized Losses This item represents the continuous unrealized loss position of available-for-sale investments, gross unrealized losses. Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule Of Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Issuance of common stock under employee plans, net (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Corporate bonds Corporate Bond Securities [Member] Money market funds Money Market Funds [Member] Sales, general and administrative expenses Selling, General and Administrative Expenses [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Issued patents Patents [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] Consolidated adjusted gross margin Adjusted Gross Margins Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Accrued income and other taxes Taxes Payable, Current Summary of changes in accumulated other comprehensive income (loss), net of tax Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Plan Name [Axis] Plan Name [Axis] Cartridges Cartridges [Member] Equity Components [Axis] Equity Components [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Debt Securities, Available-for-Sale Trademarks Trade Names [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Revision Revision of Prior Period, Adjustment [Member] Issuance of common stock under employee plans, net APIC, Share-Based Payment Arrangement, Recognition and Exercise Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Services Services It pertains to Services department under product and service. Adjustment to Compensation, Amount Adjustment to Compensation Amount Options outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid-in capital Additional Paid in Capital, Common Stock Number of award tranches Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Tranches Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Tranches Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Receivables and contract assets Increase (Decrease) in Accounts and Notes Receivable Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Unrealized gain (loss) on available-for-sale investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Developed technology Developed Technology Rights [Member] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Credit Loss [Abstract] Credit Loss [Abstract] ATM Equity Offering ATM Equity Offering Represents about At Market Offering Member. Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Schedule of roll-forward of allowance for credit losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accrued liabilities Accrued liabilities Accrued Liabilities, Current Total potentially dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Tranche 1 Share-Based Payment Arrangement, Tranche One [Member] Equity Securities without Readily Determinable Fair Value [Line Items] Equity Securities without Readily Determinable Fair Value [Line Items] Tranche 5 Share-Based Payment Arrangement, Tranche Five [Member] Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Debt securities in continuous loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash shown in the statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Realized gains Equity Securities without Readily Determinable Fair Value, Gain On Sale Of Securities Amount of gain realized from sale of equity securities without readily determinable fair value. Strategic Investments Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill balance, beginning of period Balance, end of period Goodwill balance, beginning of period Balance, end of period Accounts Receivable, Allowance for Credit Loss Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Fair Value Measurements and Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Income and payroll tax payments for net-settled stock awards Payment, Tax Withholding, Share-Based Payment Arrangement Inventory Inventory Disclosure [Text Block] Utilization of reserve Standard and Extended Product Warranty Accrual, Decrease for Payments Amount self-insured for any product claim Product Claims Self Insurance Amount the entity is self-insured for any product claim. Treasury stock, shares (in shares) Treasury stock, shares, beginning balance (in shares) Treasury stock, shares, ending balance (in shares) Treasury Stock, Common, Shares Tranche 7 Share-Based Payment Arrangement, Tranche Seven [Member] Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 2024 XSUs eXponential Stock Units [Member] Represents the information pertaining to eXponential Stock Units which are performance-based restricted stock units. Changes in carrying amount of goodwill Goodwill [Roll Forward] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Debt instrument basis spread on variable rate (as a percentage) Debt Instrument, Basis Spread on Variable Rate Other net liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Excluding Deferred Tax liabilities Amount of liabilities excluding deferred taxes assumed at the acquisition date. Award Type [Axis] Award Type [Axis] Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Options exercisable, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Hardware Hardware Equipment [Member] Issuance of replacement awards in connection with acquisitions Adjustments to Additional Paid in Capital, Replacement Awards Issued in Connection with Acquisitions Amount of increase in additional paid in capital (APIC) resulting from the issuance of replacement awards in connection with acquisitions. Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] XSUs granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Amount Amount of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Research and development Research and Development Expense Intangible assets, weighted average useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Number of shares sold to cover expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number Of Shares Sold To Cover Exercise Price And Options Holder's Tax Obligation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number Of Shares Sold To Cover Exercise Price And Options Holder's Tax Obligation Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Axon Evidence and Cloud Services Axon Evidence and cloud services Axon Evidence [Member] Cash surrender value of corporate-owned life insurance policies Cash Surrender Value, Fair Value Disclosure Dedrone Holdings, Inc. Dedrone Holdings, Inc. [Member] Dedrone Holdings, Inc. Customer deposits Customer Deposit, Current The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings. Total Shareholder Return Amount Total Shareholder Return Amount Treasury inflation-protected securities Treasury inflation-protected securities Treasury Inflation Protected Securities [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total availability under line of credit agreement Line of Credit Facility, Maximum Borrowing Capacity Concentration risk (as a percentage) Concentration Risk, Percentage Number of shares remaining to be sold Number Of Shares Remaining To Be Sold Represents the number of shares that are remaining out of the maximum shares allowed to be sold. Error Correction [Table] Error Correction [Table] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subsequent Event [Line Items] Subsequent Event [Line Items] Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Stock options exercised (in shares) Stock options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Senior Convertible Notes Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development expenses Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Marketable securities Debt Securities, Marketable Securities [Member] Debt Securities, Marketable Securities Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Other, including foreign currency translation Allowance For Doubtful Accounts Receivable Other Amount of increase (decrease) in allowance for credit loss on accounts receivable, other, including dispositions and foreign currency translation. Diluted (in shares) Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Brittany Bagley [Member] Represents information pertaining to Brittany Bagley, Chief Operating Officer and Chief Financial Officer. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] 2024 remaining Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Accumulated other comprehensive income (loss): AOI Attributable to Parent, Net of Tax [Roll Forward] Long-Term Debt, Type [Axis

Amortization of acquired intangible assets
Amortization Of Acquired Technology
Intangible Assets
The aggregate expense charged against earnings to allocate the cost of acquired technology intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Deferred income taxes
Deferred Income Tax Expense (Benefit)
Schedule of goodwill
Schedule of Goodwill [Table Text Block]
Concentration Risk Type [Domain]
Concentration Risk Type [Domain]
Letters of credit outstanding
Amount Letters of Credit Outstanding, Amount Sales, general and administrative Sales, general and administrative Selling, General and Administrative Expense
Unrealized losses and impairments
Unrealized losses and impairments
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
Amounts written off charged against the allowance
Accounts Receivable, Allowance for Credit Loss, Writeoff
Debt security strategic investment, unrealized gain
Debt Securities, Trading, Unrealized Gain (Loss)
Accordion feature allowing for increase in borrowing capacity
Debt Instrument
Borrowing Capacity Increase
Accordion Feature
Debt instrument provision allowing for an increase in borrowing capacity. Cost of product sales and service sales
Cost of Sales [Member]
Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Products
Product [Member]
Securities in unrealized loss position for 12 months or longer
Debt Securities, Available-for-Sale, Continuous
Unrealized Loss Position, 12 Months or Longer
Sale of Stock [Domain]
Sale of Stock [Domain]
Share of Common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares
Authorized
Antidilutive securities excluded from computation of earnings per share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Pension Adjustments
Prior Service Cost
Pension Adjustments
Prior Service Cost [Member]
Document
Fiscal Period Focus Document
Fiscal Period Focus
Transaction costs
Business Combination, Acquisition
Related Costs
All Executive Categories
All Executive Categories [Member]
Dilutive effect of stock-based awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Statement of Financial Position Location, Balance [Domain]
Statement of Financial Position Location, Balance [Domain]
Unrealized Gains (Losses) on Available-for-Sale Investments
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two
Changed Peer Group, Footnote
Changed Peer Group, Footnote [Text Block]
Options outstanding, Weighted Average Remaining Contractual Life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
ASSETS Assets [Abstract]
Other comprehensive (loss) income, net
Other comprehensive (loss) income
Other Comprehensive Income (Loss), Net of Tax Document Type Document Type
Derivative Contract [Domain]
Derivative Contract [Domain]
Effective interest rate
Debt Instrument, Interest Rate, Effective Percentage
Commercial paper
Commercial Paper [Member]
Pension Benefits Adjustments, Footnote
Pension Benefits Adjustments, Footnote [Text Block]
Summary of operational information relative to the company's reportable segments
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Total Shareholder Return Vs Peer Group
Total Shareholder Return Vs Peer Group [Text Block]
Number of annual vesting installments
Share Based Compensation Arrangement by Share Based Payment Award
Number Of Annual Vesting Installments
The number of annual vesting installments. Contractual interest expense
Interest Expense, Debt, Excluding Amortization
Options exercisable, Weighted Average Remaining Contractual Life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Vested in Period
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Summary of contract with customer, assets and liabilities
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Schedule of estimated amortization expense of intangible assets
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Subsequent Event [Table]
Subsequent Event [Table]
Total non-amortizable intangible assets
Indefinite-Lived Intangible Assets (Excluding Goodwill)
Maximum
Maximum [Member]
Amortization expense of intangible assets
Amortization of Intangible Assets
Contract liabilities (deferred revenue)
Total Contract with Customer, Liability
Equity Valuation Assumption Difference, Footnote
Equity Valuation Assumption Difference, Footnote [Text Block]
Total Finite-Lived Intangible Assets, Net
Other countries
Non-US [Member]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Accounts payable
Accounts Payable, Current
Schedule of roll-forward of strategic investments
Equity Securities without Readily Determinable Fair Value [Table Text Block]
Warranty expense
Standard and Extended Product
Warranty Accrual, Increase (Decrease) for
Preexisting Warranties
Business Acquisitions
Business Combination Disclosure [Text Block]
Current Fiscal Year
End Date
Current Fiscal Year
End Date
Maximum number of common stock shares to be sold (in shares) Maximum Number of Shares Allowed To Be Sold
Represents the maximum number of shares that may be sold. Short-term investments
Short-Term Investments
Statistical Measurement [Axis]
Statistical Measurement [Axis]
PEO Name
PEO Name
Non-Rule 10b5-1 Arrangement
Terminated
Non-Rule 10b5-1 Arrangement
Terminated [Flag]
Income before provision for income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Number of shares granted to employees
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period
Non-PEO NEO
Average Total Compensation Amount
Non-PEO NEO
Average Total Compensation Amount
Vesting [Axis]
Vesting [Axis]
Award Type [Domain]
Award Type [Domain]
Fair value
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value
Name
Outstanding Recovery, Individual Name
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Schedule of potentially dilutive securities excluded in calculation of diluted net income per share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Revision of Prior Period [Axis]
Revision of Prior Period [Axis]
Deferred tax assets, net
Deferred Income Tax Assets, Net
Non-PEO NEO
Non-PEO NEO [Member]
Useful Life
Finite-Lived Intangible Asset, Useful Life
Additional principal amount purchase option
Line of Credit Facility, Accordion Feature, Increase
Limit
Amount of option to purchase additional principal amount of convertible senior notes. 2024 CEO Performance Award
CEO Performance Award 2024 [Member]
Represents the information pertaining to 2024 CEO performance award. Additional Paid-in Capital
Additional Paid-in Capital [Member]
Warranty period
Warranty Period After Purchase Of Product
Warranty period after purchase of product. Award Timing
Predetermined Award Timing
Predetermined [Flag]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Acquisition 1
Acquisition 1
Acquisition One [Member]
Deferred tax liability
Business Combination, Recognized
Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities
Repurchase price (as percentage)
Debt Instrument, Redemption Price, Percentage
Customer relationships
Customer Relationships [Member]
Fusus, LLC. Fusus Inc [Member]
Represents Fusus, LLC. Recently Issued Accounting Guidance and Disclosure Rules
New Accounting Pronouncements, Policy [Policy Text Block]
Catlin Kalinowski [Member]
Catlin Kalinowski
Warranty Reserves
Standard Product
Warranty, Policy [Policy Text Block]
Convertible Senior Notes
Long-Term Debt [Text Block]
Diluted (in dollars per share) Net income per common and common equivalent - Diluted (in dollars per share) Earnings Per Share, Diluted
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Name Measure
Name Entity
Interactive Data
Current Entity
Interactive Data
Current Business Acquisitions
Series of Individually Immaterial Business Acquisitions [Member]
Deferred revenue Increase (Decrease) in Contract with Customer, Liability
Other
Other
Other [Member]
Restatement does not require Recovery
Restatement Does Not Require Recovery [Text Block]
Schedule of warrants details of convertible senior notes
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Pending Litigation
Pending Litigation [Member]
Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Treasury bills
US Treasury Bill Securities [Member]
Stock-based compensation
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Research and development tax credit studies
Effective Income Tax Rate
Reconciliation, Tax Credit, Research, Amount
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance
Tranche 2
Share-Based Payment Arrangement, Tranche Two [Member]
Guarantor Obligations, Nature [Domain]
Guarantor Obligations, Nature [Domain]
Provision for (benefit from) income taxes
Income Tax Expense (Benefit)
Interest rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Supplemental disclosures: Supplemental Cash Flow Information [Abstract]
Summary Of Significant Accounting Policy [Table]
Summary Of Significant Accounting Policy [Table]
Summary of significant accounting policy. Weighted average period over which costs are recognized
Share-Based Payment Arrangement, Nonvested Award, Cost
Not yet Recognized, Period for Recognition
Net sales Revenue from contract with customers
Revenue from Contract with Customer, Excluding Assessed Tax
Axon Fleet Systems
Axon Fleet Systems
Axon Fleet Systems [Member]
Services Service [Member]
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark [Domain]
Effective tax rate (as a percentage)
Effective Income Tax Rate
Reconciliation, Percent
Net cash (used in) investing activities
Net Cash Provided by (Used in) Investing Activities
Income from operations
Operating Income (Loss)
Total interest expense
Interest Expense, Operating and Nonoperating
Restrictions on Cash and Cash Equivalents [Table]
Restrictions on Cash and Cash Equivalents [Table]
Business Acquisition
Business Acquisition [Line Items]
Number of reportable segments of company
Number of Reportable Segments
Total liabilities and stockholders' equity
Liabilities and Equity
Subsequent Events
Subsequent Events [Text Block]
Rule 10b5-1 Arrangement
Terminated
Rule 10b5-1 Arrangement
Terminated [Flag]
All Adjustments to Compensation
All Adjustments to Compensation [Member]
Accrued salaries, commissions, benefits and bonus
Employee-related Liabilities, Current
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
TASER
TASER
TASER segment. Accumulated
Other Comprehensive Income (Loss)
Accumulated
Other Comprehensive Income (Loss) [Line Items]
Commitments and Contingencies
Disclosure [Abstract]
Commitments and Contingencies
Disclosure [Abstract]
Interest income, net
Interest Income (Expense), Nonoperating
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Underlying Security Market Price Change
Underlying Security Market Price Change, Percent
Individual: Individual [Axis]
Accumulated
Other Comprehensive Loss
AOCI Attributable to Parent [Member]
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Restricted cash balance
Restricted Cash
Expected life of options
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Inventory Total inventory
Inventory, Net Agency bonds
US Government Agencies
Debt Securities [Member]
Long-Term Debt, Type [Domain]
Long-Term Debt, Type [Domain]
Product and Service [Axis]
Product and Service [Axis]
Entity Address, State or Province
Entity Address, State or Province
Statement [Line Items]
Statement [Line Items]
Erroneous Compensation Analysis
Erroneous Compensation Analysis [Text Block]
Operating expenses: Operating Expenses [Abstract]
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Financial Instruments [Domain]
Financial Instruments [Domain]
Consideration
Consideration Business Combination, Consideration
Transferred Vesting [Domain]
Vesting [Domain]
Units outstanding, beginning of year (in dollars per share) Units outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Nonvested, Weighted Average
Grant Date Fair Value
LIABILITIES AND STOCKHOLDERS' equity
EQUITY Liabilities and Equity [Abstract]
Schedule of Error Corrections and Prior Period Adjustments
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
Unamortized debt issuance costs
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Long-term contract assets, net
Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent
Long-term notes receivable, net
Accounts and Financing
Receivable, after Allowance for Credit Loss, Noncurrent
Minimum [Member]
Restatement
Determination Date
Restatement
Determination Date
Reclassification [Table]
Reclassification [Table]
Adoption Date
Trading Arrangement
Adoption Date Pay vs Performance Disclosure
Pay vs Performance Disclosure [Table]
Deferred revenue, net of current
portion
Long-Term Contract with Customer, Liability, Noncurrent
Options outstanding, beginning of year (in dollars per share) Options outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average
Exercise Price
Erroneously Awarded Compensation Recovery
Erroneously Awarded Compensation Recovery [Table]
Options outstanding, beginning of year (in shares) Options outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Variable Interest Entity [Line Items]
Variable Interest Entity [Line Items]
Provision for expected credit losses
Accounts Receivable, Credit Loss Expense (Reversal)
Segments [Axis]
Segments [Axis]
Change in Fair Value as of Vesting Date of Prior Year
Equity Awards Vested in Covered Year
Change in Fair Value as of Vesting Date of Prior Year
Equity Awards Vested in Covered Year [Member]
Derivative Instrument [Axis]
Derivative Instrument [Axis]
Exercise Price
Award Exercise Price
Revenue
Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Condition
Relating to Operational Goals, Revenue
Amount of revenue as a vesting condition to be fulfilled for vesting of award under share-based payment arrangement. Arrangement
Duration
Trading Arrangement Duration
Subsequent Event
Subsequent Event [Member]
Stock options exercised
Stock Issued During Period, Value, Stock Options
Exercised
Goodwill and Intangible Assets
Goodwill and Intangible Assets Disclosure [Text Block]
Variable Interest Entity [Table]
Variable Interest Entity [Table]
Schedule of net carrying amount of convertible senior notes
Convertible Debt [Table Text Block]
Stockholders' equity: Equity, Attributable to Parent [Abstract]
Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Grants in Period, Weighted Average
Grant Date Fair Value (Gain) loss on strategic investments and marketable securities, net
Gain (Loss) on Investments
Investments
Equity Securities Without Readily Determinable Fair Value
Purchases Amount of purchases of equity securities without readily determinable fair value. Peer Group Issuers, Footnote
Peer Group Issuers, Footnote [Text Block]
Segments [Domain]
Segments [Domain]
2027 Warrants
2027 Warrants
2027 Warrants [Member]
Material Terms of Trading Arrangement
Material Terms of Trading Arrangement [Text Block]
2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four
All Individuals
All Individuals [Member]
Provision for bad debts and inventory Provision for Loan, Lease, and Other Losses
Patents and trademarks pending
Trademarks and Trade Names [Member]
Maturity, prior to stated maturity of convertible senior notes
Debt Instrument, Maturity, Prior to Stated Maturity of Convertible Senior Notes
The maturity period of debt, prior to stated maturity of convertible senior notes
PEO PEO [Member]
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Name
Trading Arrangement, Individual Name
Other income (loss), net
Other Nonoperating Income (Expense)
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Intangible assets, net
Intangible assets, Net Carrying Amount
Intangible Assets, Net (Excluding Goodwill)
Gross
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated
Gross Unrealized Gain, before Tax
Geographic Information and Major Customers / Suppliers
Geographic Information and Major Customers [Policy Text Block]
Disclosure of accounting policy for Geographic Information and Major Customers. Call options
Call Option [Member]
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Total allowance for expected credit losses on customer receivables
Allowance For Expected Credit Losses On Customer Receivables
Amount of allowance for expected credit losses on customer receivables. Awards
Close in Time to MNPI Disclosures, Table Awards
Close in Time to MNPI Disclosures [Table Text Block]
Tranche 3
Share-Based Payment Arrangement, Tranche Three [Member]
Transaction costs
Business Acquisition, Transaction Costs
Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Prior Year
End Fair Value of Equity Awards
Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year
Prior Year
End Fair Value of Equity Awards
Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]
Realized losses
Realized losses
Equity Securities without Readily Determinable Fair Value, Loss On Sale Of Securities
Amount of loss from sale of investment in equity security without readily determinable fair value. Cash
Cash and Cash Equivalents, Fair Value
Disclosure 2027 Notes 2027 Notes 2027 Notes [Member]
Domain names
Internet Domain Names [Member]
Aggregate
Erroneous Compensation Amount
Aggregate
Erroneous Compensation Amount
Cash, Cash Equivalents and Investments
Cash, Cash Equivalents, and Marketable Securities [Text Block]
Software and Sensors
Software and Sensors
Software And Sensors Segment [Member]
Local Phone Number
Local Phone Number
Intangible assets, Gross Carrying Amount
Intangible Assets, Gross (Excluding Goodwill)
Aggregate
Erroneous Compensation Not Yet Determined
Aggregate
Erroneous Compensation Not Yet Determined [Text Block]
Outstanding amount
Guarantor Obligations, Current Carrying Value
Total operating expenses
Operating Expenses
Contract assets, net
Contract with Customer, Asset, Allowance for Credit Loss
Unrealized gain on investments
Unrealized Gain (Loss) on Investments
Expected volatility (as percentage)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility
Rate
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Summary of restricted stock unit activity
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Other, net
Increase (Decrease) in Other Operating Assets
Change in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract]
Expected Credit Losses
Credit Loss, Financial Instrument [Text Block]
PEO Total Compensation Amount
PEO Total Compensation Amount 2022 Stock Incentive Plan 2022 Stock Incentive Plan 2022 Stock Incentive Plan [Member]
Schedule of accrued liabilities
Schedule of Accrued Liabilities [Table Text Block]
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Axis]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Thereafter
Finite-Lived Intangible Asset, Expected Amortization, after Year Five
Debt Disclosure [Abstract]
Debt

Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Non-compete agreements Noncomplete Agreements [Member] Stock Price Goal (in dollars per share) Share price (in dollars per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Long-term deferred compensation Deferred Compensation Liability, Classified, Noncurrent Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Inventory Schedule of Inventory, Current [Table Text Block] Effective tax rate, estimate before discrete adjustments (as a percentage) Effective Income Tax Rate Reconciliation Estimate Before Discrete Adjustments Percentage of estimated annual effective tax rate before discrete adjustments. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other current liabilities Off-Balance-Sheet, Credit Loss, Liability Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Stockholders' Equity Equity [Text Block] Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segment Data Segment Reporting Disclosure [Text Block] Adjustments to reconcile net income to net cash provided by (used in) operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Valuation of Goodwill, Intangibles and Long-lived Assets Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Axis] Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Liability for unrecognized tax benefits Unrecognized Tax Benefits Geographic Concentration Risk Geographic Concentration Risk [Member] Schedule of the unconsolidated non-public VIEs Schedule of Variable Interest Entities [Table Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Adj. EBITDA Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Condition Relating to Operational Goals, Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization Amount of adjusted earnings before interest, taxes, depreciation, and amortization, as a vesting condition to be fulfilled for vesting of award under share-based payment arrangement. 2024 Employee XSP Exponential Stock Plan 2024 [Member] Represents information relating to 2024 exponential Stock Plan. Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other noncash items Other Noncash Expense Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Schedule of interest expense of convertible senior notes Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Surety Bond Surety Bond [Member] Non-cash transactions Noncash Investing and Financing Items [Abstract] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Options exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Axon Body Cameras and Accessories Axon Body Cameras and Accessories Axon Body and Camera Accessories. Marketable securities Marketable Securities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Strategic investments Balance, beginning of period Balance, end of period Equity Securities without Readily Determinable Fair Value, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Term deposits Bank Time Deposits [Member] Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage) Revenue, Remaining Performance Obligation, Percentage Income Taxes Income Tax Disclosure [Text Block] Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Net income per common and common equivalent shares: Earnings Per Share [Abstract] Liability for unrecognized tax benefits Liability for Uncertainty in Income Taxes, Noncurrent Numerator for basic and diluted earnings per share: Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Expired/terminated (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Revenue from Contract with Customer Benchmark [Member] Revenue from Contract with Customer Benchmark [Member] Inventory Increase (Decrease) in Inventories Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Strategic Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Fair value adjustments: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract] Accounting Changes and Error Corrections [Abstract] Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Marketable securities, unrealized gain Marketable Security, Unrealized Gain (Loss) Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Gross margin Gross Profit Dilutive effect of 2027 Warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Summary of significant accounting policy. Summary of changes in our estimated warranty reserve Schedule of Product Warranty Liability [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Line of Credit Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Schedule of intangible assets other than goodwill Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Aggregate principal amount Principal Debt Instrument, Face Amount Summary of revenue by product and service offering and geography Disaggregation of Revenue [Table Text Block] Issuance of common stock Stock Issued During Period, Value, New Issues Balance, beginning of period Balance, end of period Accrued warranty expense Standard and Extended Product Warranty Accrual Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of share-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Convertible notes carrying amount, net Convertible Debt Basis of Presentation and Use of Estimates Basis Of Presentation And Use Of Estimates Policy [Policy Text Block] Basis of presentation and use of estimates. Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, \$0.00001 par value; 200,000,000 shares authorized; 76,084,179 and 75,301,424 shares issued and outstanding as of SeptemberÂ 30, 2024, and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued TASER Devices (Professional) TASER Devices (Professional) TASER Devices (Professional) [Member] Share-Based Payment Arrangement [Abstract] Revenue recognized in the period from: Change in Contract with Customer, Asset and Liability [Abstract] U.S. government US Government Debt Securities [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Discrete tax benefit, stock-based compensation Effective Income Tax Rate Reconciliation, Deduction, Stock-based Compensation Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock-based compensation. Litigation Status [Axis] Litigation Status [Axis] Other, net Payments for (Proceeds from) Other Investing Activities Issuance of common stock for business combination contingent consideration (in shares) Stock Issued During Period, Shares, Acquisitions Schedule of convertible note hedge transaction Schedule of Convertible Note Hedge Transactions [Table Text Block] Tabular disclosure for convertible notes hedge transaction. Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Intangible Assets Finite-Lived Intangible Assets [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Raw materials Inventory, Raw Materials, Gross Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Purchase Price Derivative, Amount of Hedged Item Preferred stock, \$0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Preferred Stock, Value, Issued Warrants exercise trading day period Warrant Exercise Trading Day Period Represents the length of the consecutive trading day period over which warrants will automatically exercise. Summary of operational goals Equity Compensation Goals [Table Text Block] Equity Compensation Goals [Table Text Block] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Finished goods Inventory, Finished Goods, Gross Stock-based awards Share-Based Payment Arrangement [Member] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Convertible notes, net Convertible Notes Payable, Noncurrent Line of credit borrowings Line of Credit Facility, Fair Value of Amount Outstanding Basic (in dollars per share) Net income per common and common equivalent - Basic (in dollars per share) Earnings Per Share, Basic Net proceeds from equity offering Proceeds from Issuance of Common Stock Cash and Cash Equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Movement in Standard and Extended Product Warranty Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Trademarks Trademarks [Member] Property and equipment purchases in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] 2027 Warrant Warrant 2027 [Member] Represents the information pertaining to 2027 Warrant. Schedule of Goodwill [Table] Goodwill [Table] Ownership interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average number of common and common equivalent shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] As Reported Previously Reported [Member] Total assets Carrying value of variable interest - assets Assets 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of sales Cost of Goods and Services Sold Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Proceeds from call, maturity, and sale of investments Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Equity Securities without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Commitments and contingencies (Note 14) Commitments and Contingencies Tranche 4 Share-Based Payment Arrangement, Tranche Four [Member] Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Business Combinations Business Combinations Policy [Policy Text Block] Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Termination Date Trading Arrangement Termination Date Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 2027 Notes Convertible Senior Notes, Due 2027 Convertible Senior Notes Due 2027 [Member] Entity Address, City or Town Entity Address, City or Town Equity investments Equity investments Represents equity investments. Expected dividend yield (as percentage) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Dividend Yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Dividend Yield Debt Instrument [Axis] Debt Instrument [Axis] Schedule of option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Warrants Warrants Represents warrants for strategic investment. Stock based compensation expense Share-Based Payment Arrangement, Expense Fair value of notes Convertible Debt, Fair Value Disclosures Net income Net income Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Gain on acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Consolidated Entities [Domain] Consolidated Entities [Domain] Schedule of allowance for expected credit losses for each type of customer receivable Allowance For Expected Credit Loss By Type Of Customer Receivable [Table Text Block] Tabular disclosure of allowance for expected credit loss by type of customer receivable. Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Other accrued expenses Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Options exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Senior Unsecured Multi Currency Revolving Credit Facility Senior Unsecured Multi Currency Revolving Credit Facility Represents the information pertaining to senior unsecured multi currency revolving credit. Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Tranche 6 Share-Based Payment Arrangement, Tranche Six [Member] Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Extended Warranties Extended warranties Extended Warranties [Member] Number of Units outstanding, beginning of year (in shares) Number of Units outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Expired/terminated (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss Inventory

Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Independent vesting conditions Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Independent Vesting Conditions Number of independent vesting conditions to be fulfilled for vesting of award under share-based payment arrangement. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Amounts included in contract liabilities at the beginning of the period Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Restatement of Previously Issued Financial Statements Reclassification, Comparability Adjustment [Policy Text Block] Total unconsolidated variable interest entities: Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract] Accounts and notes receivable, net of allowance of \$3,292 and \$2,392 as of September 30, 2024 and December 31, 2023, respectively Accounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023 Accounts and Financing Receivable, after Allowance for Credit Loss, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Unrealized gains Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Revision of Prior Period Financial Statements Reclassifications [Text Block] Retained Earnings Retained Earnings [Member] Marketable Securities Marketable Securities [Member] Represents the information pertaining to marketable securities. Restricted cash (Note 1) Restricted Cash and Cash Equivalents Amortization of debt issuance costs Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation Status [Domain] Litigation Status [Domain] Basic (in shares) Weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Long-term notes receivable, net of current portion Accounts Receivable, Allowance for Credit Loss, Noncurrent Exercises Equity Securities Without Readily Determinable Fair Value, Exercises Amount of exercises of equity securities without readily determinable fair value. Restricted Stock Units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity (Roll Forward) Increase (Decrease) in Stockholders' Equity (Roll Forward) Accrued professional, consulting and lobbying fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Purchases of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Shares Purchased Derivative Liability, Number of Instruments Held Summary of performance stock unit activity Schedule Of Share Based Compensation Performance Stock Units Award Activity [Table Text Block] Tabular disclosure of the number and weighted-average grant date fair value for performance stock units that were outstanding at the beginning and end of the year, and the number of performance stock units that were granted, vested, or forfeited during the year. Entity Filer Category Entity Filer Category Revenue, remaining performance obligation Revenue, Remaining Performance Obligation, Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Dilutive effect of 2027 Notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Loss Contingencies [Line Items] Loss Contingencies [Line Items] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] EX-101.PRE 9 axon-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep 30, 2024 Nov. 01, 2024 Cover [Abstract] A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Sep. 30, 2024 A Document Transition Report false A Entity File Number 001-16391 A Entity Registrant Name Axon Enterprise, Inc. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 86-0741227 A Entity Address, Address Line One 17800 North 85th Street A Entity Address, City or Town Scottsdale A Entity Address, State or Province AZ A Entity Address, Postal Zip Code 85255 A City Area Code 480 A Local Phone Number 991-0797 A Title of 12(b) Security Common Stock, \$0.00001 Par Value A Trading Symbol AXON A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Large Accelerated Filer A Entity Small Business false A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 76,254,776 Entity Central Index Key 0001069183 A Current Fiscal Year End Date -12-31 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Amendment Flag false A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format -MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:fileCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS -USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A Cash and cash equivalents \$ 695,144 \$ 598,545 Marketable securities 151,560 77,940 Short-term investments 311,570 644,054 Accounts and notes receivable, net of allowance of \$3,292 and \$2,392 as of September 30, 2024 and December 31, 2023, respectively 512,662 412,961 Contract assets, net 372,923 287,232 Inventory 272,295 269,855 Prepaid expenses and other current assets 117,592 103,055 Total current assets 2,433,746 2,393,642 Property and equipment, net 235,881 200,533 Deferred tax assets, net 244,317 227,784 Intangible assets, net 81,748 19,539 Goodwill 308,472 57,945 Long-term notes receivable, net 2,898 2,588 Long-term contract assets, net 119,973 84,382 Strategic investments 387,905 231,730 Other long-term assets 190,718 191,031 Total assets 4,005,658 3,409,174 Current liabilities: A Accounts payable 75,590 65,852 Accrued liabilities 209,691 193,550 Current portion of deferred revenue 505,008 470,415 Customer deposits 22,234 21,935 Other current liabilities 10,704 9,787 Total current liabilities 823,227 761,539 Deferred revenue, net of current portion 305,414 270,901 Liability for unrecognized tax benefits 20,342 18,049 Long-term deferred compensation 15,605 11,342 Long-term lease liabilities 41,223 33,550 Convertible notes, net 679,483 677,113 Other long-term liabilities 20,528 20,915 Total liabilities 1,905,822 1,793,409 Commitments and contingencies (Note 14) Stockholders' equity: A Preferred stock, \$0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 0 0 Common stock, \$0.00001 par value; 200,000,000 shares authorized; 76,084,179 and 75,301,424 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively 1 1 Additional paid-in capital 1,588,072 1,347,410 Treasury stock at cost, 20,220,227 shares as of September 30, 2024 and December 31, 2023 (155,947) (155,947) Retained earnings 676,830 434,980 Accumulated other comprehensive loss (9,120) (10,679) Total stockholders' equity 2,099,836 1,615,765 Total liabilities and stockholders' equity \$ 4,005,658 \$ 3,409,174 X - Definition The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings. + References No definition available. + Details Name: axon_CustomerDepositCurrent Namespace Prefix: axon_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10) + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and

circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 - Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-5-14AReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 - Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 - Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference> 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference> 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-8> + Details Name: us-gaap ContractWithCustomerAssetNetCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is

ditioned on something other than passage of time, classified as current, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8) + Details Name: us-gaap ContractWithCustomerAssetNetNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3:

7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount recognized for uncertainty in income taxes classified as noncurrent. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LiabilityForUncertainTaxPositionsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7)Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12:

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI

10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI

Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19:

Dec. 31, 2023 75,301,424 75,301,424 A A A Ending balance at Dec. 31, 2023 1,615,765 1 1,347,410 (155,947) 434,980 (10,679) Treasury stock, shares, ending balance (in shares) at Dec. 31, 2023 20,220,227 A A 20,220,227 A A Beginning balance (in shares) at Mar. 31, 2023 73,874,062 A A A Beginning balance at Mar. 31, 2023 1,405,930 1 1,262,099 (155,947) 305,096 (5,319) Treasury stock, shares, beginning balance (in shares) at Mar. 31, 2023 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Issuance of common stock (in shares) A 313,094 A A A Issuance of common stock 61,156 A 61,156 A A Issuance of common stock under employee plans, net (in shares) A 570,357 A A A Issuance of common stock under employee plans, net (62,214) A (62,214) A A Stock options exercised (in shares) A 5,491 A A A Stock options exercised 157 A 157 A A Stock-based compensation 31,891 A 31,891 A A Net income 11,514 A A 11,514 A A Other comprehensive (loss) income, net (1,407) A A A (1,407) Ending balance (in shares) at Jun. 30, 2023 A 74,763,004 A A A Ending balance at Jun. 30, 2023 1,447,027 1 1,293,089 (155,947) 316,610 (6,726) Treasury stock, shares, ending balance (in shares) at Jun. 30, 2023 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Issuance of common stock (101) A (101) A A Issuance of common stock under employee plans, net (in shares) A 168,693 A A A Issuance of common stock under employee plans, net (7,021) A (7,021) A A Stock-based compensation 29,987 A 29,987 A A Net income 61,309 A A 61,309 A A Other comprehensive (loss) income, net (6,143) A A A (6,143) Ending balance (in shares) at Sep. 30, 2023 74,931,697 A A A Ending balance at Sep. 30, 2023 1,525,058 1 1,315,954 (155,947) 377,919 (12,869) Treasury stock, shares, ending balance (in shares) at Sep. 30, 2023 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Net income 57,061 A A 57,061 A A Ending balance (in shares) at Dec. 31, 2023 75,301,424 75,301,424 A A A Ending balance at Dec. 31, 2023 1,615,765 1 1,347,410 (155,947) 434,980 (10,679) Treasury stock, shares, ending balance (in shares) at Dec. 31, 2023 20,220,227 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Issuance of common stock under employee plans, net (in shares) A 164,747 A A A Issuance of common stock under employee plans, net (2,710) A (2,710) A A Stock-based compensation 75,115 A 75,115 A A Issuance of replacement awards in connection with acquisitions 1,265 A 1,265 A A Net income 133,352 A A 133,352 A A Other comprehensive (loss) income, net (907) A A A (907) Ending balance (in shares) at Mar. 31, 2024 75,466,171 A A A Ending balance at Mar. 31, 2024 1,821,880 1 1,421,080 (155,947) 568,332 (11,586) Treasury stock, shares, ending balance (in shares) at Mar. 31, 2024 A A 20,220,227 A A Beginning balance (in shares) at Dec. 31, 2023 75,301,424 75,301,424 A A A Beginning balance at Dec. 31, 2023 1,615,765 1 1,347,410 (155,947) 434,980 (10,679) Treasury stock, shares, beginning balance (in shares) at Dec. 31, 2023 20,220,227 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Net income 174,825 A A A Ending balance (in shares) at Jun. 30, 2024 75,573,214 A A A Ending balance at Jun. 30, 2024 1,933,381 1 1,493,716 (155,947) 609,805 (14,194) Treasury stock, shares, ending balance (in shares) at Jun. 30, 2024 A A 20,220,227 A A Beginning balance (in shares) at Dec. 31, 2023 75,301,424 75,301,424 A A A Beginning balance at Dec. 31, 2023 1,615,765 1 1,347,410 (155,947) 434,980 (10,679) Treasury stock, shares, beginning balance (in shares) at Dec. 31, 2023 20,220,227 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Stock options exercised (in shares) A 350,000 A A A Net income 241,850 A A A Ending balance (in shares) at Sep. 30, 2024 76,084,179 76,084,179 A A A Ending balance at Sep. 30, 2024 2,099,836 1 1,588,072 (155,947) 676,830 (9,120) Treasury stock, shares, ending balance (in shares) at Sep. 30, 2024 20,220,227 A A 20,220,227 A A Beginning balance (in shares) at Mar. 31, 2024 75,466,171 A A A Beginning balance at Mar. 31, 2024 1,821,880 1 1,421,080 (155,947) 568,332 (11,586) Treasury stock, shares, beginning balance (in shares) at Mar. 31, 2024 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Issuance of common stock under employee plans, net (in shares) A 107,043 A A A Issuance of common stock under employee plans, net (2,185) A (2,185) A A Stock-based compensation 74,821 A 74,821 A A Net income 41,473 A A 41,473 A A Other comprehensive (loss) income, net (2,608) A A A (2,608) Ending balance (in shares) at Jun. 30, 2024 75,573,214 A A A Ending balance at Jun. 30, 2024 1,933,381 1 1,493,716 (155,947) 609,805 (14,194) Treasury stock, shares, ending balance (in shares) at Jun. 30, 2024 A A 20,220,227 A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Issuance of common stock under employee plans, net (in shares) A 160,847 A A A Issuance of common stock under employee plans, net (17,430) A (17,430) A A Stock options exercised (in shares) A 350,118 A A A Stock options exercised 10,006 A 10,006 A A Stock-based compensation 101,780 A 101,780 A A Net income 67,025 A A 67,025 A A Other comprehensive (loss) income, net (5,074) A A A (5,074) Ending balance (in shares) at Sep. 30, 2024 76,084,179 76,084,179 A A A Ending balance at Sep. 30, 2024 2,099,836 1 1,588,072 (155,947) 676,830 (9,120) Treasury stock, shares, ending balance (in shares) at Sep. 30, 2024 20,220,227 A A 20,220,227 A A X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of replacement awards in connection with acquisitions. + ReferencesNo definition available. + Details Name: axon AdjustmentsToAdditionalPaidInCapitalReplacementAwardsIssuedInConnectionWithAcquisitions Namespace Prefix: axon Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) to additional paid-in capital (APIC) for recognition of award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1:

action S99-Paragraph 1-Subparagraph (SX 210.5-02(23))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 1:

<https://asc.fasb.org/1943274/2147482810/280-10-50-22> + Details Name: us-gaap DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) on investment. + ReferencesReference 1: [http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap GainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInAccountsAndNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense or loss included in net income that result in no cash flow, classified as other. + ReferencesReference 1: <a href=) + Details Name: us-gaap OtherNoncashExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and

Services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1:

These levels are: Level 1 Valuation techniques in which all significant inputs are unadjusted quoted prices for active markets for assets or liabilities that are identical to the assets or liabilities being measured. Level 2 Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices from markets that are not active for assets or liabilities that are identical or similar to the assets or liabilities being measured. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. Level 3 Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability. We have cash equivalents and investments, which at September 30, 2024 comprised money market funds, U.S. government bonds, term deposits, U.S. Treasury bills, and agency bonds. Cash equivalents and investments at December 31, 2023 also included corporate bonds, commercial paper and U.S. Treasury inflation-protected securities. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Debt investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Included in the balance of other long-term assets as of September 30, 2024 and December 31, 2023 was \$8.6 million and \$7.6 million, respectively, related to corporate-owned life insurance policies, which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. We have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain (or loss) on marketable securities, which is included in other income (loss), net. We have strategic equity investments in various privately held companies as of September 30, 2024 and December 31, 2023. The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic equity investments in privately held companies, we utilize observable data available to us as discussed further in Note 7. The fair value of our 2027 Notes is determined based on the closing trading price per \$1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the 2027 Notes at September 30, 2024 and December 31, 2023 to be a Level 2 measurement based on the fair value hierarchy. The fair value is primarily affected by the trading price of our common stock and market interest rates. Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet. Restricted Cash Restricted cash balances of \$2.3 million and \$2.1 million as of September 30, 2024 and December 31, 2023, respectively, primarily relate to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. As of September 30, 2024, approximately \$2.2 million was included in prepaid expenses and other current assets on our condensed consolidated balance sheet, with the remainder in other long-term assets. Valuation of Goodwill, Intangibles and Long-lived Assets We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such events and circumstances could include a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair values computed using discounted cash flows. Finite-lived intangible assets and other long-lived assets are amortized over their estimated useful lives. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We test goodwill and indefinite-lived intangible assets for impairment on an annual basis in the fourth quarter and on an interim basis when certain events and circumstances exist. Business Combinations Acquired businesses are included in the consolidated financial statements from the date we gain control of the business. We recognize, separately from goodwill, the identifiable assets acquired and liabilities assumed at their estimated acquisition-date fair values. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record qualifying adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. In addition, uncertain tax positions, tax-related valuation allowances and pre-acquisition contingencies are initially recorded in connection with a business combination as of the acquisition date. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any qualifying adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our condensed consolidated statement of operations. In the event that we acquire an entity in which we previously held an existing minority ownership interest, the difference between the fair value of the interest as of the acquisition date and the carrying value of the interest is recorded as a gain or loss within other income (loss), net, in the condensed consolidated statement of operations. Preexisting relationships subject to termination as a result of consummating an acquisition may require the recognition of a gain or loss upon settlement, which is recognized within income from operations on the condensed consolidated statement of operations. All third-party transaction-related costs are recognized as expense in the period in which they are incurred. Stock-Based Compensation On May 10, 2024, our shareholders approved the Axon Enterprise, Inc. 2024 Exponential Stock Plan (the "2024 Employee XSP"). The 2024 Employee XSP includes an approved pool of shares of common stock to be reserved for grants of awards of exponential Stock Units ("XSUs") to employees. The grants of XSUs (the "2024 XSUs") are grants of performance-based RSUs that vest in seven substantially equal tranches. The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions: (1) stock price goals; (2) operational goals; and (3) minimum service conditions. Additionally, shareholders approved the grant of the 2024 XSUs to our CEO, Patrick W. Smith (the "2024 CEO Performance Award"). The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Refer to Note 12 for further discussion regarding ongoing progress towards reaching the aforementioned goals. Recently Issued Accounting Guidance and Disclosure Rules Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for our Annual Report on Form 10-K for the year ending December 31, 2024, and subsequent interim periods, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In December 2023, the FASB issued ASU "2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax. The provisions of ASU 2023-09 are effective for our Annual Report on Form 10-K for the year ending December 31, 2025, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In March 2024, the SEC adopted final rules under SEC Release No. 34-99678 and No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (the "Final Rules"), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The financial statement disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules pending judicial review. We are currently evaluating the impact of the Final Rules on our consolidated financial statements. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations. X - References No definition available. + Details Name: us-gaap Organization Consolidation And Presentation Of Financial Statements Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies Text Block Namespace Prefix: us-gaap_ Data Type: dt-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] A Revenues Revenues Nature of Products and Services The following tables present our revenues by primary product and service offering and reportable segment (in thousands): Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 TASER Software and Sensors Total TASER Software and Sensors Total TASER Devices (Professional) \$130,515A \$130,515A \$86,718A \$86,718A Cartridges 60,179A \$60,179A \$4,279A \$4,279A Axon Evidence and Cloud Services 13,861A 20,481A 21,342A 8,975A 151,518A 160,493A Extended Warranties 9,729A 17,306A 27,035A 8,078A 14,046A 22,124A Axon Body Cameras and Accessories 70,363A 70,363A \$52,488A 52,488A Axon Fleet Systems 23,239A 23,239A \$27,336A 27,336A Other (1) (2) 450A 8,151A 15,601A 4,520A 5,320A 9,840A Total \$221,734A \$322,540A \$544,274A \$162,570A \$250,708A \$413,278A Nine Months Ended September 30, 2024 Nine Months Ended September 30, 2023 TASER Software and Sensors Total TASER Software and Sensors Total TASER Devices (Professional) \$333,815A \$333,815A \$239,165A \$239,165A Cartridges 181,792A \$181,792A 149,504A \$149,504A Axon Evidence and Cloud Services 40,297A 57,222A 610,519A 25,575A 401,281A 426,856A Extended Warranties 27,164A 48,651A 75,815A 23,463A 40,194A 63,657A Axon Body Cameras and Accessories 180,592A 180,592A \$124,066A 124,066A Axon Fleet Systems 79,620A 79,620A \$99,015A 99,015A Other (1) (2) 14,373A 30,855A 45,228A 14,460A 13,600A 28,060A Total \$597,441A \$909,940A \$1,507,381A \$452,167A \$678,156A \$1,130,323A (1) TASER segment also includes smaller categories, such as Virtual Reality ("VR") hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales. (2) Software and Sensors segment also includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment. The following table presents our revenues disaggregated by geography (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 United States \$482,596A 89A \$341,767A 83A \$1,298,775A 86A \$954,023A 84A %Other countries 61,678A 11A 71,511A 17A 208,606A 14A 176,300A 16A Total \$544,274A 100A %\$413,278A 100A %\$1,507,381A 100A %\$1,130,323A 100A %Contract Balances The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the nine months ended September 30, 2024 (in thousands): September 30, 2024 Contract assets, net \$492,896A Contract liabilities (deferred revenue) \$810,422A Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period \$432,411A Contract liabilities (deferred revenue) consisted of the following (in thousands): September 30, 2024 December 31, 2023 Current Long-Term Total Current Long-Term Total Extended Warranty: TASER \$15,783A 18,162A \$33,945A \$14,666A \$18,828A \$33,494A Software and Sensors 20,300A 8,749A 29,049A 22,642A 8,165A 30,807A 36,083A 26,911A 62,994A 37,308A 26,993A

(in thousands) As of September 30, 2024

AmortizedCostGrossUnrealizedGainsCrossUnrealizedLossesFair ValueCash andCashEquivalentsMarketable SecuritiesShort-TermInvestmentsCash\$85,256\$ac" \$ac" \$85,256\$85,256\$ac" \$ac" Level 1:A A Money market funds\$438,408\$ac" \$ac" \$438,408\$438,408\$ac" \$ac" U.S. government140,758A 23A (5)140,776A \$ac" \$ac" \$140,776A Marketable securities90,0061,560\$ac" \$ac" \$151,560\$ac" \$ac" Treasury bills117,880A 19A (2)117,897A 48,513A \$ac" \$ac" \$69,384A Agency bonds104,780\$ac" \$ac" (13)104,767104,767\$ac" \$ac" Subtotal891,826A 61,602A (20)953,408A 591,688A 151,560A 210,160A Level 2:Term deposits119,610\$ac" \$ac" \$119,61018,200\$ac" \$ac" 101,410Subtotal119,610\$ac" \$ac" \$119,61018,200\$ac" \$ac" 101,410Totals1,096,692\$61,602(20)\$1,158,274\$695,144\$151,560\$311,570As of September 30, 2024, we had \$159.7 million of available-for-sale investments with unrealized losses, of which none have been in a continuous unrealized loss position for 12 months or longer. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases. Acquired common stock is recorded as marketable securities in the condensed consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain (or loss) on marketable securities, which is included in other income (loss), net. During the three and nine months ended September 30, 2024, we recorded an unrealized gain on marketable securities of \$44.0 million and \$73.6 million, respectively. We recorded an unrealized gain on marketable securities of \$4.1 million and \$29.6 million, respectively, for the same periods in the prior year. As of December 31, 2023AmortizedCostGrossUnrealizedGainsCrossUnrealizedLossesFair ValueCash andCashEquivalentsMarketable SecuritiesShort-TermInvestmentsCash\$406,743A \$ac" \$ac" \$406,743A \$406,743A \$ac" \$ac" Level 1:A A A Money market funds1,470A \$ac" \$ac" \$1,470A 1,470A \$ac" \$ac" A Agency bonds222,057A 2A (174)221,885A 101,635A \$ac" \$ac" \$120,250A U.S. government238,747A 120A (237)238,630A \$ac" \$ac" \$238,630A Treasury bills148,063A 28A \$ac" \$ac" \$148,091A 88,697A \$ac" \$ac" \$59,394A Marketable securities90,000A \$ac" \$ac" (12,060)77,940A \$ac" \$ac" \$77,940A \$ac" \$ac" Subtotal700,337A 150A (12,471)688,016A 191,802A 77,940A 418,274A Level 2:Term deposits128,205A \$ac" \$ac" \$128,205A \$ac" \$ac" \$128,205A Corporate bonds80,646A 8A (165)80,489A \$ac" \$ac" \$80,489A Treasury inflation-protected securities2,635A \$ac" \$ac" (5)2,630A \$ac" \$ac" \$2,630A Commercial paper14,456A \$ac" \$ac" \$14,456A \$ac" \$ac" \$14,456A Subtotal225,942A 8A (170)225,780A \$ac" \$ac" \$225,780A Total\$1,333,022A \$158A (\$12,641)\$1,320,539A \$598,545A \$77,940A \$644,054A As of December 31, 2023, we had \$420.4 million of available-for-sale investments with unrealized losses. Of this amount, \$138.8 million had been in a continuous unrealized loss position for 12 months or longer, with total gross unrealized losses of \$0.3 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases. X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent> + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Expected Credit Losses 9 Months Ended Sep. 30, 2024 Credit Loss [Abstract] A Expected Credit Losses Expected Credit LossesWe are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, contract assets, notes receivable and off-balance sheet exposures is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions. The following table provides a roll-forward of the allowance for expected credit losses for finance receivables and off-balance sheet exposures. The expected credit losses for receivables are deducted from the amortized cost basis of accounts receivable, contract assets and notes receivable to present the net amount expected to be collected (in thousands):Nine Months Ended September 30, 2024United StatesOther countriesTotalBalance, beginning of period\$3,369A \$597A \$3,966A Provision for expected credit losses\$2,606A 216A 2,822A Amounts written off charged against the allowance(700)(84)(784)Other, including foreign currency translation\$144A 14A Balance, end of period\$5,275A \$743A \$6,018A As of September 30, 2024 and December 31, 2023, the allowance for expected credit losses for each type of customer receivable and off-balance sheet exposures were as follows (in thousands):September 30, 2024December 31, 2023Accounts receivable and notes receivable, current\$3,292A 2,392A Contract assets, net\$2,678A 1,516A Long-term notes receivable, net of current portion48A 44A Other current liabilities\$144A 14A Total allowance for expected credit losses on customer receivables\$6,018A \$3,966A X - ReferencesNo definition available. + Details Name: us-gaap_CreditLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42](http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-44](http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-44)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-4>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-8>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/21](http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-20)

Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Variable Interest Entities Variable Interest EntitiesWe evaluate our investments and other significant relationships to determine whether any investee is a variable interest entity (äœvIEäEä). If we conclude that an investee is a VIE, we evaluate our power to direct the activities of the investee, our obligation to absorb the expected losses of the investee and our right to receive the expected residual returns of the investee to determine whether we are the primary beneficiary of the investee. If we are the primary beneficiary of a VIE, we will consolidate such entity and reflect the non-controlling interest of other beneficiaries of that entity. We determine whether we are the primary beneficiary of a VIE by performing an analysis that principally considers:äEäThe VIEäEä™s purpose, design, and risks the VIE was designed to create and pass through to its variable interest holders;äEäThe VIEäEä™s capital structure;äEäThe terms between the VIE and its variable interest holders and other parties involved with the VIE; andäEäRelated party affiliations.As of September 30, 2024 and December 31, 2023, the unconsolidated non-public VIEs in which we hold variable interests were as follows (in thousands):September 30, 2024December 31, 2023Carrying value of variable interest - assets (1)\$28,073\$4,986(1)Balance reflects the maximum exposure to loss, which is limited to the carrying value of the interest.The primary purpose of our U.S.-based, unconsolidated VIE investments is to create strategic partnerships with market-leading providers of law enforcement technology solutions. We present all variable interests in unconsolidated VIEs as strategic investments within the long-term assets section of the condensed consolidated balance sheet.We have provided financial support to the unconsolidated VIEs in exchange for investments in debt and preferred equity securities as well as warrants and call options that give us the ability to commit additional capital over time. Financial support provided to the unconsolidated VIEs is used to continue to finance their operations. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent + Details Name: us-gaap_VariableInterestEntityDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Liabilities 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] A Accrued Liabilities Accrued Liabilities Accrued liabilities consisted of the following at September 30, 2024 and December 31, 2023 (in thousands):September 30, 2024December 31, 2023Accrued salaries, commissions, benefits and bonus\$103,566Ä \$125,636Ä Accrued income and other taxes27,911Ä 5,784Ä Accrued inventory in transit11,428Ä 12,197Ä Accrued professional, consulting and lobbying fees10,870Ä 7,377Ä Accrued warranty expense7,227Ä 7,374Ä Other accrued expenses48,689Ä 35,182Ä Accrued liabilities\$209,691Ä \$193,550Ä X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/193274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/193274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/193274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/193274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Convertible Senior Notes 9 Months Ended Sep. 30, 2024 Convertible Notes Payable [Abstract] A Convertible Senior Notes Convertible Senior Notes2027 NotesIn December 2027, we issued \$690.0 million aggregate principal amount of our 2027 Notes in a private offering, which aggregate principal amount included the exercise in full of the initial purchasersäEä™ option to purchase up to an additional \$90.0 million principal amount of the Notes. The Notes mature on December 15, 2027 and bear interest at a fixed rate of 0.50% per annum, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023. The effective interest rate for the Notes was 0.99% and included interest payable and amortization of debt issuance cost. On or after December 22, 2025, we may redeem for cash all or any portion of the notes in accordance with the optional redemption terms of the convertible debt agreement.If we undergo a fundamental change (as defined in the indenture governing the Notes), holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, up to but excluding the fundamental change repurchase date. In addition, following certain corporate events or if we issue a notice of redemption, it will increase the conversion rate for holders who elect to convert their Notes in connection with such corporate event or during the relevant redemption period.The following table summarizes the carrying value of the Notes (in thousands):September 30, 2024December 31, 2023Principal\$690,000Ä \$690,000Ä Unamortized debt issuance costs(10,517)Ä (12,887)Ä Convertible notes carrying amount, net\$679,483Ä \$677,113Ä We consider the fair value of the Notes to be a Level 2 measurement. The estimated fair value of the Notes at September 30, 2024 and December 31, 2023 is based on the closing trading price per \$1,000 of the Notes as of the last day of trading for each period as follows (in millions): September 30, 2024December 31, 20232027 Notes\$1,239.8Ä \$873.3Ä Interest expense related to the Notes was as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Contractual interest expense\$862Ä \$863Ä \$2,588Ä \$2,588Ä Amortization of debt issuance costs803Ä 797Ä 2,368Ä 2,328Ä Total interest expense\$1,665Ä 1,660Ä \$4,956Ä \$4,916Ä Note HedgeTo reduce the impact of potential economic dilution upon conversion of the Notes, we entered into a convertible note hedge transaction (the äEäNote HedgeäEä or äEä2027 Note HedgeäEä) with certain investment banks, with respect to our common stock, concurrently with the issuance of the 2027 Notes.Purchase PriceShares Purchased2027 Note Hedges\$194,994Ä 3,016,680The Note Hedge covers shares of our common stock at a strike price per share that corresponds to the initial conversion price of the respective Notes, subject to adjustment, and is exercisable upon conversion of the Notes. If exercised, we may elect to receive cash, shares of our common stock, or a combination of cash and shares. We have accounted for the aggregate amount of purchase price for the Note Hedge as a reduction to additional paid-in capital. The Note Hedge will expire upon the maturity of the Notes. The Note Hedge is intended to reduce the potential economic dilution upon conversion of the Notes in the event that the market value per share of our common stock at the time of exercise is greater than the conversion price of the Notes. The Note Hedge is a separate transaction and is not part of the terms of the Notes. Holders of the Notes do not have any rights with respect to the Note Hedge. The Note Hedge does not impact earnings per share, as it was entered into to offset any dilution from the Notes. As of September 30, 2024, 3,016,680 shares remain subject to the Note Hedge. Note WarrantsProceedsSharesStrike PriceFirst Expiration2027 Warrants\$124,269Ä 3,016,680\$338.86Ä March 15, 2028Separately, we entered into Warrant transactions with certain investment banks, whereby we sold Warrants to acquire, subject to adjustment, the number of shares of our common stock shown in the table above. If the average market value per share of our common stock on each expiration date exceeds the strike price of the Warrants expiring on that day, such Warrants would have a dilutive effect on our earnings per share to the extent we report net income. According to the terms of the Warrants, the Warrants will be automatically exercised over a 60-trading day period beginning on the first expiration date as set forth above. X - ReferencesNo definition available. + Details Name: us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] A Income Taxes Income Taxes We file income tax returns for federal purposes and in most states, as well as in multiple foreign jurisdictions. Our tax filings remain subject to examination by applicable tax authorities for a certain length of time, generally three to four years, but can be up to ten years in some jurisdictions following the tax year to which these filings relate. Deferred Tax AssetsNet deferred income tax assets at September 30, 2024, primarily include R&D capitalization net of amortization, deferred revenue, convertible debt net of amortization, accruals and reserves, and stock-based compensation expense, partially offset by accelerated depreciation expense, amortization of intangibles, unrealized gains on certain investments, and valuation allowance reserves. Our total net deferred tax assets at September 30, 2024 were \$244.3 million. In preparing our condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating our ability to recover our deferred income tax assets, management considers all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining our provisions for income taxes, our deferred tax assets and liabilities, and our future taxable income for purposes of assessing our ability to utilize any future tax benefit from our deferred tax assets.As of September 30, 2024, management continues to believe the positive evidence from projected future earnings outweighs the negative evidence and a valuation allowance is only needed on specific deferred tax assets. We have concluded that a valuation allowance is necessary against unrealized investment losses as well as transaction costs incurred in connection with certain investments. Additionally, we have Arizona R&D tax credits expiring unutilized each year; therefore, management has concluded that it is more likely than not that our Arizona R&D deferred tax asset will not be realized, and a valuation allowance has been recorded against this net asset.In Australia, we have determined that sufficient deferred tax liabilities will reverse in order to realize all assets except one long-lived intangible where there is not an expectation that the asset may be realized. Therefore, we continue to recognize a partial valuation allowance for Australia.We complete R&D tax credit studies for each year that an R&D tax credit is claimed for federal and state income tax purposes. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of \$27.4 million as of September 30, 2024. Should the unrecognized benefit of \$27.4 million be recognized, our effective tax rate would be favorably impacted. Approximately \$6.8 million of the unrecognized tax benefit, net of federal benefit, associated with R&D credits has been netted against the R&D deferred tax asset.Effective Tax RateOur overall effective tax rate for the nine months ended September 30, 2024, after discrete period adjustments, was 18.6%. Before discrete adjustments, the estimated annual effective tax rate was 23.3%, which differs from the federal statutory rate due to the impact of state taxes net of federal benefit and executive compensation limitation under IRC Section 162(m) on projected pre-tax income for the year, partially offset by R&D tax credits and a net gain related to an investment transaction not recognized for tax. The effective tax rate was favorably impacted by a net \$13.0 million discrete tax benefit associated with net windfalls related to stock-based compensation for RSUs and PSUs that vested, in addition to non-qualified stock options that were exercised during the nine months ended September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/193274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/193274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/193274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/193274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/193274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/193274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/193274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/193274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Stockholders' Equity StockholdersäEä™ Equity2024 Employee XSP and 2024 CEO Performance AwardOn May 10, 2024, our shareholders approved the 2024 Employee XSP. The 2024 Employee XSP includes an approved pool of 4.5 million shares of common stock to be reserved for grants of XSU awards to employees under the 2024 Employee XSP. A total of approximately 3.8 million 2024 XSUs were granted in the nine months ended September 30, 2024. The 2024 XSUs are grants of performance-based RSUs that vest in seven substantially equal tranches. The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions, described in the following table:Operational Goals(1) (in millions)Stock PriceGoalMinimum Service RequirementTrancheRevenueAdj. EBITDAEmployee XSPCEO AwardGoal Expiration1\$1,834Ä or\$393Ä and\$247.40Ä andJune 2025December 2028December 31, 202622,93Ä or\$08Ä and309.25Ä andDecember 2025December 2028December 31, 202732,866Ä or\$655Ä and386.56Ä andJune 2026December 2029December 31, 202843,583Ä or\$45Ä and483.20Ä andDecember 2026December 2029December 31, 202954,479Ä or1,088Ä and604.00Ä andJune 2027December 2030December 31, 203065,599Ä or1,400Ä and755.00Ä andDecember 2027December 2030December 31, 203176,999Ä or1,750Ä and943.75Ä andJune 2028December 2030December 31, 2032(1) Operational goals are measured, as of any date, for the previous four consecutive fiscal quarters, beginning with the Company's first full fiscal quarter ending after the fiscal quarter in which the grant date occurredAdditionally, shareholders approved the 2024 CEO Performance Award to grant 679,102 shares of the 2024 XSUs to our CEO, Patrick W. Smith. The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period.Stock-based compensation expense associated with the 2024 XSU awards is recognized over the requisite service period, which is considered the longest explicit, implicit or derived service period for each respective tranche. We utilized Monte Carlo simulations to evaluate a range of possible future stock price goals over the term of the awards at each of the respective grant dates. The median of all iterations of the simulation was used as the basis for the derived service period for each tranche. We measured the grant date fair value of each tranche using a Monte Carlo simulation with the following assumptions: risk-free interest rate of 4.3% - 4.5%, expected volatility of 41.4% äEä 41.5%, expected term of 8.6 years, and dividend yield of 0.0%. We utilized a blended volatility assumption, equally weighting both historical volatility and implied volatility, resulting in a weighted-average expected volatility of 41.4%. An illiquidity discount is considered in our estimate of the fair value of shares during post-vesting holding periods. The mandatory post-vesting holding periods for 2024 XSU awards will lapse on the earlier of (i) December 31, 2030, or (ii) the date that a subsequent tranche vests and settles. Therefore, the illiquidity discount is

dependent upon projected tranche vesting dates, determined via the Monte Carlo simulation. This simulation is based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis. Even though no tranche with respect to either the 2024 Employee XSP or the 2024 CEO Performance Award vests unless the stock price goal, operational goal and corresponding minimum service condition are achieved, stock-based compensation expense is recognized when an operational goal is considered probable of attainment regardless of the achievement of the stock price and minimum service conditions. As of September 30, 2024, we consider some of the tranches probable and will recognize the expense ratably over their respective expected vesting periods. This may result in volatility and higher upfront expense recognition and is subject to change based on periodic probability assessments.Restricted Stock UnitsThe following table summarizes RSU activity for the nine months ended September 30, 2024 (number of units and aggregate intrinsic value in thousands):Number ofUnitsWeighted AverageGrant-Date Fair ValueAggregateIntrinsic ValueUnits outstanding, beginning of year1,615\$193.09Â Granted595269.18Â Released(488)185.33Â Forfeited(128)202.01Â Units outstanding, end of period1,594\$223.16Â \$636,869Â Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was \$399.60 per share, multiplied by the number of RSUs outstanding. As of September 30, 2024, there was \$252.7 million in unrecognized compensation costs related to RSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.2 years. RSUs are settled when vesting requirements are met.On January 2, 2024, we granted an aggregate of 0.4 million RSUs to employees whose compensation was under a specified threshold. The RSUs generally vest in five annual installments from March 2024 through March 2028. For the nine months ended September 30, 2024, there was \$38.3 million of stock compensation expense related to these RSUs that was primarily recorded within cost of product and service sales. Performance Stock UnitsThe following table summarizes PSU activity for the nine months ended September 30, 2024 (number of units and aggregate intrinsic value in thousands):Number ofUnitsWeighted AverageGrant-Date Fair ValueAggregateIntrinsic ValueUnits outstanding, beginning of year394\$201.61Â Granted4,517240.07Â Released(11)149.49Â Forfeited(345)232.01Â Units outstanding, end of period4,555\$237.57\$1,820,338Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was \$399.60 per share, multiplied by the number of PSUs outstanding. As of September 30, 2024, there was \$585.0 million in unrecognized compensation expense related to PSUs under our stock plans for awards that are expected to vest. Of the balance, there was \$579.5 million of total unrecognized stock-based compensation expense related to XSP for performance goals that were considered probable of achievement, which will be recognized over a weighted-average period of 3.7 years.Stock Option ActivityThe following table summarizes stock option activity for the nine months ended September 30, 2024 (number of options and aggregate intrinsic value in thousands):Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (years)AggregateIntrinsic ValueOptions outstanding, beginning of year531\$28.58Grantedâ€”â€”â€”Exercised(350)28.58Expired / terminatedâ€”â€”â€”Options outstanding and exercisable, end of period181\$28.583.41\$67,085Aggregate intrinsic value represents the difference between the exercise price of the underlying stock options and the closing stock price on the last trading day of the period ended September 30, 2024, which was \$399.60 per share.Of the total stock options exercised during the nine months ended September 30, 2024, 0.2 million shares were immediately sold to cover the exercise price and the option holderâ€™s tax obligation for the applicable income and other employment taxes.Stock-based Compensation ExpenseThe following table summarizes the composition of stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Cost of product sales and service sales\$10,123Â \$1,687Â \$48,235Â \$4,685Â Sales, general and administrative expenses\$5,248Â 12,886Â 117,036Â 43,232Â Research and development expenses\$36,409Â 15,414Â \$8,445Â 48,311Â Total stock-based compensation expense\$101,780Â \$29,987Â \$251,716Â \$96,228Â Stock Incentive PlanIn May 2024, our shareholders approved the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan (the “Amended 2022 Plan”) authorizing an additional 2.2 million shares, plus remaining available shares under prior plans, for issuance under the Amended 2022 Plan. Combined with the shares of our common stock available under our legacy stock incentive plans, there are 3.7 million shares of our common stock available for grant under the Amended 2022 Plan as of September 30, 2024.At-The-Market Equity OfferingWe participate in an “at-the-market” equity offering program (the “ATM”), pursuant to which we are authorized to sell up to a total of approximately 2.0 million shares of our common stock. As of September 30, 2024, there were approximately 2.0 million shares remaining. There were no issuances under the ATM during the nine months ended September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.4-08(e)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30-120.htm IDEA: XBRL DOCUMENT v3.24.3 Line of Credit 9 Months Ended Sep 30, 2024 Debt Disclosure [Abstract] Â Line of Credit Line of CreditIn December 2022, we entered into a credit agreement that provides for a senior unsecured multi-currency revolving credit facility (the “Credit Agreement”) in an aggregate principal amount of up to \$200.0 million, \$30.0 million of which is available for the issuance of letters of credit. The Credit Agreement will mature on the earlier of December 15, 2027 or the date that is six months prior to the stated maturity date of the 2027 Notes unless the Notes have been redeemed, repurchased, converted or defeased in full. Additionally, the Credit Agreement has an accordion feature which allows for an increase in the total line of credit up to \$300.0 million, in each lenderâ€™s sole discretion.As of September 30, 2024, no amounts were drawn under the Credit Agreement and outstanding letters of credit totaled \$8.2 million. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest expense, taxes, depreciation and amortization ratio, which for the purposes of the Credit Agreement excludes investment interest income. “SOFR” is defined as a rate equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York or a successor administrator of the secured overnight financing rate. We are required to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, and a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense. As of September 30, 2024, we are in compliance with the associated covenants under the Credit Agreement. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph 1-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph 1-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.4-08\(c\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.4-08(c))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1E-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1E-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1) + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Commitments and ContingenciesProduct LitigationAs a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products. We are currently named as a defendant in one such lawsuit in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn. They seek compensatory and sometimes punitive damages, often in unspecified amounts.We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results of operations or cash flows. We are self-insured for the first \$5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products liability case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period.Other MattersDespite the FTCâ€™s dismissal of its administrative enforcement complaint against Axon without consent decree or other condition in October 2023, other parties continue to allege that Axonâ€™s May 2018 acquisition of an insolvent body-worn camera competitor, Viewu LLC (â€”Viewuâ€”), was anticompetitive. Two purported antitrust lawsuits based largely on the FTCâ€™s unproven allegations are pending in the District of New Jersey (Case No. 3:23-cv-7182) and District of Arizona (Case No. 2:24-cv-01869-SMB). Axon denies all allegations of anticompetitive or other misconduct and is vigorously defending the cases. Axon has also received a request for information from the Pennsylvania Office of Attorney General regarding this same consummated Viewu transaction. Axon is cooperating with the investigation to resolve any concerns of the Commonwealth.GeneralFrom time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss

or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time. Based on our assessment of outstanding litigation and claims as of the date of these financial statements, we have determined that it is not reasonably possible that these losses, if any, from lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

Off-Balance Sheet Arrangements Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At September 30, 2024, we had outstanding letters of credit issued under our credit facility of \$8.2 million that are expected to expire through 2025. We also had outstanding letters of credit of \$0.1 million that do not draw against our credit facility. Additionally, we had \$13.6 million of outstanding surety bonds as of September 30, 2024, with expiration dates ranging through 2029.

X - References No definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference> 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference) 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference> 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference) 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated Other Comprehensive Income (Loss) 9 Months Ended Sep. 30, 2024 Equity [Abstract] **Accumulated Other Comprehensive Income (Loss)** Accumulated Other Comprehensive Income (Loss) The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands): Unrealized Gains (Losses) on Available-for-Sale Investments Foreign Currency Translation Total Balance, December 31, 2023 \$(399) \$(10,280) \$(10,679) Other comprehensive loss (106) (801) (907) Balance, March 31, 2024 \$(505) \$(11,081) \$(11,586) Other comprehensive income (loss) 119 (2,727) (2,608) Balance, June 30, 2024 \$(386) \$(13,808) \$(14,194) Other comprehensive income 4344 4,640 5,074 Balance, September 30, 2024 \$484 \$(9,168) \$(9,120) Unrealized Gains (Losses) on Available-for-Sale Investments Foreign Currency Translation Total Balance, December 31, 2023 \$(1,251) \$(5,928) \$(7,179) Other comprehensive income 184 1,676 1,860 Balance, March 31, 2023 \$(1,067) \$(4,252) \$(5,319) Other comprehensive loss (85) (557) (1,407) Balance, June 30, 2023 \$(1,917) \$(4,809) \$(6,726) Other comprehensive income (loss) 656 (6,799) (6,143) Balance, September 30, 2023 \$(1,261) \$(11,608) \$(12,869) **X - Definition** The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference) 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent> + Details Name: us-gaap ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Data 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] **Segment Data** Our operations comprise two reportable segments: the development, manufacture and sale of fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share and analyze video and other digital evidence (collectively, the "Software and Sensors" segment); and the manufacture and sale of our CEDs, batteries, accessories, extended warranties and other products and services (collectively, the "TASER" segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer, who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. During the nine months ended September 30, 2024, the segment measure of profit and loss used by the CODM was changed from gross margin to adjusted gross margin, defined as gross margin before stock-based compensation expense and amortization of acquired intangible assets. This change in segment measure allows the CODM to better assess operating results over time and is consistent with how the CODM evaluates our businesses. Accordingly, we have updated our segment disclosure for the three and nine months ended September 30, 2023 to conform to the new presentation. Information relative to our reportable segments was as follows (in thousands): Three Months Ended September 30, 2024 2023 TASER segment net sales \$221,734 \$162,570 Software and Sensors segment net sales \$322,540 250,708 Total consolidated net sales \$544,274 \$413,278 TASER adjusted gross margin \$139,632 \$102,151 Software and Sensors adjusted gross margin \$204,258 157,147 Total segment adjusted gross margin \$343,890 \$259,298 Stock-based compensation expense \$10,123 \$1,687 Amortization of acquired intangible assets \$3,020 955 Gross margin \$330,747 \$256,656 Sales, general and administrative \$192,189 \$122,357 Research and development \$114,477 \$6,880 Interest income, net \$10,978 \$10,458 Other income (loss), net \$4,510 \$3,852 Income (loss) before provision for (benefit from) income taxes \$79,569 \$1,729 Nine Months Ended September 30, 2024 2023 TASER segment net sales \$597,441 \$452,167 Software and Sensors segment net sales \$909,940 678,156 Total consolidated net sales \$1,507,381 \$1,130,323 TASER adjusted gross margin \$374,072 \$280,875 Software and Sensors adjusted gross margin \$777,992 417,460 Total segment adjusted gross margin \$952,064 \$698,335 Stock-based compensation expense \$48,235 4,685 Amortization of acquired intangible assets \$8,298 2,189 Gross margin \$895,531 \$691,461 Sales, general and administrative \$514,228 \$357,611 Research and development \$307,008 219,747 Interest income, net \$1,134 29,787 Other income (loss), net \$191,510 (42,569) Income before provision for income taxes \$296,939 \$101,321 **X - References** No definition available. + Details Name: us-gaap SegmentReportingAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference> 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference) 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference) 6: [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference) 7: [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference) 9: [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference) 10: [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference) 11: [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference) 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference> 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference> 17: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference> 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference> 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference) 22: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference> 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference) 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference) 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Business Acquisitions 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] **Business Acquisitions** Business Acquisitions Fusus, LLC. On January 31, 2024, we acquired the remaining 79.7% interest in Fusus, LLC ("Fusus"), a global leader in real-time crime center technology, for total consideration transferred of approximately \$241.3 million, subject to customary adjustments (the "Fusus acquisition"). The acquisition expands our ability to aggregate live video, data and sensor feeds, which enhances situational awareness and investigative capabilities for our customers in public safety, education and enterprise. Total transaction costs related to the acquisition were \$0.3 million and \$4.6 million for the three and nine months ended September 30, 2024, respectively. These transaction costs were expensed as incurred in sales, general and administrative expenses ("SG&A"). In our condensed consolidated statements of operations, Our existing 20.3% interest had a fair value at the acquisition date of \$63.3 million, which resulted in a non-taxable gain of \$42.3 million recorded in other income (loss), net in our condensed consolidated statement of operations. Prior to the step acquisition, the fair value of the previously held investment was determined using Level 3 valuation techniques, which include inputs to the valuation methodology that are considered unobservable and significant to the fair value measurement. The purchase price allocation is subject to revision during the measurement period, which is expected to be completed in the fourth quarter of 2024. Based on the purchase price allocation, we recorded \$250.1 million of goodwill, \$72.9 million of identifiable intangible assets, and other net liabilities assumed of \$7.8 million, excluding deferred taxes. We recorded a net deferred tax liability of \$10.5 million. With the assistance of third-party valuation experts, we calculated the fair values of intangible assets using the multi-period excess earnings method for the acquired developed technology and the with and without method for customer relationships. The weighted average amortization period of the acquired intangible assets was 7.5 years. The goodwill generated from the acquisition is primarily attributable to synergies that are expected to be achieved from the integration of the business and is not deductible for tax purposes. Following the acquisition, the consolidated results of Fusus are included in the Company's Software and Sensors operating segment. **X - References** No definition available. + Details Name: us-gaap BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference) 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent> + Details Name: us-gaap BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] **Subsequent Events** In October 2024, we acquired the remaining outstanding stock of Dedrone Holdings, Inc. ("Dedrone"), a global leader in air space security, for approximately \$400 million, subject to customary purchase price adjustments. This acquisition will be recorded to our Software and Sensors segment, and it represents alignment to our mission and positions us to accelerate the next generation of drone and air space solutions. Prior to this transaction, we had an approximately 20% ownership interest in Dedrone. This transaction is considered a "step acquisition" under GAAP whereby our ownership interest in Dedrone held before the acquisition is required to be remeasured to fair value at the date of the acquisition. We expect to recognize a gain on our previously held strategic equity investment as a result of this transaction in the fourth quarter of 2024. Due to the proximity of the closing date of the acquisition of the

maintaining interest in Dedrone to the date of this filing, the initial acquisition costs related to the acquisition were approximately \$7.54 million for the nine months ended September 30, 2024. These transaction costs were expensed as incurred in SG&A in our condensed consolidated statements of operations. X - References No definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/855/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483399/855-10-50-2> + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Revision of Prior Period Financial Statements 9 Months Ended Sep. 30, 2024 Accounting Changes and Error Corrections [Abstract] A Revision of Prior Period Financial Statements Revision of Prior Period Financial StatementsAs discussed in Note 1, in preparing the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024, we identified errors in our previously issued financial statements related to our historical conclusions of principal vs. agent accounting of certain reseller arrangements under ASC 606 and concluded they were not material to any previously issued financial statements. The identified errors impacted our previously issued 2021 and 2022 annual financial statements, 2023 quarterly and annual financial statements, and 2024 quarterly financial statements through June 30, 2024. We have made adjustments to the prior period amounts presented in these financial statements accordingly. Additionally, we have made adjustments to correct for other previously identified immaterial errors. The following tables reflect the impact of the revision to the specific line items presented in our previously reported (a) consolidated balance sheet as of December 31, 2023; (b) consolidated statements of operations and comprehensive income for the years ended December 31, 2023, December 31, 2022, and December 31, 2021, and for the quarterly periods ended June 30, 2024, March 31, 2024, December 31, 2023, and September 30, 2023; (c) consolidated statements of cash flows for the years ended December 31, 2023 and December 31, 2022, and for the year to date periods ended June 30, 2024, March 31, 2024, September 30, 2023, and (d) consolidated statements of stockholder's equity for the quarterly periods ending December 31, 2022 through June 30, 2024.Consolidated Balance Sheet (in thousands)As of December 31, 2023As ReportedRevisionAs RevisedAccounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023\$417,690A (\$4,729)\$412,961A Contract assets, net\$275,779A 11,453A 287,232A Prepaid expenses and other current assets\$112,786A (9,731)\$103,055A Total current assets\$2,396,649A (3,007)\$2,393,642A Deferred tax assets, net\$229,513A (1,729)\$227,784A Long-term contract assets, net\$77,710A 6,672A 84,382A Other long-term assets\$20,638A (29,607)\$19,031A Total assets\$4,36,845A (27,671)\$4,309,174A Accounts payable\$88,326A (22,474)\$65,852A Accrued liabilities\$188,230A 5,320A 193,550A Current portion of deferred revenue\$491,691A (21,276)\$470,415A Total current liabilities\$799,969A (38,430)\$761,539A Deferred revenue, net of current portion\$281,852A (10,951)\$270,901A Other long-term liabilities\$2,936A 17,979A 20,915A Total liabilities\$1,824,811A (31,402)\$1,793,409A Retained earnings\$431,249A 3,731A 434,980A Total stockholders' equity\$1,615,765A 1,615,765A Total liabilities and stockholders' equity\$3,439,174A (\$2,671)\$3,436,503A Consolidated Statements of Operations and Comprehensive Income (in thousands, except per share data)Three Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\$295,185A (2,422)\$292,763Net sales from services\$208,914A 55,920A 244,834A Total sales\$503,899A (1,898)\$502,001A Cost of product sales\$145,154A (52,712)\$142,627A Cost of service sales\$55,210A (757)\$54,453A Cost of sales\$200,364A (3,284)\$197,080Gross margin\$303,735A 421,306A 156Sales, general and administrative\$169,427A 53,717A 164Total operating expenses\$270,861A 53,727A 238Income from operations\$32,874A 884A 33,758Income before provision for income taxes\$50,590A 884A 51,474A Provision for (benefit from) income taxes\$9,793A 208A 10,001A Net income\$40,797A 676A 41,473A Net income per common and common equivalent shares - Basic\$0.54\$0.01\$0.55Comprehensive income\$38,189A \$676A \$38,865A There was no impact on disclosed diluted basic and common equivalent shares for the three months ended June 30, 2024.Six Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\$567,233A (4,046)\$563,187Net sales from services\$397,602A 318,399A 721Net sales\$960,835A (1,728)\$959,107A Cost of product sales\$296,852A (2,065)\$294,787A Cost of service sales\$104,202A (666)\$103,536A Cost of sales\$401,054A (2,731)\$398,323Gross margin\$563,781A 1,003,564A 156Sales, general and administrative\$322,096A (573)\$321,523A Total operating expenses\$421,627A (573)\$421,054A Income from operations\$142,157A 570A 142,727A Income before provision for income taxes\$151,060A 570A 151,630A Provision for (benefit from) income taxes\$216,310A 1,060A 217,370A Provision for (benefit from) income taxes\$42,595A 250A 42,845A Net income\$109,265A 325A 109,590A Net income per common and common equivalent shares - Basic\$2.31\$0.01\$2.32Net income per common and common equivalent shares - Diluted\$2.25\$0.01\$2.26Comprehensive income\$170,500A \$810A 171,310A Three Months Ended March 31, 2024As ReportedRevisionAs RevisedNet sales from products\$272,048A (1,624)\$270,424A Net sales from services\$188,688A 59,189A 247,813A Total sales\$459,736A (1,035)\$458,701A Cost of product sales\$151,698A 625A 152,323A Cost of service sales\$48,992A 149,083A 149,241A Total cost of sales\$200,690A 603,520A 241,211A Gross margin\$259,046A (1,418)\$257,628A Sales, general and administrative\$152,669A (1,594)\$151,034A Total operating expenses\$322,352A 1,594A 323,946A Income from operations\$136,384A 1,594A 137,978A Income before provision for income taxes\$165,720A 1,594A 167,314A Provision for (benefit from) income taxes\$32,502A 424A 32,926A Net income\$133,218A \$134A 133,352A Comprehensive income\$132,311A \$134A 132,445A There was no impact on disclosed basic and diluted income per common and common equivalent shares for the three months ended March 31, 2024.Three Months Ended December 31, 2023As ReportedRevisionAs RevisedNet sales from products\$258,405A (1,966)\$256,439A Net sales from services\$173,732A 107A 173,839A Total sales\$430,137A (829)\$429,308A Cost of product sales\$125,664A (1,764)\$123,900A Cost of service sales\$42,591A (107A)42,484A Cost of sales\$168,255A (1,871)\$166,384A Gross margin\$261,882A 829A 262,711A Sales, general and administrative\$137,106A 167A 137,273A Total operating expenses\$221,078A 167A 221,245A Income from operations\$140,604A 829A 141,433A Income before provision for income taxes\$155,802A (62)\$155,740A Provision for (benefit from) income taxes\$1,469A 148A (1,321)A Net income\$157,271A (\$210)\$156,061A Comprehensive income\$155,461A (\$210)\$155,251A There was no impact on disclosed basic and diluted income per common and common equivalent shares for the three months ended December 31, 2023.Year Ended December 31, 2023As ReportedRevisionAs RevisedNet sales from products\$967,711A (3,709)\$964,002A Net sales from services\$595,680A 1,017A 596,697A Net sales\$1,563,391A (2,692)\$1,560,699A Cost of product sales\$450,718A (3,010)\$447,708A Cost of service sales\$157,291A 247A 157,538A Cost of sales\$608,009A (2,763)\$605,246A Gross margin\$955,382A 1,955A 957,337A Sales, general and administrative\$496,874A (1,990)\$494,884A Total operating expenses\$800,593A (1,990)\$798,603A Income from operations\$156,743A 1,955A 158,698A Income before provision for income taxes\$155,000A 2,061A 157,061A Provision for (benefit from) income taxes\$19,227A 505A (18,722)A Net income\$135,773A 1,550A 137,323A Net income per common and common equivalent shares - Basic\$2.35\$0.02\$2.37Net income per common and common equivalent shares - Diluted\$2.31\$0.02\$2.33Comprehensive income\$170,727A \$1,556A 172,283A Three Months Ended September 30, 2023As ReportedRevisionAs RevisedNet sales from products\$256,443A (1,388)\$255,055A Net sales from services\$157,158A 1,065A 158,223A Total sales\$412,201A (3,253)\$408,948A Cost of product sales\$126,278A (1,665)\$124,513A Cost of service sales\$42,051A (442)\$41,609A Cost of sales\$168,329A (2,110)\$166,219A Gross margin\$243,872A 1,634A 245,516A Sales, general and administrative\$123,279A (922)\$122,357A Total operating expenses\$200,159A (922)\$199,237A Income from operations\$143,635A 1,132A 144,767

1Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended 9 Months Ended Sep. 30, 2024 shares Sep. 30, 2024 shares Trading Arrangements, by Individual A Material Terms of Trading Arrangement A The table below describes the contracts, instructions or written plans for the purchase or sale of securities adopted by our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) during the three months ended September 30, 2024, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).Name and TitleAdoption DateExpiration DateAggregate Number of Securities to be SoldBrittany Bagley, Chief Operating Officer and Chief Financial OfficerAugust 16, 2024December 31, 20256,325Caitlin Kalinowski, DirectorAugust 20, 2024December 31, 2025450 Non-Rule 10b5-1 Arrangement Adopted true A Adoption Date August 16, 2024 A Expiration Date December 31, 2025 A Arrangement Duration 502 days A Aggregate Available 6,325 6,325 Caitlin Kalinowski [Member] A Trading Arrangements, by Individual A Name Caitlin Kalinowski A Title Director A Rule 10b5-1 Arrangement Adopted true A Adoption Date August 20, 2024 A Expiration Date December 31, 2025 A Arrangement Duration 498 days A Aggregate Available 450 450 X - ReferencesReference 1:

Restricted Cash Restricted CashRestricted cash balances of \$2.3 million and \$2.1 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, primarily relate to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. As of SeptemberÂ 30, 2024, approximately \$2.2 million was included in prepaid expenses and other current assets on our condensed consolidated balance sheet, with the remainder in other long-term assets. Valuation of Goodwill, Intangibles and Long-lived Assets Valuation of Goodwill, Intangibles and Long-lived AssetsWe evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such events and circumstances could include a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair values computed using discounted cash flows. Finite-lived intangible assets and other long-lived assets are amortized over their estimated useful lives. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We test goodwill and indefinite-lived intangible assets for impairment on an annual basis in the fourth quarter and on an interim basis when certain events and circumstances exist. Business Combinations Business CombinationsAcquired businesses are included in the consolidated financial statements from the date we gain control of the business. We recognize, separately from goodwill, the identifiable assets acquired and liabilities assumed at their estimated acquisition-date fair values. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record qualifying adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. In addition, uncertain tax positions, tax-related valuation allowances and pre-acquisition contingencies are initially recorded in connection with a business combination as of the acquisition date. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any qualifying adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our condensed consolidated statement of operations. In the event that we acquire an entity in which we previously held an existing minority ownership interest, the difference between the fair value of the interest as of the acquisition date and the carrying value of the interest is recorded as a gain or loss within other income (loss), net, in the condensed consolidated statement of operations. Preexisting relationships subject to termination as a result of consummating an acquisition may require the recognition of a gain or loss upon settlement, which is recognized within income from operations on the condensed consolidated statement of operations. All third-party transaction-related costs are recognized as expense in the period in which they are incurred. Stock-Based Compensation Stock-Based CompensationOn MayÂ 10, 2024, our shareholders approved the Axon Enterprise, Inc. 2024 xponential Stock Plan (the "2024 Employee XSP"). The 2024 Employee XSP includes an approved pool of shares of common stock to be reserved for grants of awards of xponential Stock Units ("2024 XSUs") to employees. The grants of XSUs (the "2024 XSUs") are grants of performance-based RSUs that vest in seven substantially equal tranches. The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions: (1) stock price goals; (2) operational goals; and (3) minimum service conditions. Additionally, shareholders approved the grant of the 2024 XSUs to our CEO, Patrick W. Smith (the "2024 CEO Performance Award"). The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Refer to Note 12 for further discussion regarding ongoing progress towards reaching the aforementioned goals. Recently Issued Accounting Guidance and Disclosure Rules Recently Issued Accounting Guidance and Disclosure RulesStandards Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for our Annual Report on Form 10-K for the year ending DecemberÂ 31, 2024, and subsequent interim periods, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In December 2023, the FASB issued ASU "2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax. The provisions of ASU 2023-09 are effective for our Annual Report on Form 10-K for the year ending December 31, 2025, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements. In March 2024, the SEC adopted final rules under SEC Release No. 34-99678 and No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors (the "Final Rules"), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The financial statement disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules pending judicial review. We are currently evaluating the impact of the Final Rules on our consolidated financial statements. X - DefinitionBasis of presentation and use of estimates. + ReferencesNo definition available. + Details Name: axon_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock Namespace Prefix: axon_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for Geographic Information and Major Customers. + ReferencesNo definition available. + Details Name: axon_GeographicInformationAndMajorCustomersPolicyTextBlock Namespace Prefix: axon_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4) + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(1\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1> + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent> + Details Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1> + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for standard warranties including the methodology for measuring the liability. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8) + Details Name: us-gaap_StandardProductWarrantyPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT V3.24.3 Organization and Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of weighted average number of shares outstanding and earnings per share The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Numerator for basic and diluted earnings per share:Net income\$67,025Â \$61,309Â \$241,850Â \$118,722Â Denominator:Â Â Â Â Weighted average shares outstanding75,697Â 74,826Â 75,543Â 73,904Â Dilutive effect of stock-based awards1,317Â 1,126Â 1,298Â 1,308Â Dilutive effect of 2027 Notes1,015Â Â 773Â Â 773Â Â Dilutive effect of 2027 Warrants51Â Â 51Â Â 51Â Â Diluted weighted average shares outstanding78,080Â 75,952Â 77,614Â 75,212Â Net income per common share:Basic0.89Â 0.82Â \$3.20Â 1.61Â Diluted0.86Â 0.81Â \$3.12Â 1.58Â Schedule of potentially dilutive securities excluded in calculation of diluted net income per share Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023Stock-based awards4,574Â 481Â 4,620Â 470Â 2027 Notes2,002Â 3,017Â 2,244Â 3,017Â 2027 Warrants2,966Â 3,017Â 3,017Â 3,017Â Total potentially dilutive securities9,542Â 6,515Â 9,881Â 6,504Â Summary of changes in our estimated warranty reserve Changes in our estimated product warranty liabilities were as follows (in thousands):Nine Months Ended September 30,20242023Balance, beginning of period\$7,374Â \$811Â Utilization of reserve(5,007)(901)Warranty expense4,860Â 3,381Â Balance, end of period\$7,227Â \$3,291Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT V3.24.3 Revenues (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Summary of revenue by product and service offering and geography The following tables present our revenues by primary product and service offering and reportable segment (in thousands):Three Months Ended September 30, 2024Three Months Ended September 30, 2023TASERSoftware and SensorsTotalTASERSoftware and SensorsTotalTASER Devices (Professional)\$130,515Â \$130,515Â \$86,718Â \$86,718Â Cartridges60,179Â Â 60,179Â 54,279Â Â 54,279Â Axon Evidence and Cloud

(2) Software and Sensors segment includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment. The following table presents our revenues disaggregated by geography (in thousands):

	Three Months Ended September 30,	Nine Months Ended September 30,	2024	Nine Months Ended September 30,	2023
Total	\$482,596A	\$1,341,767A	\$83A % \$1,298,775A	\$6A % \$954,023A	\$84A % Other
Countries:	61,678A	11A 71,511A	17A 208,606A	14A 176,300A	16A Total\$544,274A 100% % \$413,278A 100% % \$1,507,381A 100% % \$1,130,323A 100%

% Summary of contract with customer, assets and liabilities. The following table presents our contract assets, contract liabilities and information related to these balances as of and for the nine months ended September 30, 2024 (in thousands):

	September 30,	2024 Contract Assets,	net\$492,896A	Contract liabilities (deferred revenue)	\$810,422A	Revenue recognized in the period from:	A Amounts included in contract liabilities at the beginning of the period	\$432,411A	Contract liabilities (deferred revenue) consisted of the following (in thousands):	September 30,	2024 December 31,	2023 Current Long-Term Total Extended Warranty:	TASER\$15,783A	\$18,162A	\$33,945A	\$14,666A	\$18,828A	\$33,494A	Software and Sensors	\$20,300A	Hardware:	\$8,749A	\$29,049A	22,642A	\$8,165A	\$30,807A	\$36,083A	\$26,911A	\$62,994A	\$37,308A	\$26,993A	\$64,301A	TASER	\$43,322A	\$32,737A	\$76,059A	\$35,845A	\$29,689A	\$65,534A

Sensors\$65,067A 136,105A 201,172A 63,299A 117,024A 180,323A 108,389A 168,842A 277,231A 99,144A 146,713A 245,857A Services:\$505,008A 5,141A 13,651A 7,832A 3,983A 1 and Sensors\$352,026A 104,520A 456,546A 326,131A 93,212A 419,343A 360,536A 109,661A 470,197A 33,963A 97,195A 431,158A Total\$505,008A \$305,414A \$810,422A \$470,415A \$270,901A \$741.316A X - Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-1+Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.+ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5+Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -ReferencesNo definition available.+Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents and Investments (Tables) 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] A Summary of cash, cash equivalents, marketable securities, and available-for-sale investments. The following tables summarize our cash, cash equivalents, marketable securities and available-for-sale investments at September 30, 2024 and December 31, 2023 (in thousands).As of September 30, 2024 Amortized CostGrossUnrealized GainsGrossUnrealized LossesFair ValueCash and CashEquivalentsMarketplace SecuritiesShort-TermInvestmentsCash\$85,256A sâ€œ sâ€œ \$85,256A sâ€œ sâ€œ Level 1:A A Money market funds\$438,408A â€œ â€œ \$438,408A Treasury deposits\$119,610A sâ€œ sâ€œ \$119,610A Subtotal\$119,610A sâ€œ sâ€œ \$119,610A 200A (1),119,610A 200A (1),101Total\$1,096,692A sâ€œ sâ€œ (\$20,)158,274A sâ€œ sâ€œ \$695,144A sâ€œ sâ€œ \$151,560A sâ€œ sâ€œ \$311,570A As of December 31, 2023 Amortized CostGrossUnrealized GainsGrossUnrealized LossesFair ValueCash and CashEquivalentsMarketplace SecuritiesShort-TermInvestmentsCash\$406,743A sâ€œ sâ€œ \$406,743A sâ€œ sâ€œ \$406,743A sâ€œ sâ€œ Level 1:A A Money market funds1,470A â€œ â€œ \$1,470A 1,470A â€œ â€œ Agency bonds\$22,057A 2A (174)221,885A 101,635A â€œ â€œ \$120,250A U.S. government\$238,747A 120A (237)238,630A â€œ â€œ \$238,630A Treasury bills\$148,063A 28A â€œ â€œ \$148,091A 88,697A â€œ â€œ \$59,394A Marketable securities\$9,000A â€œ â€œ \$(12,060)77,940A â€œ â€œ \$77,940A â€œ â€œ Subtotal\$700,337A 150A (12,471)688,016A 191,802A 77,940A 418,274A Level 2:Term deposits\$128,205A â€œ â€œ \$128,205A Corporate bonds\$80,464A 8A (165)80,489A â€œ â€œ \$80,489A Treasury inflation-protected securities\$2,635A â€œ â€œ \$(5)2,630A â€œ â€œ \$2,630A Commercial paper\$14,456A â€œ â€œ \$14,456A Subtotal\$225,942A 8A (170)225,780A â€œ â€œ \$225,780A Total\$1,333,022A \$158A (\$12,641)\$1,320,539A \$598,545A \$77,940A \$644,054A X -ReferencesNo definition available.+Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionTabular disclosure of the components of cash, cash equivalents, and investments.+ReferencesNo definition available.+Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Expected Credit Losses (Tables) 9 Months Ended Sep. 30, 2024 Credit Loss [Abstract] A Schedule of roll-forward of allowance for credit losses. The following table provides a roll-forward of the allowance for expected credit losses for finance receivables and off-balance sheet exposures. The expected credit losses for receivables are deducted from the amortized cost basis of accounts receivable, contract assets and notes receivable to present the net amount expected to be collected (in thousands).Nine Months Ended September 30, 2024 United StatesOther countriesTotalBalance, beginning of period\$3,369A \$597A \$3,966A Provision for expected credit losses\$2,606A 216A 2,822A Amounts written off charged against the allowance(700)(84)(784)Other, including foreign currency translationâ€œ â€œ 14A 14A Balance, end of period\$5,275A \$743A \$6,018A Schedule of allowance for expected credit losses for each type of customer receivable As of September 30, 2024 and December 31, 2023, the allowance for expected credit losses for each type of customer receivable and off-balance sheet exposures were as follows (in thousands):September 30, 2024December 31, 2023Accounts receivable and notes receivable, current\$3,292A \$2,392A Contract assets, net\$2,678A 1,516A Long-term notes receivable, net of current portion\$484 44A Other current liabilitiesâ€œ â€œ 14A Total allowance for expected credit losses on customer receivables\$6,018A \$3,966A X -DefinitionTabular disclosure of allowance for expected credit loss by type of customer receivable.+ReferencesNo definition available.+Details Name: axon_AllowanceForExpectedCreditLossByTypeOfCustomerReceivableTableTextBlock Namespace Prefix: axon_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -DefinitionTabular disclosure of allowance for credit loss on accounts receivable.+ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13+Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -ReferencesNo definition available.+Details Name: us-gaap_CreditLossAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] A Inventory inventory consisted of the following at September 30, 2024 and December 31, 2023 (in thousands):September 30, 2024December 31, 2023Raw materials\$100,526A \$104,112A Finished goods\$171,769A \$165,743A Total inventory\$272,295A \$269,855A X -ReferencesNo definition available.+Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.+ReferencesReference 1: http://fasb.org/us-gaap/roref/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6)(b)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6)(c)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147

[illegible]

[0,2023\\$\(1,917\) \\$\(4,809\) \\$\(6,726\) Other comprehensive income \(loss\) 656A \(6,799\) \(6,143\) Balance, September 30, 2023\\$ \(1,261\) \\$\(11,608\) \\$\(12,869\) X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income \(loss\). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14A>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481674/830-50-1-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-45-20-1> + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML \\$2 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Data \(Tables\) 9 Months Ended Sep. 30, 2024 Segment Reporting \[Abstract\] A Summary of operational information relative to the company's reportable segments Information relative to our reportable segments was as follows \(in thousands\):Three Months Ended September 30,20242023TASER segment net sales\\$221,734A \\$162,570A Software and Sensors segment net sales322,540A 250,708A Total consolidated net sales\\$544,274A \\$413,278A TASER adjusted gross margins139,632A 102,151A Software and Sensors adjusted gross margin204,258A 157,147A Total segment adjusted gross margins\\$343,890A \\$259,298A Stock-based compensation expense10,123A 1,687A Amortization of acquired intangible assets3,020A 955A Gross margins\\$330,747A \\$256,656A Sales, general and administrative192,189A 122,357A Research and development114,477A 6,880A Interest income, net10,978A 10,458A Other income \(loss\), net\\$44,510A 3,852A Income \(loss\) before provision for \(benefit from\) income taxes\\$79,569A \\$71,729A Nine Months Ended September 30,20242023TASER segment net sales\\$597,441A \\$452,167A Software and Sensors segment net sales909,940A 678,156A Total consolidated net sales\\$1,507,381A \\$1,130,323A TASER adjusted gross margin\\$374,072A \\$280,875A Software and Sensors adjusted gross margin\\$77,992A 41,460A Total segment adjusted gross margin\\$952,064A \\$698,335A Stock-based compensation expense\\$48,235A 4,685A Amortization of acquired intangible assets\\$8,298A 2,189A Gross margins\\$895,531A \\$691,461A Sales, general and administrative\\$514,228A 357,611A Research and development\\$307,008A 219,747A Interest income, net\\$31,134A 29,787A Other income \(loss\), net\\$191,510A \(42,569\)Income before provision for income taxes\\$296,939A \\$101,321A X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts \(a\) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or \(b\) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-25>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Revision of Prior Period Financial Statements \(Tables\) 9 Months Ended Sep. 30, 2024 Accounting Changes and Error Corrections \[Abstract\] A Schedule of Error Corrections and Prior Period Adjustments The following tables reflect the impact of the revision to the specific line items presented in our previously reported \(a\) consolidated balance sheet as of December 31, 2023; \(b\) consolidated statements of operations and comprehensive income for the years ended December 31, 2023, December 31, 2022, and December 31, 2021, and for the quarterly periods ended June 30, 2024, March 31, 2024, December 31, 2023, and September 30, 2023; \(c\) consolidated statements of cash flows for the years ended December 31, 2023 and December 31, 2022, and for the year to date periods ended June 30, 2024, March 31, 2024, September 30, 2023; and \(d\) consolidated statements of stockholders' equity for the quarterly periods ending December 31, 2022 through June 30, 2024.Consolidated Balance Sheet\(in thousands\)As of December 31, 2023As ReportedRevisionAs RevisedAccounts and notes receivable, net of allowance of \\$2,392 as of December 31, 2023\\$417,690A \(\\$4,729\)\\$412,961A Contract assets, net\\$275,779A 11,453A 287,232A Prepaid expenses and other current assets\\$12,786A \(9,731\)103,055A Total current assets\\$2,396,649A \(3,007\)2,393,642A Deferred tax assets, net\\$229,513A \(1,729\)227,784A Long-term contract assets, net\\$77,710A 6,672A 84,382A Other long-term assets\\$220,638A \(29,607\)191,031A Total assets\\$3,436,845A \(27,671\)3,409,174A Accounts payable\\$88,326A \(22,474\)65,852A Accrued liabilities\\$88,230A 5,320A 193,500A Current portion of deferred revenue\\$491,691A \(21,276\)470,415A Total current liabilities\\$79,969A \(38,430\)761,539A Deferred revenue, net of current portion\\$181,852A \(10,951\)270,901A Other long-term liabilities\\$2,936A 17,979A 20,915A Total liabilities\\$1,824,811A \(31,402\)1,793,409A Retained earnings\\$431,249A 3,731A 434,980A Total stockholders'equity\\$1,612,034A 3,731A 1,615,765A Total liabilities and stockholders'equity\\$3,436,845A \(\\$27,671\)\\$3,409,174A Consolidated Statements of Operations and Comprehensive Income \(in thousands, except per share data\)Three Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\\$295,185A \(2,422\)\\$292,763Net sales from services\\$208,914A 55,921A 264,835A Net sales\\$504,099A \(863\)503,236Cost of product sales\\$145,154A \(2,527\)142,627Cost of service sales\\$55,210A \(757\)54,453Cost of sales\\$200,364A \(3,284\)197,080Gross margin\\$303,735A 42,130A 156Sales, general and administrative\\$169,427A 53,717A 125Total operating expenses\\$270,861A 53,727A 294Income before provision for income taxes\\$27,874A 92,410A 120Income taxes\\$7,934A 208A 8,142Net income\\$20,940A 92,618A 113Net income per common and common equivalent shares - Basic\\$0.54\\$0.51\\$0.55Comprehensive income\\$138,189A \\$676A \\$38,865A Six Months Ended June 30, 2024As ReportedRevisionAs RevisedNet sales from products\\$567,233A \(4,046\)\\$563,187Net sales from services\\$397,602A 31,839A 429,446Net sales\\$960,839A \(3,207\)957,632Cost of product sales\\$296,852A \(2,065\)294,787Cost of service sales\\$104,202A \(666\)103,536Cost of sales\\$401,054A \(2,713\)398,341Gross margin\\$559,785A 784Sales, general and administrative\\$322,096A \(57,322\)322,039Total operating expenses\\$514,627A \(57,514\)570Income from operations\\$49,151A 60,520A 109Income before provision for income taxes\\$216,310A 1,060A 217Provision for \(benefit from\) income taxes\\$42,295A 250A 42,545A Net income\\$174,015A \\$810A \\$174,825A Net income per common and common equivalent shares - Basic\\$2.31\\$0.01\\$2.32Net income per common and common equivalent shares - Diluted\\$2.25\\$0.01\\$2.26Comprehensive income\\$170,500A \\$810A \\$171,310A Three Months Ended March 31, 2024As ReportedRevisionAs RevisedNet sales from products\\$272,048A \(1,624\)\\$270,424Net sales from services\\$188,688A 791A 189,479Net sales\\$460,736A \(833\)459,903Cost of product sales\\$151,698A 461A 152,159A Cost of service sales\\$48,992A 149A 49,141A Cost of sales\\$200,690A 530A 201,220Gross margin\\$259,746A 308A 259,954Sales, general and administrative\\$152,669A \(1,594\)151,075Total operating expenses\\$243,766A \(1,594\)241,172Income from operations\\$166,170A 1,616A 167Income before provision for income taxes\\$165,720A 1,76A 167Income taxes\\$32,502A 42A](#)

[illegible]

https://asc.fasb.org/1943274/2147483443/250-10-50-Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetIncomeLossAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbr

Cloud Services | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers 203,481 | A | A | 151,518 | A | 570,222 |
401,281 | A | A | Software and Sensors | Extended Warranties | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with
customers 17,306 | A | A | 14,046 | 48,651 | 40,194 | A | A | Software and Sensors | Axon Body Cameras and Accessories | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A |
A | A | A | A | A | A | A | A | Revenue from contract with customers 70,363 | A | A | 52,488 | 180,592 | 124,066 | A | A | Software and Sensors | Axon Fleet Systems | A | A | A | A | A | A | A | A |
Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers 23,239 | A | A | 27,336 | 79,620 | 99,015 | A | A | Software and Sensors | Other | A |
A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers \$ 8,151 | A | A | \$ 5,320 | A | \$ 30,855 | 13,600 | A | X -
DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes
to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147479806/606-10-50-50Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section
55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic
10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4:
http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -
Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -
Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7:
http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -
Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix:
us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance
obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific
revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -
Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5:
http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99
Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8:
http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11:
http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50
Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 SubTopic
10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-
gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name:
srt ProductOrServiceAxis=axon_TaserDevicesProfessionalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt ProductOrServiceAxis=axon_CartridgesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=axon_AxonEvidenceMember
Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=axon_ExtendedWarrantiesMember Namespace Prefix: Data Type: na Balance Type:
Period Type: X - Details Name: srt ProductOrServiceAxis=axon_AxonBodyAndCameraAccessoriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt ProductOrServiceAxis=axon_AxonFleetSystemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=axon_OtherMember
Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementBusinessSegmentsAxis=axon_TaserSegmentMember Namespace Prefix: Data Type: na
Balance Type: Period Type: X - Details Name: us-gaap StatementBusinessSegmentsAxis=axon_SoftwareAndSensorsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period
Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Revenues By Geographic Area (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended 9 Months Ended 12
Months Ended Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Sep 30, 2024 Sep 30, 2023 Dec 31, 2023 Dec 31, 2021 Disaggregation of
Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers \$ 544,274 \$ 503,236 \$ 459,871 \$ 430,376 \$ 413,278 \$ 963,107 \$ 1,303,323 \$ 1,560,699 \$
1,187,143 \$ 895,638 United States | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers 482,596 | A | A |
341,767 | A | 1,298,775 954,023 | A | A | Other countries | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Revenue from contract with customers
\$ 61,678 | A | A | \$ 71,511 | A | \$ 208,606 \$ 176,300 | A | A | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | A | A | A | A | A | A | A | A | Disaggregation of
Revenue [Line Items] | A | A | A | A | A | A | A | A | Concentration risk (as a percentage) 100.00% | A | A | 100.00% | A | 100.00% | 100.00% | A | A | Revenue from Contract with Customer
Benchmark | Geographic Concentration Risk | United States | A | A | A | A | A | A | A | A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Concentration risk (as a
percentage) 89.00% | A | A | 83.00% | A | 86.00% | A | 84.00% | A | A | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Other countries | A | A | A | A | A | A | A | A |
A | Disaggregation of Revenue [Line Items] | A | A | A | A | A | A | A | A | Concentration risk (as a percentage) 11.00% | A | A | 17.00% | A | 14.00% | 16.00% | A | X - DefinitionFor an entity that
discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage
derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -
Publisher

us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Summary of Deferred Revenue (Details) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Disaggregation of Revenue [Line Items] A Current \$ 505,008 \$ 470,415 Long-Term 305,414 270,901 Total 810,422 741,316 TASER A A Disaggregation of Revenue [Line Items] A Current 67,615 58,343 Long-Term 56,040 52,500 Total 123,655 110,843 Software and Sensors A Disaggregation of Revenue [Line Items] A Current 437,393 412,072 Long-Term 249,374 218,401 Total 686,767 630,473 Extended Warranty A Disaggregation of Revenue [Line Items] A Current 36,083 37,308 Long-Term 26,911 26,993 Total 62,994 64,301 Extended Warranty | TASER A A Disaggregation of Revenue [Line Items] A Current 15,783 14,666 Long-Term 18,162 18,828 Total 33,945 33,494 Extended Warranty | Software and Sensors A A Disaggregation of Revenue [Line Items] A Current 20,300 22,642 Long-Term 8,749 8,165 Total 29,049 30,807 Hardware A A Disaggregation of Revenue [Line Items] A Current 108,389 99,144 Long-Term 168,842 146,713 Total 277,231 245,857 Hardware | TASER A A Disaggregation of Revenue [Line Items] A Current 43,322 35,845 Long-Term 32,737 29,689 Total 76,059 65,534 Hardware | Software and Sensors A A Disaggregation of Revenue [Line Items] A Current 65,067 63,299 Long-Term 136,105 117,024 Total 201,172 180,323 Services A A Disaggregation of Revenue [Line Items] A Current 306,536 333,963 Long-Term 109,661 97,195 Total 470,197 431,158 Services | TASER A A Disaggregation of Revenue [Line Items] A Current 8,510 7,832 Long-Term 5,141 3,983 Total 13,651 11,815 Services | Software and Sensors A A Disaggregation of Revenue [Line Items] A Current 352,026 326,131 Long-Term 104,520 93,212 Total \$ 456,546 \$ 419,343 X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1:

-Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=axon MarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_FinancialInstrumentAxis=axon TreasuryInflationProtectedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents and Investments - Narrative (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash and Cash Equivalents [Abstract] Å Å Å Debt securities in continuous loss position \$ 159.7 Å \$ 159.7 Å \$ 420.4 Securities in unrealized loss position for 12 months or longer Å Å Å 138.8 Continuous unrealized loss position of available-for-sale investments, gross unrealized losses Å Å Å 0.3 Marketable securities, unrealized gain \$ 44.0 Å 4.1 Å 73.6 Å 29.6 Å X - DefinitionThis item represents the continuous unrealized loss position of available-for-sale investments, gross unrealized losses. + ReferencesNo definition available. + Details Name: axon_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8>Reference 2: <http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8>Reference 2: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4) + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Expected Credit Losses (Details) \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) Accounts Receivable, Allowance for Credit Loss [Roll Forward] Å Balance, beginning of period \$ 3,966 Provision for expected credit losses 2,822 Amounts written off charged against the allowance (784) Other, including foreign currency translation 14 Balance, end of period 6,018 United States Å Accounts Receivable, Allowance for Credit Loss [Roll Forward] Å Balance, beginning of period 3,369 Provision for expected credit losses 2,606 Amounts written off charged against the allowance (700) Other, including foreign currency translation 0 Balance, end of period 5,275 Other countries Å Accounts Receivable, Allowance for Credit Loss [Roll Forward] Å Balance, beginning of period 597 Provision for expected credit losses 216 Amounts written off charged against the allowance (84) Other, including foreign currency translation 14 Balance, end of period \$ 743 X - DefinitionAmount of increase (decrease) in allowance for credit loss on accounts receivable, other, including dispositions and foreign currency translation. + ReferencesNo definition available. + Details Name: axon_AllowanceForDoubtfulAccountsReceivableOther Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13) + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of direct write-downs of accounts receivable charged against the allowance. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13) + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Expected Credit Losses - Type Of Customer Receivable (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Credit Loss [Abstract] Å Accounts receivable and notes receivable, current \$ 3,292 \$ 2,392 Contract assets, net 2,678 1,516 Long-term notes receivable, net of current portion 48 44 Other current liabilities 0 14 Total allowance for expected credit losses on customer receivables \$ 6,018 \$ 3,966 X - DefinitionAmount of allowance for expected credit losses on customer receivables. + ReferencesNo definition available. + Details Name: axon_AllowanceForExpectedCreditLossesOnCustomerReceivables Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13) + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CreditLossAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expected credit loss for credit exposure on off-balance-sheet commitment, including but not limited to, loan commitment, standby letter of credit, financial guarantee not accounted for as insurance. Excludes off-balance sheet credit exposure accounted for as insurance and instrument accounted for under derivatives and hedging. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482454/460-10-45-1> + Details Name: us-gaap_OffBalanceSheetCreditLossLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Å Å Raw materials \$ 100,526 \$ 104,112 Finished goods 171,769 165,743 Total inventory \$ 272,295 \$ 269,855 X - ReferencesNo definition available. + Details

Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1:

gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternetDomainNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Narrative (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Å Å Å Amortization expense of intangible assets \$ 3.8 \$ 1.3 \$ 10.7 \$ 3.2 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Å Å 2024 remaining \$ 3,840 Å 2025 12,536 Å 2026 12,341 Å 2027 11,400 Å 2028 11,289 Å 2029 11,105 Å Thereafter 17,515 Å Total \$ 80,026 \$ 17,696 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Strategic Investments - Schedule Of Roll-Forward Of Strategic Investments (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Strategic Investments Å Å Å Å Balance, beginning of period \$ 363,134 \$ 233,637 \$ 231,730 \$ 296,563 \$ 246,903 Investments 24,322 5,275 100,950 16,192 Å Fair value adjustments: Å Å Å Å Realized gains Å Å 45,183 0 57,495 Realized losses Å Å (2,870) 0 (2,870) Unrealized gains 449 0 76,225 0 180,115 Unrealized losses and impairments 0 (113) 0 (73,956) (84,009) Exercises 0 1,500 (63,313) 1,500 4,817 Balance, end of period 387,905 240,299 387,905 240,299 387,905 Equity investments Å Å Å Å Strategic Investments Å Å Å Å Balance, beginning of period 340,108 215,945 212,996 277,676 217,948 Investments 24,322 4,099 93,450 15,016 Å Fair value adjustments: Å Å Å Å Realized gains Å Å 45,162 0 57,474 Realized losses Å Å 0 0 0 Unrealized gains 0 0 74,784 0 149,601 Unrealized losses and impairments 0 0 (72,648) (82,304) Exercises 0 1,500 (61,962) 1,500 36,257 Balance, end of period 364,430 221,544 364,430 221,544 364,430 Warrants Å Å Å Å Strategic Investments Å Å Å Å Balance, beginning of period 2,356 459 1,501 1,654 4,222 Investments 0 1,176 0 1,176 Å Fair value adjustments: Å Å Å Å Realized gains Å Å 0 0 0 Realized losses Å Å 0 0 0 Unrealized gains 0 855 0 29,928 Unrealized losses and impairments 0 (113) 0 (1,308) (1,705) Exercises 0 0 0 (30,089) Balance, end of period 2,356 1,522 2,356 1,522 2,356 Call options Å Å Å Å Strategic Investments Å Å Å Å Balance, beginning of period 13,033 17,233 17,233 17,233 Investments 0 0 0 0 0 Fair value adjustments: Å Å Å Å Realized gains Å Å 21 0 21 Realized losses Å Å (2,870) 0 (2,870) Unrealized gains 0 0 0 0 0 Unrealized losses and impairments 0 0 0 0 0 Exercises 0 0 (1,351) 0 (1,351) Balance, end of period 13,033 \$ 17,233 13,033 \$ 17,233 Debt investments Å Å Å Å Strategic Investments Å Å Å Å Balance, beginning of period 7,637 Å 0 Å 7,500 Investments 0 Å 7,500 Å Fair value adjustments: Å Å Å Å Realized gains Å Å 0 Å 0 Realized losses Å Å 0 Å 0 Unrealized gains 449 Å 586 Å 586 Unrealized losses and impairments 0 Å 0 Exercises 0 Å 0 Å 0 Balance, end of period \$ 8,086 Å \$ 8,086 Å \$ 8,086 X - DefinitionAmount of exercises of equity securities without readily determinable fair value. + ReferencesNo definition available. + Details Name: axon_EquitySecuritiesWithoutReadilyDeterminableFairValueExercises Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain realized from sale of equity securities without readily determinable fair value. + ReferencesNo definition available. + Details Name: axon_EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from sale of investment in equity security without readily determinable fair value. + ReferencesNo definition available. + Details Name: axon_EquitySecuritiesWithoutReadilyDeterminableFairValueLossOnSaleOfSecurities Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of purchases of equity securities without readily determinable fair value. + ReferencesNo definition available. + Details Name: axon_EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases Namespace Prefix: axon_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3) + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from downward price adjustment on investment in equity security without readily determinable fair value. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3) + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain from upward price adjustment on investment in equity security without readily determinable fair value. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3) + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=axon_WarrantsForStrategicInvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CallOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Strategic Investments - Narrative (Details) - USD (\$) \$ in Millions 1 Months Ended 9 Months Ended Jan. 31, 2024 Sep. 30, 2024 Equity Securities without Readily Determinable Fair Value [Line Items] Å Å Gain on acquisition \$ 42.3 Å Strategic investments and warrants Å Å Equity Securities without Readily Determinable Fair Value [Line Items] Å Å Unrealized gain on investments Å Å \$ 75.6 Debt investments Å Å Equity Securities without Readily Determinable Fair Value [Line Items] Å Å Debt security strategic investment, unrealized gain Å Å \$ 0.6 Acquisition 1 Å Å Equity Securities without Readily Determinable Fair Value [Line Items] Å Å Fair value \$ 63.3 Å X - DefinitionFair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\)\(1\) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g)(1) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2) + Details Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIn a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(g\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2) + Details Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading). +

[References](#)[Reference 1:](#) <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14-Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-14>[Reference 2:](#)

[Data Type: xbrli:stringItemType Balance Type: na period Type: duration X - Definition](#)[Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. + References](#)[Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(c\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrual Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)[Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + References](#)[Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Convertible Senior Notes - Narrative \(Details\) - 2027 Notes - USD \(\\$ \\$\) in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2022 Senior Convertible Notes Á Á Á Aggregate principal amount \\$ 690,000 \\$ 690,000 \\$ 690,000 Additional principal amount purchase option Á Á \\$ 90,000 Interest rate \(as a percent\) 0.50% Á 0.50% Effective interest rate Á Á 0.99% Repurchase price \(as percentage\) 100.00% Á Á X - Definition](#)[Amount of option to purchase additional principal amount of convertible senior notes. + References](#)[No definition available. + Details Name: axon_LineOfCreditFacilityAccordionFeatureIncreaseLimit Namespace Prefix: axon_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)[Face \(par\) amount of debt instrument at time of issuance. + References](#)[Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)[Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + References](#)[Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Definition](#)[Contractual interest rate for funds borrowed, under the debt agreement. + References](#)[Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Definition](#)[Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References](#)[Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Cod](#)

-Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 24: <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I)Reference 26: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1> + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1) + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=axon ConvertibleNoteHedge2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Convertible Senior Notes - Hedge (Details) - Sep. 30, 2024 - 2027 Note Hedge USD (\$) instrument security Senior Convertible Notes Á Á Purchase Price \$ 194,994 Á Á Shares Purchased Á 3,016,680 3,016,680 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 11: [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I)Reference 26: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1> + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=axon ConvertibleNoteHedge2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Convertible Senior Notes - Warrants (Details) - 2027 Warrant 9 Months Ended Sep. 30, 2024 USD (\$) / security shares Senior Convertible Notes Á Proceeds | \$ 124,269 Shares (in shares) | shares 3,016,680 Strike Price (in dollars per share) | \$ / security 338.86 Warrants exercise trading day period 60 days X - DefinitionRepresents the length of the consecutive trading day period over which warrants will automatically exercise. + ReferencesNo definition available. + Details Name: axon_WarrantExerciseTradingDayPeriod Namespace Prefix: axon_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 11: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 12: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 13: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 14: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 16:

Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe strike price on the price risk option contract such as a put option or a call option. + ReferencesReference 1:

year, five months, and thirteen days). + ReferencesReference 1:

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 10 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 89 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Reported Stock-Based Compensation (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Á Á Á Stock-based compensation expense \$ 101,780 \$ 29,987 \$ 251,716 \$ 96,228 Cost of product sales and service sales Á Á Á Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Á Á Á Stock-based compensation expense 10,123 1,687 48,235 4,685 Sales, general and administrative expenses Á Á Á Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Á Á Á Stock-based compensation expense 55,248 12,886 117,036 43,232 Research and development expenses Á Á Á Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Á Á Á Stock-based compensation expense \$ 36,409 \$ 15,414 \$ 86,445 \$ 48,311 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details) - 2022 Stock Incentive Plan - shares shares in Millions Sep. 30, 2024 May 31, 2024 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Common stock reserved for issuance (in shares) Á 2.2 Shares available for grant (in shares) 3.7 Á X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=axon_A2022StockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R81.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - At-the-Market equity offering - Additional Information (Details) - ATM Equity Offering shares in Millions 9 Months Ended Sep. 30, 2024 shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Maximum number of common stock shares to be sold (in shares) 2.0 Number of shares remaining to be sold 2.0 Issuance of common stock (in shares) 0.0 X - DefinitionRepresents the maximum number of shares that may be sold. + ReferencesNo definition available. + Details Name: axon_MaximumNumberOfSharesAllowedToBeSold Namespace Prefix: axon_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionRepresents the number of shares that are remaining out of the maximum shares allowed to be sold. + ReferencesNo definition available. + Details Name: axon_NumberOfSharesRemainingToBeSold Namespace Prefix: axon_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15:

Paragraph 3 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 - Details Name: us-gaap LossContingenciesLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of pending claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap LossContingencyPendingClaimsNumber Namespace Prefix: us-gaap Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap GuaranteeObligationsByNatureAxis=us-gaap SuretyBondMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=axon AnotherCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LitigationStatusAxis=us-gaap PendingLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R84.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated Other Comprehensive Income (Loss) (Details) - USD (\$) in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2023 Jun. 30, 2023 Mar. 31, 2023 Accumulated other comprehensive income (loss): \$ \$ \$ \$ \$ \$ Beginning balance 1,933,381 \$ 1,821,880 \$ 1,615,765 \$ 1,447,027 \$ 1,405,930 \$ 1,270,666 Other comprehensive (loss) income 5,074 (2,608) (907) (6,143) (1,407) 1,860 Ending balance 2,099,836 1,933,381 1,821,880 1,525,058 1,447,027 1,405,930 Accumulated Other Comprehensive Loss \$ \$ \$ \$ \$ \$ Accumulated other comprehensive income (loss): \$ \$ \$ \$ \$ \$ Beginning balance (14,194) (11,586) (10,679) (6,726) (5,319) (7,179) Other comprehensive (loss) income 5,074 (2,608) (907) (6,143) (1,407) 1,860 Ending balance (9,120) (14,194) (11,586) (12,869) (6,726) (5,319) Unrealized Gains (Losses) on Available-for-Sale Investments \$ \$ \$ \$ \$ \$ Accumulated other comprehensive income (loss): \$ \$ \$ \$ \$ \$ Beginning balance (386) (505) (399) (1,917) (1,067) (1,251) Other comprehensive (loss) income 434 119 (106) 656 (850) 184 Ending balance 48 (386) (505) (1,261) (1,917) (1,067) Foreign Currency Translation \$ \$ \$ \$ \$ \$ Accumulated other comprehensive income (loss): \$ \$ \$ \$ \$ \$ Beginning balance (13,808) (11,081) (10,801) (4,809) (4,252) (5,928) Other comprehensive (loss) income 4,640 (2,727) (801) (6,799) (557) 1,676 Ending balance \$ (9,168) \$ (13,808) \$ (11,081) \$ (11,608) \$ (4,809) \$ (4,252) X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap AOIArbitrableToParentNetOfTaxRollForward Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-

before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2:> <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3:> [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7:) [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8:](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9:](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9:) <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11:](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11:) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12:](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12:) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income \(expense\) classified as nonoperating. + ReferencesReference 1:](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2:) <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3:> http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNetNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2:](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2:) [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3:](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegmentsNamespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of income \(expense\) related to nonoperating activities, classified as other. + ReferencesReference 1:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegmentsNamespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1:)

350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482548/350-20-55-24>Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Subparagraph \(SX 210.5-02\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1>Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(10\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=axon_FusiusIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R87.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) - Dedrone Holdings, Inc. - Subsequent Event \$ in Millions 1 Months Ended Oct. 31, 2024 USD (\$) Subsequent Event [Line Items] A Consideration \$ 400.0 Remaining interest acquired 20.00% Transaction costs \$ 7.5 X - DefinitionAmount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2) + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7> + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2> + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=axon_DedroneHoldingsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 98 R88.htm IDEA: XBRL DOCUMENT v3.24.3 Revision of Prior Period Financial Statements - Balance Sheets (Details) - USD (\$) in Thousands Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2023 Reclassification [Line Items] A A A A A A A A Accounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023 \$ 512,662 A A A A A A Contract assets, net 372,923 A A A A A A Prepaid expenses and other current assets 117,592 A A A A A A Total current assets 2,433,746 A A A A A A Deferred tax assets, net 244,317 A A A A A A Long-term contract assets, net 119,973 A A A A A A Other long-term assets 190,718 A A A A A A Total assets 4,005,658 A A A A A A Accounts payable 75,590 A A A A A A Accrued liabilities 209,691 A A A A A A Current portion of deferred revenue 505,008 A A A A A A Total current liabilities 823,227 A A A A A A Deferred revenue, net of current portion 305,414 A A A A A A Other long-term liabilities 20,528 A A A A A A Total liabilities 1,905,822 A A A A A A Retained earnings 676,830 A A A A A A Total stockholders' equity 2,099,836 \$ 1,933,381 \$ 1,821,880 \$ 1,615,765 \$ 1,525,058 \$ 1,447,027 \$ 1,405,930 \$ 1,270,666 Total liabilities and stockholders' equity 4,005,658 A A A A A A Accounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023 \$ 2,392 A A A A A A As Reported A A A A A A Reclassification [Line Items] A A A A A A Accounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023 A A A A A A Contract assets, net A A A A A A Prepaid expenses and other current assets A A A A A A Total current assets A A A A A A Deferred tax assets, net A A A A A A Long-term contract assets, net A A A A A A Other long-term assets A A A A A A Total assets A A A A A A Accounts payable A A A A A A Accrued liabilities A A A A A A Current portion of deferred revenue A A A A A A Total current liabilities A A A A A A Deferred revenue, net of current portion A A A A A A Other long-term liabilities A A A A A A Total liabilities A A A A A A Retained earnings A A A A A A Total stockholders' equity A A A A A A Retained earnings A A A A A A Other long-term liabilities A A A A A A Total liabilities and stockholders' equity A A A A A A Reclassification [Line Items] A A A A A A Accounts and notes receivable, net of allowance of \$2,392 as of December 31, 2023 A A A A A A (4,729) A A A A A A Contract assets, net A A A A A A Prepaid expenses and other current assets A A A A A A Total current assets A A A A A A (3,007) A A A A A A Deferred tax assets, net A A A A A A (1,729) A A A A A A Long-term contract assets, net A A A A A A 6,672 A A A A A A Other long-term assets A A A A A A (29,607) A A A A A A Total assets A A A A A A (27,671) A A A A A A Accounts payable A A A A A A Accrued liabilities A A A A A A 5,320 A A A A A A Current portion of deferred revenue A A A A A A (21,276) A A A A A A Total current liabilities A A A A A A (38,430) A A A A A A Deferred revenue, net of current portion A A A A A A (10,951) A A A A A A Other long-term liabilities A A A A A A Total liabilities A A A A A A (31,402) A A A A A A Retained earnings A A A A A A 3,731 A A A A A A Total stockholders' equity A A A A A A 4,541 \$ 3,865 3,731 \$ 3,941 \$ 2,029 \$ 2,935 \$ 2,175 Total liabilities and stockholders' equity A A A A A A (27,671) A A A A A A X - DefinitionAmount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/852-10-55-10> + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(i\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (i)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28:

reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3)

0 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(5)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(i)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(B)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(5)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 852 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 852 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition: Amount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(17)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherAssetsNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition: Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(24)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition: Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(9)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition: Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 205 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap ReclassificationLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition: Amount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(30)(a)(3)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef - Topic 852 - SubTopic 10 - Name Accounting Standards Codification - Section 55 - Paragraph 10 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 40 - Name Accounting Standards Codification - Section 65 - Paragraph 2 - Subparagraph (g)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 40 - Name Accounting Standards Codification - Section 65 - Paragraph 2 - Subparagraph (g)(2)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.7-03(a)(23)(a)(4)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.6-04(17)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 505 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.3-04) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition: Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(30)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://asc.fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(31)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef - Topic 852 - SubTopic 10 - Name Accounting Standards Codification - Section 55 - Paragraph 10 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef - Topic 946 - SubTopic 830 - Name Accounting Standards Codification - Section 55 - Paragraph 12 - Publisher FASB - URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.6-04(19)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.6-05(4)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(6)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(6)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(7)) - Publisher FASB - URI https://asc.fasb.org/1943274/214747

the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1:

<https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(1))) - Publisher FASB -URI

srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: us-gaap_ProductMember
Namespace Prefix: Data Type: us-gaap_ProductMember
USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023
Jun. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance \$ 1,933,381 \$ 1,821,880 \$ 1,615,765 \$ 1,525,058 \$ 1,447,027 \$ 1,405,930 \$ 1,270,666 \$ 1,615,765 \$ 1,615,765 \$ 1,270,666 Á Á Net income 67,025 41,473 133,352 57,061 61,309 11,514 45,899 174,825 241,850 118,722 175,783 146,930 (56,339) Ending balance 2,099,836 1,933,381 1,821,880 1,615,765 1,525,058 1,447,027 1,405,930 1,933,381 2,099,836 1,525,058 1,615,765 1,270,666 Á As Reported Á Á Á Á Á Á Á Á Á Á Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance 1,928,840 1,818,015 1,612,034 1,521,117 1,444,998 1,402,995 1,268,491 1,612,034 1,612,034 1,268,491 Á Á Net income 40,797 133,218 57,271 59,397 12,420 45,139 174,015 116,956 174,227 147,139 (60,018) Ending balance 1,928,840 1,818,015 1,612,034 1,521,117 1,444,998 1,402,995 1,268,491 1,928,840 1,521,117 1,612,034 1,268,491 Á Revision Á Á Á Á Á Á Á Á Á Á Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance 4,541 3,865 3,731 3,941 2,029 2,935 2,175 3,731 3,731 2,175 2,175 Á Á Net income 4,541 3,865 3,731 3,941 2,029 2,935 2,175 4,541 3,865 3,731 3,941 2,029 2,935 2,175 Á Retained Earnings Á Á Á Á Á Á Á Á Á Á Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance 609,805 568,332 434,980 377,919 316,610 305,096 259,197 434,980 434,980 259,197 Á Á Net income 67,025 41,473 133,352 57,061 61,309 11,514 45,899 Á Á Á Ending balance 676,830 609,805 568,332 434,980 377,919 316,610 305,096 609,805 676,830 377,919 434,980 259,197 Á Retained Earnings | As Reported Á Á Á Á Á Á Á Á Á Á Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance 605,264 564,467 431,249 373,978 314,581 302,161 257,022 431,249 431,249 257,022 Á Á Net income 40,797 133,218 57,271 59,397 12,420 45,139 Á Á Á Ending balance 605,264 564,467 431,249 373,978 314,581 302,161 257,022 Á Á Retained Earnings | Revision Á Á Á Á Á Á Á Á Á Á Increase (Decrease) in Stockholders' Equity [Roll Forward] Á Á Á Á Á Á Á Á Á Á Beginning balance 4,541 3,865 3,731 3,941 2,029 2,935 2,175 4,541 3,865 3,731 3,941 2,029 2,935 2,175 Á 4,541 Á 3,941 Á 3,731 Á 2,175 Á X - Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: per Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(ii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)

publ:fasb-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsAndNotesReceivable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInInventories Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (a) -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://asc.fasb.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a

[illegible]

[illegible]

[illegible]

ML5L5Z@<Q<7R5WATC)VX#>J6ONZFAXWMEF8!F+>8RFVXE&I|J+>5<M_3=N#N18TIT"OKI">#"/>DS4YKE/D3-MT-1+YC2M-1+>66=|UT>NZO-1.17IXL.9LS-W8-1+UT&
<=>D9PQ31JOH31M5YOPU2&F/!E4-!<S@>00HN|>=|NT%F.XM>C%24J7PMN?>=>R2J1M4L-W=DXHWL6=>=>KDV.N4.M5?T<02?NDXZ%F.YFLIC!%F&
7ZIL4Z.04B301!>|>K9EWMMDGVC9P/OPV3?71?T?Y&W_6&7?>|YFUSDJ|J?<S_#B%2285MDQXU|X2T?LA25.DIT86%7YU|?62?K|Y+T&831M6N1GMSU@/7H?E>SOX%M4\$!#H0|<
"REPUQGRANZP2|(|@>0+>PO-VIR-W.H665T3K#NKR1+0.6|E8C9Z4?>R&C<=>|PSF513X|+0JAUTS#1MND?A.O.<?>|U5Y|H|FM9A0|WH|L.VH9REY@JDP4?CAY<1!%T.7LMA|<|<
V|E2M4IDGYR4D|V@<E|E08Z1V@<I73(OCGL<+WE&H+K?7#WVK?M_1|H+4+M%3|9D-AZY41CEL-V|VH4V@&_Y4CLBN1_MRO|>1|HMC0L<8R2?ZT?|V=>=<S2?RO.XT.KR0?7S
|E.P8<0AIGZ4Z.WZ|>?>#?D<X*80R.XWVW1?M2-M2?>M0Q1WA|<|AFY2L5F|>|<D?JCS<4L.RBC3230LVOZL?|Z3L.M5?2PL+?R.VXG81?6H?9<=>31&7?>=<31&7?>
"SS.OLEK1WKP80SUALHXF#N#1.M2XMK.V.S.2|C<=>H.NV4L0?74.F4E|01&=AEHJL0R3|<5K1KEIR254J4&MDG&2CD<32&59J.X6\$181?|8DX@>=>A.LF<0BYUD&AH74U|<|KRI1#8
M2?PE<82-1L|<UUMZM2.NF.ZX?>|P9.OV3@<0=>SWSF&6C1K?TSV&PO-VIR-W.H665T3|E6QO|BAHLM-?7?G|>SS<+>|AUUCU?L|UZX93?1.H3U|G60|ZC<63W>?CYG|6L54Q|A?E-
1U2.MO@<V.OI9?NG<3.M48R1M6?42H|6I2O1|KBX3F6B?1&?E.P4R5?K52Y.M41.Y&CDD?1%0N#X>A30141+1?>+KOK<=<20?|7B1-0R2U>+D1|U3U9U&8.M5=4H&4&5&KRI&S>U<UUT|
<2&FZO?N"7LVK5>|<1.5.5G3|Z4>|R?2.G.A<M-%>|P|L4V#|H.0|<6&SZ.U&H?FE8C&<U?>.OO.H|Z-?U?|M?V55|5P6<=>L?ME<MR60E8&_L@?%>OYF9?>XM&B.5=X|7?|?>7&O4TFX
MO|>=>1&7&Z3O<=>L|<D.PMX+|U0O|0|8?Z1<N?>2APPO.7?0W|6E.M.TXK.15D.X3N.O.P|>#>M&B&B&M&O.U.S.VT|E7|U6|L+?6M|XK|W&4.S0V|H4U=MA0?6/8<|>|.OPF
MT1|8B?|+<F&Z4T?D>BK<YDAP1.Y&C@>87H|12?I0R?Y&K?#9B.MGCF|E19&X&H.4<4<=>|41|85SMV?TP@90?|LPY+8VP?CQ8M54&9S|H|YTW-8H|ME4IX|>Y+Y
|Z2MOR2NB&L+<N7L3K3B-84&2C&8Y=1_|J|UX6M.VU95.O?M.72G5GLV%>X&ZAVSSGGC|O#H&809?>J0M?>|1|Y&A2&|>BQPOQD?BQOFCPP?S.MTLB<=>YLP?B?EG.N760
2?S_1|U2Z90A|U|U923|<P|H|D.D&A3XK?T?M&EPH|F|U|S?|IXY<#?>1|18\$>G7A?<P|K&X?>X23\$|ZJ.DM.O&W&O.5L|HHS?>O|V|O?>1L?>4<H&9|O?F.DPSD15H?LFD|OK5W?WQ@<G
@<M.R<_M42>|DX.D81B+<6N4O|UKNUM|MD8M1.B.B<_O3-M?>|J|D|G|H?G|0|9|<1?>6&F|E|C@<OC&P&1TK1?L<=>M6G&N2M>P&COW|KIL4?7&6&S<|P|H|NR2>4<4.SV9O?Z=<Q&
|K|P=>N12+T990<O.MF8|>1<?>2.09%>D&S&X&C42<F?E=P|H?E.M?2?K&E?|Y4V6?2<N2|NR1?M?<S|W?>F.NNA9@<=>|AVP93|Z3S=15|H?>D
M1|G3|D4E1>NT&?V|7|KKC<Z|4DNCBRL4?KA.8T.ZY.O.LY@<0=>198?V.HH1#3G3G6?23?Y&KK62B.7|>84+CA.9A%|XAD&G.N26|?1F&4.CC3|C<SK.MC5=4|<H?2
R7U|U?N9|>78R05Z1|<=>=<=>W.O?|?P?N%W=<K"|3WYR#7>M0P048H6|L9GHVZO?W&VNZVH|5&LOMN1?>|<?|WU=>?V?Y&#3-7?|>M1+P04"|L6=9<=>+|1P?=>#P&60
<1L+W=0?E4&E|T29K<=>0|0M2.IB.Y=361|H|S21?2.DF10?5.9|30WT|5>E&K&S231R<3&Z?|<0N|>O?|Y?70C?6|0I00>|Y?Y.RHW.M80>|1%>2|N|P&166?2?C3?2USUK?
BVA?>|0D?M?>|.FO|O?R?XK1.M3LPN&C|X&XZ41S?2.4&NM&C&S?YB|DWSL|?CTW@|Y|PVO|>|<MOP|B|?G|<+H?>#B|X@<C&(\$Z.SW2WL.M3>=>|<0|G|O?V|8G?TKFM1280|1
4V|<U>|>?>2&E1R|U@<#<K1|89.M|9%>(<+X&A>|Y&E18W|MG|TU5|<A|X?<3B.Y5&#?>|G|U?L|<6"6"OE.Y.VM1&+<?02BW?2+E30?31VER|D2U2|>|<N<=>
M&F1|U|L8|WWDMP@<|I+V|M1|H<=>B-M|<X?<3|<0I06@<45.5WR|N&Y&S21P|M1P&G?C|<=>P&00M#3?<N&S_|B?<G|<6K.98B?F&S1SU2R?P?<8<=>670C2@<R&+?5|4|>2?>
M"CCF">4W?Z3C<U>|<G.21DMKYMX<M&MA|JOU<E34X?T|R7&3?|C92&H.M|L|JGRZ?>B4P2?>8|S5ED?<3XRSRT.MDQ|A|H&N&S?Z#<0=>P&?<K?<Y41-W&L&E1WHA
Y&W<4T|V+N?X&N&Y&R&W&E|M|<=>9133?813LUX&HUNRYN+?Z>8A|H.M|<S1A?>E233XU&W<ZKQ|04|G|OY.CX|SYU&UGL83?5?>|<H|<O&Q&0?<K3B?V0|RRB@<6&F&X2
|S6G|ZN&F5|6|92?C6|?>L?>B&S=5MB13?>=<6M11?5=PHR\$>Y&H?1%YX?|O?EU&?<F&E|AP0T?>|5C4?A.<?<F|>U8?M?P.YO?>Z&XU?<X?M&C?<8&G.9D|V>=>S&G&E=RT#?YR#4
6G|C|>=>8.YZ2Z33S.S0-JO.H|>|>DBT2|8D?>P&8&S&DB231M9|H|<=>F|U|H<R#5H3Q0<0?D?5.9M&M|<S?>2.5?YQ23S.M=Q0522D1-L#O?HX24%<CZG2.D.E3|61R.D.D>8|W.Z|H
V|U@<=>4VUW?U4.M1P#<KZW=>N-|?>BV3102P.S%<=>K*5G60&C|O=>@<5@<8D.IX.M|?W-W|K&U|C55-1|P?M|TKA#<=>+<96C1<98F.M|H?V|O|H|H\$>S=8-AAT4FXF?R|HGR767S|P=KP.38
>8HDB?|C?<9<=>U>XV|U=>K|RE2S|G.C.338|<(\$4?|H?4C#Z|<S&X>7?M?F|J2M.016AFK6B&8&I|<E.V.O|A0Q&O&H|DWTB&S_2&69.M|H?V?MAI43.M4O?T4D?<G&K|>|<=>W2MK<=>S%&V?>
O|L6.9.EK.X|<2RV.81FV|H|W|XV1.O.M|JYXO.S>=>UADG<A&G&Z

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

@KTLXUYU T6NPSK9Y M@VEPKC551L3G5L1#ZV6U4 FVUC9Z25P1UNN<+Y# HZXV>%E&L ML01-Q (-%+ P04 "L16=9JEIK00" IS"> @&0 AL+V=0XX3V04F96ZF071FEQ
 ME2DA&N3Q0HH/1U#11M01Q9K5XZ/1A K'K' NX80R60MF1+9. #RWOV.85M<C'192J1UARET1T1@7D70 MX31X13&EMJD Q@C.K3M&S=R4J41. GA7&PKB1JDC'F1H1UJ. 4BY\$5M
 M&E&MUUV7>+> @3. RUI11>A1<5 Z0KWH221YU' &V'H1H'J1H'. 1M272012'>C'>PCC7WD M.P.2Y'PIWRN1#R2J. 1# G01JX.R6TK'P'013Z02-B1#W0J. W=0072>OTVJ
 247275WGO>HEU>EL HS. =&ULM90M:N9C78. A1<2<L4V5D21Y1Z>=HF. 1T">D&8F1< KUY MD. &QF171Z>VC.W25WGR<R5W1Z>AVRW2 MFHO7T6W7E0E35IX
 1W4F219572MEZU41&SQ0QR= B7L21K>29J1#R<OL21J1. 1 M6Z<9J1 COFFK13<XXV+>GOZO C.IW'1H'Q1U VPVH. 2<C'U P1M(6D.Y'8M'==11F2G7B96RQ219719W.
 W7U2M'4>=>V>L'KFAK1N'U1C'RM'MJ1Z<NZJ1Z>=>15C5Z2'2M1J.R-MITS.15230#>5013A1<B3U597G71M'>K1U1'Y00F6R'=>G1T1'7> "R1I (2HNF6'<C7U4<Z.8K1U>=>MMA1-N
 M+1'N0Q03UN&K21K16V76DB0EWFJE. N270<1Y5QW1Z>7F3G0&SWO<O MU M'HCY8&XOPRC&F@C.U.CF17'G1M'>41U1'Z27ZN946.GY<<L0'>= MKZ8Y5.
 W7S.YX1F+>S.G1N9T19W. QM'XW'1C'&C2G&S'<5C.62F'2P1-RSU.MM'==&V6Q290 1E+ZW1UM1UJQG1F'>K1>5ZZ#>JDEAI=>#EFKWBW'Q8R' MU7 V27K7KOA2R2D'THO'FGC
 C.P.SD1G&S=N1.S1.T27N2Z07&W.FE1X#P.M.MJ1.HY1F+1. 1J6A3&1<4%MEF1'=>#5B0R51A'<W1L8%YQ9.8UTN1LHJ.M1E.6(EV1DLO.M
 J9Y'Q01M@M8H0&IAB'8#8&8YX.C'&H8X5H0=EU1 7%>USOZ<G>14 RA91Q M8+&P\$7<9921/4B.@EVY1NR 1<80N&UY\$>129VX'CC<K>J>P12FJSG#44 M5RDA9F1H)MPI<@'90
 1814C<F+1'LOXCFGL'FN' L LCO.S1.180SC.S MCG%>229212PDH0M31350<QW1= MF1M< T61R= X&=6.@AS434Y'ZV0VK MP
 A1. 1%7L'Z'>T'>@C8T8.Z'22@W075UB8 UTTEF71913&ZQB0A'F1< @013D MU'0122'0%ISEG/HLSB.K1\$E'U'6T'V1'>=>#GPI(13'>L0 3MD+<G?EN5 M\$VHAL\$&67
 3&P1Y1 JRD4A44H1H@1&181H&K1U1'&VBN81H'DH1V1. AD'V19' M@1D= T1MR. M#HA3.21J186Y52'&HDSN U'>#<G12.004'Q'QTE1PSCI Q17A8 M1K2P265D2>38'>0Q>P2V180Y
 56Q0&5'G82'&GFB>J1C@3 41&S 11T1 M#N81H1 2%&ADP10JPRE=F&X M.XH&S'&100X010'QMM&C'BL&6JCBH1' M461 UJCBGL'P0LH 2'1 P MLN1>Z'>F1%11'<NHHZ1'>#%J5
 W1NK60<T8E1Q105<=>#PAAH1U.G07T@W.M1NK&0<T8E1Q1O OXKPL1 P1P1P 2.2 2.21A1F1F1C Y0 2.2ZCHX1U1 1IDN'>#<K35G&B8A0&S1>1J4E'F'>#U08BT1' 2 M@I041#J1B+&E&P
 M1 P1R16161(N3B1L2 D1X1=HG 3%8.00D+ M2M4AB(AR2'Q1 BXSE'<#XCB8R13'<N1U1'&130H4Y3N3 1GGO4X1R21YH1'<#>ED591M7&N1>C1>W2 P0'<H&P1UXZ1L1
 1U8%1A1 L<+X6YMIU4\$=6.@MAS434Y'Z'VK1(WX167JW1'8Y&8\$<=<@R.K8.D2JQ1F9Z10C.B71<#<MC2S@'M R1+&A'01A'JAWCN.%40'IN'2@=>#H04#<ZB=W320R@<(HRA.M)1 4
 93.04C&S.GK1Y K4Y'P7&C7K1Y@<1@<10.HX3X L= MS&E296H120181P1'>77#6&S7.R61O'V1Y5.N.2M'1'7'1'FVYK1DG2'2'3C1HB MHP10@<F11 M5017>
 Q>SR1V&N1Q.GRDH1#>+> 2 FOI2A.YC1M1G1G1U' C7C M1X&R'DWD065 U12XFC1L1W8'83.5 W&NHFH ST E7T1LOWT ODW09'>9E9B H1R101'>#MNM1IA@186W'X'F'63T2@1'>#8M&C
 M@1D'1F3D301QOF1T1=65451&K'& M21G&S'<IR41KBE#141#SBR>Z1631S767A150MM+WH@UOG31A2CH<Q<1X M1Y1'>Y'CE1T'<LJLQ52'>MLX
 M5750R1V'<FMBR1F01Q@1H9C124=56@921@=>A'<F161904 M8U1>N7.6501'12KD>1832G14&AFG1W1'<R5SD5&Y'1H'<SV101'>1O9SQW<=>M1MRR1A1VX1V1
 1U1#&2.61DMR166191Q&C1A859T5 3'>PW COC.8'1 M6<3D<17X.G17R>=SQSIR 0ZP1'<625P1YX1Q1'&C'61F 98.S'<P01P42X1Z'2N&S'>D32&S7V1E1T1R1J14'<5'>W0ZM1@D1Y'<
 M1U1R1U1QX0Q17L1U'<8PM1A&S1.GN'>61 11WHD1 Y3YDDGRG1'<7517R2<E8941PM6M.FE1R1M1YVN.31U9'>P23% @=>1&1Y181IMFRD1341E86'>08HP1X MOA1'
 1#<17B1D1C1U003'U1.9&V1T7'&81.W'W'U1V1>D ZEG5.DH>>HX1161VW1M21C1<1&1L.M.G1Y'<0V&7L1B1E+>3Y31X&SXMZHF18<<D1LFC2F2'W&S2X1<8+
 M&K<ND1Z6'F02 F.E3Y1Y1M.FH1H6104VZFA1Z32=1H10<6'F<#<AF.5=03 M641LM1H1J'<9E.9144D18M1W1E1Z>#>JPZ1ZHEAR1+Z1FM38X1V>#01P'W9U1L MTZ>
 1< O O#%1&502.Z&Z&C'&Q'<X&S1'>18'6ZMP&A1KFW=14@1DP7M1U M1M'KMSFO'&XOZ&#<X7A 5&KEBC'8850.S'<1XZ&ULM90=1 D1OK51AN90A303BY26&G>=1KX3'>@S&W
 M.V7U9 W>>1V'52%MX1K1U71Y1Y1T1 E7M1B+11EM4M1<33ZF61E1RN1=M1@NWR17>=7M'1'6'<Q'N111KE8W1Y4AN39P7 7&GURVZ75G 71Q1NUV@Q7'<7 MOF1LSTW1P1GULT'>
 1'<P1OONX 5<19NRRS741R<K'>+>1OX1S71U1P41PW.MXV UO6.G12D192&C'12W1>W1>=>Y1WS3M1L1'7'>5&S16R>Q'7'>=312GGFW1
 M1Y>1O1NSP1L6>14KOB1S1M1W1R1Z1.EC'<1'>WGS17SE19>D>2Z>=ERIK M.G0T7&5.37ULKH1LX1SO805250'>QOY427Q1SNR.SN1 W=1U01E1SR19>1JMG1AN1M1VH1
 MNM2&C1W1Z'<MSS'M270EG1Q1 (<F&K1Q1OC12168T1F8&EY&X&E1Q575J1Q MO8 1#R1T2'>Y1KARRD=GSZNL U.W\$=T2'F7 76N19 C621J1M1HY M1R2'<NCF7>1'<1'50J.261%7&
 1'<P&M1H1Y.F1<1'<N'<S1E1R=1L1D1YV0'<8J2PBH2.8'>1U'>1LA2V.BTKD21N1M2'>514DQ17POH1B&S11D&QZ.N184M16&S'>X1K991AG210T24'<6Y'<8=7E2

[illegible]

[illegible]

1JGU#L13Z)UHFTR=>T.LX=&27.1JGU#L13Z)TG MPUB82Z)UHFTR=>T.LX=&27.1JGU#L13Z)VHMQ+HK-BW\$NBMJ+<2Z>VHMQ+H MK-BW\$NBMJ+<2Z>V3PR8>BOHKO1Z< JM\HKJZT>AOJ.O1Z&< IM\H.ZFTS M-AOJ.O1Z&< IM\H.ZFTS>AOJ.O1ZV~2P(< AGH=>Z&< AN\WHYZ>X>CGHI M<=>Z>CN\WHYZ>X>CGHI=>Z< CN\WHYZ>X>CGHI=>X>Z>Q-H>CWDZ>=>X-Z-M-P1Z-ZAWY>Z#H<7)HORWUQ+O\GHXOWVRWQU<Z>WQS8613T" #O.P\$&P %M#<YYT96Y7TUIY<&5S72YX M6\$6S-VHNV4Q<Q>70.FM2(CGV&SJO6EWN_5B+<XZD3DGVVRWHV_#H<FSJT MBBDGVA<H<I29\$<=>VUO<Q>Y1Z7QSZ.O<Q>9?I"PG+?>VSO?I< DAKFOYU1O MOJF<#<UWC583?Q6\$?JO(<=>A+<_OIG\$S76>WYK&B<I+<=>A+<OQV&3_.OY9%(<I MVGC,VB1FFKJVB-G&N9TJ#UO<B44C2?G/7<73OXI<DBR<O<=>W1>=>GWJ> MBREZ>3PQANWL4ADRVYS+C&N0?CY<S/GUXW.MCJ?>74RQD?76C/O?>8BOJ1M?O9XIO/V.OE<K&S>ZL&S/PV?RX<Q<G2%<_O<V2(1H)<?>2M\$?<O2A M(7U4D#16D#< IR?>41BJE+<A<2<8FL9366G1D36.TJKN84G<K<(<BJZ)<#<BBR M?HGC/B?<KH<O<I+<C<BBR<Q<N9R?<I09?<ZHS<A460N<K<5%UH<B<K1M<#<(6EID M<2BRB2UHLDB<K<I<J+<#<B1R2<(NDR<HVL?<K<(B<TF1M<3<(6EID+2FRE1A9.M2XJL4)476BD<K2&K&ULB<+<JBR<#<(NBR<HHLB<B<K<(HBJZ<J<(BBR<HHLB<K<MLB<J<#<JBR< (GNFR<HHLF<K<)HBJZ<(6EID2KBR5A19<VHL4)476BB<K1&K&U MHLA.462M?<N\$<N<Z<L1W<Q<X.CXYV.FW9X<F2_K<K<=>102P\$<_4 M<H<16E=91T?<8H\$<Q<=>9&I<C4)O<=>O M87?P+GAM:<#<+0<4QO<(<RE9UDOX6E<I<=>I<+I M<+<I D.V-O&UL M4\$!<A0#%<@<K*5G6?<1&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G M60<I&W8KD<P<LB4<I<=>I<^<QD <+<I W=O&PO=VIR-W-H M965T&UL4\$!<A0#%<@<K*5G6?<=&#R1<P V<D<I M<#<I Z#P<A1<I W=OQT<F7<8<=>9Q<I X<I W M<K&PO=VIR-W-H965T&UL M4\$!<A0#%<@<K*5G6?<PO=VIR-W-H965T&UL4\$!<A0#%<@<MK*5G63?7JES<I 0<PTT<I D<I W<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G6H18<@<Q<@<MG<8<I D<I<I<HH <+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G674<8BOUO<0<8B<=<I D M<#<I B<I Y<+<I W=O&PO=VIR-W-H M965T&UL4\$!<A0#%<@<K*5G65D<(<5U P D0<I D<I<Y<P<+<I M<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G M6?U F9?I KPD<I D<I<B&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G6?<@<K<EBI0<I L1 M<I D<I Z<I D<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G62<GML0<I 00<I D M<#<I P0P<+<I W=O&PO=VIR-W-H965T M&UL4\$!<A0# M%<@<K*5G6?<JZ1<=>B<4<I D<I<6IX<+<I W=O M&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G60<S C1<I 0<=>508<I D<I<2P<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G625N\$<N<I 21<I D<I M<#<I H&S<PO M=VIR-W-H965T&UL4\$!<A0#%<@<K*5G69<E<P HJ50 GS<I D<I<I M JF8<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G6<X>10H P<_O4<I D<I<QV<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G6<MFE<M<I 0<I D<I<I T7L<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G674K<I H<P B T D M<#<I<I THP<+<I W=O&PO=VIR M-W-H965T&UL M4\$!<A0#%<@<K*5G6?<118K2<P<=>I D<I<I Z<I M<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<MK*5G664<1<S<R P VOX<I D<I<O<I L1 W=O&UL4\$!<A0#%<@<K*5G6629>ZIF<I M&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G61<TOAM<?I<I D<I M<#<I U&PO=VIR-W-H M965T&SD0<I 0<_9 M<#<I<2W9<0IX<I W<M&K&UL4\$!<A0#%<@<K*5G69<YB&T<P<P L<I D<I<I<P<+<I M<+<I W=O0&+<I M<#<I P<0<@<I X<S>>PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G M67MAH<I P S<D<I D<I<I E<+<I L1 W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G69PL>P3<I @<G<M<I D<I<I>X<I<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G671*Q4<I D<I M<#<I<I<+<I W=O&PO=VIR-W-H965T M&UL4\$!<A0# M%<@<K*5G6<6PO<D<I<D14<I D<I<40H<+<I W=O M&PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G63<U MM<G<H<I R<I D<I<I<PO=VIR-W-H965T&UL4\$!<A0#%<@<K*5G6<=<S%<I< PT8<I D M<#<I 0<+<I W=O&PO M=VIR-W-H965T0<M<#<I 9<=>3PQ<@<I X<I W<M&K&UL4\$!<A0#%<@<K*5G69?<Z<I D<I<I M<#<I<+<I W=O&PO=VIR-W-H965T&UL4\$!<A0# M<#<I G&M<TEY<M&#<A7X<I D<I<7F4<+<I W=O&Q&PO7H<E>O<=>VIR~UO.VEN<=>UL<I G<E>:02P\$<_M<#<I 4<I L16<=>9S8613T" #O.P\$&P<@<6?P<6T<O.FGIE.G135?EP9?<=>GAM<+<I O8<P<I C<P<=>I&<end XML 103 Show is IDEFA-YRRL DOCUMENT<I Edgaar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission

Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=

```
f() Show.LastAR=null;var showAR=function(a,t,w){if(!Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e.parentNodeName!='TABLE')
var ref=(window?w=document:document).getElementById(r){if(ref){e=ref.cloneNode(0);e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e.e.style.display='block';Show.LastAR=c);Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.parentNodeName!='TABLE')e=e.nextSibling;if(!e.parentNodeName!='TABLE')e=e.nextSibling;if(!e.parentNodeName!='TABLE')
e.style.display=d;if(a.textContent){e.textContent=p+a.textContent.substr(1)}else{a.innerHTMLText=p+a.innerHTMLText.substr(1)}}}
XML 104 report.css XDEA: XBRL DOCUMENT
Updated 2009-11-04 %/v2.2.0.24 %/DefRef Styles %/report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
report table.authRefData { display: block; font-weight: bold; } report table.authRefData p { margin-top: 0px; } report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } report table.authRefData .hide a { hover { background-color: #2F4497; } report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } report table.authRefData table { font-size: 1em; } %/report Styles %/pl a: visited { color: black; text-decoration: none; } %/table %/
report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } report hr { border: 1px
solid #acf; } %/Top labels %/report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } report th { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; }
word-wrap: break-word; } report td.pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; } report td.pl div a { width: 200px; } report td.pl a { hover {
```

background-color: #fff; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report.rc { background-color: #f0f0f0; } /* Even rows... */ .report.re, .report.reu { background-color: #def; } .report.reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report.ro, .report.rou { background-color: white; } .report.rou td { border-bottom: 1px solid black; } .report.rou table td, .report.rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report.fn { white-space: nowrap; } /* styles for numeric types */ .report.num, .report.nump { text-align: right; white-space: nowrap; } .report.nump { padding-left: 2em; } .report.nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report.text { text-align: left; white-space: normal; } .report.text.big { margin-bottom: 1em; width: 17em; } .report.text.more { display: none; } .report.text.note { font-style: italic; font-weight: bold; } .report.text.small { width: 10em; } .report.sup { font-style: italic; } .report.outerFootnotes { font-size: 1em; } XML 106 Filing Summary.xml IDEA: XBRL DOCUMENT 3.24.3.html 623 364 1 false 97 0 false 12 false R1.htm 00000001-Document - Cover Sheet http://axon.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical-CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOESTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical-CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 9952157 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Revenues Sheet http://axon.com/role/Revenues Revenues Notes 9 false false R10.htm 9952159 - Disclosure - Cash, Cash Equivalents and Investments Sheet http://axon.com/role/CashCashEquivalentsandInvestments Cash, Cash Equivalents and Investments Notes 10 false false R11.htm 9952160 - Disclosure - Expected Credit Losses Sheet http://axon.com/role/ExpectedCreditLosses Expected Credit Losses Notes 11 false false R12.htm 9952161 - Disclosure - Inventory Sheet http://axon.com/role/Inventory Inventory Notes 12 false false R13.htm 9952162 - Disclosure - Goodwill and Intangible Assets Sheet http://axon.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 9952163 - Disclosure - Strategic Investments Sheet http://axon.com/role/StrategicInvestments Strategic Investments Notes 14 false false R15.htm 9952164 - Disclosure - Variable Interest Entities Sheet http://axon.com/role/VariableInterestEntities Variable Interest Entities Notes 15 false false R16.htm 9952165 - Disclosure - Accrued Liabilities Sheet http://axon.com/role/AccruedLiabilities Accrued Liabilities Notes 16 false false R17.htm 9952166 - Disclosure - Convertible Senior Notes Notes http://axon.com/role/ConvertibleSeniorNotes Convertible Senior Notes Notes 17 false false R18.htm 9952167 - Disclosure - Income Taxes Sheet http://axon.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 9952168 - Disclosure - Stockholders' Equity Sheet http://axon.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 9952169 - Disclosure - Line of Credit Sheet http://axon.com/role/LineofCredit Line of Credit Notes 20 false false R21.htm 9952170 - Disclosure - Commitments and Contingencies Sheet http://axon.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 9952171 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://axon.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 22 false false R23.htm 9952172 - Disclosure - Segment Data Sheet http://axon.com/role/SegmentData Segment Data Notes 23 false false R24.htm 9952173 - Disclosure - Business Acquisitions Sheet http://axon.com/role/BusinessAcquisitions Business Acquisitions Notes 24 false false R25.htm 9952174 - Disclosure - Subsequent Events Sheet http://axon.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 9952175 - Disclosure - Revision of Prior Period Financial Statements Sheet http://axon.com/role/RevisionofPriorPeriodFinancialStatements Revision of Prior Period Financial Statements Notes 26 false false R27.htm 9954410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbirl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 27 false false R28.htm 995443 - Disclosure - Insider Trading Arrangements Sheet http://xbirl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 28 false false R29.htm 9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies 29 false false R30.htm 9954472 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies 30 false false R31.htm 9954473 - Disclosure - Revenues (Tables) Sheet http://axon.com/role/RevenuesTables Revenues (Tables) Tables http://axon.com/role/Revenues 31 false false R32.htm 9954474 - Disclosure - Cash, Cash Equivalents and Investments (Tables) Sheet http://axon.com/role/CashCashEquivalentsandInvestmentsTables Cash, Cash Equivalents and Investments (Tables) Tables http://axon.com/role/CashCashEquivalentsandInvestments 32 false false R33.htm 9954475 - Disclosure - Expected Credit Losses (Tables) Sheet http://axon.com/role/ExpectedCreditLossesTables Expected Credit Losses (Tables) Tables http://axon.com/role/ExpectedCreditLosses 33 false false R34.htm 9954476 - Disclosure - Inventory (Tables) Sheet http://axon.com/role/InventoryTables Inventory (Tables) Tables http://axon.com/role/Inventory 34 false false R35.htm 9954477 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://axon.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://axon.com/role/GoodwillandIntangibleAssets 35 false false R36.htm 9954478 - Disclosure - Strategic Investments (Tables) Sheet http://axon.com/role/StrategicInvestmentsTables Strategic Investments (Tables) Tables http://axon.com/role/StrategicInvestments 36 false false R37.htm 9954479 - Disclosure - Variable Interest Entities (Tables) Sheet http://axon.com/role/VariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://axon.com/role/VariableInterestEntities 37 false false R38.htm 9954480 - Disclosure - Accrued Liabilities (Tables) Sheet http://axon.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://axon.com/role/AccruedLiabilities 38 false false R39.htm 9954481 - Disclosure - Convertible Senior Notes (Tables) Notes http://axon.com/role/ConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://axon.com/role/ConvertibleSeniorNotes 39 false false R40.htm 9954482 - Disclosure - Stockholders' Equity (Tables) Sheet http://axon.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://axon.com/role/StockholdersEquity 40 false false R41.htm 9954483 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://axon.com/role/AccumulatedOtherComprehensiveIncomeLoss 41 false false R42.htm 9954484 - Disclosure - Segment Data (Tables) Sheet http://axon.com/role/SegmentDataTables Segment Data (Tables) Tables http://axon.com/role/SegmentData 42 false false R43.htm 9954485 - Disclosure - Revision of Prior Period Financial Statements (Tables) Sheet http://axon.com/role/RevisionofPriorPeriodFinancialStatementsTables Revision of Prior Period Financial Statements (Tables) Tables http://axon.com/role/RevisionofPriorPeriodFinancialStatements 43 false false R44.htm 9954486 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails Organization and Summary of Significant Accounting Policies - Narrative (Details) Details http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details) Details 45 false false R46.htm 9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details) Details 46 false false R47.htm 9954489 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Warranty Reserve (Details) Sheet http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesSummaryofChangesinEstimatedWarrantyReserveDetails Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Warranty Reserve (Details) Details 47 false false R48.htm 9954490 - Disclosure - Revenues - Revenues by Products and Service Offerings (Details) Sheet http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails Revenues - Revenues by Products and Service Offerings (Details) Details 48 false false R49.htm 9954491 - Disclosure - Revenues - Revenues by Geographic Area (Details) Sheet http://axon.com/role/RevenuesRevenuesbyGeographicAreaDetails Revenues - Revenues by Geographic Area (Details) Details 49 false false R50.htm 9954492 - Disclosure - Revenues - Contract Assets, Contract Liabilities (Details) Sheet http://axon.com/role/RevenuesContractAssetsContractLiabilitiesDetails Revenues - Contract Assets, Contract Liabilities (Details) Details 50 false false R51.htm 9954493 - Disclosure - Revenues - Summary of Deferred Revenue (Details) Sheet http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails Revenues - Summary of Deferred Revenue (Details) Details 51 false false R52.htm 9954494 - Disclosure - Revenues - Remaining Performance Obligations (Details) Sheet http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails Revenues - Remaining Performance Obligations (Details) Details 52 false false R53.htm 9954495 - Disclosure - Cash, Cash Equivalents and Investments - Schedule Of Investments (Details) Sheet http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails Cash, Cash Equivalents and Investments - Schedule Of Investments (Details) Details 53 false false R54.htm 9954496 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details) Sheet http://axon.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails Cash, Cash Equivalents and Investments - Narrative (Details) Details 54 false false R55.htm 9954497 - Disclosure - Expected Credit Losses (Details) Sheet http://axon.com/role/ExpectedCreditLossesDetails Expected Credit Losses (Details) Details http://axon.com/role/ExpectedCreditLossesTables 55 false false R56.htm 9954498 - Disclosure - Expected Credit Losses - Type Of Customer Receivable (Details) Sheet http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails Expected Credit Losses - Type Of Customer Receivable (Details) Details 56 false false R57.htm 9954499 - Disclosure - Inventory (Details) Sheet http://axon.com/role/InventoryDetails Inventory (Details) Details http://axon.com/role/InventoryTables 57 false false R58.htm 9954500 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details) Sheet http://axon.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails Goodwill and Intangible Assets - Schedule of Goodwill (Details) Details 58 false false R59.htm 9954501 - Disclosure - Goodwill and Intangible Assets - Definite-Lived Intangible Assets Other than Goodwill (Details) Sheet http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails Goodwill and Intangible Assets - Definite-Lived Intangible Assets Other than Goodwill (Details) Details 59 false false R60.htm 9954502 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://axon.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 60 false false R61.htm 9954503 - Disclosure - Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Details) Sheet http://axon.com/role/GoodwillandIntangibleassetsEstimatedAmortizationExpenseofIntangibleAssetsDetails Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Details) Details 61 false false R62.htm 9954504 - Disclosure - Strategic Investments - Schedule Of Roll-Forward Of Strategic Investments (Details) Sheet http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails Strategic Investments - Schedule Of Roll-Forward Of Strategic Investments (Details) Details 62 false false R63.htm 9954505 - Disclosure - Strategic Investments - Narrative (Details) Sheet http://axon.com/role/StrategicInvestmentsNarrativeDetails Strategic Investments - Narrative (Details) Details 63 false false R64.htm 9954506 - Disclosure - Strategic Investments - Schedule Of Debt Security Strategic Investment (Details) Sheet http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails Strategic Investments - Schedule Of Debt Security Strategic Investment (Details) Details 64 false false R65.htm 9954507 - Disclosure - Variable Interest Entities (Details) Sheet http://axon.com/role/VariableInterestEntitiesDetails Variable Interest Entities (Details) Details http://axon.com/role/VariableInterestEntitiesTables 65 false false R66.htm 9954508 - Disclosure - Accrued Liabilities (Details) Sheet http://axon.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://axon.com/role/AccruedLiabilitiesTables 66 false false R67.htm 9954509 - Disclosure - Convertible Senior Notes - Narrative (Details) Notes http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails Convertible Senior Notes - Narrative (Details) Details 67 false false R68.htm 9954510 - Disclosure - Convertible Senior Notes - Net carrying amount (Details) Notes http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails Convertible Senior Notes - Net carrying amount (Details) Details 68 false false R69.htm 9954511 - Disclosure - Convertible Senior Notes - Estimated Fair Value (Details) Notes http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails Convertible Senior Notes - Estimated Fair Value (Details) Details 69 false false R70.htm 9954512 - Disclosure - Convertible Senior Notes - Interest Expense (Details) Notes http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails Convertible Senior Notes - Interest Expense (Details) Details 70 false false R71.htm 9954513 - Disclosure - Convertible Senior Notes - Hedge (Details) Notes http://axon.com/role/ConvertibleSeniorNotesHedgeDetails Convertible Senior Notes - Hedge (Details) Details 71 false false R72.htm 9954514 - Disclosure - Convertible Senior Notes - Warrants (Details) Notes http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails Convertible Senior Notes - Warrants (Details) Details 72 false false R73.htm 9954515 - Disclosure - Income Taxes (Details) Sheet http://axon.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://axon.com/role/IncomeTaxes 73 false false R74.htm 9954516 - Disclosure - Stockholders' Equity - 2024 eXponential Stock Plan and 2024 CEO Performance Award

Details) Sheet <http://axon.com/role/StockholdersEquity2024XponentialStockPlanand2024CEOPerformanceAwardDetails> Stockholders' Equity - 2024 eXponential Stock Plan and 2024 CEO Performance Award (Details) Details 74 false false R75.htm 9954517 - Disclosure - Stockholders' Equity - Operational Goals (Details) Sheet <http://axon.com/role/StockholdersEquityOperationalGoalsDetails> Stockholders' Equity - Operational Goals (Details) Details 75 false false R76.htm 9954518 - Disclosure - Stockholders' Equity - Summary of RSU and PSU Activity (Details) Sheet <http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails> Stockholders' Equity - Summary of RSU and PSU Activity (Details) Details 76 false false R77.htm 9954519 - Disclosure - Stockholders' Equity - RSU, PSU and Stock Option Activity - Additional Information (Details) Sheet <http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails> Stockholders' Equity - RSU, PSU and Stock Option Activity - Additional Information (Details) Details 77 false false R78.htm 9954520 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) Sheet <http://axon.com/role/StockholdersEquityStockOptionActivityDetails> Stockholders' Equity - Stock Option Activity (Details) Details 78 false false R79.htm 9954521 - Disclosure - Stockholders' Equity - Reported Stock-Based Compensation (Details) Sheet <http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails> Stockholders' Equity - Reported Stock-Based Compensation (Details) Details 79 false false R80.htm 9954522 - Disclosure - Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details) Sheet <http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails> Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details) Details 80 false false R81.htm 9954523 - Disclosure - Stockholders' Equity - At-the-Market equity offering - Additional Information (Details) Sheet <http://axon.com/role/StockholdersEquityAtTheMarketequityofferingAdditionalInformationDetails> Stockholders' Equity - At-the-Market equity offering - Additional Information (Details) Details 81 false false R82.htm 9954524 - Disclosure - Line of Credit (Details) Sheet <http://axon.com/role/LineofCreditDetails> Line of Credit (Details) Details 82 false false R83.htm 9954525 - Disclosure - Commitments and Contingencies (Details) Sheet <http://axon.com/role/CommitmentsandContingenciesDetails> Commitments and Contingencies (Details) Details 83 false false R84.htm 9954526 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet <http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails> Accumulated Other Comprehensive Income (Loss) (Details) Details 84 false false R85.htm 9954527 - Disclosure - Segment Data (Details) Sheet <http://axon.com/role/SegmentDataDetails> Segment Data (Details) Details 85 false false R86.htm 9954528 - Disclosure - Business Acquisitions (Details) Sheet <http://axon.com/role/BusinessAcquisitionsDetails> Business Acquisitions (Details) Details 86 false false R87.htm 9954529 - Disclosure - Subsequent Events (Details) Sheet <http://axon.com/role/SubsequentEventsDetails> Subsequent Events (Details) Details 87 false false R88.htm 9954530 - Disclosure - Revision of Prior Period Financial Statements - Balance Sheets (Details) Sheet <http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails> Revision of Prior Period Financial Statements - Balance Sheets (Details) Details 88 false false R89.htm 9954531 - Disclosure - Revision of Prior Period Financial Statements - Statements of Operations and Comprehensive Income (Details) Sheet <http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails> Revision of Prior Period Financial Statements - Statements of Operations and Comprehensive Income (Details) Details 89 false false R90.htm 9954532 - Disclosure - Revision of Prior Period Financial Statements - Shareholders' Equity (Details) Sheet <http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails> Revision of Prior Period Financial Statements - Shareholders' Equity (Details) Details 90 false false R91.htm 9954533 - Disclosure - Revision of Prior Period Financial Statements - Cash Flow Statement (Details) Sheet <http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails> Revision of Prior Period Financial Statements - Cash Flow Statement (Details) Details 91 false false All Reports Book All Reports axon-20240930.htm axon-20240930.xsd axon-20240930_cal.xml axon-20240930_def.xml axon-20240930_lab.xml axon-20240930_pre.xml <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/ed/2024> <http://xbrl.sec.gov/ed/2024> true JSON 109 MetaLinks.json IDEA: XBRL DOCUMENT - {"version": "2.2", "instance": "axon-20240930.htm", "nsPrefix": "axon", "nsURI": "http://axon.com/20240930", "dts": {"inline": "axon-20240930.htm"}, "schema": {"local": "axon-20240930.htm", "remote": "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ir/role/net-2009-12-16.xsd", "http://www.xbrl.org/ir/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "http://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/ed/2024/ed-2024.xsd", "https://xbrl.sec.gov/ed/2024/ed-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xml"}, "calculationLink": {"local": "axon-20240930_cal.xml"}, "definitionLink": {"local": "axon-20240930_def.xml"}, "labelLink": {"local": "axon-20240930_lab.xml"}, "presentationLink": {"local": "axon-20240930_pre.xml"}, "keyStandard": 325, "keyCustom": 39, "axisStandard": 30, "axisCustom": 0, "memberStandard": 54, "memberCustom": 43, "hidden": {"total": 8, "http://xbrl.sec.gov/ed/2024": 5, "http://xbrl.sec.gov/ed/2024": 2, "http://fasb.org/us-gaap/2024": 1, "contextCustom": 623, "entityCount": 1, "segmentCount": 97, "elementCount": 709, "unitCount": 12, "baseTaxonomies": {"http://fasb.org/us-gaap/2024": 1994, "http://xbrl.sec.gov/ed/2024": 29, "http://xbrl.sec.gov/ed/2024": 18, "report": {"R1": {"role": "http://axon.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "menuCat", "Cover": "order", "1": "firstAnchor", "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body": "html", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":

[illegible]

```

firstAnchor": "c-1", "name": "us-gaap:ScheduleOffInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOffInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R35": { "role": "http://axon.com/role/GoodwillAndIntangibleAssetsTables", "longName": "9954477 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "disclosure": "subGroupType", "tables": "menuCat", "Tables": "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R36": { "role": "http://axon.com/role/StrategicInvestmentsTables", "longName": "9954478 - Disclosure - Strategic Investments (Tables)", "shortName": "Strategic Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R37": { "role": "http://axon.com/role/VariableInterestEntitiesTables", "longName": "9954479 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R38": { "role": "http://axon.com/role/AccruedLiabilitiesTables", "longName": "9954480 - Disclosure - Accrued Liabilities (Tables)", "shortName": "Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R39": { "role": "http://axon.com/role/ConvertibleSeniorNotesTables", "longName": "9954481 - Disclosure - Convertible Senior Notes (Tables)", "shortName": "Convertible Senior Notes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R40": { "role": "http://axon.com/role/StockholdersEquityTables", "longName": "9954482 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "axon:EquityCompensationGoalsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "axon:EquityCompensationGoalsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R41": { "role": "http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954483 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R42": { "role": "http://axon.com/role/SegmentDataTables", "longName": "9954484 - Disclosure - Segment Data (Tables)", "shortName": "Segment Data (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R43": { "role": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsTables", "longName": "9954485 - Disclosure - Revision of Prior Period Financial Statements (Tables)", "shortName": "Revision of Prior Period Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R44": { "role": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954486 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "axon:WarrantyPeriodAfterPurchaseOfProduct", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "span": "div", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": "c-1", "name": "axon:WarrantyPeriodAfterPurchaseOfProduct", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "span": "div", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R45": { "role": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberofSharesOutstandingandEarningsPerShareDetails", "longName": "9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ { "span": "td", "tr", "table", "div", "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "contextRef": "c-13", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ { "span": "td", "tr", "table", "div", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, { "R46": { "role": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails", "longName": "9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:Antid
```

[illegible]

```

{"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": {"contextRef": "c-90", "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-90", "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R70": {"role": "http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "longName": "9954512 - Disclosure - Convertible Senior Notes - Interest Expense (Details)", "shortName": "Convertible Senior Notes - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": {"contextRef": "c-408", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-408", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R71": {"role": "http://axon.com/role/ConvertibleSeniorNotesHedgeDetails", "longName": "9954513 - Disclosure - Convertible Senior Notes - Hedge (Details)", "shortName": "Convertible Senior Notes - Hedge (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": {"contextRef": "c-412", "name": "us-gaap:DerivativeAmountOffHedgedItem", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-412", "name": "us-gaap:DerivativeAmountOffHedgedItem", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R72": {"role": "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails", "longName": "9954514 - Disclosure - Convertible Senior Notes - Warrants (Details)", "shortName": "Convertible Senior Notes - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": {"contextRef": "c-413", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-413", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R73": {"role": "http://axon.com/role/IncomeTaxesDetails", "longName": "9954515 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": {"contextRef": "c-3", "name": "us-gaap:DeferredTaxAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:DeferredTaxAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R74": {"role": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "longName": "9954516 - Disclosure - Stockholders' Equity - 2024 eXponential Stock Plan and 2024 CEO Performance Award (Details)", "shortName": "Stockholders' Equity - 2024 eXponential Stock Plan and 2024 CEO Performance Award (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": {"contextRef": "c-415", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-415", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R75": {"role": "http://axon.com/role/StockholdersEquityOperationalGoalsDetails", "longName": "9954517 - Disclosure - Stockholders' Equity - Operational Goals (Details)", "shortName": "Stockholders' Equity - Operational Goals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": {"contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R76": {"role": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "longName": "9954518 - Disclosure - Stockholders' Equity - Summary of RSU and PSU Activity (Details)", "shortName": "Stockholders' Equity - Summary of RSU and PSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": {"contextRef": "c-435", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-435", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R77": {"role": "http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails", "longName": "9954519 - Disclosure - Stockholders' Equity - RSU, PSU and Stock Option Activity - Additional Information (Details)", "shortName": "Stockholders' Equity - RSU, PSU and Stock Option Activity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": {"contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R78": {"role": "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "longName": "9954520 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)", "shortName": "Stockholders' Equity - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": {"contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R79": {"role": "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails", "longName": "9954521 - Disclosure - Stockholders' Equity - Reported Stock-Based Compensation (Details)", "shortName": "Stockholders' Equity - Reported Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": {"contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "uniqueAnchor": {"contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {"span": "td", "tr": "table", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "axon-20240930.htm", "first": true, "unique": true }}, "R80": {"role": "http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails", "longName": "9954522 - Disclosure - Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details)", "shortName": "Stockholders' Equity - Stock Incentive and Repurchase Plan - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
```


[illegible]

"terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent." } } } , "auth_ref": "r5", "r13", "r24", "r103", "r104", "r201", "r202", "r589", "r590", "r591", "r592", "r593", "r1040" } } } , "us-gaap-AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, weighted average useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in PnYnMnDtHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days." } } } , "auth_ref": "r368", "r839" } } } , "axon-AcquisitionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AcquisitionOneMember", "presentation": { "http://axon.com/role/StrategicInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Acquisition 1", "label": "Acquisition 1", "documentation": "Acquisition One [Member]" } } } , "auth_ref": { "ecd-Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } } , "auth_ref": "r962" } } } } , "us-gaap-AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 6.0 } } , "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } } , "auth_ref": "r94" } } } , "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } , "auth_ref": "r745", "r1051", "r1052", "r1053", "r1055", "r1155", "r1229" } } } , "ecd-AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } } , "auth_ref": "r975" } } } , "ecd-AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } } , "auth_ref": "r975" } } } , "ecd-AdjToNonPeeNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote", "label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]" } } } , "auth_ref": "r975" } } } , "ecd-AdjToPeeCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } } , "auth_ref": "r975" } } } , "axon-AdjustedGrossMargins": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AdjustedGrossMargins", "crdr": "credit", "presentation": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "terseLabel": "Consolidated adjusted gross margin", "label": "Adjusted Gross Margins", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } } , "auth_ref": { "us-gaap-AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Abstract" } } } , "auth_ref": { "axon-AdjustmentsToAdditionalPaidInCapitalReplacementAwardsIssuedInConnectionWithAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalReplacementAwardsIssuedInConnectionWithAcquisitions", "crdr": "credit", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "terseLabel": "Issuance of replacement awards in connection with acquisitions", "label": "Adjustments to Additional Paid in Capital, Replacement Awards Issued in Connection with Acquisitions", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of replacement awards in connection with acquisitions." } } } , "auth_ref": { "us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "crdr": "credit", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock under employee plans, net", "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement." } } } , "auth_ref": { "us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } } , "auth_ref": "r53", "r54", "r489" } } } , "ecd-AggtChngPnsnValInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } } , "auth_ref": "r1008" } } } , "ecd-AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } } , "auth_ref": "r934", "r944", "r954", "r986" } } } , "ecd-AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } } , "auth_ref": "r937", "r947", "r957", "r989" } } } , "ecd-AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } } , "auth_ref": "r1009" } } } , "ecd-AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } } , "auth_ref": "r975" } } } , "ecd-AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } } , "auth_ref": "r982" } } } , "ecd-AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Individuals [Member]" } } } , "auth_ref": "r938", "r948", "r958", "r982", "r990", "r994", "r1002" } } } , "ecd-AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } } , "auth_ref": "r1000" } } } , "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://axon.com/role/SegmentDataDetails": { "http://axon.com/role/StockholdersEquityRSPUSandStockOptionActivityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } , "auth_ref": "r518", "r520" } } } , "us-gaap-AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } } , "auth_ref": "r188", "r287", "r330", "r334", "r337", "r1195" } } } , "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "parentTag": "axon-AllowanceForExpectedCreditLossesOnCustomerReceivables", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentHetical": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Allowance on accounts receivable", "terseLabel": "Accounts receivable and notes receivable, current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } } , "auth_ref": "r188", "r287", "r330" } } } , "us-gaap-AllowanceForDoubtfulAccountsReceivableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableNoncurrent", "crdr": "credit", "calculation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "parentTag": "axon-AllowanceForExpectedCreditLossesOnCustomerReceivables", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-term notes receivable, net of current portion", "label": "Accounts Receivable, Allowance for Credit Loss, Noncurrent", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as noncurrent." } } } , "auth_ref": "r287", "r330" } } } , "axon-AllowanceForDoubtfulAccountsReceivableOther": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AllowanceForDoubtfulAccountsReceivableOther", "crdr": "credit", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Other, including foreign currency translation", "label": "Allowance For Doubtful Accounts Receivable Other", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable, other, including dispositions and foreign currency translation." } } } , "auth_ref": { "us-gaap-AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } , "auth_ref": { "us-gaap-AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Amounts written off charged against the allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } } , "auth_ref": "r336" } } } , "axon-AllowanceForExpectedCreditLossByTypeOfCustomerReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://axon.com/20240930", "localname": "AllowanceForExpectedCreditLossByTypeOfCustomerReceivableTableTextBlock", "presentation": { "http://axon.com/role/ExpectedCreditLossesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of allowance for expected credit losses for each type of customer receivable", "label": "Allowance For Expected Credit Loss By Type Of Customer Receivable [Table Text Block]", "documentation": "Tabular disclosure of allowance for expected credit loss by type of customer receivable." } } } , "auth_ref": { "axon-AllowanceForExpectedCreditLossesOnCustomerReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AllowanceForExpectedCreditLossesOnCustomerReceivables", "crdr": "credit", "calculation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": {

{ "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total allowance for expected credit losses on customer receivables", "label": "Allowance For Expected Credit Losses On Customer Receivables", "documentation": "Amount of allowance for expected credit losses on customer receivables." } } }, "auth_ref": { "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://axon.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": { "axon AmortizationOfAcquiredTechnologyIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AmortizationOfAcquiredTechnologyIntangibleAssets", "crdr": "debit", "presentation": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization Of Acquired Technology Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired technology intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": { "us-gaap AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization expense of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": { "r9", "r365", "r372", "r862" } }, "axon_AnotherCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AnotherCreditFacilityMember", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Another Credit Facility", "label": "Another Credit Facility", "documentation": "Another Credit Facility" } } }, "auth_ref": { "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationOfEPSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total potentially dilutive securities", "label": "Antidilutive Securities Excluded From Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r246" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationOfEPSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r36" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationOfEPSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationOfEPSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r36" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Carrying value of variable interest - assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r146", "r163", "r186", "r213", "r249", "r255", "r274", "r278", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r553", "r555", "r585", "r689", "r773", "r874", "r855", "r898", "r925", "r1117", "r1118", "r1181" } }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": { "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r180", "r190", "r213", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r553", "r555", "r585", "r689", "r773", "r874", "r855", "r898", "r925", "r1117", "r1118", "r1181" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": { "axon_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AtMarketOfferingMember", "presentation": { "http://axon.com/role/StockholdersEquityAtTheMarketequityofferingAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "ATM Equity Offering", "label": "ATM Equity Offering", "documentation": "Represents about At Market Offering Member." } } }, "auth_ref": { "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 }, "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r296" } }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 }, "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r297" } }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r293", "r344", "r688" } }, "axon_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses", "crdr": "debit", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Continuous unrealized loss position of available-for-sale investments, gross unrealized losses", "label": "Available for Sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Gross Unrealized Losses", "documentation": "This item represents the continuous unrealized loss position of available-for-sale investments, gross unrealized losses." } } }, "auth_ref": { "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available for Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r294", "r344", "r570", "r681", "r886", "r890", "r1067", "r1160", "r1161", "r1162" } }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r997" } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r998" } }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosure [Line Items]" } } }, "auth_ref": { "r993" } }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r993" } }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r993" } }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r993" } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r993" } }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r993" } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails": { "http://axon.com/role/StockholdersEquityOperationalGoalsDetails": { "http://axon.com/role/StockholdersEquityRSPSUandStockOptionActivityAdditionalInformationDetails": { "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": {

"r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517" }, "ecdAwardUnderlySecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUnderlySecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r496" } }, "ecdAwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r495" } }, "ecdAwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures {Table}" } } }, "auth_ref": { "r494" } }, "ecdAwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures {Table Text Block}" } } }, "auth_ref": { "r494" } }, "axonAxonBodyAndCameraAccessoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AxonBodyAndCameraAccessoriesMember", "presentation": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Axon Body Cameras and Accessories", "label": "Axon Body Cameras and Accessories" } } }, "auth_ref": { "axonAxonEvidenceMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AxonEvidenceMember", "presentation": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Axon Evidence and Cloud Services", "label": "Axon Evidence and cloud services", "documentation": "Axon Evidence {Member}" } } }, "auth_ref": { "axonAxonFleetSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "AxonFleetSystemsMember", "presentation": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Axon Fleet Systems", "label": "Axon Fleet Systems", "documentation": "Axon Fleet Systems {Member}" } } }, "auth_ref": { "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance {Axis}", "label": "Statement of Financial Position Location, Balance {Axis}", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r386", "r197", "r198" } }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance {Domain}", "label": "Statement of Financial Position Location, Balance {Domain}", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r72", "r74", "r386", "r197", "r198" } }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term deposits", "label": "Bank Time Deposits {Member}", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": { "r157" } }, "axonBasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://axon.com/20240930", "localname": "BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Use of Estimates", "label": "Basis Of Presentation And Use Of Estimates Policy {Policy Text Block}", "documentation": "Basis of presentation and use of estimates." } } }, "auth_ref": { "axonBrittanyBagleyMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "BrittanyBagleyMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Brittany Bagley {Member}", "documentation": "Represents information pertaining to Brittany Bagley, Chief Operating Officer and Chief Financial Officer." } } }, "auth_ref": { "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/StrategicInvestmentsNarrativeDetails", "http://axon.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree {Domain}", "label": "Business Acquisition, Acquiree {Domain}", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations) which may include the name or other type of identification of the acquiree." } } }, "auth_ref": { "r366", "r367", "r368", "r369", "r370", "r549", "r880", "r881" } }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/StrategicInvestmentsNarrativeDetails", "http://axon.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition {Axis}", "label": "Business Acquisition {Axis}", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": { "r56", "r59", "r366", "r367", "r368", "r369", "r370", "r549", "r880", "r881" } }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": { "http://axon.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": { "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r549" } }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Remaining interest acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": { "r57" } }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": { "r55" } }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation {Abstract}" } } }, "auth_ref": { "us-gaap_BusinessCombinationConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred", "crdr": "credit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "en-us": { "role": { "verboseLabel": "Consideration", "label": "Consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": { "r1", "r2", "r12" } }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://axon.com/role/BusinessAcquisitions" }, "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions", "label": "Business Combination Disclosure {Text Block}", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": { "r136", "r550" } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": { "r60" } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Identifiable intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": { "r60" } }, "axonBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredTaxLiabilities", "crdr": "credit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other net liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Excluding Deferred Tax Liabilities", "documentation": "Amount of liabilities excluding deferred taxes assumed at the acquisition date." } } }, "auth_ref": { "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue", "crdr": "credit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/StrategicInvestmentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": { "r17" } }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": { "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "crdr": "credit", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails", "http://axon.com/role/StrategicInvestmentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Gain on acquisition", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": { "r58" } }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy {Policy Text Block}", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": { "r137", "r138", "r139", "r140" } }, "axonCaitlinKalinowskiMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "CaitlinKalinowskiMember", "presentation": {

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, {"lang": "en-us", "role": "role", "label": "Caitlin Kalinowski [Member]", "documentation": "Caitlin Kalinowski" }, {"auth_ref": "I-1", "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CallOptionMember", "presentation": { "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails" } } }, {"http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails" }, {"lang": "en-us", "role": "role", "label": "Call options", "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } }, {"auth_ref": "r811", "r812" }, {"us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": { "http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWSParenthetical" }, {"lang": "en-us", "role": "role", "label": "Property and equipment purchases in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, {"auth_ref": "r30", "r31", "r32" } }, {"axon_CartridgesMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "CartridgesMember", "presentation": { "http://axon.com/role/RevenuesRevenuesByProductsandServiceOfferingsDetails" }, {"lang": "en-us", "role": "role", "label": "Cartridges", "label": "Cartridges [Member]" } } }, {"auth_ref": "I-1", "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": "en-us", "role": "role", "label": "Cash and Cash Equivalents [Abstract]", "label": "Cash and Cash Equivalents [Abstract]" } } }, {"auth_ref": "I-1", "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://axon.com/role/CODENSEDCONSOLIDATEDBALANCESHEETS" }, {"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } } }, {"http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWSParenthetical": { "parentTag": "us-gaap_CashAndCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } } }, {"presentation": { "http://axon.com/role/CODENSEDCONSOLIDATEDBALANCESHEETS" }, {"http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWSParenthetical" }, {"lang": "en-us", "role": "role", "label": "Cash and cash equivalents", "label": "Cash and Cash Equivalents at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, {"auth_ref": "r27", "r182", "r843" } }, {"us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails" } } }, {"lang": "en-us", "role": "role", "label": "Cash", "label": "Cash and Cash Equivalents Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "r1158", "r1159" } }, {"us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails" }, {"lang": "en-us", "role": "role", "label": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "I-1", "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "role", "label": "Restricted Cash", "label": "Cash and Cash Equivalents Restricted Cash and Cash Equivalents Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, {"auth_ref": "r28", "r145" } }, {"us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestments" }, {"lang": "en-us", "role": "role", "label": "Cash, Cash Equivalents and Investments", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, {"auth_ref": "r1066" } }, {"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWSParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } } }, {"presentation": { "http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWS" } } }, {"http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWSParenthetical" }, {"lang": "en-us", "role": "role", "label": "Cash and cash equivalents and restricted cash, beginning of period", "label": "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "r27", "r119", "r210" } }, {"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } } }, {"presentation": { "http://axon.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFASCASHFLOWS" }, {"lang": "en-us", "role": "role", "label": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "r3", "r119" } }, {"us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" }, {"lang": "en-us", "role": "role", "label": "Cash surrender value of corporate-owned life insurance policies", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, {"auth_ref": "r1158", "r1159", "r1160", "r1161", "r1162", "r1169" } }, {"axon_GeoPerformanceAward2024Member": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "GeoPerformanceAward2024Member", "presentation": { "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails" } } }, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, {"lang": "en-us", "role": "role", "label": "2024 CEO Performance Award", "label": "CEO Performance Award 2024 [Member]", "documentation": "Represents the information pertaining to 2024 CEO performance award." } } }, {"auth_ref": "I-1", "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract", "presentation": { "http://axon.com/role/RevenuesContractAssetsContractLiabilitiesDetails" }, {"lang": "en-us", "role": "role", "label": "Revenue recognized in the period from:", "label": "Change in Contract with Customer Asset and Liability [Abstract]" } } }, {"auth_ref": "I-1", "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "role", "label": "Changed Peer Group Footnote", "label": "Changed Peer Group Footnote [Text Block]" } } }, {"auth_ref": "r973" } }, {"ecd_ChngInFrValAsOfYstngDtOfPrYrEqtyAwrdsVstdnCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfYstngDtOfPrYrEqtyAwrdsVstdnCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, {"lang": "en-us", "role": "role", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, {"auth_ref": "r970" } }, {"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "role", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, {"auth_ref": "r968" } }, {"dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://axon.com/role/Cover" }, {"lang": "en-us", "role": "role", "label": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, {"auth_ref": "I-1", "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails" }, {"lang": "en-us", "role": "role", "label": "Shares (in shares)", "label": "Class of Warrant or Right Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into
```

"sharesItem": {"type": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": "http://axon.com/role/StockholdersEquityStockIncentiveAndRepurchasePlanAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Common stock reserved for issuance (in shares)", "label": "Common Stock Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance.", "auth_ref": "r93", "us-gaap": "CommonStockMember", "xbrli": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer.", "auth_ref": "r915", "r916", "r917", "r919", "r920", "r921", "r922", "r1051", "r1052", "r1055", "r1155", "r1228", "r1229", "us-gaap": "CommonStockParOrStatedValuePerShare", "xbrli": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical", "lang": "en-us", "role": "terseLabel", "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock.", "auth_ref": "r93", "us-gaap": "CommonStockSharesAuthorized", "xbrli": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical", "lang": "en-us", "role": "terseLabel", "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "auth_ref": "r93", "r761", "us-gaap": "CommonStockSharesIssued", "xbrli": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical", "lang": "en-us", "role": "terseLabel", "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "auth_ref": "r93", "us-gaap": "CommonStockSharesOutstanding", "xbrli": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical", "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "auth_ref": "r14", "r93", "r761", "r779", "r1229", "r1230", "us-gaap": "CommonStockValue", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 1.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": "en-us", "role": "terseLabel", "Common stock, \$0.00001 par value; 200,000,000 shares authorized; 76,084,179 and 75,301,424 shares issued and outstanding as of Septemberu00a0030, 2024, and Decemberu00a0031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "auth_ref": "r93", "r693", "r898", "ecd": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "auth_ref": "r979", "ecd": "CompActuallyPaidVsNetIncomeTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "auth_ref": "r978", "ecd": "CompActuallyPaidVsOtherMeasureTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "auth_ref": "r980", "ecd": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "label": "Compensation Actually Paid vs. Total Shareholder Return", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "auth_ref": "r977", "us-gaap": "CompensationRelatedCostsPolicyTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "lang": "en-us", "role": "terseLabel", "Stock-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "auth_ref": "r132", "r134", "us-gaap": "ComprehensiveIncomeNetOfTax", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails", "lang": "en-us", "role": "totalLabel", "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "auth_ref": "r25", "r197", "r199", "r204", "r683", "r702", "r703", "us-gaap": "ComprehensiveIncomeNoteTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": "http://axon.com/role/AccumulatedOtherComprehensiveIncomeLoss", "lang": "en-us", "role": "terseLabel", "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "auth_ref": "r102", "r203", "r682", "r700", "us-gaap": "ConcentrationRiskBenchmarkDomain", "xbrli": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "auth_ref": "r38", "r40", "r77", "r78", "r285", "r825", "us-gaap": "ConcentrationRiskByBenchmarkAxis", "xbrli": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk.", "auth_ref": "r38", "r40", "r77", "r78", "r285", "r739", "r825", "us-gaap": "ConcentrationRiskByTypeAxis", "xbrli": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to: asset, liability, net assets, geographic, customer, employees, supplier, lender.", "auth_ref": "r38", "r40", "r77", "r78", "r285", "r825", "r1020", "us-gaap": "ConcentrationRiskPercentage1", "xbrli": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Concentration risk (as a percentage)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the benchmark (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "auth_ref": "r38", "r40", "r77", "r78", "r285", "us-gaap": "ConcentrationRiskTypeDomain", "xbrli": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "auth_ref": "r38", "r40", "r77", "r78", "r285", "r825", "srt": "ConsolidatedEntitiesAxis", "xbrli": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": "http://axon.com/role/VariableInterestEntitiesDetails", "lang": "en-us", "role": "terseLabel", "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "auth_ref": "r215", "r553", "r554", "r555", "r556", "r607", "r831", "r1116", "r1119", "r1120", "srt": "ConsolidatedEntitiesDomain", "xbrli": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": "http://axon.com/role/VariableInterestEntitiesDetails", "lang": "en-us", "role": "terseLabel", "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "auth_ref": "r215", "r553", "r554", "r555", "r556", "r607", "r831", "r1116", "r1119", "r1120", "us-gaap": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "crdr": "credit", "calculation": "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails", "parentTag": "axon:AllowanceForExpectedCreditLossesOnCustomerReceivables", "weight": 1.0, "order": 3.0, "presentation": "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails", "lang": "en-us", "role": "terseLabel", "Contract assets, net", "label": "Contract with Customer, Asset, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "auth_ref": "r330", "r337", "r466", "us-gaap": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "xbrli": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": "http://axon.com/role/RevenuesTables", "lang": "en-us", "role": "terseLabel", "Summary of contract with customer, assets and liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "auth_ref": "r1122", "us-gaap": "ContractWithCustomerAssetNet", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": "http://axon.com/role/RevenuesContractAssetsContractLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Contract assets, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "auth_ref": "r464", "r466", "r477", "us-gaap": "ContractWithCustomerAssetNetCurrent", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap:Assets", "weight": 1.0, "order": 5.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails", "lang": "en-us", "role": "terseLabel", "Contract assets, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "auth_ref": "r464", "r466", "r477", "us-gaap": "ContractWithCustomerAssetNetNoncurrent", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetNoncurrent", "crdr": "debit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap:Assets", "weight": 1.0, "order": 8.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails", "lang": "en-us", "role": "terseLabel", "Long-term contract assets, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "auth_ref": "r464", "r466", "r477", "us-gaap": "ContractWithCustomerLiability", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://axon.com/role/RevenuesContractAssetsContractLiabilitiesDetails", "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "lang": "en-us", "role": "terseLabel", "Contract liabilities (deferred revenue)", "totalLabel": "Total", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "auth_ref": "r464", "r465", "r477", "us-gaap": "ContractWithCustomerLiabilityCurrent", "xbrli": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 }, "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Current portion of deferred revenue", "verboseLabel": "Current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": { "r464", "r465", "r477" } } }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Long-Term", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": { "r464", "r465", "r477" } } }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": { "http://axon.com/role/RevenuesContractAssetsContractLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amounts included in contract liabilities at the beginning of the period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": { "r478" } } }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "calculation": { "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "lang": { "en-us": { "role": { "totalLabel": "Convertible notes carrying amount, net", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": { "r21", "r149", "r1193" } } }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value of notes", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to the entity's common stock." } } }, "auth_ref": { "r1159", "r1160", "r1161", "r1162", "r1169" } } }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of net carrying amount of convertible senior notes", "label": "Convertible Debt Table Text Block", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": { "r1159", "r1160", "r1161", "r1162", "r1169" } } }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "verboseLabel": "Convertible notes, net", "label": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": { "r21" } } }, "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable Abstract", "label": "Convertible Notes Payable Abstract", "documentation": "Convertible Notes Payable Abstract" } } }, "auth_ref": { "r21" } } }, "axon_ConvertibleNoteHedge2027Member": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ConvertibleNoteHedge2027Member", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027 Note Hedge", "label": "Convertible Note Hedge 2027", "documentation": "It represents the information pertaining to convertible note hedge transaction (the 2027 Note Hedge) or 2027 Note Hedge) with certain investment banks, with respect to the Company's common stock concurrently with the issuance of the 2027 Notes." } } }, "auth_ref": { "r21" } } }, "axon_ConvertibleSeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ConvertibleSeniorNotesDue2027Member", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails": "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": "http://axon.com/role/LineofCreditDetails", "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027 Notes", "label": "Convertible Senior Notes, Due 2027", "documentation": "Convertible Senior Notes Due 2027 Member" } } }, "auth_ref": { "r21" } } }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleofInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities Member", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": { "r21" } } }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": { "r108", "r109", "r647" } } }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales and service sales", "label": "Cost of Sales Member", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": { "r21" } } }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://axon.com/role/LineofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility Axis", "label": "Credit Facility Axis", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { "r409", "r1114" } } }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://axon.com/role/LineofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility Domain", "label": "Credit Facility Domain", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { "r409", "r1114", "r1115" } } }, "us-gaap_CreditLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossAbstract", "lang": { "en-us": { "role": { "terseLabel": "Credit Loss Abstract", "label": "Credit Loss Abstract", "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security." } } }, "auth_ref": { "r288", "r289", "r332", "r340", "r341", "r342", "r343", "r345", "r349" } }, "us-gaap_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://axon.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": { "r21" } } }, "axon_CustomerDepositCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "CustomerDepositCurrent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Customer deposits", "label": "Customer Deposit, Current", "documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings." } } }, "auth_ref": { "r21" } } }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships Member", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": { "r64", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1100", "r1101" } } }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure Abstract", "label": "Debt Disclosure Abstract", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": { "r126", "r211", "r381", "r382", "r383", "r384", "r385", "r408", "r409", "r419", "r425", "r426", "r427", "r428", "r429", "r430", "r435", "r442", "r443", "r445", "r597" } } }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": "http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails", "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails", "http://axon.com/role/LineofCreditDetails": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Axis", "label": "Debt Instrument Axis", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": { "r21", "r83", "r84", "r147", "r149", "r215", "r420", "r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r464", "r465", "r466", "r467", "r468", "r469", "r1048", "r1103", "r1104", "r1105", "r1176", "r1178" } } }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://axon.com/role/LineofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument basis spread on variable rate (as a percentage)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": { "r21" } } }, "axon_DebtInstrumentBorrowingCapacityIncreaseAccordionFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "DebtInstrumentBorrowingCapacityIncreaseAccordionFeature", "crdr": "credit", "presentation": { "http://axon.com/role/LineofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accordion feature allowing for increase in borrowing capacity", "label": "Debt Instrument Borrowing Capacity Increase Accordion Feature", "documentation": "Debt instrument provision allowing for an increase in borrowing capacity." } } }, "auth_ref": { "r21" } } }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "verboseLabel": "Principal", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt


```
"instrument-at-time-of-issuance." } } }, "auth_ref": { "r420", "r597", "r598", "r865", "r866", "r897" } } }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrlType":  
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": {  
"http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate,  
Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue  
discount or premium." } } }, "auth_ref": { "r86", "r447", "r597", "r598", "r897" } } }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrlType": "percentItemType",  
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": {  
"http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": {  
"en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for  
funds borrowed under the debt agreement." } } }, "auth_ref": { "r86", "r421" } } }, "us-gaap_DebtInstrumentLineItems": { "xbrlType": "stringItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails":  
"http://axon.com/role/ConvertibleSeniorNotesHedgeDetails": "http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails",  
"http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails",  
"http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails": "http://axon.com/role/LineOfCreditDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Senior Convertible  
Notes", "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table.  
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r215", "r420",  
"r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r864", "r865", "r866", "r867", "r868", "r897",  
"r1048", "r1176", "r1178" } } }, "axon_DebtInstrumentMaturityPriorToStatedMaturityOfConvertibleSeniorNotes": { "xbrlType": "durationItemType", "nsuri":  
"http://axon.com/role/20240930", "localname": "DebtInstrumentMaturityPriorToStatedMaturityOfConvertibleSeniorNotes", "presentation": {  
"http://axon.com/role/LineOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maturity, prior to stated maturity of convertible senior notes", "label": "Debt  
Instrument, Maturity, Prior To Stated Maturity Of Convertible Senior Notes", "documentation": "The maturity period of debt, prior to stated maturity of convertible senior  
notes" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"DebtInstrumentNameDomain", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails":  
"http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails": "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails",  
"http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": "http://axon.com/role/LineOfCreditDetails",  
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name  
fDomain", "label": "Debt Instrument, Name fDomain", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt  
instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r21", "r215", "r420", "r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433",  
"r434", "r436", "r437", "r438", "r439", "r440", "r441", "r864", "r865", "r866", "r867", "r868", "r897", "r1048", "r1103", "r1104", "r1105", "r1176", "r1178" } } }, "us-  
gaap_DebtInstrumentRedemptionPricePercentage": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"DebtInstrumentRedemptionPricePercentage", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel":  
"Repurchase price (as percentage)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at  
which debt can be redeemed by the issuer." } } }, "auth_ref": { "r159" } } }, "us-gaap_DebtInstrumentTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-  
gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesEstimatedFairValueDetails":  
"http://axon.com/role/ConvertibleSeniorNotesHedgeDetails": "http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails",  
"http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails": "http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails",  
"http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails": "http://axon.com/role/LineOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term  
Debt Instruments fTable", "label": "Schedule of Long-Term Debt Instruments fTable", "documentation": "Disclosure of information about long-term debt instrument or  
arrangement." } } }, "auth_ref": { "r21", "r46", "r47", "r79", "r129", "r130", "r215", "r420", "r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433", "r434", "r436", "r437",  
"r438", "r439", "r440", "r441", "r444", "r864", "r865", "r866", "r867", "r868", "r897", "r1048", "r1176", "r1178" } } }, "us-  
gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": {  
"http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "parentTag": "us-gaap_ConvertibleDebt", "weight": -1.0, "order": 2.0 } } }, "presentation": {  
"http://axon.com/role/ConvertibleSeniorNotesNetcarryingamountDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label":  
"Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance  
costs." } } }, "auth_ref": { "r431", "r446", "r596", "r597", "r598", "r865", "r866", "r897" } } }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {  
"xbrlType": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",  
"presentation": { "http://axon.com/role/LineOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Variable Interest Rate, Type fExtensible  
Enumeration", "label": "Debt Instrument, Variable Interest Rate, Type fExtensible Enumeration", "documentation": "Indicates type of variable interest rate on debt  
instrument." } } }, "auth_ref": { "r687" } } }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrlType": "monetaryItemType",  
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": {  
"http://axon.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Securities in unrealized loss position for 12 months  
or longer", "label": "Debt Securities, Available For Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security  
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12  
months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r166", "r347", "r860" } } }, "us-  
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails": {  
"lang": { "en-us": { "role": { "terseLabel": "Debt securities in continuous loss position", "label": "Debt Securities, Available for Sale, Unrealized Loss Position",  
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in  
unrealized loss position without allowance for credit loss." } } }, "auth_ref": { "r165", "r346", "r860" } } }, "axon_DebtSecuritiesMarketableSecuritiesMember": { "xbrlType":  
"domainItemType", "nsuri": "http://axon.com/20240930", "localname": "DebtSecuritiesMarketableSecuritiesMember", "presentation": {  
"http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Debt  
Securities, Marketable Securities fMember", "documentation": "Debt Securities, Marketable Securities" } } }, "auth_ref": { } }, "us-gaap_DebtSecuritiesMember": { "xbrlType":  
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": {  
"http://axon.com/role/StrategicInvestmentsNarrativeDetails": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",  
"http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt investments", "label":  
"Debt Securities fMember", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } },  
"auth_ref": { "r44", "r917", "r1232" } } }, "us-gaap_DebtSecuritiesTradingUnrealizedGainLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
"localname": "DebtSecuritiesTradingUnrealizedGainLoss", "crdr": "credit", "presentation": { "http://axon.com/role/StrategicInvestmentsNarrativeDetails": { "lang": { "en-us": {  
"role": { "terseLabel": "Debt security strategic investment, unrealized gain", "label": "Debt Securities, Trading, Unrealized Gain (Loss)", "documentation": "Amount of  
unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": { "r1068", "r1070"  
} } }, "axon_DedroneHoldingsInc.Member": { "xbrlType": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "DedroneHoldingsInc.Member", "presentation": {  
"http://axon.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Dedrone Holdings, Inc.", "label": "Dedrone Holdings, Inc. fMember",  
"documentation": "Dedrone Holdings, Inc." } } }, "auth_ref": { } } }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrlType": "monetaryItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": {  
"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } } }, "presentation": {  
"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred compensation", "label": "Deferred  
Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation  
arrangements payable beyond one year (for the operating cycle, if longer)." } } }, "auth_ref": { } } }, "us-gaap_DeferredIncomeTaxAssetsNet": {
```

"LiabilityNumberOffinstrumentsHeld", "presentation": "http://axon.com/role/ConvertibleSeniorNotesHedgeDetails", "lang": "en-us", "role": "terseLabel", "Shares Purchased", "label": "Derivative Liability. Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative liability or group of derivative liabilities held by the entity.", "auth_ref": "r70", "r71", "us-gaap_DerivativePriceRiskOptionStrikePrice", "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativePriceRiskOptionStrikePrice", "presentation": "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails", "lang": "en-us", "role": "terseLabel", "Strike Price (in dollars per share)", "label": "Derivative, Price Risk Option Strike Price", "documentation": "The strike price on the price risk option contract such as a put option or a call option.", "auth_ref": "r812", "r813", "us-gaap_DevelopedTechnologyRightsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": "en-us", "role": "terseLabel", "Developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "auth_ref": "r141", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1100", "r1101", "us-gaap_DisaggregationOfRevenueLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "http://axon.com/role/RevenuesRevenuesByProductsandServiceOfferingsDetails", "http://axon.com/role/RevenuesSummaryOfDeferredRevenueDetails", "lang": "en-us", "role": "terseLabel", "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r476", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "us-gaap_DisaggregationOfRevenueTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "http://axon.com/role/RevenuesRevenuesByProductsandServiceOfferingsDetails", "http://axon.com/role/RevenuesSummaryOfDeferredRevenueDetails", "lang": "en-us", "role": "terseLabel", "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "auth_ref": "r476", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "us-gaap_DisaggregationOfRevenueTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": "http://axon.com/role/RevenuesTables", "lang": "en-us", "role": "terseLabel", "Summary of revenue by product and service offering and geography", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "auth_ref": "r1123", "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": "en-us", "role": "label", "Share-Based Payment Arrangement [Abstract]", "auth_ref": "def_DocumentFiscalPeriodFocus", "xbrltype": "FiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-Q statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "auth_ref": "Q1", "Q2", "Q3", "dei_DocumentFiscalYearFocus", "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "auth_ref": "dei_DocumentPeriodEndDate", "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "auth_ref": "dei_DocumentQuarterlyReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report.", "auth_ref": "r929", "dei_DocumentTransitionReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report.", "auth_ref": "r961", "dei_DocumentType", "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "auth_ref": "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRwRflctdInTtCompForCvrdYrMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRwRflctdInTtCompForCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "auth_ref": "r972", "axon_ExponentialStockUnitsMember", "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ExponentialStockUnitsMember", "presentation": "http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Exponential Stock Units", "label": "Exponential Stock Units", "documentation": "Exponential Stock Units [Member]", "auth_ref": "us-gaap_EarningsPerShareAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberofSharesOutstandingandEarningsPerShareDetails", "lang": "en-us", "role": "terseLabel", "Net income per common and common equivalent shares", "label": "Earnings Per Share [Abstract]", "auth_ref": "us-gaap_EarningsPerShareBasic", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberofSharesOutstandingandEarningsPerShareDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel", "Basic (in dollars per share)", "verboseLabel": "Net income per common and common equivalent - Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "auth_ref": "r205", "r221", "r222", "r224", "r225", "r226", "r228", "r233", "r235", "r243", "r244", "r245", "r248", "r547", "r552", "r567", "r568", "r684", "r704", "r847", "us-gaap_EarningsPerShareDiluted", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberofSharesOutstandingandEarningsPerShareDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel", "Diluted (in dollars per share)", "verboseLabel": "Net income per common and common equivalent - Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "auth_ref": "r205", "r221", "r222", "r224", "r225", "r226", "r228", "r235", "r243", "r244", "r245", "r248", "r547", "r552", "r567", "r568", "r684", "r704", "r847", "us-gaap_EarningsPerSharePolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "lang": "en-us", "role": "terseLabel", "Income per Common Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "auth_ref": "r36", "r37", "r247", "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": "en-us", "role": "terseLabel", "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r586", "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": "http://axon.com/role/IncomeTaxesDetails", "lang": "en-us", "role": "terseLabel", "Effective tax rate (as a percentage)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "auth_ref": "r528", "r885

```

http://axon.com/role/StockholdersEquityRSPUSandStockOptionActivityAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Unrecognized stock-based compensation expense"},"label":"Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"},"documentation":"Amount of cost not yet recognized for nonvested award under share-based payment arrangement."}}},"auth_ref":{"r519"}},"us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"},"xbrltype":"durationItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"},"presentation":{"http://axon.com/role/StockholdersEquityRSPUSandStockOptionActivityAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Weighted average period over which costs are recognized"},"label":"Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"},"documentation":"Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."}}},"auth_ref":{"r519"}},"us-gaap-EmployeeStockOptionMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EmployeeStockOptionMember"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Employee Stock Option"},"label":"Share-Based Payment Arrangement, Option {Member}"},"documentation":"Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."}}},"auth_ref":{"dei-EntityAddressAddressLine1"},"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityAddressAddressLine1"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Address, Address Line One"},"label":"Entity Address, Address Line One"},"documentation":"Address Line 1 such as Attn, Building Name, Street Name"}}},"auth_ref":{"dei-EntityAddressCityOrTown"},"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityAddressCityOrTown"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Address, City or Town"},"label":"Entity Address, City or Town"},"documentation":"Name of the City or Town"}}},"auth_ref":{"dei-EntityAddressPostalZipCode"},"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityAddressPostalZipCode"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Address, Postal Zip Code"},"label":"Entity Address, Postal Zip Code"},"documentation":"Code for the postal or zip code"}}},"auth_ref":{"dei-EntityAddressStateOrProvince"},"xbrltype":"stateOrProvinceItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityAddressStateOrProvince"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Address, State or Province"},"label":"Entity Address, State or Province"},"documentation":"Name of the state or province."}}},"auth_ref":{"dei-EntityCentralIndexKey"},"xbrltype":"centralIndexKeyItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityCentralIndexKey"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Central Index Key"},"label":"Entity Central Index Key"},"documentation":"A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."}}},"auth_ref":{"r927"}},"dei-EntityCommonStockSharesOutstanding":{"xbrltype":"sharesItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityCommonStockSharesOutstanding"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Common Stock, Shares Outstanding"},"label":"Entity Common Stock, Shares Outstanding"},"documentation":"Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A {Member}, Common Class B {Member} or Partnership Interest {Member} onto the Instrument {Domain} of the Entity Listings, Instrument."}}},"auth_ref":{"dei-EntityCurrentReportingStatus"},"xbrltype":"yesNoItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityCurrentReportingStatus"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Current Reporting Status"},"label":"Entity Current Reporting Status"},"documentation":"Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports) and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}},"auth_ref":{"dei-EntityEmergingGrowthCompany"},"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityEmergingGrowthCompany"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Emerging Growth Company"},"label":"Entity Emerging Growth Company"},"documentation":"Indicate if registrant meets the emerging growth company criteria."}}},"auth_ref":{"r927"}},"dei-EntityFileNumber":{"xbrltype":"fileNumberItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityFileNumber"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity File Number"},"label":"Entity File Number"},"documentation":"Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."}}},"auth_ref":{"dei-EntityFilerCategory"},"xbrltype":"filerCategoryItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityFilerCategory"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Filer Category"},"label":"Entity Filer Category"},"documentation":"Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}},"auth_ref":{"r927"}},"dei-EntityIncorporationStateCountryCode":{"xbrltype":"edgarStateCountryItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityIncorporationStateCountryCode"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Incorporation, State or Country Code"},"label":"Entity Incorporation, State or Country Code"},"documentation":"Two-character EDGAR code representing the state or country of incorporation."}}},"auth_ref":{"dei-EntityInteractiveDataCurrent"},"xbrltype":"yesNoItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityInteractiveDataCurrent"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Interactive Data Current"},"label":"Entity Interactive Data Current"},"documentation":"Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}},"auth_ref":{"r1011"}},"dei-EntityRegistrantName":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityRegistrantName"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Registrant Name"},"label":"Entity Registrant Name"},"documentation":"The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}},"auth_ref":{"r927"}},"dei-EntityShellCompany":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityShellCompany"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Shell Company"},"label":"Entity Shell Company"},"documentation":"Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}},"auth_ref":{"r927"}},"dei-EntitySmallBusiness":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntitySmallBusiness"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Small Business"},"label":"Entity Small Business"},"documentation":"Indicates that the company is a Smaller Reporting Company (SRC)."}}},"auth_ref":{"r927"}},"dei-EntityTaxIdentificationNumber":{"xbrltype":"employerIdItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"EntityTaxIdentificationNumber"},"presentation":{"http://axon.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Entity Tax Identification Number"},"label":"Entity Tax Identification Number"},"documentation":"The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}},"auth_ref":{"r927"}},"ecd-EqtyAwrdsAdjFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjFnTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Equity Awards Adjustments, Footnote"},"label":"Equity Awards Adjustments, Footnote {Text Block}"}"},"auth_ref":{"r966"}},"ecd-EqtyAwrdsAdjExclgValPrtdInSummaryCompstnTblMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjExclgValPrtdInSummaryCompstnTblMember"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Equity Awards Adjustments, Excluding Value Reported in Compensation Table"},"label":"Equity Awards Adjustments, Excluding Value Reported in the Compensation Table {Member}"}"},"auth_ref":{"r1007"}},"ecd-EqtyAwrdsAdjMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsAdjMember"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Equity Awards Adjustments"},"label":"Equity Awards Adjustments {Member}"}"},"auth_ref":{"r1007"}},"ecd-EqtyAwrdsInSummaryCompstnTblForApblYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"EqtyAwrdsInSummaryCompstnTblForApblYrMember"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table {Member}"},"label":"Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table {Member}"}"},"auth_ref":{"r1007"}},"us-gaap-EquityAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquityAbstract"},"lang":{"en-us":{"role":{"terseLabel":"Equity {Abstract}"},"label":"Equity {Abstract}"}"},"auth_ref":{"axon-EquityCompensationGoalsTableTextBlock"},"xbrltype":"textBlockItemType","nsuri":"http://axon.com/20240930","localname":"EquityCompensationGoalsTableTextBlock"},"presentation":{"http://axon.com/role/StockholdersEquityTables"},"lang":{"en-us":{"role":{"terseLabel":"Summary of operational goals"},"label":"Equity Compensation Goals {Table Text Block}"},"documentation":"Equity Compensation Goals {Table Text Block}"}"},"auth_ref":{"us-gaap-EquityComponentDomain"},"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquityComponentDomain"},"presentation":{"http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"},"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"},"http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsShareholdersEquityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Equity Component {Domain}"},"label":"Equity Component {Domain}"},"documentation":"Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}},"auth_ref":{"r14","r175","r200","r201","r202","r216","r217","r218","r220","r226","r229","r231","r250","r326","r329","r378","r463","r537","r538","r544","r545","r546","r548","r551","r552","r557","r558","r559","r560","r561","r562","r566","r587","r589","r590","r594","r592","r593","r600","r602","r606","r700","r728","r729","r730","r745","r799"}"},"axon-EquityInvestmentsMember":{"xbrltype":"domainItemType","nsuri":"http://axon.com/20240930","localname":"EquityInvestmentsMember"},"presentation":{"http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails"},"http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Equity investments"},"label":"Equity investments"},"documentation":"Represents equity investments."}}},"auth_ref":{"us-gaap-EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"},"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"},"crdr":"debit"},"calculation":{"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"},"parentTag":"us-gaap-Assets","weight":1.0,"order":6.0},"presentation":{"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"},"http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails"},"http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Strategic investments"},"label":"Strategic investments"},"periodStartLabel":"Balance, beginning of period","periodEndLabel":"Balance, end of period"},"label":"Equity Securities without Readily Determinable Fair Value, Amount"},"documentation":"Amount of investment in equity security without readily determinable fair value."}}},"auth_ref":{"r323"}"},"us-gaap-EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"},"crdr":"debit"},"presentation":{"http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails"},"http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails"},"lang":{"en-us":{"role":{"negatedLabel":"Unrealized losses and impairments"},"negatedTerseLabel":"Unrealized losses and impairments"},"label":"Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount"},"documentation":"Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value."
```

```

"role": "StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"href": "http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Equity Securities without Readily Determinable Fair Value",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"auth_ref": "r1071", "r1072", "r1073",
"localname": "Equity Securities Without Readily Determinable Fair Value Loss On Sale Of Securities",
"xbrltype": "monetaryItemType",
"nsuri": "http://axon.com/20240930",
"localname": "Equity Securities Without Readily Determinable Fair Value Loss On Sale Of Securities",
"credit": "debit",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"lang": "en-us",
"role": "negatedLabel",
"negatedLabel": "Realized losses",
"documentation": "Amount of loss from sale of investment in equity security without readily determinable fair value.",
"auth_ref": "http://axon.com/20240930",
"localname": "Equity Securities Without Readily Determinable Fair Value Purchases",
"xbrltype": "monetaryItemType",
"nsuri": "http://axon.com/20240930",
"localname": "Equity Securities Without Readily Determinable Fair Value Purchases",
"credit": "debit",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Investments",
"documentation": "Amount of purchases of equity securities without readily determinable fair value.",
"auth_ref": "http://axon.com/20240930",
"localname": "Equity Securities Without Readily Determinable Fair Value Sales",
"xbrltype": "monetaryItemType",
"nsuri": "http://axon.com/20240930",
"localname": "Equity Securities Without Readily Determinable Fair Value Sales",
"credit": "credit",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"lang": "en-us",
"role": "negatedLabel",
"negatedLabel": "Sales",
"documentation": "Amount of sales of equity securities without readily determinable fair value.",
"auth_ref": "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Equity Securities Without Readily Determinable Fair Value Table",
"presentation": "http://axon.com/role/StrategicInvestmentsNarrativeDetails",
"href": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Equity Securities without Readily Determinable Fair Value",
"documentation": "Disclosure of information about investment in equity security without readily determinable fair value.",
"auth_ref": "r1071", "r1072", "r1073",
"us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Equity Securities Without Readily Determinable Fair Value Table Text Block",
"presentation": "http://axon.com/role/StrategicInvestmentsTables",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Schedule of roll-forward of strategic investments",
"documentation": "Equity Securities without Readily Determinable Fair Value Table Text Block",
"tabular disclosure of investment in equity security without readily determinable fair value.",
"auth_ref": "r1071", "r1072", "r1073",
"us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount",
"credit": "credit",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Unrealized gains",
"documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
"auth_ref": "r324",
"ecd_EquityValuationAssumptionDifferenceFnTextBlock",
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Equity Valuation Assumption Difference Fn Text Block",
"presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Equity Valuation Assumption Difference. Footnote",
"documentation": "Equity Valuation Assumption Difference. Footnote [Text Block]",
"auth_ref": "r976",
"ecd_ErrCompAnalysisTextBlock",
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompAnalysisTextBlock",
"presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Erroneous Compensation Analysis",
"documentation": "Erroneous Compensation Analysis [Text Block]",
"auth_ref": "r934", "r944", "r954", "r986",
"ecd_ErrCompRecoveryTable",
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompRecoveryTable",
"presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Erroneously Awarded Compensation Recovery",
"documentation": "Erroneously Awarded Compensation Recovery [Table]",
"auth_ref": "r931", "r941", "r951", "r983",
"us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
"presentation": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsCashFlowStatementDetails",
"href": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsShareholdersEquityDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Error Corrections and Prior Period Adjustments Restatement",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"auth_ref": "r221", "r222", "r223", "r228", "r229", "r230", "r231", "r248",
"ecd_ExecutiveCategoryAxis",
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ExecutiveCategoryAxis",
"presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Executive Category",
"documentation": "Executive Category [Axis]",
"auth_ref": "r982",
"axon_ExpiringInTwoThousandTwentyFourMember",
"xbrltype": "domainItemType",
"nsuri": "http://axon.com/20240930",
"localname": "ExpiringInTwoThousandTwentyFourMember",
"presentation": "http://axon.com/role/CommitmentsandContingenciesDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Expiring In Two Thousand Twenty Four",
"documentation": "Expiring In Two Thousand Twenty Four [Member]",
"auth_ref": "http://axon.com/20240930",
"localname": "ExponentialStockPlan2024Member",
"xbrltype": "domainItemType",
"nsuri": "http://axon.com/20240930",
"localname": "ExponentialStockPlan2024Member",
"presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"href": "http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "2024 Employee XSP",
"documentation": "Exponential Stock Plan 2024 [Member]",
"presentation": "http://axon.com/role/StockholdersEquityOperationalGoalsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "2024 XSUs",
"documentation": "Exponential Stock Units [Member]",
"presentation": "http://axon.com/role/StockholdersEquityOperationalGoalsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Extended Warranties",
"documentation": "Extended Warranties [Member]",
"auth_ref": "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Strategic Investments",
"documentation": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
"auth_ref": "us-gaap_FairValueByFairValueHierarchyLevelAxis",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value By Fair Value Hierarchy Level Axis",
"presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]",
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"auth_ref": "r433", "r481", "r482", "r483", "r484", "r485", "r486", "r569", "r571", "r572", "r573", "r574", "r577", "r578", "r580", "r614", "r615", "r616", "r665", "r666", "r677", "r678", "r679", "r686", "r690",
"us-gaap_FairValueInputsLevel1Member",
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Inputs Level 1 Member",
"presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Level 1",
"documentation": "Fair Value, Inputs, Level 1 [Member]",
"presentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"auth_ref": "r433", "r481", "r486", "r571", "r578", "r614", "r677", "r678", "r679", "r686",
"us-gaap_FairValueInputsLevel2Member",
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Inputs Level 2 Member",
"presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Level 2",
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"auth_ref": "r433", "r481", "r486", "r571", "r572", "r578", "r615", "r665", "r666", "r677", "r678", "r679", "r686",
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases Sales Issuances Settlements Abstract",
"presentation": "http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Fair value adjustments",
"documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]",
"auth_ref": "us-gaap_FairValueMeasurementsFairValueHierarchyDomain",
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Measurements Fair Value Hierarchy Domain",
"presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]",
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"auth_ref": "r433", "r481", "r482", "r483", "r484", "r485", "r486", "r569", "r571", "r572", "r573", "r574", "r577", "r578", "r580", "r614", "r615", "r616", "r665", "r666", "r677", "r678", "r679", "r686", "r690",
"us-gaap_FairValueOffFinancialInstrumentsPolicy",
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Fair Value Off Financial Instruments Policy",
"presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
"lang": "en-us",
"role": "terseLabel",
"terseLabel": "Fair Value Measurements and Financial Instruments",
"documentation": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
"presentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"auth_ref": "r11",
"us-gaap_FinancialInstrumentAxis",
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",

```

"PIY5M13D": represents the reported fact of one year, five months, and thirteen days." } }], "auth_ref": ["r184", "r351", "r371", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r184", "r351", "r371", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1098", "r1236"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r373", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024 remaining", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1236"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r373", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r373", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r373", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r373", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r364", "r366", "r367", "r368", "r370", "r371", "r375", "r376", "r648", "r649", "r839"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r351", "r371", "r649", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r364", "r371", "r375", "r376", "r377", "r648", "r839", "r862"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r364", "r366", "r367", "r368", "r370", "r371", "r375", "r376", "r839"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": null, "order": null, "root": true }, "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "http://axon.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r648", "r1097"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r938", "r948", "r958", "r990"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r938", "r948", "r958", "r990"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r938", "r948", "r958", "r990"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r938", "r948", "r958", "r990"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r938", "r948", "r958", "r990"] }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PypDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r971"] }, "axon_FususIncMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "FususIncMember", "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fusus, LLC", "label": "Fusus Inc [Member]", "documentation": "Represents Fusus, LLC." } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on strategic investments and marketable securities, net", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": ["r113", "r115", "r1012"] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": { "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": ["r139", "r825"] }, "axon_GeographicInformationAndMajorCustomersPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://axon.com/20240930", "localname": "GeographicInformationAndMajorCustomersPolicyTextBlock", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies": {

{ "en-us": { "role": { "terseLabel": "Geographic Information and Major Customers - Suppliers", "label": "Geographic Information and Major Customers - Policy Text Block"}, "documentation": "Disclosure of accounting policy for Geographic Information and Major Customers." } }, { "auth_ref": { "us-gaap_Goodwill": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://axon.com/role/BusinessAcquisitionsDetails": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Goodwill", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } }, "auth_ref": { "r183", "r352", "r680", "r855", "r861", "r887", "r898", "r1080", "r1087" } }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired", "label": "Goodwill Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } }, "auth_ref": { "r355", "r861" } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrlType": "stringItem", "stringItem": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } }, "auth_ref": { "r355", "r861" } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssets": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } }, "auth_ref": { "r1078", "r1090" } }, "us-gaap_GoodwillAndIntangibleAssetsIndefiniteLivedPolicy": { "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIndefiniteLivedPolicy", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Valuation of Goodwill, Intangibles and Long-lived Assets", "label": "Goodwill and Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets." } }, "auth_ref": { "r1090" } }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } }, "auth_ref": { "r359" } }, "us-gaap_GoodwillLineItems": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill Line Items", "label": "Goodwill Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": { "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r861" } }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase accounting adjustments", "label": "Goodwill Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } }, "auth_ref": { "r0", "r1086" } }, "us-gaap_GoodwillRollForward": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": { "http://axon.com/role/GoodwillAndIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Changes in carrying amount of goodwill", "label": "Goodwill Roll Forward", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } }, "auth_ref": { "r359" } }, "us-gaap_GrossProfit": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } }, "auth_ref": { "r106", "r110", "r162", "r213", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r585", "r849", "r854", "r1058", "r1060", "r1061", "r1062", "r1063", "r1117" } }, "us-gaap_GuaranteeObligationsByNatureAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsByNatureAxis", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Guarantor Obligations, Nature [Axis]", "label": "Guarantor Obligations, Nature [Axis]", "documentation": "Information by nature of guarantee." } }, "auth_ref": { "r399", "r400", "r401", "r402" } }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsCurrentCarryingValue", "crdr": "credit", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding amount", "label": "Guarantor Obligations, Current Carrying Value", "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees." } }, "auth_ref": { "r401" } }, "us-gaap_GuaranteeObligationsNatureDomain": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsNatureDomain", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Guarantor Obligations, Nature [Domain]", "label": "Guarantor Obligations, Nature [Domain]", "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees." } }, "auth_ref": { "r399", "r400", "r401", "r402" } }, "axson_HardwareEquipmentMember": { "xbrlType": "domainItem", "nsuri": "http://axon.com/20240930", "localname": "HardwareEquipmentMember", "presentation": { "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Hardware", "label": "Hardware", "documentation": "Hardware Equipment [Member]" } }, "auth_ref": { "r399", "r400", "r401", "r402" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "label": "Income (loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } }, "auth_ref": { "r107", "r155", "r162", "r685", "r698", "r849", "r854", "r1058", "r1060", "r1061", "r1062", "r1063" } }, "us-gaap_IncomeStatementAbstract": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } }, "auth_ref": { "r399", "r400", "r401", "r402" } }, "us-gaap_IncomeStatementLocationAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } }, "auth_ref": { "r379", "r386", "r387", "r575", "r576", "r579", "r725", "r727", "r784", "r839", "r889", "r1199" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } }, "auth_ref": { "r386", "r387", "r575", "r576", "r579", "r725", "r727", "r784", "r839", "r889", "r1199" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } }, "auth_ref": { "r399", "r400", "r401", "r402" } }, "us-ga

"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }}, "presentation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r646", "r1045" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails"}}, "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r8" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Change in assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { } }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails"}}, "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": { "r8" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails", "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of 2027 Warrants (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": { "r236", "r237", "r238", "r245" } }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails", "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of 2027 Notes (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": { "r240", "r241", "r245" } }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails", "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of stock-based awards (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share-based payment arrangements using the treasury stock method." } } }, "auth_ref": { "r236", "r237", "r239", "r245", "r491" } }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r364", "r369", "r374", "r862" } }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r364", "r374", "r377", "r862" } }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Total non-amortizable intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r351", "r374", "r862" } }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": { "r364", "r369", "r374", "r862" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": { "r938", "r948", "r958", "r982", "r990", "r994", "r1002" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r1000" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r930", "r1006" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r930", "r1006" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r930", "r1006" } }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, Gross Carrying Amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": { "r183" } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, Net Carrying Amount", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r364", "r1097", "r1099" } }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": {
"http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "lang": { "en-us": { "role": { "totalLabel": "Total interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating, includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": { "r249", "r255", "r259", "r265", "r278", "r595", "r854", "r855" } }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": {
"http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://axon.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Contractual interest expense", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": { "r114", "r440", "r867", "r868" } }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of interest expense of convertible senior notes", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": { } }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/SegmentDataDetails"}}, "lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": { "r854", "r1043", "r1060" } }, "us-gaap_InternetDomainNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-

```

axson/2024", "localname": "InternetDomainNamesMember", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": "en-us", "role": "terseLabel", "Domain names", "label": "Internet Domain Names [Member]", "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.", "auth_ref": "r62", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1100", "r1101", "us-gaap_InventoriesDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]", "auth_ref": "us-gaap_InventoriesDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": "http://axon.com/role/Inventory", "lang": "en-us", "role": "terseLabel", "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "auth_ref": "r350", "us-gaap_InventoriesFinishedGoods", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": "http://axon.com/role/InventoryDetails", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0, "presentation": "http://axon.com/role/InventoryDetails", "lang": "en-us", "role": "terseLabel", "Inventory", "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "auth_ref": "r1036", "us-gaap_InventoriesNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0, "http://axon.com/role/InventoryDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/InventoryDetails", "lang": "en-us", "role": "terseLabel", "Inventory", "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "auth_ref": "r189", "r844", "r898", "us-gaap_InventoriesRawMaterials", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": "http://axon.com/role/InventoryDetails", "parentTag": "us-gaap_InventoriesNet", "weight": 1.0, "order": 1.0, "presentation": "http://axon.com/role/InventoryDetails", "lang": "en-us", "role": "terseLabel", "Raw materials", "label": "Inventory. Raw Materials. Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "auth_ref": "r1037", "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": "en-us", "role": "terseLabel", "Investments. Debt and Equity Securities [Abstract]", "label": "Investments. Debt and Equity Securities [Abstract]", "auth_ref": "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": "http://axon.com/role/StrategicInvestments", "lang": "en-us", "role": "terseLabel", "Strategic Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities.", "auth_ref": "r158", "r173", "r290", "r291", "r582", "r583", "r1190", "us-gaap_LetterOfCreditMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": "http://axon.com/role/LineOfCreditDetails", "lang": "en-us", "role": "terseLabel", "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "auth_ref": "us-gaap_LettersOfCreditOutstandingAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": "http://axon.com/role/CommitmentsandContingenciesDetails", "http://axon.com/role/LineOfCreditDetails", "lang": "en-us", "role": "terseLabel", "Letters of credit outstanding amount", "label": "Letters of Credit Outstanding. Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "auth_ref": "us-gaap_Liabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails", "lang": "en-us", "role": "totalLabel", "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.", "auth_ref": "r21", "r83", "r84", "r85", "r88", "r89", "r90", "r91", "r213", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r554", "r555", "r556", "r585", "r759", "r848", "r925", "r1117", "r1181", "r1182", "us-gaap_LiabilitiesAndStockholdersEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails", "lang": "en-us", "role": "totalLabel", "Total liabilities and stockholders'2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": "r98", "r151", "r696", "r998", "r1049", "r1074", "r1173", "us-gaap_LiabilitiesAndStockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": "en-us", "role": "terseLabel", "LIABILITIES AND STOCKHOLDERS'2019 EQUITY", "label": "Liabilities and Equity [Abstract]", "auth_ref": "us-gaap_LiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails", "lang": "en-us", "role": "totalLabel", "Total current liabilities", "label": "Liabilities. Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "auth_ref": "r87", "r181", "r213", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r554", "r555", "r556", "r585", "r898", "r1117", "r1181", "r1182", "us-gaap_LiabilitiesCurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": "en-us", "role": "terseLabel", "Current liabilities", "label": "Liabilities. Current [Abstract]", "auth_ref": "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0, "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": "en-us", "role": "terseLabel", "Liability for unrecognized tax benefits", "label": "Liability for Uncertainty in Income Taxes. Noncurrent", "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "auth_ref": "r69", "axon_LineOfCreditFacilityAccordionFeatureIncreaseLimit", "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": "http://axon.com/role/ConvertibleSeniorNotesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Additional principal amount purchase option", "label": "Line of Credit Facility. Accordion Feature. Increase Limit", "documentation": "Amount of option to purchase additional principal amount of convertible senior notes.", "auth_ref": "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": "http://axon.com/role/LineOfCreditDetails", "lang": "en-us", "role": "terseLabel", "Line of credit borrowings", "label": "Line of Credit Facility. Fair Value of Amount Outstanding", "documentation": "Fair value of the amount outstanding under the credit facility.", "auth_ref": "r584", "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": "http://axon.com/role/LineOfCreditDetails", "lang": "en-us", "role": "terseLabel", "Total availability under line of credit agreement", "label": "Line of Credit Facility. Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "auth_ref": "r82", "r87", "us-gaap_LineOfCreditMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": "http://axon.com/role/CommitmentsandContingenciesDetails", "http://axon.com/role/LineOfCreditDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "auth_ref": "us-gaap_LitigationStatusAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": "http://axon.com/role/CommitmentsandContingenciesDetails", "lang": "en-us", "role": "terseLabel", "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation.", "auth_ref": "r1103", "r1104", "r1105", "r1108", "us-gaap_LitigationStatusDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": "http://axon.com/role/CommitmentsandContingenciesDetails", "lang": "en-us", "role": "terseLabel", "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation.", "auth_ref": "r1103", "r1104", "r1105", "r1108", "dei_LocalPhoneNumber", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": "http://axon.com/role/Cover", "lang": "en-us", "role": "terse
```

"http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": { "r152", "r1035" } }, "axon_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "MarketableSecuritiesMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities [Member]", "documentation": "Represents the information pertaining to marketable securities." } } }, "auth_ref": { "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Marketable securities - unrealized gain", "label": "Marketable Security - Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": { "r113" } }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "http://axon.com/role/LineOfCreditDetails": { "http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r393", "r394", "r395", "r396", "r407", "r521", "r574", "r645", "r724", "r726", "r738", "r751", "r752", "r804", "r806", "r808", "r809", "r817", "r837", "r838", "r859", "r869", "r882", "r890", "r891", "r895", "r896", "r909", "r1121", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188" } }, "axon_MaximumNumberOfSharesAllowedToBeSold": { "xbrltype": "sharesItemType", "nsuri": "http://axon.com/20240930", "localname": "MaximumNumberOfSharesAllowedToBeSold", "presentation": { "http://axon.com/role/StockholdersEquityAtTheMarketquityOfferingAdditionalInformationDetails": { "en-us": { "role": { "terseLabel": "Maximum number of common stock shares to be sold (in shares)", "label": "Maximum Number of Shares Allowed To Be Sold", "documentation": "Represents the maximum number of shares that may be sold." } } }, "auth_ref": { "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": { "r974" } }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": { "r974" } }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "http://axon.com/role/LineOfCreditDetails": { "http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r393", "r394", "r395", "r396", "r407", "r521", "r574", "r645", "r724", "r726", "r738", "r751", "r752", "r804", "r806", "r808", "r809", "r817", "r837", "r838", "r859", "r869", "r882", "r890", "r891", "r895", "r909", "r1121", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188" } }, "booleanItemType": { "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": { "r993" } }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": { "r1124" } }, "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesSummaryofChangesinEstimatedWarrantyReserveDetails": { "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard and Extended Product Warranty", "label": "Movement in Standard and Extended Product Warranty Accrual Increase (Decrease) [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": { "r1001" } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": { "r975" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed; or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r208" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r208" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r119", "r120", "r121" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r111", "r121", "r156", "r179", "r195", "r198", "r202", "r213", "r219", "r221", "r222", "r224", "r225", "r226", "r230", "r231", "r242", "r325", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r547", "r552", "r568", "r585", "r699", "r781", "r797", "r798", "r923", "r1117" } }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails": { "en-us": { "role": { "terseLabel": "Numerator for basic and diluted earnings per share", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": { "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Guidance and Disclosure Rules", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r938", "r948", "r958", "r982", "r990" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": { "r964" } }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": { "r982" } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r1001" } }, "ecd_NonRule10b51ArrTrmmtFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmmtFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r1001" } }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other countries", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": { "r1231", "r1233", "r1234", "r1235" } }, "us-

gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASHFLOWSParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash transactions", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": { "us-gaap_NoncompleteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompleteAgreementsMember", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-complete agreements", "label": "Noncomplete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": { "r63": { "r1091": { "r1092": { "r1093": { "r1094": { "r1096": { "r1097": { "r1100": { "r1101": { "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments of company", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": { "r850": { "r858": { "r1059": { "axon_NumberOfSharesRemainingToBeSold": { "xbrltype": "sharesItemType", "nsuri": "http://axon.com/20240930", "localname": "NumberOfSharesRemainingToBeSold", "presentation": { "http://axon.com/role/StockholdersEquityAtTheMarketquityOfferingAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of shares remaining to be sold", "label": "Number Of Shares Remaining To Be Sold", "documentation": "Represents the number of shares that are remaining out of the maximum shares allowed to be sold." } } }, "auth_ref": { "us-gaap_OffBalanceSheetCreditLossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffBalanceSheetCreditLossLiability", "crdr": "credit", "calculation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "parentTag": "axon_AllowanceForExpectedCreditLossesOnCustomerReceivables", "weight": 1.0, "order": 4.0 }, "presentation": { "http://axon.com/role/ExpectedCreditLossesTypeOfCustomerReceivableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Off-Balance-Sheet, Credit Loss, Liability", "documentation": "Amount of expected credit loss for credit exposure on off-balance-sheet commitment including but not limited to loan commitment, standby letter of credit, financial guarantee not accounted for as insurance. Excludes off-balance sheet credit exposure accounted for as insurance and instrument accounted for under derivatives and hedging." } } }, "auth_ref": { "r331": { "r397": { "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": { "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": { "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r162": { "r849": { "r1058": { "r1060": { "r1061": { "r1062": { "r1063": { "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "verboseLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r603": { "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Organization and Summary of Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": { "r80": { "r122": { "r123": { "r142": { "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://axon.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": { "http://axon.com/role/AccruedLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale investments", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": { "r7": { "r13": { "r143": { "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r5": { "r700": { "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "income_net": "verboseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r14": { "r20": { "r196": { "r199": { "r203": { "r226": { "r587": { "r588": { "r593": { "r682": { "r700": { "r1040": { "r1041": { "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r84": { "r898": { "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r89": { "axon_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "OtherMember", "presentation": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other", "documentation": "Other [Member]" } } }, "auth_ref": { "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Other noncash items", "label": "Other Noncash Expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": { "r121": { "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other income (loss), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r116": { "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r974": { "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r936": { "r946": { "r956": { "r988": { "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": { "r939": { "r949": { "r959": { "r991": { "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r939": { "r949": { "r959": { "r991": { "us-

gaap PatentsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": {"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": {"lang": "en-us", "role": "terseLabel", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." }}, "auth_ref": {"r141", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1100", "r1101"}, "ecd PayVsPerformanceDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": "en-us", "role": "label", "label": "Pay Vs Performance Disclosure [Line Items]", "auth_ref": {"r963"}, "us-gaap PayablesAndAccrualsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": "en-us", "role": "terseLabel", "label": "Payables and Accruals [Abstract]", "auth_ref": {"r111", "us-gaap PaymentsForProceedsFromOtherInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"lang": "en-us", "role": "negatedLabel", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." }}, "auth_ref": {"r1013", "r1044"}, "us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"lang": "en-us", "role": "negatedLabel", "label": "Income and payroll tax payments for net-settled stock awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." }}, "auth_ref": {"r207"}, "us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"lang": "en-us", "role": "negatedLabel", "label": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." }}, "auth_ref": {"r26"}, "us-gaap PaymentsToAcquireInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"lang": "en-us", "role": "negatedLabel", "label": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." }}, "auth_ref": {"r117"}, "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {"lang": "en-us", "role": "negatedLabel", "label": "Proceeds from call, maturity, and sale of investments", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." }}, "auth_ref": {"r118"}, "ecd PeerGroupIssuersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]", "auth_ref": {"r973"}, "ecd PeerGroupTotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount", "auth_ref": {"r973"}, "us-gaap PendingLitigationMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": {"http://axon.com/role/CommitmentsandContingenciesDetails": {"lang": "en-us", "role": "terseLabel", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." }}, "auth_ref": {"r1108"}, "ecd PeoActuallyPaidCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount", "auth_ref": {"r965"}, "ecd PeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "PEO", "label": "PEO [Member]", "auth_ref": {"r982"}, "ecd PeoName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "PEO Name", "label": "PEO Name", "auth_ref": {"r975"}, "ecd PeoTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount", "auth_ref": {"r964"}, "axon PerformanceBasedRestrictedStockUnitMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "PerformanceBasedRestrictedStockUnitMember", "presentation": {"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Performance Based Restricted Stock Unit", "label": "Performance Based Restricted Stock Unit", "documentation": "Performance based restricted stock unit." }}, "auth_ref": {"r111", "axon PerformanceStockUnitsMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "PerformanceStockUnitsMember", "presentation": {"http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails": {"http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Performance Stock Units", "label": "Performance Stock Units (PSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after specified performance conditions are met." }}, "auth_ref": {"r111", "us-gaap PlanNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": {"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": {"http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails": {"http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails": {"lang": "en-us", "role": "terseLabel", "label": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." }}, "auth_ref": {"r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150"}, "us-gaap PlanNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": {"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": {"http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails": {"http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails": {"lang": "en-us", "role": "terseLabel", "label": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." }}, "auth_ref": {"r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150"}, "ecd PnsnAdjsPrrSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]", "auth_ref": {"r966"}, "ecd PnsnAdjsSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]", "auth_ref": {"r1010"}, "ecd PnsnBnftsAdjFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "label": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]", "auth_ref": {"r965"}, "us-gaap PreferredStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_PreferedStockSharesAuthorized", "weight": -1.0, "order": 4.0}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": "en-us", "role

"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from equity offering", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r6": { "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": { "r6": { "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from call, maturity, and sale of investments", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": { "r6": { "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from options exercised", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r6": { "r18": { "axon_ProductClaimsSelfInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "ProductClaimsSelfInsurance", "crdr": "debit", "presentation": { "http://axon.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amount self-insured for any product claim", "label": "Product Claims Self Insurance", "documentation": "Amount the entity is self-insured for any product claim." } } }, "auth_ref": { "r18": { "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Products", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": { "r18": { "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails": { "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "auth_ref": { "r281": "r647", "r717": "r718", "r719", "r720", "r721", "r722", "r723", "r840", "r870", "r908", "r909", "r910", "r913", "r914", "r1111", "r1112", "r1123", "r1196", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227" } }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrual", "crdr": "credit", "calculation": { "http://axon.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/AccruedLiabilitiesDetails": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesSummaryofChangesinEstimatedWarrantyReserveDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "terseLabel": "Accrued warranty expense", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": { "r148": "r401", "r404", "r407" } }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesSummaryofChangesinEstimatedWarrantyReserveDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Utilization of reserve", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": { "r145": { "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualPreexistingIncreaseDecrease", "crdr": "credit", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesSummaryofChangesinEstimatedWarrantyReserveDetails": { "lang": { "en-us": { "role": { "terseLabel": "Warranty expense", "label": "Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties", "documentation": "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties." } } }, "auth_ref": { "r406": { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails": { "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "auth_ref": { "r281": "r647", "r717": "r718", "r719", "r720", "r721", "r722", "r723", "r840", "r870", "r908", "r909", "r910", "r913", "r914", "r1111", "r1112", "r1123", "r1196", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r10": "r604", "r686", "r697", "r898" } }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Provision for expected credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": { "r206": "r335" } }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForLoanLeaseAndOtherLosses", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Provision for bad debts and inventory", "label": "Provision for Loan, Lease, and Other Losses", "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value." } } }, "auth_ref": { "r8": "r154", "r164" } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": { "r963": { "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "auth_ref": { "r963": { "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "http://axon.com/role/LineofCreditDetails": { "http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "auth_ref": { "r393": "r394", "r395", "r396", "r400", "r407", "r514", "r515", "r516", "r521", "r574", "r617", "r629", "r645", "r724", "r726", "r738", "r751", "r752", "r804", "r806", "r808", "r809", "r817", "r837", "r838", "r859", "r869", "r882", "r890", "r891", "r895", "r896", "r909", "r917", "r1106", "r1121", "r1161", "r1184", "r1185", "r1186", "r1187", "r1188" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails": { "http://axon.com/role/LineofCreditDetails": { "http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "auth_ref": { "r393": "r394", "r395", "r396", "r400", "r407", "r514", "r515", "r516", "r521", "r574", "r617", "r629", "r645", "r724", "r726", "r738", "r751", "r752", "r804", "r806", "r808", "r809", "r817", "r837", "r838", "r859", "r869", "r882", "r890", "r891", "r895", "r896", "r909", "r917", "r1106", "r1121", "r1161", "r1184", "r1185", "r1186", "r1187", "r1188" } }, "us-gaap_ReclassificationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationLineItems", "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Line Items]", "label": "Reclassification [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r177": { "us-gaap_ReclassificationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTable", "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Table]", "label": "Reclassification [Table]", "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": { "r177": { "us-gaap_Reclassifications": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Reclassifications", "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatements": { "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period Financial Statements", "label": "Reclassifications [Text Block]", "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted." } } }, "auth_ref": { "r80": { "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": { "r931": "r941", "r951", "r983" } }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/SegmentDataDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r522": "r839", "r854", "r1189" } }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": { "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails": { "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails": {

"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Revision"},"label":"Revision of Prior Period, Adjustment [Member]"} } },"auth_ref":{"r216","r217","r218","r228","r229","r248","r566","r567","r601","r1014","r1015",
"r1016","r1017","r1021","r1024","r1025","r1064"} } },"srt_RestatementAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/srt/2024","localname":
"RestatementAxis","presentation":{"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Revision of Prior Period [Axis]"},"label":"Revision of Prior Period [Axis]"} } },"auth_ref":{"r176","r216","r217","r218","r219","r220","r221","r222","r223","r224",
"r227","r228","r229","r230","r231","r232","r248","r327","r328","r545","r546","r547","r548","r551","r552","r565","r566","r567","r568","r599","r601","r605",
"r606","r728","r729","r730","r731","r732","r733","r734","r735","r736","r737","r740","r1064"} } },"ecd_RestatementDateAxis":{"xbrltype":"stringItemType","nsuri":
"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDateAxis","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"
"terseLabel":"Restatement Determination Date"},"label":"Restatement Determination Date [Axis]"} } },"auth_ref":{"r932","r942","r952","r984"} } },"
ecd_RestatementDeterminationDate":{"xbrltype":"dateItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDeterminationDate","presentation":{"
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Restatement Determination Date"},"label":"Restatement Determination Date"}
} } },"auth_ref":{"r933","r943","r953","r985"} } },"ecd_RestatementDoesNotRequireRecoveryTextBlock":{"xbrltype":"textBlockItemType","nsuri":
"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDoesNotRequireRecoveryTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"
"en-us":{"role":{"terseLabel":"Restatement does not require Recovery"},"label":"Restatement Does Not Require Recovery [Text Block]"} } },"auth_ref":{"r940","r950",
"r960","r992"} } },"srt_RestatementDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"RestatementDomain","presentation":{"
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsCashFlowStatementDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Revision of Prior Period [Domain]"},"label":"Revision of Prior Period [Domain]"} } },"auth_ref":{"r176","r216","r217","r218","r219","r220","r221","r222","r223",
"r224","r227","r228","r229","r230","r231","r232","r248","r327","r328","r545","r546","r547","r548","r551","r552","r565","r566","r567","r568","r599","r601",
"r605","r606","r728","r729","r730","r731","r732","r733","r734","r735","r736","r737","r740","r1064"} } },"us-gaap_RestrictedCash":{"xbrltype":"monetaryItemType",
"nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedCash","crdr":"debit","presentation":{"
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Restricted cash balance",
"label":"Restricted Cash","documentation":"Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits
with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } },"auth_ref":{"r1034","r1047","r1191","r1194"} } },"us-
gaap_RestrictedCashAndCashEquivalents":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedCashAndCashEquivalents",
"crdr":"debit","calculation":{"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentetical":{"parentTag":"us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","weight":1.0,"order":1.0},"presentation":{"
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentetical"},"lang":{"en-us":{"role":{"verboseLabel":"Restricted cash (Note 1)",
"label":"Restricted Cash and Cash Equivalents","documentation":"Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited
to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but
are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant
risk of changes in value because of changes in interest rates." } } },"auth_ref":{"r27","r145","r182","r210","r691"} } },"us-
gaap_RestrictedCashAndCashEquivalentsItemsLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"RestrictedCashAndCashEquivalentsItemsLineItems","presentation":{"http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails"},"lang":{"
"en-us":{"role":{"terseLabel":"Restricted Cash and Cash Equivalents Items [Line Items]"},"label":"Restricted Cash and Cash Equivalents Items [Line Items]"},
"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } },"auth_ref":{"r1194"} } },"axon_RestrictedCashIncludingPrepaidExpensesAndOtherAssets":{"xbrltype":"monetaryItemType",
"nsuri":"http://axon.com/20240930","localname":"RestrictedCashIncludingPrepaidExpensesAndOtherAssets","crdr":"debit","presentation":{"
"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restricted cash including
prepaid expenses and current assets"},"label":"Restricted Cash Including Prepaid Expenses and Other Assets","documentation":"Amount of restricted cash included in
prepaid expenses and other assets." } } },"auth_ref":{"r1194"} } },"us-gaap_RestrictedStockUnitsRSUMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-
gaap/2024","localname":"RestrictedStockUnitsRSUMember","presentation":{"
"http://axon.com/role/StockholdersEquityRSUPSummaryandStockOptionActivityAdditionalInformationDetails",
"http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails"},"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"
"terseLabel":"Restricted Stock Units"},"label":"Restricted Stock Units (RSUs) [Member]"},"documentation":"Share instrument which is convertible to stock or an equivalent
amount of cash, after a specified period of time or when specified performance conditions are met." } } },"auth_ref":{"r1194"} } },"us-gaap_RetainedEarningsAccumulatedDeficit":{"
xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsAccumulatedDeficit","crdr":"credit","calculation":{"
"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS":{"parentTag":"us-gaap_StockholdersEquity","weight":1.0,"order":5.0},"presentation":{"
"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"},"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsBalanceSheetsDetails"},"lang":{"en-
us":{"role":{"terseLabel":"Retained earnings"},"label":"Retained Earnings (Accumulated Deficit)","documentation":"Amount of accumulated undistributed earnings
(deficit)."} } } },"auth_ref":{"r95","r131","r695","r732","r737","r743","r762","r698"} } },"us-gaap_RetainedEarningsMember":{"xbrltype":"domainItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsMember","presentation":{"
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Retained Earnings"},"label":
"Retained Earnings [Member]"},"documentation":"Accumulated undistributed earnings (deficit)."} } } },"auth_ref":{"r175","r216","r217","r218","r220","r226","r229",
"r231","r326","r329","r378","r537","r538","r544","r545","r546","r548","r551","r552","r557","r559","r560","r562","r566","r600","r602","r728","r730","r745",
"r1229"} } },"us-gaap_RevenueFromContractWithCustomerAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"RevenueFromContractWithCustomerAbstract"},"lang":{"en-us":{"role":{"terseLabel":"Revenue from Contract with Customer [Abstract]"},"label":"Revenue from Contract
with Customer [Abstract]"} } } },"auth_ref":{"r1194"} } },"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax":{"xbrltype":"monetaryItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"RevenueFromContractWithCustomerExcludingAssessedTax","crdr":"credit","calculation":{"
"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME":{"parentTag":"us-gaap_GrossProfit","weight":1.0,
"order":1.0},"presentation":{"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"},"
"http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails"},"http://axon.com/role/RevenuesRevenuesByProductsandServiceOfferingsDetails",
"http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails"},"http://axon.com/role/SegmentDataDetails"},"
lang":{"en-us":{"role":{"terseLabel":"Net sales"},"verboseLabel":"Revenue from contract with customers"},"label":"Revenue from Contract with Customer, Excluding
Assessed Tax","documentation":"Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or
service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing
transaction, including, but not limited to, sales, use, value added and excise." } } },"auth_ref":{"r160","r161","r249","r256","r257","r272","r278","r281","r283","r285",
"r475","r476","r647"} } },"us-gaap_RevenueFromContractWithCustomerMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"RevenueFromContractWithCustomerMember","presentation":{"http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails"},"lang":{"en-us":{"role":{"
"terseLabel":"Revenue from Contract with Customer Benchmark"},"label":"Revenue from Contract with Customer Benchmark [Member]"},"documentation":"Revenue from
satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } } },"
auth_ref":{"r285","r1019"} } },"us-gaap_RevenueFromContractWithCustomerTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024",
"localname":"RevenueFromContractWithCustomerTextBlock","presentation":{"http://axon.com/role/Revenues"},"lang":{"en-us":{"role":{"terseLabel":"Revenues",
"label":"Revenue from Contract with Customer [Text Block]"},"documentation":"The entire disclosure of revenue from contract with customer to transfer good or service and
to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in
judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } }
} },"auth_ref":{"r172","r467","r468","r469","r470","r471","r472","r473","r474","r479"} } },"us-gaap_RevenueRemainingPerformanceObligation":{"xbrltype":
"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueRemainingPerformanceObligation","crdr":"credit","presentation":{"
"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenue, remaining performance obligation"},"label":
"Revenue, Remaining Performance Obligation, Amount","documentation":"Amount of transaction price allocated to performance obligation that has not been recognized as
revenue." } } },"auth_ref":{"r168"} } },"us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems":{"xbrltype":"stringItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems","presentation":{"
"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenue, Remaining Performance Obligation, Expected
Timing of Satisfaction [Line Items]"},"label":"Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"},"documentation":"Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } },"auth_ref":{"r1194"} } },"us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1":{"xbrltype":"durationItemType","nsuri":
"http://fasb.org/us-gaap/2024","localname":"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1","presentation":{"
"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenue, remaining performance obligation, expected
timing of satisfaction, period"},"label":"Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period","documentation":"Period in which remaining
performance obligation is expected to be recognized as revenue, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months,
and thirteen days." } } },"auth_ref":{"r169"} } },"us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis":{"xbrltype":
"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
"presentation":{"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenue, Remaining Performance
Obligation, Expected Timing of Satisfaction, Start Date [Axis]"},"label":"Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"},
"documentation":"Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } },"auth_ref":{"r169"} } },"us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable","presentation":{"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"
lang":{"en-us":{"role":{"terseLabel":"Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"},"label":"Revenue, Remaining Performance
Obligation, Expected Timing of Satisfaction [Table]"},"documentation":"Disclosure of information about expected timing for satisfying remaining performance obligation." } }
} },"auth_ref":{"r1194"} } },"us-gaap_RevenueRemainingPerformanceObligationPercentage":{"xbrltype":"percentItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"RevenueRemainingPerformanceObligationPercentage","presentation":{"http://axon.com/role/RevenuesRemainingPerformanceObligationsDetails"},"lang":{"en-us":{"
"role":{"terseLabel":"Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage)"},"label":"Revenue, Remaining Performance
Obligation, Percentage","documentation":"Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } } },"
auth_ref":{"r1018"} } },"ecd_Rule10b51ArrAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Rule10b51ArrAdoptedFlag",
"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"terseLabel":"Rule 10b5-1 Arrangement Adopted"},"label":"Rule
10b5-1 Arrangement Adopted [Flag]"} } } },"auth_ref":{"r1001"} } },"ecd_Rule10b51ArrFrmntdFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024",
"localname":"Rule10b51ArrFrmntdFlag","presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"terseLabel":"Rule 10b5-
1 Arrangement Terminated"},"label":"Rule 10b5-1 Arrangement Terminated [Flag]"} } } },"auth_ref":{"r1001"} } },"us-gaap_SaleOfStockNameOfTransactionDomain":{"

"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": "http://axon.com/role/StockholdersEquityAtTheMarketEquityOfferingAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Sale of Stock {Domain}", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": "r1", "srt_ScenarioPreviouslyReportedMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsBalanceSheetsDetails", "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsCashFlowStatementDetails", "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsShareholdersEquityDetails", "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsStatementsOfOperationsandComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel", "label": "Previously Reported {Member}", "auth_ref": "r176", "r216", "r218", "r219", "r220", "r221", "r222", "r231", "r248", "r545", "r547", "r548", "r551", "r552", "r565", "r566", "r567", "r599", "r601", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r1021", "r1022", "r1023", "r1024", "r1034", "r1064", "r1075", "r1076", "r1156", "r1179", "r1180", "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": "http://axon.com/role/AccruedLiabilitiesTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of accrued liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": "r24", "r1174", "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": "http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "lang": "en-us", "role": "terseLabel", "label": "Summary of changes in accumulated other comprehensive income (loss), net of tax", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "auth_ref": "r24", "r1175", "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails", "lang": "en-us", "role": "terseLabel", "label": "Antidilutive Security, Excluded EPS Calculation {Table}", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": "r36", "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of potentially dilutive securities excluded in calculation of diluted net income per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS pursuant to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": "r36", "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": "http://axon.com/role/BusinessAcquisitionsDetails", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Business Acquisitions, by Acquisition {Table}", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": "r56", "r59", "r549", "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsTables", "lang": "en-us", "role": "terseLabel", "label": "Summary of cash, cash equivalents, marketable securities, and available-for-sale investments", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": "r1", "axon_ScheduleOfConvertibleNoteHedgeTransactionsTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://axon.com/20240930", "localname": "ScheduleOfConvertibleNoteHedgeTransactionsTableTextBlock", "presentation": "http://axon.com/role/ConvertibleSeniorNotesTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of convertible note hedge transaction", "documentation": "Tabular disclosure for convertible notes hedge transaction." } } }, "auth_ref": "r1", "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of weighted average number of shares outstanding and earnings per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": "r1056", "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails", "lang": "en-us", "role": "terseLabel", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount {Table}", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": "r52", "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "presentation": "http://axon.com/role/StockholdersEquityTables", "lang": "en-us", "role": "terseLabel", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount {Table Text Block}", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": "r52", "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsCashFlowStatementDetails", "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsShareholdersEquityDetails", "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsStatementsOfOperationsandComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel", "label": "Error Correction {Table}", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth_ref": "r221", "r222", "r223", "r228", "r229", "r230", "r231", "r248", "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": "http://axon.com/role/RevisionOfPriorPeriodFinancialStatementsTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Error Corrections and Prior Period Adjustments", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": "r33", "r34", "r35", "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "presentation": "http://axon.com/role/ExpectedCreditLossesDetails", "lang": "en-us", "role": "terseLabel", "label": "Financing Receivable, Allowance for Credit Loss {Table}", "documentation": "Disclosure of information about allowance for credit loss on financing receivable." } } }, "auth_ref": "r174", "r1077", "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": "en-us", "role": "terseLabel", "label": "Schedule Of Intangible Assets {Table}", "documentation": "Intangible Asset, Finite-Lived {Table}", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": "r364", "r371", "r375", "r376", "r377", "r648", "r839", "r862", "us-gaap_ScheduleOfGoodwillTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsScheduleOfGoodwillDetails", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Goodwill {Table}", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r861", "us-gaap_ScheduleOfGoodwillTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of goodwill", "documentation": "Schedule of Goodwill {Table Text Block}", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": "r861", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": "en-us", "role": "terseLabel", "label": "Intangible Asset, Indefinite-Lived {Table}", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": "r364", "r374", "r377", "r862", "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of intangible assets other than goodwill", "documentation": "Schedule of Indefinite-Lived Intangible Assets {Table Text Block}", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": "r862", "r1099", "us-gaap_ScheduleOfInventoryCurrentTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": "http://axon.com/role/InventoryTables", "lang": "en-us", "role": "terseLabel", "label": "Inventory", "documentation": "Schedule of Inventory, Current {Table Text Block}", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": "r22", "r99", "r100", "r101", "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "lang": "en-us", "role": "terseLabel", "label": "Summary of changes in our estimated warranty reserve", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": "r403", "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "presentation": "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails", "lang": "en-us", "role": "terseLabel", "label": "Restrictions on Cash and Cash Equivalents {Table}", "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": "r19", "r145", "r1194", "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": "http://axon.com/role/SegmentDataDetails", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Segment Reporting Information, by Segment {Table}", "documentation": "Schedule of Segment Reporting Information, by Segment {Table Text Block}", "label": "Schedule of Segment Reporting Information, by Segment {Table Text Block}" } } }

of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }
"auth_ref": { "r41": "r42", "r43" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": { "http://axon.com/role/SegmentDataTables" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of operational information relative to the company's reportable segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": { "r41": "r42", "r43" } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardAwardDetails", "http://axon.com/role/StockholdersEquityAtTheMarketequityofferingAdditionalInformationDetails", "http://axon.com/role/StockholdersEquityRSUPSAndStockOptionActivityAdditionalInformationDetails", "http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails", "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r488": "r490", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517" } }, "axon_ScheduleOfShareBasedCompensationPerformanceStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://axon.com/20240930", "localname": "ScheduleOfShareBasedCompensationPerformanceStockUnitsAwardActivityTableTextBlock", "presentation": { "http://axon.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of performance stock unit activity", "label": "Schedule Of Share Based Compensation Performance Stock Units Award Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for performance stock units that were outstanding at the beginning and end of the year, and the number of performance stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://axon.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of restricted stock unit activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r133" } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://axon.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of option activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year; grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r15", "r16", "r133" } }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of warrants details of convertible senior notes", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": { "r50" } }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": { "http://axon.com/role/VariableInterestEntitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Table]", "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": { "r65", "r66", "r67", "r68", "r69", "r553", "r554", "r555", "r556", "r625", "r626", "r627" } }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": { "http://axon.com/role/VariableInterestEntitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of the unconsolidated non-public VIEs", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE, a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": { "r65", "r66", "r67", "r68", "r69" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of estimated amortization expense of intangible assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r862", "r1098" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://axon.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r926" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://axon.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r928" } }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://axon.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails", "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails", "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "http://axon.com/role/SegmentDataDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r160", "r161", "r162", "r163", "r249", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r283", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r377", "r388", "r389", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r851", "r854", "r855", "r861", "r912", "r1196", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://axon.com/role/ExpectedCreditLossesDetails", "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": { "r163", "r249", "r251", "r252", "r253", "r254", "r255", "r268", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r850", "r852", "r853", "r854", "r856", "r857", "r858" } }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://axon.com/role/SegmentDataDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsStatementsofOperationsandComprehensiveIncomeDetails", "http://axon.com/role/SegmentDataDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sales, general and administrative", "verboseLabel": "Sales, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r142" } }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": { "http://axon.com/role/StockholdersEquityReportedStockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sales, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": { "axon_SeniorUnsecuredMultiCurrencyRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930",

"localname": "SeniorUnsecuredMultiCurrencyRevolvingCreditFacilityMember", "presentation": "http://axon.com/role/LineofCreditDetails", "lang": "en-us", "role": "terseLabel", "label": "Senior Unsecured Multi-Currency Revolving Credit Facility", "documentation": "Represents the information pertaining to senior unsecured multi-currency revolving credit." }, {"auth_ref": "1", "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": "http://axon.com/role/BusinessAcquisitionsDetails", "lang": "en-us", "role": "terseLabel", "label": "Business Acquisitions", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." }, {"auth_ref": "59", "us-gaap_ServiceMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "lang": "en-us", "role": "terseLabel", "label": "Services", "documentation": "It pertains to Services department under product and service." }, {"auth_ref": "1", "us-gaap_ShareBasedCompensation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": "1.0", "order": "12.0", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": "en-us", "role": "terseLabel", "label": "Share-based compensation", "documentation": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." }, {"auth_ref": "r0", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "negatedLabel", "label": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." }, {"auth_ref": "r508", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." }, {"auth_ref": "r508", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "auth_ref": "r506", "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAmount": "xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAmount", "crdr": "credit", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "XSUs granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Amount", "documentation": "Amount of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "auth_ref": "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "auth_ref": "r506", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "periodStartLabel", "label": "Number of Units outstanding, beginning of year (in shares)", "periodEndLabel": "Number of Units outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "auth_ref": "r503", "r504", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "periodStartLabel", "label": "Units outstanding, beginning of year (in dollars per share)", "periodEndLabel": "Units outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "auth_ref": "r503", "r504", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "auth_ref": "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "negatedTerseLabel", "label": "Released (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "auth_ref": "r507", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Released (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "auth_ref": "r507", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "Expected volatility (as percentage)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "auth_ref": "r514", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "auth_ref": "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "auth_ref": "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "auth_ref": "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": "en-us", "role": "terseLabel", "label": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." }

presentation": f "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": f "en-us", "role": f "terseLabel", "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": f "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": f "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "http://axon.com/role/StockholdersEquityAdditionalInformationDetails": "http://axon.com/role/StockholdersEquityOperationalGoalsDetails", "http://axon.com/role/StockholdersEquityRSUPSAndStockOptionActivityAdditionalInformationDetails", "http://axon.com/role/StockholdersEquityStockIncentiveandRepurchasePlanAdditionalInformationDetails", "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": f "488", "r490", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": f "http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Number of Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": f "1", "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments": f "xbrltype": "integerItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments", "presentation": f "http://axon.com/role/StockholdersEquityRSUPSAndStockOptionActivityAdditionalInformationDetails", "lang": f "en-us", "role": f "terseLabel", "Number of annual vesting installments", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Number of Annual Vesting Installments", "documentation": "The number of annual vesting installments." } } }, "auth_ref": f "1", "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfIndependentVestingConditions": f "xbrltype": "integerItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfIndependentVestingConditions", "presentation": f "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": f "en-us", "role": f "terseLabel", "Independent vesting conditions", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Independent Vesting Conditions", "documentation": "Number of independent vesting conditions to be fulfilled for vesting of award under share-based payment arrangement." } } }, "auth_ref": f "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": f "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": f "en-us", "role": f "terseLabel", "Share of Common stock (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": f "r883" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": f "http://axon.com/role/StockholdersEquity2024eXponentialStockPlanand2024CEOPerformanceAwardDetails", "lang": f "en-us", "role": f "terseLabel", "Shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": f "r51" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Options exercisable, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": f "r497" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Options exercisable, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": f "r497" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "negatedTerseLabel", "Expired/terminated (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": f "r502" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Expired/terminated (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": f "r4131" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": f "r499" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": f "r509" } } }, "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesSoldToCoverExercisePriceAndOptionsHoldersTaxObligation": f "xbrltype": "sharesItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesSoldToCoverExercisePriceAndOptionsHoldersTaxObligation", "presentation": f "http://axon.com/role/StockholdersEquityRSUPSAndStockOptionActivityAdditionalInformationDetails", "lang": f "en-us", "role": f "terseLabel", "Number of shares sold to cover expenses", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares Sold To Cover Exercise Price And Options Holder's Tax Obligation", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares Sold To Cover Exercise Price And Options Holder's Tax Obligation" } } }, "auth_ref": f "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Options outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": f "r51" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "periodStartLabel", "Options outstanding, beginning of year (in shares)", "periodEndLabel": "Options outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": f "r495", "r496" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": f "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "periodStartLabel", "Options outstanding, beginning of year (in dollars per share)", "periodEndLabel": "Options outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": f "r495", "r496" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": f "http://axon.com/role/StockholdersEquityStockOptionActivityDetails", "lang": f "en-us", "role": f "terseLabel", "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": f "1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedIn

ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingConditionRelatingToOperationalGoalsAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization - {"crdr": "credit", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Adj. EBITDA", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Condition Relating to Operational Goals, Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization", "documentation": "Amount of adjusted earnings before interest, taxes, depreciation, and amortization, as a vesting condition to be fulfilled for vesting of award under share-based payment arrangement."}}}}, "auth_ref": []}, "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingConditionRelatingToOperationalGoalsRevenue": {"xbrltype": "monetaryItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingConditionRelatingToOperationalGoalsRevenue", "crdr": "credit", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Revenue", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Condition Relating to Operational Goals, Revenue", "documentation": "Amount of revenue as a vesting condition to be fulfilled for vesting of award under share-based payment arrangement."}}}}, "auth_ref": []}, "axon_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches": {"xbrltype": "integerItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches", "presentation": {"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": {"http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of award tranches", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Tranches", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Tranches"}}}}, "auth_ref": []}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": {"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": {"http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails": {"http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails": {"http://xbrl.sec.gov/ed/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement."}}}}, "auth_ref": ["r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517"]}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": {"http://axon.com/role/StockholdersEquityStockOptionActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."}}}}, "auth_ref": ["r500"]}, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 1", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 3", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 2", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "axon_ShareBasedPaymentArrangementTrancheFiveMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFiveMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 5", "label": "Share-Based Payment Arrangement, Tranche Five [Member]", "documentation": "Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "axon_ShareBasedPaymentArrangementTrancheFourMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 4", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "documentation": "Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "axon_ShareBasedPaymentArrangementTrancheSevenMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheSevenMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 7", "label": "Share-Based Payment Arrangement, Tranche Seven [Member]", "documentation": "Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "axon_ShareBasedPaymentArrangementTrancheSixMember": {"xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheSixMember", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Tranche 6", "label": "Share-Based Payment Arrangement, Tranche Six [Member]", "documentation": "Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."}}}}, "auth_ref": []}, "us-gaap_SharePrice": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": {"http://axon.com/role/StockholdersEquityOperationalGoalsDetails": {"http://axon.com/role/StockholdersEquityRSUPSUandStockOptionActivityAdditionalInformationDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Stock Price Goal (in dollars per share)", "terseLabel": "Share price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company."}}}}, "auth_ref": []}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "crdr": "debit", "presentation": {"http://axon.com/role/StockholdersEquitySummaryofRSUandPSUActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."}}}}, "auth_ref": []}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": {"http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails": {"lang": {"en-us": {"role": {"terseLabel": "Expected life of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in PnYnMnDnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days."}}}}, "auth_ref": ["r513"]}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": {"http://axon.com/role/StockholdersEquityStockOptionActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Options exercisable, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."}}}}, "auth_ref": ["r51"]}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": {"http://axon.com/role/StockholdersEquityStockOptionActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Options exercisable, Weighted Average Remaining Contractual Life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in PnYnMnDnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days."}}}}, "auth_ref": ["r51"]}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": {"http://axon.com/role/StockholdersEquityStockOptionActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Options outstanding, Weighted Average Remaining Contractual Life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in PnYnMnDnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days."}}}}, "auth_ref": ["r135"]}, "axon_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDividendYield": {"xbrltype": "percentItemType", "nsuri": "http://axon.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDividendYield", "presentation": {"http://axon.com/role/StockholdersEquity2024ExponentialStockPlanand2024CEOPerformanceAwardDetails": {"lang": {"en-us": {"role": {"terseLabel": "Expected dividend yield (as percentage)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Dividend Yield", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Dividend Yield"}}}}, "auth_ref": []}, "us-gaap_ShortTermInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0}}, "presentation": {"http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"verboseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available for sale securities, held-to-maturity securities, and short-term investments classified as other and current."}}}}, "auth_ref": ["r152", "r153", "r1038"]}, "us-gaap_ShortTermInvestmentsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": {"http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Short-Term Investments", "label": "Short-Term Investments [


```

"ability": "1", "auth_ref": "r1113", "us-gaap_StatementBusinessSegmentsAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": "http://axon.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails", "http://axon.com/role/RevenuesRevenuesByProductsandServiceOfferingsDetails", "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "http://axon.com/role/SegmentDataDetails", "lang": "en-us", "role": "terseLabel", "SegmentsAxis", "label": "SegmentsAxis", "documentation": "Information by business segments", "1", "auth_ref": "r160", "r161", "r162", "r163", "r178", "r249", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r285", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r377", "r380", "r388", "r389", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r851", "r854", "r855", "r861", "r912", "r1196", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "us-gaap_StatementEquityComponentsAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": "http://axon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "http://axon.com/role/RevisionofPriorPeriodFinancialStatementsShareholdersEquityDetails", "lang": "en-us", "role": "terseLabel", "EquityComponentsAxis", "label": "EquityComponentsAxis", "documentation": "Information by component of equity", "1", "auth_ref": "r14", "r93", "r96", "r97", "r175", "r200", "r201", "r202", "r216", "r217", "r218", "r220", "r226", "r229", "r231", "r250", "r326", "r329", "r378", "r463", "r537", "r538", "r544", "r545", "r546", "r548", "r551", "r552", "r557", "r558", "r559", "r560", "r561", "r562", "r566", "r587", "r589", "r590", "r591", "r592", "r593", "r600", "r602", "r606", "r700", "r728", "r730", "r745", "r799", "srt_StatementGeographicalAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": "http://axon.com/role/ExpectedCreditLossesDetails", "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "GeographicalAxis", "label": "GeographicalAxis", "1", "auth_ref": "r283", "r284", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r747", "r748", "r749", "r805", "r807", "r810", "r818", "r824", "r827", "r828", "r829", "r830", "r832", "r833", "r834", "r835", "r836", "r871", "r876", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r911", "r917", "r1123", "r1196", "r1200", "r1201", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "us-gaap_StatementLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "StatementLineItems", "label": "StatementLineItems", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "1", "auth_ref": "r216", "r217", "r218", "r250", "r602", "r647", "r741", "r746", "r753", "r754", "r755", "r756", "r757", "r758", "r761", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r774", "r775", "r776", "r777", "r778", "r780", "r782", "r783", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r799", "r918", "us-gaap_StatementOfCashFlowsAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": "en-us", "role": "terseLabel", "StatementOfCashFlowsAbstract", "label": "StatementOfCashFlowsAbstract", "1", "auth_ref": "1", "us-gaap_StatementOfFinancialPositionAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": "en-us", "role": "terseLabel", "StatementOfFinancialPositionAbstract", "label": "StatementOfFinancialPositionAbstract", "1", "auth_ref": "1", "us-gaap_StatementOfStockholdersEquityAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": "en-us", "role": "terseLabel", "StatementOfStockholdersEquityAbstract", "label": "StatementOfStockholdersEquityAbstract", "1", "auth_ref": "1", "us-gaap_StatementTable": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "StatementTable", "label": "StatementTable", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity", "1", "auth_ref": "r216", "r217", "r218", "r250", "r286", "r602", "r647", "r741", "r746", "r753", "r754", "r755", "r756", "r757", "r758", "r761", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r774", "r775", "r776", "r777", "r778", "r780", "r782", "r783", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r799", "r918", "ecd_StkPrCOrTsrEstimationMethodTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "StockPriceorTSREstimationMethod", "label": "StockPriceorTSREstimationMethodTextBlock", "1", "auth_ref": "r935", "r945", "r955", "r987", "us-gaap_StockAppreciationRightsSARSMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": "http://axon.com/role/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "StockAppreciationRights(SARs)", "label": "StockAppreciationRights(SARs)Member", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period", "1", "auth_ref": "1", "us-gaap_StockCompensationPlanMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails", "lang": "en-us", "role": "terseLabel", "Stock-based awards", "label": "Share-Based Payment ArrangementMember", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares", "1", "auth_ref": "r1057", "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "Issuance of common stock for business combination contingent consideration (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions", "1", "auth_ref": "r92", "r93", "r131", "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": "en-us", "role": "terseLabel", "Issuance of common stock under employee plans, net (in shares)", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan", "1", "auth_ref": "1", "us-gaap_StockIssuedDuringPeriodSharesNewIssues": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "http://axon.com/role/StockholdersEquityAttheMarketequityofferingAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period", "1", "auth_ref": "r14", "r92", "r
```

"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": f

"http://axon.com/role/BlockItemSubsequentEvents", "lang": f "en-us": f "role": f "terseLabel": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } , "auth_ref": f "r608", "r610" } } , "us-gaap_SubsidiarySaleOfStockAxis": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": f

"http://axon.com/role/StockholdersEquityAtTheMarketEquityOfferingAdditionalInformationDetails", "lang": f "en-us": f "role": f "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } , "auth_ref": f "axon_SummaryOfSignificantAccountingPolicyLineItems": f "xbrltype": "stringItemType", "nsuri": "http://axon.com/20240930", "localname": "SummaryOfSignificantAccountingPolicyLineItems", "presentation": f

"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "lang": f "en-us": f "role": f "terseLabel": "Summary Of Significant Accounting Policy [Line Items]", "label": "Summary Of Significant Accounting Policy [Line Items]", "documentation": "Summary of significant accounting policy." } } , "auth_ref": f "axon_SummaryOfSignificantAccountingPolicyTable": f "xbrltype": "stringItemType", "nsuri": "http://axon.com/20240930", "localname": "SummaryOfSignificantAccountingPolicyTable", "presentation": f "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "lang": f "en-us": f "role": f "terseLabel": "Summary Of Significant Accounting Policy [Table]", "label": "Summary Of Significant Accounting Policy [Table]", "documentation": "Summary of significant accounting policy." } } , "auth_ref": f "us-gaap_SupplementalCashFlowInformationAbstract": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": f

"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentetical", "lang": f "en-us": f "role": f "terseLabel": "Supplemental disclosures:", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": f "us-gaap_SuretyBondMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SuretyBondMember", "presentation": f "http://axon.com/role/CommitmentsandContingenciesDetails", "lang": f "en-us": f "role": f "terseLabel": "Surety Bond", "label": "Surety Bond [Member]", "documentation": "An obligation arising from a three-party agreement that legally binds together a principal who needs the bond, an obligee who requires the bond and a surety company that sells the bond." } } , "auth_ref": f "ecd_TabularListTableTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": f "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us": f "role": f "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]", "auth_ref": f "r981" } } , "axon_TaserDevicesProfessionalMember": f "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "TaserDevicesProfessionalMember", "presentation": f

"http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails", "lang": f "en-us": f "role": f "terseLabel": "TASER Devices (Professional)", "label": "TASER Devices (Professional)", "documentation": "TASER Devices Professional [Member]", "auth_ref": f "axon_TaserSegmentMember": f "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "TaserSegmentMember", "presentation": f "http://axon.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails", "http://axon.com/role/RevenuesRevenuesbyProductsandServiceOfferingsDetails", "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails", "http://axon.com/role/SegmentDataDetails", "lang": f "en-us": f "role": f "terseLabel": "TASER", "label": "TASER", "documentation": "TASER segment." } } } , "auth_ref": f "us-gaap_TaxesPayableCurrent": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": f "http://axon.com/role/AccruedLiabilitiesDetails": f "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } } , "presentation": f

"http://axon.com/role/AccruedLiabilitiesDetails", "lang": f "en-us": f "role": f "terseLabel": "Accrued income and other taxes", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } , "auth_ref": f "r83", "r84" } } , "ecd_TotalShareholderRtnAmt": f "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": f

"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us": f "role": f "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } , "auth_ref": f "r973" } } , "ecd_TotalShareholderRtnVsPeerGroupTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": f "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us": f "role": f "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]", "auth_ref": f "r980" } } , "us-gaap_TradeNamesMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": f

"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Trademarks", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } , "auth_ref": f "r61" } } , "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1099", "r1100", "r1101" } } , "us-gaap_TradeMarksAndTradeNamesMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeMarksAndTradeNamesMember", "presentation": f

"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Patents and trademarks pending", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } , "auth_ref": f "r61", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1099", "r1100", "r1101" } } , "us-gaap_TradeMarksMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeMarksMember", "presentation": f

"http://axon.com/role/GoodwillandIntangibleAssetsDefiniteLivedIntangibleAssetsOtherthanGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } } , "auth_ref": f "r61", "r862", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1099", "r1100", "r1101" } } , "ecd_TradingArrAxis": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]", "auth_ref": f "r1000" } } , "ecd_TradingArrByIndTable": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]", "auth_ref": f "r1002" } } , "del_TradingSymbol": f "xbrltype": "TradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingSymbol", "presentation": f

"http://axon.com/role/Cover", "lang": f "en-us": f "role": f "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } , "auth_ref": f "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": f

"http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails", "http://axon.com/role/StrategicInvestmentsNarrativeDetails", "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails", "http://axon.com/role/StrategicInvestmentsScheduleOfRollForwardOfStrategicInvestmentsDetails", "lang": f "en-us": f "role": f "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } , "auth_ref": f "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r444", "r460", "r563", "r581", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r628", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r701", "r886", "r888", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r899", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1069", "r1071", "r1072", "r1073", "r1157", "r1160", "r1161", "r1162", "r1169", "r1172" } } , "ecd_TrdrArrAdoptionDate": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": f

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } , "auth_ref": f "r1003" } } , "ecd_TrdrArrDuration": f "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } , "auth_ref": f "r1004" } } , "ecd_TrdrArrExpirationDate": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } , "auth_ref": f "r1004" } } , "ecd_TrdrArrIndName": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } , "auth_ref": f "r1002" } } , "ecd_TrdrArrIndTitle": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } , "auth_ref": f "r1002" } } , "ecd_TrdrArrSecuritiesAggAvailAmt": f "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } , "auth_ref": f "r1005" } } , "ecd_TrdrArrTerminationDate": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": f "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f "en-us": f "role": f "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } , "auth_ref": f "r1003" } } , "axon_TreasuryInflationProtectedSecuritiesMember": f "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "TreasuryInflationProtectedSecuritiesMember", "presentation": f

"http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails", "lang": f "en-us": f "role": f "terseLabel": "Treasury inflation-protected securities", "label": "Treasury inflation-protected securities", "documentation": "Treasury Inflation Protected Securities [Member]", "auth_ref": f "us-gaap_TreasuryStockCommonMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": f

"http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": f "en-us": f "role": f "terseLabel": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } , "auth_ref": f "r48" } } , "us-gaap_TreasuryStockCommonShares": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": f "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical", "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY", "lang": f "en-us": f "role": f "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Treasury stock, shares, beginning balance (in shares)", "periodEndLabel": "Treasury stock, shares, ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } , "auth_ref": f "r48" } } , "us-gaap_TreasuryStockValue": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": f "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": f "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } } , "presentation": f "http://axon.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": f "en-us": f "role": f "negatedLabel": "Treasury stock at cost, 20.220.227 shares as of Septemberu00a0030, 2024 and Decemberu00a0031, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } , "auth_ref": f "r48", "r49", "r93", "r96" } } , "axon_TwoThousandTwentySevenNotesMember": f "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "TwoThousandTwentySevenNotesMember", "presentation": f

"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails", "lang": f "en-us": f "role": f "terseLabel": "2027 Notes", "label": "2027 Notes", "documentation": "2027 Notes [Member]", "auth_ref": f "axon_TwoThousandTwentySevenWarrantsMember": f "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "TwoThousandTwentySevenWarrantsMember", "presentation": f

"http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationofEPSDetails", "lang": f "en-us": f "role": f "terseLabel": "2027 Warrants", "label": "2027 Warrants", "documentation": "2027 Warrants [Member]", "auth_ref": f "country-US": f "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": f "http://axon.com/role/ExpectedCreditLossesDetails", "http://axon.com/role/RevenuesRevenuesByGeographicAreaDetails", "lang": f "en-us": f "role": f "terseLabel": "United States", "label": "UNITED STATES" } } , "auth_ref": f "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": f "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails", "lang": f "en-us": f "role": f "terseLabel": "Agency bonds", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and

debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). } } }, "auth_ref": { "r946": "r877", "r192": } }, "us-gaap-USGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentDebtSecuritiesMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "U.S. government", "label": "US Government Debt Securities [Member]", "documentation": "Debt securities issued by the United States government." } } }, "auth_ref": { "r192": } }, "us-gaap-USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": { "http://axon.com/role/CashCashEquivalentsandInvestmentsScheduleOfInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": { "r192": } }, "ecd-UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent", "documentation": "Information regarding changes in the market price of the underlying security." } } }, "auth_ref": { "r999": } }, "us-gaap-UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": { "http://axon.com/role/StrategicInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": { "r9": } }, "us-gaap-UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": { "http://axon.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": { "r524": "r532", "r884": } }, "us-gaap-VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": { "http://axon.com/role/VariableInterestEntities": { "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": { "r142": } }, "us-gaap-VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": { "http://axon.com/role/VariableInterestEntitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity Line Items", "label": "Variable Interest Entity Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r553": "r554", "r555", "r556", "r625", "r626", "r627": } }, "us-gaap-VariableInterestEntityNotPrimaryBeneficiaryDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityNotPrimaryBeneficiaryDisclosuresAbstract", "presentation": { "http://axon.com/role/VariableInterestEntitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total unconsolidated variable interest entities", "label": "Variable Interest Entity Not Primary Beneficiary Disclosures [Abstract]", "documentation": "Information regarding variable interest entities that do not meet the criteria for consolidation." } } }, "auth_ref": { "r142": } }, "us-gaap-VariableInterestEntityNotPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": { "http://axon.com/role/VariableInterestEntitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity Not Primary Beneficiary", "label": "Variable Interest Entity Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity." } } }, "auth_ref": { "r142": } }, "us-gaap-VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": { "http://axon.com/role/StockholdersEquityOperationalGoalsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vesting Axis", "label": "Vesting Axis", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1125": "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150"} } }, "us-gaap-VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": { "http://axon.com/role/StockholdersEquityOperationalGoalsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vesting Domain", "label": "Vesting Domain", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150"} } }, "ecd-YstngDfFrValOffEqtyAwrdsGrntdAndYstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YstngDfFrValOffEqtyAwrdsGrntdAndYstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "documentation": "Information regarding equity awards granted and vested in covered years." } } }, "auth_ref": { "r969": } }, "axon-Warrant2027Member": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "Warrant2027Member", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027 Warrant", "label": "Warrant 2027 [Member]", "documentation": "Represents the information pertaining to 2027 Warrant." } } }, "auth_ref": { "r142": } }, "axon-WarrantExerciseTradingDayPeriod": { "xbrltype": "durationItemType", "nsuri": "http://axon.com/20240930", "localname": "WarrantExerciseTradingDayPeriod", "presentation": { "http://axon.com/role/ConvertibleSeniorNotesWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Warrants exercise trading day period", "label": "Warrant Exercise Trading Day Period", "documentation": "Represents the length of the consecutive trading day period over which warrants will automatically exercise." } } }, "auth_ref": { "r142": } }, "axon-WarrantsForStrategicInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "WarrantsForStrategicInvestmentMember", "presentation": { "http://axon.com/role/StrategicInvestmentsScheduleOfDebtSecurityStrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants", "documentation": "Represents warrants for strategic investment." } } }, "auth_ref": { "r142": } }, "axon-WarrantyMember": { "xbrltype": "domainItemType", "nsuri": "http://axon.com/20240930", "localname": "WarrantyMember", "presentation": { "http://axon.com/role/RevenuesSummaryofDeferredRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Extended Warranty", "label": "Warranty", "documentation": "Warranty [Member]" } } }, "auth_ref": { "r142": } }, "axon-WarrantyPeriodAfterPurchaseOfProduct": { "xbrltype": "durationItemType", "nsuri": "http://axon.com/20240930", "localname": "WarrantyPeriodAfterPurchaseOfProduct", "presentation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Warranty period", "label": "Warranty Period After Purchase Of Product", "documentation": "Warranty period after purchase of product." } } }, "auth_ref": { "r142": } }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r234", "r245": } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common and common equivalent shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": { "r234", "r245": } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails": { "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://axon.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "http://axon.com/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageNumberOfSharesOutstandingandEarningsPerShareDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r233", "r245": } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

IGC>?KT,M7I2+>R*#LHB|0NE@EH|U=6S5Q7T>./HH1#TWV MWMBZDMC@52VAT60->|5I70>R:FF>?JL,c\$W=\$#UZI6>S#R#|RHD1-W79%
M4=5c6C6T|&8,EFT0%Q|V?P5UWQPF5Y4%7%1YH,XZ?K @105-DQ?15 MNF,FF+>4-5850)GCJAP,c#ABSD&B5%CLK9,ZIX68%#A*X&6(IPQ0-
7USJUS,1018RR0&SLHR,43YXHE@%\$6% M26SE&.&-J|N=VXEFT&36/R51&LGF3,LF@= "TO|PY?HR57HQ5?80Y0H)M,ZUJ,IMWAG6QKEK<N"A6|
<6W|DU,B4X|I8:T|6QHM#&=M\$US:EHU7QHP12|+ M=MS>N96HA#22|@=N36L SAMU|C20714N>+>+CML|MQ?5\$96->G8E5AG#>R MKO|D|RM"A4:AEU9%
HO%,,,B=48/UY18+>X(I&Z<>K0@=00%HO507,K40R/MQ!8+K7|JGYE/|)L+>S"C:3DZC@Q=,US*U\$1CT08"Z|<@+R=-T%#6@T+8/G MC:>KMG=N%2JR>2/+&M)YL*%@>-
&T36Q|V5Y?>K3M+Q|H@U,63+80#UY5 M0>1G&N;J&SRR<|MG5N16G@CP<K\$USUNZ\$478FC,?P2CNF, #3T<4T2> Q74 IZ31+>E3K
M+|BKJ|>MYEP001HH>=US-1CG625%1NRRB@|H4|YBD@X2I8>=5|51FYBRMZM1M-76AIC@>P WEPW|RJ|JCS|&S!>LZ"K!28,56G|66BIC|?E4B7 @-0K M,@3G,1U(524C,RRH?<+
>|JP,H?7K#>?22(I7WEOX\$&=<2\$5of57DC2?<@<M@1151JL7">@<3@0?H-W4J0-05SGPRA51*P#50VD,L?>@<OE0E,51OD+>M/K\$55%QXVZPTR50P#JCA8|UYWYI(2@<KEU#
<4WNVFE623XJ9K53U3M1%2I,M)9Y|Q0S1YQ+>+A#A)A,EHE|U:IS2FE|NKFIU#>THD;N6%A4>D>9#P.MITI|8:2I-V|3I9P%WPEF52-B#FN2ZB8MA4SOT:OK+>@<STR>2|
(Z/N@|LT,MUU-6WPR9%F-DRW%%31750+>A\$2X#R3 *4@9HY<8%+D5%"/M?I2D"GGF-VY4I5-05Q|>EL@KSWA9^O+>M#8|SRX00+>QF1DVN3\$9ZB>7"(G)SQ(WKF M**+>
HBI\$5R|K!>H29?GIWZ|053(3+&#>|8X P#RWQ10 #A3W|U@UEFFO,MIAKH|28T@UEF6QD|I9\$>#?2AIG+>PIB\$W|8 2I|>CVA,,377**E<B|D5 M9\$Q@>@D7K 90>|E|89%#M/RJ
0F8I4\$YOR\$1J5<@<DL6,P7\$=Z%0%& MWZ-,590,4M5,X8?93^U>|0>JL J6NVN@>82,19:H=&,%8> CYS33,9 M9S|>@>2-8FYSMCJ3THJ,|JM4^>V\$B>@>16T^>N|H
(3T(WKVW|S|DA<C&NYIT,MA2\$>#ZILAR|(134FFC6C|K?7">?PNT|TBI?>P?4FN6E|@<FNI1N-6C5 MFMI|
@<K9T|XQ5ZMB>0C,KI?>1>X5<K|TG@>3-IC20ZWI4M9S|(9P4&N6DN44,MA\$>S|U@93LC@>U\$>K3I|>FNU|+69I2=>=<E6I,TL#>N4H|>U01,3>N|MT02-76OZB-4960%
S:XU|,P5+># GF,7F@|<C>PY,P\$>S\$>W|F-69K 55(U)H" M;#XZ5B=(U|H2;\$2\$5BL|<-|E|N@6FKZ|P|T<@9H|6JQK\$%>^2TS7F2#-F0\$Q55,QR0W|H MI<BK X2|H|O>|>+&C<|25">?Y|<
<X=Q|>1|DR3+PK \$43B|<|>N>P?+>|MYV9,1J-5L*OX<H|QY@>10>,%0%& R>J|JMG68|A7M?>EZK9|Z3J6Y|>P**S MRS#PHQ?>R90+>A60BT|NDD>C5%|A1+Rf3D3T3<
S6S2S0SR6+N6 M(0W4BRXYD@>|HQPZL1BW3K%Q|T3 I=1>S,D@<KE+&H9|65ME|0^>0%JMO M#>3C%>=<OX@>(N|+>4|HOH|CAI2>+>USG6(725B-XZD9-IB6+U8D)>9D@5
M|2|CQCTJ?>M4M7IS=>12ZT7B"4G3"&#>,%94M%0) MCX|>U0 E4H|6E+G+7.5?>7?P|M?T=|S=B>6*6|SP@<E|C">%,Q|T|B6* M|REN2|GHNZ RY7|+>,&OH9.\$%P,&KCN/B1-LOE^>?>
22G-D|<=<29|D|T9|A-MZQ0EWFY&3;3H5,5U|U+R|L6;G|FE:UMW|P|I&@<O M|V|T>Q&KL L|O|E7|BM|,6A|U|K5B\$K<R<2B|3EJCF@Q6 I,2>3?6W^>OEH%EZ M\$N>T.#>IZ-
4M/XOR5Y^4I=*KBY|>,>AXU2T,HBH<|N0Q2QZE8I2U|^E#9-MY6@%>^2>B=N@>38G5X%6I=>^|B|>?D01^>H|VJM\$4YNNTDEUK|>)C%F\$
*9021<CB7,|UUVB>B62515U1C?2 PF|B0-,M3WZL5P\$6_N_<@SR2\$330F,10F^VYD55>NKR#9790H=554>45H^V|VMV557>
M0@=>9B,7FE25>B>5)FK\$M(V=>S=<S&F^OU6=>H>24B>S MMS&SU,N\$Y66G@<V%>A-20,6P# =>P0>|B7T5>1,2%>X,+>^ HR3U|P|FEZ8+>|MR(G19R=|W@>4^6RE|+>+>OFP|T-
100E6K>U>+>1F8I8<XZ+>Q0&F00BR10^>V M+L#NGZ-ZCN<6>Y,H<X<#R4N,Y,6810>^>Q|H|Q0C5+>3F,5<E025>=<#C>UZTS(GM,?>2>X^>?>V9K&+25W>+>|HQ|>+>AG|YSK+>
|MUW0H|JEMPO,ZT6P|A4>|H>Y8F|M|P?12,NKK0\$2P|>A>T|EN|BFC@Q=Z MOD?H"EF%|L|>Q->5-XT=>+>1/3%>NT8&B600|H@>H|D>D>X^>J|>|OXU9WKH|M^E9A|+>+>?72-
#0<=>VYSBSM-4|>Q<=>W\$&-CWTV|H|Q|LP?>?R|PFKM>=>69Y-MX^H%SH2-8Y88K5H|A-(<S#>%50MC3EH6YK#XJ7IF0.SW-FZ|+>0^>N|>=<@>) M#>S1%>%LF8A|A<A&8|B>B>
G|RZ<^1 MZHR>#&3@H|>E?Z"CF<A>5,5@<D0YX5646P\$>>8T^K Q2B<WROQ|Q3621QCF0=8P|>?>X\$R4|>M=>|
(G/%%|H|>7@&#&B>9)3\$83U1M0DE|S831W|L,676|Z&9|A+PH^>22, M\$>1 Z2&R2R1H4^>U4C &A#>NKK|K|Z(9A0)G|N MA-UAMO<R,D8>UG>7>SH|10<3M5+>|S#H>SN^>^>
87>=<S6S2L1B->2#>I24#>M,"3M,|P|H9,NOCC|WH|CZ=<6&9E|H92&HZS%\$>ZW3NO B=4I0V|Z3\$5S U-M|PD>@6F|Z9L3|VIAK2|>2L+>V|+>+>GP,6K3?VYGXN-Z^>N^>2H M|>+>
\$V|V|FE-JY5 M<W8I2,4EZK9N<A>|UO|Q|Z1^>Q2V4,6YDS|AG|H|CH|ED<V,6>N|N|Q@<H K M06N42@|ICY 3^>2Y#>W>CZL;XX?H2T2G85>@<E3,K|K&+83X|H|L3H533^>#>|
ML|AE4SBPCCTR=>T6I6\$Q2WLP-TL|JCTY H4CNUO,%>|H|O|Y@<H-Y4S|4)HBE M|3BPCK?NS=>C>O75H486LRP&LZ>A<J892\$XL+ME71BA5>I;S-<S)K2H30A MF
2^E\$M>@<G>46VYU|B88U5M03NPH@<G|>M"=W|L763 (KFA|,0B6+>@<1L9> M\$K44FV2>WUT6,6%>=<B|L^>0P230G^>B|S+>+5 M|I>N>@<VW@>^>LHN|E>A9|Y|T3M3>PAF5>,Q|>GVG6#>
SP|<A5M+>Z>?>J|L1<X M1<X>M2>P#W|>L|P|>@<H&C|S|J-ICGH|L|>K&Y+>|W|P5V|HFSMBN|Z|H| M5|BMU|L|>C4GL^>3K 9P DP422>,>YN<^>^>X^>3>@<U6YCL|T28W\$>|
M|>6\$>|BR|L<1%>AKG|5|H+>+>W|W0|W\$W=>=,=<6)9|H|H7R M<VNYR U4^>F|OM|H|L4|&3|S1<@<N?>2>H M^>XO|H|F>,>F^<C F%> (<6|6|U>+<4L5
MP@<1|XK^>L4C,>GVL>23ZU|>K|KE|BNS^>ZGR^>RSM4P2>^>P5%>A6H1R&X5P,M-X+>A<0%>29ANE,<C|L|B&X?PZ|>Z|>@<F6|>BN\$26>Q0>6W|ZAX>Z,>C K76I=>M6%>E?>
B-YI28KA<^>B|Z%>95480+>M88)>#B,K|F^>F^>Q M,0|H|>R|U+>S^KL|J>+>L#19(4Q2|J05V-6HAA RHYH^>NOJMP|SWX\$40\$5CT-MP5->7T\$>=<@>AV6I>X5=B?>
KY|5>@<4>=5>@<6329>?>1=>0>,>4W>@>A537UE|E MU0J3#>A5,9-(H|P|B>O>A7>|>->E>B7GZ<4&D59\$>0H+>|>X3Z>ZB->09KZJ M-Z%>J|U8>U<1,W|J|MC|P<X|H0<1U|>
C5D DU13D0P<#>4%>S|P<A>P25N|N|H2I M2OU,FE-5D@<B#>N^>5>55-ORH=7K3?W8Z|H0?>#>J>2 PE:WOX|>S^>PAL<RUKK K
M4K%>0>29(4272DPDY,Y|D|I^>A0%>6)9>54S|J9|>@<J7?>F&S|P^>KPIY^>2R0 M^>U54%5I&A>D>4U|H@<+>C@>^>SOHG|G<P-7+M^>I03?7>LIM I#>S^>F|X<1%>4ZS^>9|>A|>+>+>TK0@<GE@>
M^>KY6E<K?>X50?2P>53?7Y MH6,|H7|29|E7|F4942|>N<9>D,F0|>H0?<H|E0%>J|K=>93|6 K4U|H,5^>8* M\$>A\$>3&MB|XFF%5&K YD|>I#>=<5>W8|H8X3+2C|>9 M-
/5>@>S^>Y|>EHL9U:N^>6J05U|X=16K7<42MBI9CC|J0^>F9?ZZI04,|Y,Z-M|>=75&036U7847>@<BG96@>%D^>A-H^>8X@>19^>|H+>=>L/RPX5M5Q\$>2E7^>V2EA
M586>@>2^>C|L^>U44T^>U63 N^>V+>SVROFVY6^KU|E@>AV5,>#<I^>XZ6?>^>HMI^>R^>S^>M|E|+>KSHJ|16=>M|D6G50S(U|H|>2L U|H5H8>3&^>V#7,?>Q3|>H|>,>D\$F M0<0^>@<1
M4>|>7>|B>|>U|A=UDP6 N^>Y|A=>565%4U#>=>16>HFK,2F T|HLDG06@<|S?>MGRH0 S^>A356M442L|V22T>G|JH|>13VOY2B=>A|<L2HC>Q2>|>Z P^>FZ7Y1Y13 M^>YU|>K|O|DY8>2->
@<B@<^>1H4H0.SX:P3B=>#9^>P|L|>W<=>SND<AMWT=<@<M R|G3|B<^>|>"">+>P^>4DTL|G|>V X#<C<D48Q0&@<M^>
F14\$1>=>2LOH04Q|XG|N\$>+>+>+>OLX0U|YTGZ^>890^>7%>O>"">L#8M,|M^>YU|VYU762763?>+>YW^>M,|N|REH|>+>@1?|>O|H|>L>O&L|WDBJ>=>S4 MR#>XFSB>|YDU>+>*(C/>^>
3>?>U@<EXGV7=>@<S?2I6|>=>U^>SWD+>P-Y>?>K| MOG|H>=>|/L N#97 P->H<+>|W=7157|@<G5I22OU-70Q^>2OU>7H|X^>?>M,C^>X MNKEN|>6TK5|A<TXR IRD42A+E^>V+>M|J0HM^>E7O)?>
HG@<L 0^>1X\$>C?>D8>N#>M>8>YPR|I/5%>4NC@<D.PA-0R|M7M|H49D>P>Z^>F5430,9^>=>@<OOCF|>|A|V|>R+>OWS MOTTFA,X88G?>
6+GD|CN|DN\$>H|>=>#>P5Y|V|UG5L|5%>I0Y|H|ZE4A.EV1 3X MM^>G= 2|N2 DN|ZMS=>W|H+>M|H|O|H|>K>^>C^>@<1@<@<22>@<6E>U>Z>9.4L7V0)>^E MFR-2>H|>
<&ISUW|>@<14 EKMZL2B^>H,KIMY?>7>4C|T^>A|0%>0129>@<@<0+>+>M@<IUEOR|G5|7SR\$CSX>3=>QBA^>I|XVCSQDOERX4,4%>KB#>N|F|>FE6WNB^>+>#>M8|>9DYV|A,PF9IS7#4E
ETU:RZ|>D<8|U|RP80>=>#>B>Q|BZ>W&S0R=<M^>YH8 M^>C5Y|L|WYU|U?>Z|G|OZV M^>C^>26L3I^>"">@<L|>S^>F|ZCZGW, G|>="|I4Y>P^>W> MZB|<C T&U32%>Q|<=<87>M|H<=<#2>H03_G^>VY|
(R3,RAJ2=H<^>@<16Z3L7A?>MU6R^>3H,N-M^>Y9|Y5>|UE|>+>@<U2N<>@<B0P^>25,W|T^>C^>GCIY0\$>?HDDZ2I|TVWM\$>MA&7ZAV>Y^>@<2GR>2.R|CY M|H|
|2WA|E|B|DREW3\$>3NZV095AM5768X<W>YZX^>F5)3MEG0^>M4+79B1P>=>3Y%>V|H|+>M53|GYA|>I+>R<=>|JMG<=TX4RU^>U30|FV|L-H6EXQN-
WU T9|<6|23NC A SIAE:ESU|ROK,<K|E|U|M|D|ZXTD0\$>=|J>9>|J>5|VANTM|G|F\$Q@<YFS+>9&7|2|E|H|S|MY|Y|7HR2 M|>|5|B?>
60C5J|NG6K<B@<K|B>=>39J0S@<(T12C|NXPZ0W#97>12PSYX|G|> M|PEX>^>^>A3^>=>^>8R132PATA5L B 2.6|B6TA+>P|UN|G|7@<7CGL2?>3>VAD55 M57P>@<7B#>1^>?>9|EC<E|H-
A&M3T|M|S|L|>9|+>C|<@<U|W|N5|P|0?%>=>CZSR>0> MT MR|YZ A^>L^>B^>PH^>S|A?>^>H^>|>GEE|E|S|O|N^>F+>C^>F9|SRM|O|H|>T,0 M^>4MY|K=ZAJV9V5U2P>GJ59(H|H|G|O)>#>#>C%>SXB
M3TTP<#>3D^>9C|U|>#>=>AUK Q>|>0^>|<^>W#<C|G5\$|S&9QLD4TYMD,\$5 M^>A2M9>?>2L8A\$>D|&G|O|>^>3^>K5-K|TE|TLZV|="93=>+W=M?>3.GEC3/8 M-
80|W3F4P2DM&R<3>3W|>0|>8|>6N2+>V|V|M|C|K2^>=>V2) 85,8/42?>35EGK M5K^>LX^>46^>3?>70.P15Z9RZ9|>|O>=>3#>IZ<^>L0S|>N|VDBK^>FXW^>3RT/23>4> MB^>G#R-,2^>1%>M70.DP
H4|H4QPF00M|>J2>7>6<L|F|U2|JOWAK|H|>=>?>3W<=,24,D M|I#<K>=>P|B163N,2P4&P@<R^>XK>6>7C|ST\$>=>E9V>YB|B(V8 M\$>A9|>@<7>3UKV MC@<^>=<C^>X=1857
|N1L+>4>1WP>O|TTS|<@<6>75232T72MTB3XQ32,X7>9 M8D L2U.GG29S4|>0^>A^>Y^>TY225|FV|K6<#<SR<^>XY^>J^>F80@<S5V^>00^>3G0TND|6S|U>@<A00W|H M|G-
V6U70#>19|>K|S6^>2^>66G2V6P3P<^>7Y|>Z^>M^>Q@<XV,57\$>=>MM9I^>M+>V3M5|D8SR>S^>U|O|8|3^>?>70C+>6XT@<S7P2EXX^>6
M9|Z+>Z4>5|D2L|H|L|V1+>S^>U|JFW>U.G<^>WRV|>K B|T#|B|>+>+>M^>Q M29672Y>Z>D2M|JQXEC^>H95U<@<2N9IXF+>^>E|LCCS2|&R7|Q@<V|N%>=>|CMZ MA4|X<9-
|W<@<K^>H8972>,(W|H|>3>,>S^>C:8>3>?>4RTD|ZCH|6J5M92% M^>U|S+>I<@<Q5%>S|>Z<HDO<^>A<=>8M9,W6|2@<FSPI^>@<|CP<BN^>H&H|C|B|>M^>D+>R|I>?>=I+>+>F|>=>
|CABW^>Q|>043?B|HWE20|SL|K^>0#>4E%>CJ9|>1^>M^>H^>C^>1^>7"">65,83|H8FGYN2<^>H5>B|B|>4^>FUGY\$>1/5+>15D>O|2 M-
EBCS+>|PVY>Z406GN#>#>MOBB\$>B|C|T9|>@<YX=96NFRU>22|R^>F^>H|L0W46GZ MZY|X+>@<P-->0>D7?>ZSA<^>@<S|T>?>O.EUI3\$>3%>Y\$>=>55H|2+>15A3+>K6 G M+V2>100Z#>2W^>#>M-Z8J-
0#>|>ZD^>GOL NKK<L^>F5|EQB^>1A-D|G<@<OREF V M#>YB|>1 M|J7XAA6<E^>F|>R>S>S9>L3CZ8A6U<G>Q|B|+>U51OE^>ORZ>D|H M0KKZ>=>YTY?>
4GSD,2I=>T_9L2UTSVKKY|FOF04Z->MVP06#> &GM;UKRS8PMN8-C\$>Q<K YB\$X>8N3|>.&S|>I3|WAV9@<F6W-HNQX;H M<5R3?L>I>Z IXB8|>#8,|>+>N3^>M?>
W<O>N2M|Y7Y-NKB<^>Y>5ANF M<^>M3>FE9N1>G>X<H>+>|G3|L RQY|H|N3>2>+>FN MHS5TVZ>U|BVS0>Z=>=>RLR?>Y>^>1/2,7WU>Q|>#>09F@<I#>9WR^>+>%&
M|W|PZL|>K>^>C>Q|09>Y>Q|R->R<=>#>O&E&G|IOM<WR>RZ>=>?>S|Z0P^>Q|>M0|9 H|H|W\$>H&K^>Q-L|D^>SRRD@<=>H@>=>D>+>2|M3>U>G<4>?>JUS|5 M M|K/87 T7PX\$>X@>?>
+>Y44?>O|W>U>X^>A?>|72Q I08XMXM9<#>UZF&S20A2V2>WZ3^>U>?>9+>N38^>ND|BZ|H8TDCZ>DRH2>D &SVO6 M 0@<I9M,|>L>L5JG|G9L|F|E|T|P?>YYS8YWS>XJ|6?>N-
/L|S?2>Y>VD88.O&K&M&=<X2U0Y7.547\$S|U02W ^>G1&M| ME&R\$>18+>P23^>W|C|P@<R9B|FXW-YP,1L G<+>=>WYR0|AS508,1K^>9>=>UMBFW-S WK|3N|U& M-
M|9HUE|+>8@<EM6|882>I>C6%><4K<@<L^>E<2>=<4>E.F3VYOL\$G|N|OC^>%>Q8V^>P2 M^>HM5^>FRV5SC9K0|>W^>W^>N^>S^>NPK2-L5\$>40ME|O6I5R6S7>T@<WID^>X5
M9>H|YX9>2CFO4DM8<VM5>#>R^>V|T|>P^>P01^>7HP3ZIZRA^>6USCU5F|P M|>OU^>V^>W^>N Y^>F4G9@<E+>L>R3>3WY^>M,55?>2MHV>54T|XOYJ|PU3C<6=>M34A
N>J>JGX3|>3&R<L>Y>0UOEQ>=>f>E2H|Y<ZX05^>A92V^>E>XAJ&6085 M\$>^>?>%>0BR&6GA3P2Z>=>XPD|>H|E|T|C|>07 MX6X2>=>6F65>G>F|>R|J>X4|6KZ\$>N>N>=>L|V/2
|>74|>OQO V|E|RF4>9 M WUW|W|MK|G|X|M9^>6=>=>Q>S>^>K0 50%>+>@<OC0XURV5\$336S|O^>P|T6I|L02P|H M<^>SPP<=>E|C|O|H4|O4K|I|O|6Z| OXX?>
3=>HGM0E/V4S|>T=>5>5|F|DAZ7^>CP M+>C|DX=>P9+>SK^>H<8>@<9B>=>+>B+>74|X>9N2|V|A|>P|>+>4+>OCG^>SGD8P|>H|K M^>0#>?>L>=>E^>A<H<C|8>P>+>+>YVH\$>|G|U-MR&N5>@<I?>^>
(D|A,OCKRIF^>8.0>.&3|>83>B3.P44>+>D|>L>.&WD-0A|P%>2C V M>B^>5|L^>A.20|>5^>+>+>XWA>88.*>+>=&|<=&5C^>P 0%>G|Y?>+>+>JZ|H|>+>|2L
M8>Z<L5P|X9>F<@<R>+>0>9|9AK^>1N|>S^>R|P0#>5^>PL>28&1>O|X3^>3R|F|B M|B|>Y>|H>85W|D|E<R|W8,8X2>=>0^>72T^>7+>G,Y@<8?>Y^>X^>X|>%>@<I> OPY3WX4^>Z05-MH|UDT|Y^>(^>#>4-
M|>L|P|C|P|C|>+>1^>N|H|>O4<=>1^>Y|>|>H|X&A^>5^>S^>K@<1&3^>=<400G|1F>=>9 M8H|A9&MCA1<=<K|6>14<=>S-R?<=>1^>I^>B0M64 TEB5<H(G|H|G|Y|D|A+>T0E-MK^>8%>D|I
G.H|H<H|H|3C>S|D>3>2I^>3>#>J8R>"">ZR>=>QSH6|>L0A>0^>MDO@<L|>F>+>A&E|X|62|J|N=M|Y0P|L|G^>K^>A&A4<G|>S^>1 MDM|D&X|H|L|SD|H7^>A^>L^>F>@<3RP|O|J<ONP<=>U^>+>?>7
L|G|5>Y>3>=>MSS>90?>U|H|O?>7K|>L|>3+>=>O&S\$Y>?>D7SR>748,8<H|>G|Y>481|F4B^>0E^>Q T M7>|H|W|>1%>MOL^>R20T?>J98|MHV@<H|RM^>P|>15|>W|R>780B|2|89
MQW45Y|>N\$>Y+>A\$|>Q|>+>L^>S|>F|H|F|OAC|_Y#>1>0>71|>@<0.S0#>M^>S3 XUP|C|UB+>|2>1&3|Z|OZ|ET3^>P|FZ|Q<=>?>DH>+>|F6+>A9>UDL82<^>O^>MP&6^>316W^>RMV|MQ\$>P+>W|E@<U-
C|EJOZ\$>C^>X^>155\$<C^>H|>W|>RPX|B#>8P M29>=>D\$P|T3|U<=<G7|X?>Z>5X^>E^>4GT0>Y|B7E|<G7HPLA6^>PQN<U-
S70\$00R62=>9|(GH@<Y|G1WY0+>24@<U0.124

3JFIE196LENN8EY<?ZC MI<GK J3<-C-BB9&TW>.%F915FYH25<?64 W>ZVY>ZG300312NOH4U1>1G<.-'MY<?P<G<O2L2V3K1ETPNX<S.MDK75<1<2N'>S.DUD1H7>MRG<^J>T-.)
 (F>^>.-U.CS<K%5VW<H1.W%8I8R2T.MWL.2%.5LK5DJC.4V2KHJ>.-W3./0>1-L.0&IKG.T4>?U0<43>XIF.7YKN<MDQ>QGS'>FQ<L18-U/AQ.R<#?>
 Q.O1B>.44S<378+EE6N.M2%t0!E>V2N&..HERLNY>KL<F5<U0!>I7<R3#R3>J0!FYVNI6<^NEB-0J>S.M-74=Z6<GM-/LW.'11LK=3#+C.HUJW.TC<ME<.
 H1MY45WQ/O'NSW435>>WBIBY00'>T0N2Z7F1JL>A2>Z<U>B4<+A1N'-M8'NT4<I76-BD1U>U>+I7+66L23FOC1W7M<C%>A3H<Z8073R'ZHG<E4I<.
 MF6>YIGI<C1.4>T>.WU9401==1B79>LEMI+UG<H1B6'>25FE5P>SGO3<31#5R+T.MV'V67Q<R.NDJSN=C^\\V\$J&1+Y<N.980<^77R<.'%JOPY<I5P>D<.
 M0I5T2ZUL4>S%K0<L7Z6<N/AX.M4U<P1-^R144I6-Q2JK'>BMDI8R0.K693<I7L>URSTX5Y8'>X89<QI4GPI18DR<^<#87>=51%>S.MR&S<+IN>E9<S'V>^<EH'N#0Z<.
 #20454.3GY2MC>Z6'9Q<L1BZFI>Z9.H/KP1.M66L9P<..B0N690J.CNEDE4EX<X'XRM.M<^%Y'X<4H<^..CM\$A51<3<^Y0M0.JP<69C8H.KR0K<7'G6+>RRE>I&?>
 MAW+4UT=H3!>S.SJ=&0&^42A<(>SMYN<6.O.0FN<G&S'P.9!<I7BR'E+D97W+2DIXTZP5<+YKR4F0..MKLRI4U0>7IE9R3<JVTKC<W'D-1.%>LCX<S.2^+O<^P0>
 M2>+8<TAE<0%>U'>+T<F+H1%00GX.YR>V1<J&E'&F4Q0.6A.DH4<M1<56G<C'DV1<5+>+7CC<VPI'H6F2YV<?7R0TVA<WRV4+&#>E14RGM.3'>RDEJH<3TFRZ<.
 <^ORH'>PHMM2<U'>K1U.27VB(A67)>..8B+MEN+MGO<C<G'>2CKA62VN..MSC6B1<I7ZHQ'>B>?D>=BF.9E'>P6.73<J3W32W'S.SUB47A<#UGI<02C3.M.5L5K'>?F.H'U'UWNT0I?>
 3%<+H&+>P1#N3Z<OIPLS'>(^N'Z<IEV%<SKD1M<..M.Y72<QB2>HHE.FTK<O.CI9INP1F<I&HJ>EG<#>Q'U'>+2F0<J7JWB61<3>6.MVD<=OY<VQ>^<I&H-0V20>..
 <IMBIK6&KNN<^>6'>I476<=2RV10Q5<V7LD1>..MW09I<7OW27>HLL<.%>DHT<5MC<C'D.M'Z<XLI&E77H<..GLZ6&OGWL<S'8<=M3QB1T<+>HDB7<9XRV7'U.BKG<=15&=<
 H3JH7.85MU6NE.8<S\$<I36A'IZB<^>=M..P%>OS+>I89EYJLH'HF62<I6L'FHC8I'<CB#<+>I.BAAU7<9L<I&ABAE'>D..MN13U'UWW<^>2&I'P3<I&KP5<JZZ.H<#>F.K6G<J9<^<43<.
 J7>H07<73F-BK'>T.MB<=V2C6H4<NNQI'YIQC<0C9Y>8MX<H5H6&KSF<+I3PFU8D>Y>+>T3<3DOMZ.M&A'JTW4C<IOH<I<+>IME2<I7596I&=R.A?>X<S<67<5KJN%?>
 E8U5W5C<+1+37.M<P'>XJ3<+>C6#>..177<JKS<F>YZ9I9M0I.G<-E>H<+>J1X<C<Y25<#>+TIR<+>UV.MVC.ZG<#>MIL<V.5<C'>D&E'>2BI2Z<=MEC?>
 09<09S5BXON<1D<^>+>#B<^>WX67<P>79<QKKC.T0>P<^>7<LFVCR2X..MSV4<=92.0>R3D<WB<F<XSTUJ4J4.NHT<614.GK'>E<^>E5<^>W.X<I.IB0<+>^>P.NJ+>
 WZ<11L2IUX..K<S4>2Y<..MSD9<3295U6.DIB..T.T7L5N0D.109XYK0I<K<ZEUS>+>C04>S<^>R.A.U'XU1L680<RZJF75.NRK1<I<JUIH.HD9\$N2<=I04>S<^>D6P6XFXFD<16Y5I2
 M16FX00<3NIF0.Q.EOXTO<0<+>I>..1^>A1<C4<..H7DBG9D>BIZ6<=Z&TBIO<+>I%1<M.WOQ<JG41D<I&+>2<+>I'YKH3<1.0<^>X1TSYD?>
 H/GCIDN7\$>RI<I009'G1O<S&B>)<WMH6<7CW\$W>W\$77<0C<I&E'>F.2<I&C<M6Y'>XJOTK<JID<I>IDJ0F<Y2O<^>UT4HS<PHHH<?>7&M3XBQ7Y<G3FC?>.#\$LSLBR?>..64^>I?>
 4Z<=>R.4G<+>H1'>PCNO<02W'R'U'U<M'W>=..NR67C<^>O9K44M51PWN<MOH2>+>O+>#23<1PS2.X'3B1<R'IVJ3<+>C<=MUA?>
 N/<I4.F6R6EN6<Q40R60I<=83%WYBZCQ384B<I<H'Q<I<6<^>QO..>+>A&..M.FJ<=I2W<^>CKR8H01G1S'>ODIOP.6<LDH<+>AE7Y<G6C.39G3B'2G3S<+>X0I'MB<OZ<IOM<+>
 (H'V2&0<JRIUW<^>PJ>=00D<+>1<@L<GVYH10N'>H0..>M'YDVFU'>AXWQ'>NX<IHN<AK8<#>2JL1'>06<I6W'>F7<=B>I&C2VADIG<PC51V>=>W'B2.MH4L'F=XPZ?>
 B\$!<^>GXIG<QCEW'>S<E54<3<+>U'V67B<..8L1<7LB..W2Y<K.WM.CM3D.3>+>K'V<I<BLF?>+>4>B1<B67.4K<4<LE7<?2.C.AN2D.W555D.M'G<S<E110<^>7&6<GS<H1Y>)<YTF4I'B?>S<
 ML1Z09.9<9QI23<XN<I.6A<#>M<CUA..8L1<84I6TYKYV<S'JL<8K0T'>I3QPW.MA'>17Z146Z7B'>F'>F56X<I'>40X7<OLO<VZ3I159H3D2<4HOV<A<^>4I4ZO.MKY?>
 98TI<^>AO%2.R8<+7>L.U'>7<C0I4<0J?A<I..038<C<G+ORA<BLP.R<I3.M<I8D<T/!19.DS.<5IE\$SU>2DKIUB<E.C^>P>F7I+7L.P<I'DF<I'KH<4Z<2<..M'>I0?>S'>H'>G<I..G9G<^>0!>VFW'>9<..
 YXISIA<^>V'N6<4D5<+7>L'>BEHR.M8<QW<I7W<75.6<SDCJF<+>ZMAE'>F.C6XW'>K<C<^>6F10<+>7'>K3<J3<+>C<MR3<I&PFR.0I63<OEOY'>P<O!>H<
 <#>H3X<H'>Y8H<I?>I<P<IG.R5D7YXB<I5\$>JW.MV14<0'>BO..>I&#>GIZ<CHHX'>2<+>I62<22<G\$>EM.SXRU6<MHTC'>I'>XIRGL<I'>GFS<I031<^>3U'I<A<X\$>Y.4<^>#>WP%<CAA2>^>A<^>
 <I'U>B.M&N<A4I<FC9<I8SNZAD<M<=J<Z.3&S<+>R+T'>F<Y&UYP'>H1N2..9F0D<M'DFL<G5.M18<K<I<#>CVC'>F'GA<=800QA<

(The following text contains extremely noisy and nonsensical characters, likely representing corrupted or encrypted data. It does not contain meaningful information.)

[illegible]

01H1Z371#F#&L.UH19.2W.M#S7K%K.M#B.ZKQ31&NG+>@E48M<0*?>J.HJN18IOU9M.#FN.E.#M6N?>#P&EMKM'FX;@O141H7
L.F58FF2C2J#K@<LFI<N&H&A#N&H<N1.M#J.S.G\$0<0<C50B.8+V.PAWB#BOS<53>U6Z720T#FW=>@P6%G.1UF21.MP.M.X+ELX4V?PZ?0X>@<6*61P7F7I'XRL?2'L.UC*ZR
XZ>H3N7.L?2D3M144%K?JMU'L=>ARQJ<A#&A9J.M9\$W7?&JE'>B<L?V500K.ANH?Z>S\$B0'>H1<>'T041C5.3V#B.L1J1=>E32DWL17'HTFYNF=>AH&GBA<8VBYF
R8+<C10RA.B.T&N&L.L1T1.0'>Z#1.M.W.4>'298CY1.L?2WB?>XPH1A<40'>S9G'4'>WKL1T?>S&NCG>LXFIQK0&LW.M3<0'2X'V0'2'>H0=RT#2A'>ON?0.1'>2JTCW.
>JZK53.>V7R8.P@M<K.M#153EW.MJ0YS>.>L'>XFFY.P<L.M&WY+PORZT<K.M&HOHFHP?>J9MG>.>3.M3<E207L'>TV2M9K3N.30'>X70'>L17ZNM&X7VTHG+7D.'>J07K'>L?>
Z110'>K8.RKBF3H.5NA'>N87\$>87R.FEIZY.MPHLSS.4U+6M&HP?>J9MG>.>KB9E218WY4X&D30'>LX.P21X0.UGU9.M'>Z>.>D1GK7POLLO?>GGI?>D?>^MZ\$>W\$3ZES1C.8?>L
&^A.G<0'>MA1T'M7>8+>+T1G<D1>+>X.SCN.L\$Q.D1HLH.LA1'>F&G2.UH1E19U272R0HDS1\$>M'>WJF'>3AHP<0'>L1P\$1<.&2\$589#K1C\$>L?2T9.01'>C?
&'>9HKH3+ODP#3'>XB81'>?>'>T8+>+>^>^>P.H6<PS>+MPH.KW6F>=>SFP.P'>M.YX1A9.OOM<2'>C878%>SAHPV5'>#IX1I.L.HQ.AA'>F.B'>K'>L'>MOA8'>L'>^>fJ.0>=>8\$.IBG?
@<101X.8'>F1YIES<\$.S\$YLLK1>+ZT1.>+T1'>YR'T1'>L'>YOMH.U2'>N63<LW.MZY(H420<.>2%>0'>Y9(F1P<=<9.V)H?>F1J0'>L\$C'>T1015F1J01C.MXW80DU8<QP9PA41'>
HN05<C+13F1F1'>L6'>YV1.M'61.3M5Y'>U.B.19.VX91'>#>HQ<=>31'>C9C.DH14C<NHOQ3J5B1H1'>5PT.MH1\$<C598F'>WNXQ>.>VYD1<=>RF1\$3L'>EB'>F'>U'>W8'D.K'>N51?>
1A5\$>4#>M'+Y.C'>KW1<C'>2E#>K'>T6>PJH7'>H'>Y>J5D5L1J573EW?>K'>P2>TRG<B.TM'>H1'>I'>4P1J5T'>QX19M5GQ2'>IWO<L'>V9M1R8'>^>.>L'>W'>C'>H'>^>YR1BP<E.H.M710'>L'>B'>F<
F1'>+85H1V1'>I1'>=>8L1MHRSF.2A810N'>T'>M.X1E1A1'>6'>LMRA.6'MKIU<U'>XQ0\$>N.K91'>A.MMLF<0'>D.P2S1'>I'>S'>L'>F'>L'>T'>MIO'>Y'>V1'>+Y1ZSN\$>.>Q'>MV\$>50EK<?>H'>Q'>AB9>
<+P'>5'E'>KJL1B1'>+18E'>L4616Z'>U8X'>A'>J'>U'>Z'>O'>M&A'>O'>H'>F'>B'>+14A'>E2ZGQ1&0.N1'>S24'>Y91'>0'>L'>SK'>=>M.M'>3?>V1'>I'>L'>M
M.6GP'>T1H'>+>DVMX.M'>Q'>S'>T'>1'>4B1'>H'>Y'>Y'>I'>@>FCE.GV1'>B'>M'>Z'>W'>S'>M8WA'>1'>5N'>+F'>B'>G153J'>L'>4'>HJEM2K2'>+14'>3N'>+>R'>C'>O'D'>P'>T5G'>V'>+>J'>E'>M91\$>OFP3'>@5?>
H1J74E0'>3C1'>@>OFP3.5C1LJ84'>3V1'>=>0N'>+179ZRVUY.MF1'>3?>C1U1'>8'>2'>OQO'>P'>OMIT'>4'>+JDS.G1'>R'>D'>2'>S'>.%A.9'>Z'>O'>2'>P1'>MHJ66Z'>B'>M'>58'>=>P'>+>9'>=>+>Y1.A1K0'>=>
>3'>@>#1'>7'>6T'>A'>C9\$>B2Z2E2M'>+>UW.M'>F'>D'>P'>73'>PDU624'>L'>9B1'>=>=>LUU62'>D'>Z'>B'>L'>Y'>L'>E'>V'>L'>6'>U'>C'>GFH'>.>#>ME1'>+1'>35QH3V'>A0'>20V'>COXK&0D'>OHU'>L'>A'>M'>=>A'>.%302
M2.95C'>@>N'>C'>Z'>0'>Q1Y0R2'>@>16<=>(>7'>ID'>L'>V'>H1VAH20A'>ZOF'>#>Y1'>Z'>+>W'>59'>9A'>L'>O'>1'>E'>V'>L'>63'>035'>2'>9'>K'>A'>W'>+>S'>R'>C'>M'>+1H14&8'>0'>D'>61Z'>@>P'>C'>L'>+>V'>O'>M'>H'>D'>1'>M'>J'>T
'>Y'>U'>X'>+>D'>C'>M'>H'>H'>A'>0'>D'>F'>0'>9'>H'>F'>C'>H'>+1Q29LN2HHA0'>ZOF'>#>Y1'>8'>W'>O'>D41GQ\$8'>I'>P21\$>M'>H'>F'>70'>=>2'>1'>N&8'>V'>5'>0'>.&I'>B'>X'>+>.&I'>M'>F'>H'>H'>J'>B'>N'>B'>+>Y7D1E'>O'>J'>M'>K'>51'>P'>X'
M'>C'>8'>+>ODEZM'>.>.>#>Q'>J'>T'>N'>Q'>A'>2'>J'>F'>1'>J'>U'>A'>W'>=>M4'>N1'>Z'>H'>V'>H'>U'>R'>1'>C'>G'>H'>B'>J'>R'>6'>M'>X'>L'>1'>5K19GZV1T'>1'>5'>I'>A'>O'>X'>F'>T'>T8D'>G'>+>8'>W'>O'>5A'>H19'>+>AEZ'>I'>P'>N'>+>H2'>M'>Z'>H'>M'
L1.C6A13G35'>N'>H'>I'>P'>P'>B315'>L'>H'>U'>L'>H'>A'>A'>B'>I'>S'>@>L'>H'>7'>O'>G'>G'>H'>V'>H'>I'>B'>M'>L'>H'>A'>J'>R'>6'>C'>G'>R'>X'>L'>1'>N'>I'>S'>K'>G'>7'>Q'>U'>3'>U'>=>Z'>J'&

[illegible]

[illegible][illegible]

[illegible]

Q2KQDIFMRO2S21*17,70CXB4-^0)0FE(EN^,QAQH>65V\$ MF17R 0YW1J-KJ\$H1,2^50GCU^*N58@OCPLY-1A^Z?>^#H16-4^0\$SQ66 M\$=JLPl,Y.FE(YQ)=X\$,G,H=7Y@/1^7?>
Q2ZGOE6N60,19Q@=V1W06QDQ>F3E1M,38L^55;G,^*2=H5/E@Y1YKA1YW@=7,2^P\$=5^GMV,1HWPVGZ1,GGV1N^ZP,1J,1J3K1AR,0GK1GV<
MOW5SX1X>@213,0HG-RU^,Z^R^6D-01VS>Z^1,6^CA'0,HG^R^2Q^>V35U,M5RNFV^1B+JF_3V^,3-JGOZV1N>^MN-,N^S2V1B<0SS^PSW0^KM^1L1) MB\$=-
U^>0YLGR0AWE1B,WR15F^W0G\$37IGM1X^2^15^>08^YH\$N^M6(B^,M^EHF1,76HBCX21^1^B<^N1=,1^6U1Q23^2FHZ3^XQ\$H6,1B@N-1N^1H^MS1^M1^7Z^7ZW@+1+
(+0611)1H1M4E5,B31Y-/Q1Z^2>21Q\$%^1JOCDDZ,)+28K7EB-1<=L11(7^C1W-L1H0-,+00NRT,SO_515C^41L4_CU^,1VQ\$,1MOR^18Z,3^706_B<0BK^K^YMR>N+0^7E-
MSW<0^>0FGZ0F2D-HM1Y1Q0B,\$\$W.6%,M2%)MH1EV,C^\$1X3V,3D2,(2L7R4^XZ262_+9A<BB^4KA^4N(ZCD,MNCA=0Q2^UOH7Q_14,6^1,^GRW-,E0)=,#0
3HRG:BSQ&BGS==DF)+1+MAZG>^1,6Z7,7#3<^,0LVZ\$<46,T61MA,M^X&ER\$0^X3T6,K#1=17FF0NF=7%0#=#=^,0T3GT433V^1,=-2,=-6^MFOV4DVV^>0)W1\$IG\$1

[illegible]

```

ZRR>@JX4.3%F2N/20T&L2HL9=Z15UT2164XJGRUQ?R@S0#&8S21.3SLB-MNLE%-2"Th#-1S)H1A2AL=CIKX%3G< @Z>1&^2D8Y3IHHMCG^2TMKOAOOZYPL#DB-
9LJ$5%V.GEN2PDX0;0B;U0414H1A91MJ(7D3?G-F7.63A-(TGWALPIEXDW%==I>#>+T+L1-VNKR7@663GVFVU?7A-M^S9TOYNN==7LSJTCIYE4&=93-751BA=TWF3FO.656$#6-
M3JN60(P2V7)(6M^O+WLDMW1QO15GUB1#1E8;0Y:3==>WD)+71VVJU1A(KZH?ZDBDF.(SOE@6MO.F75+X5;Q1WV:KQPH:7441A)B#1B-5#681H0Z<#%2XV
5<Y0>6-#1IMHPMV7TK&==98-&R>2>X(2X,D+TWS<42>O)T5AZOOLPFTB1S06XKQAS=O&K&E-TMDU.SB)IR&A&K;01-0M(BVUVIRIM:UJ1TKGYK2KQIF.R;G$P108ZL.R.@
M561F12V3AP4ET4X?4-2EE)>X^N&B6(N&C/FW$<2>O)T1A(LRN?7MJB.RSLAQADS)E#E=1ZG>3-NH.GA7$>16-50K^B6X%FL^1)YJ@8B,MJ#
#NLEF3Z&E5MSWJAKO6=<M-M^7L1+E@D91.DFU.M(HPOIWF=&@UUV.N2.B1JAI#71ZISF+I9.BLLF)T@1BSLKL<816J84N.MJPZB0<8I2?WEIJOJBS=K+9+*#N2
7K$9>Z&E=RBH;PQDEU1W1W-(85WY&X^T-M39V6W=W)6X$M1-/U-HN1<^G<K.8Y54YG&B0YV.N-DEH1@U4K1X25MMQD-N-U<^Z<1<87HMOBZ?>==&<.>)-U23);
(8V^+QTK>&1I^O-0YTB0^MKT8(4MX@@<7#3RFJ&12TYNAHE3I?WPT4I/LIFD5UMLJ|U=1>B|..NQ&A?_MOMJM^&S65&KH&X^HD(K#1F^*=1I-
5VGHW+1#V2?QUJQIY|@>Y2^M1=35PPTSSD(SWC+7GN6MTSS31CUN#);VMPDDNZYI@1^S8PXTCTF1R9-#MOIFAW+1Z+1<6@F1RW+4I9M(HJQK)O^
SCZZXALW@B%JHQQOR1Z?Y2^MLS<K.EA41.YM7L1PCEFE=7F4FIEM=BIQ;YVNP9V|U|@Q26M>C>2>1D0^M<=>IT<..H8K<6>J|RGJEXD9#QOSMCLCATM-C5IMK?>
M94.AW15.D1@17=>5DH1M^ZDS<C+1-0.6-ZN9^G2U.N1#6H1HXZ1%2P.MMO1FQO1(RYPLIWL.M^<WT9S1225K@S5HB(K@KT?T&E+>>>+7.OW$1M^?
0AB%K&ZUK<GF^U+H^2>.(FRF>H|R>3FW+ASJ#4=>+V77FTZ?U1J3>=>Y1O.M4V.S1@6A1RDL^<K(K9#0JMU$>9Y1J5724I>1MFTYTG6G&5>T5^
M%$>1BSC1<=F%ZIH9(X^4/5^5+&=F.61>/-W43-&P^&+H2.B%IAC#BTM3E.M7IAGHJ-T^=JX8FJ>#V^UMN1JO-KUA9<N&ILR$XOW71KU$S4.6A-M9XY&HKPHEP-
P^BFL+@0S0.<0+N)M.KO(A1?PFB&BU?N#2H|HJG|P^MZE2F2FDP^C@LZH(GK|@<1+V>S5(X70QC5UI2Y$Q(N9B@X467G@HLEFA.M+@LVR>W6)I@<O?X7H00|D|E-
K=>5V.H3V7?ROYL9.9+4I2V6G12TQOXF#<M^O&GSJG?T2K<@<B24I(11JL51N1226JUNDRQ3BMBR1U)20WJIK7E_M_GIA1I1?>
12?GE1K818DM+ON&+1)PIB1YD12A1412.N4IP-RCG1>19ME^UW41^2K92>5UYB028?B_HYV1P^U^IV^<^9UG62.CYMIIE7VLR6TXYVR
MX2#1XJHMBZ13DVP>5FT9FD2.6+CI(B1-6LRL+9333@B@5SDTGLX^B1>=HKV31Y+<#M.MH1-9.D76XRO?M#BLP?TB/SCGE7=IW+U9?Q?V416T#X)6H15.YJ9
MGOWN#K17WYQOM>=0DMN6I<1V02WJ614FI^)(RNT+X^SQO1.M72MWH9.#<=1Z$ISN=5B?N$A#<=&D<9M8T7WOKJIBAWD=8%WYGG.GD4%31%F)E|
M|@HT>1WPAIDN89L2P+HM9QUATH1D7=0^E6=V$W#>-1X282@<=&R7.5%8=810MY#V2H16">=>X1HBX564I(Y10?7Z#9RG(W^4%&I2^?>H)>H|Z@K$A=1$@
M_RGU+OY7JDFG.<#8199MEIVQ31#Y$K|NMJG@S%97H1L.EL2OYY122.&K-MKY$0=T^V3.O-3FKK1<7C16^08RV#Q4>TG?Q1+U.WE<F<C4ACH>ZLO|MAUV>38D034Z
K1<2L1&L.DRCM2?>WYEL(C"6GK#&49P)*74@FBB?R56K M5ONIC4M12IU8+9$A$10W3.11@BRH27325Y1SN-IH.SUHIK<^#ZUB60
M.BWZ2?<0^L.KZ0$>.BHS<6#Z2N^MN@L50^1R2-M7J31=IWP1V$XBDG=M^D.MYU8H.8MSD5M5+1X=IKN^N)G1.8ZTYKH#BG+>PTP&S^F#IU^C.&8=1+MF=LD
05VHIFL<=>1H5B02BY&<#MTH=I9M.B0%<#S$ZIU+EW^Y_A#2GY68CI=06/A4#67^7^D1$R2.MQ.7=I0P<@QI>7<6L^&CB3@Y2<=<UJM.H&IR^JHR42L0W&U^TDB>
M.AY.O1^BB3$S@NRH?7Z4MDL+T^2C64@<S7V51+5LNSW1Y+61CZ@<C4MX?2Y1LRAO1>/TFIC&5VJ#(I.Y1Y?>=&1B3.2^1XH<4F3Z3_OPGM?BI<J&MH><^<
J1M9D13B&GR-M6T.ZHO?2^M^>.(YTP?>R43.11#SP16J&_0M25P?D1I2=&6+M7YXGDR2IR$XCM93=T^C.WZC^&AZND;#A+ZTY9R7AYFU?TDS>1@<0SC1MMAA^Y
#1BK85$2&R1@<GW>F=>=&L&N72HZ<4LST2>KMW5KFBI19VS0LHJ.ML@B=<G>.>1FSD4Y|QV1.DVQ1|L+U.624UR96FO.U1O6^K^QOR^44Z22^MFJM>FFZ-U6
SR.CJR.12|F|^#GY#P^OIC.M^YB<4LST2>KMJ12+@<A>D1L.GM1^2@2R1L=>LRL=CXCCXN1?>E>1SH7L2^O1+AA&D&B-C$MB9U4S9V@N-MO7&SIEFIOK(N@%
IL#L(1+($8H<=&DIBK1$ZIU(DY-7%521K1+PBP@<E55F1#/-BA.MA9H86G&75FV^>14^4MC$H.HKNJ#S^#GG2T9H=N)F7?N.PE+^<EFTSP.A6I.KNJ15N
M&KKN1AU+U10.T=>E%K.DL$Z(RN-83=W=1J0^H.Z82HNMG4%<R1T&3^13^M1-MH3JDEIZZ=>1XPM12EH>2MZGBGM.Y1B.NB1A@JHLE1^1CG0<4GWF
M=>9.ZFQWQKY?TSRY%1A)BY.BB-14CB<1&H165:HXFAF$H10^&T^CXMY51H3>.BFEET1&6OZ1X$5A1YV1VJ.NJH1KUB146=>7%JH0-IT-CP13^ZUB.N^ZZY=W90X@
M9.LRE<3^N5N<5XLU100^K1U6R190>B1CYV.DP8#41.VG+12.0UY9K.M2E?>LASQ6.U5^K3KMY$AWKBS^F1X4V(OPYD1@YM1I2C^L6<=E1+W-M#LB:K1Q4DK8H%$4?
Y>1&+JF$<6%W1O1^<9)50A>@BDAJU=>M1OJ8<0U.MJ1+Y1FWK(I@LEIU|TBIU1ZUSMSQVZV19A.F#J.UGO72+9Z.ML&1TWO0Y0.U.TIG&
B.LY11<6%N1H+1V24)1#66F7.P7JR1S=WMP1+7M@MOF)SPM^HYN+Y+XJQ60&6=6C1H149KZC2@2V19Y>6DY&VP>BG^>M.N<26(BL-T1_UXM2H0U
K41PICR1E7<7.L0AM1.25.6Z1F1H8$3HRA1.1V3MEX.G$H10F&K$S&112H5ZGR6OMELNA1O1@#6)O>#L12H.D.MORH^<M.HJH8KH&GUCP<=<S<1<=F^E^H0U:7
7KKNV1^1NX+<Y1^1?64=XZ780<4M>>146)72D01%?5=K03IK:2H5Z1&A^HKI=X>^<Z^B-J5XPK1JM^6V)K(M)X:IZ-BMIP7+<8AZ$==1P)H2JPP5C-W=ZYS-T7+<7=
R001@<#^F2>2+2+PFPMPH2431P2C241D16.H121025%#?54AATN4J.SD3K^9C(WU125B M77>?B0^1HDDQ..L.F>=W1H7>M4&51DKZ<#C%9^VB1=>BA)
K7$>1F.M2<=<KL@<B01^#Y747JDI/LT8>10<=<LR9D7H1SIBF&1=YGN+K1P.XK.MX^CB2B?12YCEIUMM%6S3LB5.C=OL>P>10..18^6.XYVDW#H02K&EYV+
M^VNYV.K%9S&15A.NA7HKL7K1M=M1J3VY2^Q<O<@<1=>M1@.D4>AW.O&SK@<1U
```

[illegible]

5A5 %0Z3GZ1^0W\^I=OKV[2]AL^%10P^%ABOD>.&3Z-15\$3P^MP5;7-HT^=Q:XRI&.&18HUKKHJ^G^D^I^Y2@S:F9PHEG^'^^?ITVJS RW@<~M P\$+(7>=><E^466XNFDP>.>Y^T^V^F^E^B^1+>AMR)6SKL\$P3HDHN^<6~M>9A^H1<~AIRHJG+A^T^H3(3^>30^6 BLO^3YT@K@<^/I&@IQH^0FE&:UW3 M2UX4IC.FBWDD.LJ9N^/I^C^ZN^XB>(B#)<~B5^3^H^M^A9H.N^>Y^C^%R5IP-MB^<C^%KSEY^T<9I^T^1^S^XN3.N3I^T.LCLO<6WAXHVOVA512^/AZ M4G1L#^+T2MM9LC=(^9(I^STWXY^%3^ZRI^JH7IE6OY1.(#&#AK&H#M^=0P9.N^IE^U86G^>.7W^2WXI@>J.BT.S^8WRTP.198&E^J^=J^K<99\$IL^& MBG^T^>H^>I^Z^1I@~W^E.CK0<L^1.2NK7.RQ-(C^XY^CLDF:P5I:UY151+@# M6(IQ3+I)H.H.%5D +I.\$Q9V7 REU9@%LV2D=C.(O%~@GD^I\$KCY+~B M^#887R.^Q&Q0I0(L2L)7I^SI+5XAX4>IWB^6IQ^M^HK-AH+R=^=WA2N%(MTPC=\$BTRKUAHJ9R4FIK8FI>490+I)MUZ@OV(P+I@O%~@R@8ZIH^N^F8 M^C<~&8NVN^&^&?&S^MPXN^IQ-BABH^HOCN3Y=5F3UO+I=L^5NA&R^&CPH^M^M=49@P%I^W^HHR1^C65A^M^>M^4Y4UW/DPIHS^M+I+~B2.O=EG.5%~&E=8Z@+^L7Z.6FSHRLD\$Y^E^E^S^M^M^C^K\$5AU^E^F^10@S.D^>Y^Z^G^V^M7+IPEEADP>@%#I+~8&K^6D^E80U5^19R-304RI^7F16O45PFI^7LW8N^Y2^M^ZE&E^M^Z&Y^TN10=O^K^E-OWH^J^E^K>#U^75(B0@<9L.BI^%\$IEI1^@<I^4P.O^M^DH7^%D^?>2DK:B1=(I\$4U^I^>H^2&IU9>A^@B6.I1Z@<R^>#E^I=5>0)N^9OEBXK^2O16I0.P3<^UXDB<E^F2G.M0I^Y2^4YVG2@9Y6I9HVH>A&E8.H9KIN^<#C^WZ^>N^7I:A^Z^M3ZID5GB51(=TQJ4(I=672=(^OI+^I4<I^T97IGBXI^R(=W^>^TIP8?MA)I^#^RS^FOQ^M^@.R1.GC^I^D5I^F5\$3(>^%?(SZ>B^KIV1+I^F9675P+2I^H&3H^I^>I1<I^164M1I\$#^VANN^K^R=^&3<I^YI^9T8@<QV^MHWZ^I^Z^&55^?P9W5^?KA.AX^#O^I^L^M0&.<~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~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^70LM^@?E^I^PW73^T^I^Z^I^M^>Y^>S^>Y^>B^>O^<X^<I^>L^>C^>I^>AB5Y^I^2^OP^>+^I^>I^>4^>J^>H^>I^>4^>B^>N^>W^>3^>B^>W^>I^>O^>K^>Z^>I^>^>4^>3^>M^>S^>E^>FQW^?I^F0B^>Y^>S^>I^>HDPLA^8I^>2I^>D5^>I^>7^>4^>A^>I^>X^>REU^03I^?^E^M^I^>M^>W^>Y^>H5^>S^>U^>4^>A908I^>I^>2I^>M6F^>9>U^>L^>W^>UZE7^H^O3ZIGU^I^VSP^I^M5@0GQ^ZD^N5^IAZN^I^>I^>L^>I^>Z^I^T^H^R^K^I^35I^%>H^T^#1^0@E^F^G^P4I^#^?^D10+SS^MP4?>#^<6^<Z^C^N^%ARY^>I^>6^>P1A^>I^>3656^>Y^&^<7^N1^>2^K^>M^>MUP^8M^>M^>U0Z^?7<^>O43WBGL^>I^>1^>I^>2^>DMCFI^W^X^85=C5^R=RGG.^>I^>Y^>?F^GIV^Q^X^M^E^EQDVL^>V8T^>P^F^I^N>2^IBX^>I^>E^N^2^N^0^DLIU^1^>R4^>A^>M^>U^>S^>W^I^>W^I^>M^>V^>U^>D4Z^F^W^S^7^>6^>R^>E^>N^0^GB<~>K14^>M^>R^>0^>3^>H^>I^>BDI^<I^>5^>H^>I^>Z^>F80H^>M^>0^>6B5^>M^>C4^>NZ^>2^>U^>7^K^>Z^>S^>958W^4^I^>U^>Z^>+I^>55C^>W^>Z^>I^>V^>X^>W^>G^>ODD>N^&^&M^>J^>7^>S^>W>FOY9AIP0.^GU^08BB^YB_ZG^?U^>3^>W^>S^>^>9^>8D>=>FI@<^UK^A8^Y^K^%#^M^>NGP6^%M^I^EXU^CA^I^S^9EKL^>X^A4>FOG^I^DE+^7

0HE5SB7Z<IRSYZ@Z>".MLUSUZYR (O4">3X@ZMZYF7.R@M(28>R+<#CB2422#171\$XCXCE D<03%K52<J0.<1Y-G-K-Q8/C JC"-M.SB@P08Z@DU#27C2NUX
 0JBI.FIWBK<R+>+<#LH85K.SAAKPM/M@700R7PB:6S031670X3@<J">J06VJHC(K2.VZC0PM0&5MHT<823RI@S.(##>O.A1B5\$XW)G380<U
 0H76V2GNG9AS(KHF)Z<Z<#CJ48BKPDP+>WJH IZPF#F95+>9B.M4U4==>HHCXD:~>F8282RI21+6*~>O5<VM.MIBB#(BLEIRTZ+>06%ZJ4<6PLH0U3W+H+<
 0JHURUC<0R56Z&K/ZU?>J.MC<W2.HJ93L"UJDL<K21
+>K>>0N/L1YQI@09B0P==>J#>#S12.M6U5%)%~>+6PW>F.C68M\$<KT#5160W1M1RFBOM#(Z(=C
 0U51R"JHNM.M"RWRJZBR0610D<23081DLD<85T0M#(QPSH=(UD=)~>J0?QXIC@HO)M(97M)JH"JHU.H=AOVY:~>N17J1UWXS<2J\$ASBBNN25<6Q27?>=M1HNRI
 F..OUT898<8.Y*VG.7<@NQS#E1GWB7465+=+5U" FJTLGIUV25Z@9.M2"=W5IUGJKK300K.D\$>R1#<K="G>S1ZZ#MBL<1+IR203BM.O4QYVYK
 M.O.D.=>X"YF00\$S4"FLQ"WC0Y9NR9R7LJYJL"GT0105>SH+>XAO.C1M#<5FP8B2.UC<VYK.MK7=N"1?>23IP=W00O1JHWN9Q.OMFJ3M#<A/OJ.UZ&J4.52T=UN5ZNI
 MEH&VYF77+BPVJL(FE<1WT3.ZLKMKMD2KHO"18>=C@M0#G9U<@N1L93 MP2+UKLPT5VZNYU1V16T?>@&@&#PQCXF&1)VBU0FWB0ZHBNL#<M#<D_7M?4
 M#OASQJZLX323IGGTA.EHJHIS901KJ<2>E.CN0#PXB+AR9B74M59SFVZ">MH1H.14O.K0R0S2+>R&05&5U\$<K\$TDPQ9SDBI2A<0.IOGV?>
 M1GR5\$5DXI&F78UW.S#VLL1=VTN1L#<R.1002B2B@B14.T7"5L MJRY3@:<@>MFF#MVLH@ZIX.HYU1U12(HGGL4J7TJ\$RIFI<@<MY7."M\$R-\$"GB=O"W("0.S85">
 M25XZL>#>#H1<#<K5N1H30GUK7EUA.176A>JON.H#<N>/4\$82IQ0K&QY.MQ&68XKIJ#<#<BN7+>4GK0.0.52>V>=J02X"U.DI<JdIRD<?XVAAH58.Q
 M1Z<+OPK=ROSK21MGL7ER>ZUYN0WPMCALJ.RB>B#K0E#MAG#0W2&4A.BB4.M4H.FGS&2S1JYMONIC.5"~>C<#1&+F<OD=L3VPFWJ>=(A&7D.&K0SDCWO16+M3V<~
 10.OX46#<W=M)4T2PE<==UGI2175HJ8K6#D<9PCB5Q>PQV9R2ND04.A2IUT2JZT=SU<~
 M1Y00/>1P\$5B6#<IMXBDH82.M\$GL\$IA&EQM0&=<07=MM771H"ZD.D1H&M\$7%G0/8%#H4ZL.FHE.UV.U0GE%<X>Z>@BB.CK2X<Z>Z6D<15%<LPHH3T<MAS(<07%
 08(HL2P)Q20(\$@P+P.FCXG6WNZ3.38V21#7.KY0K#HYM\$5.M.U.AR<+>TJ5>MOUR.NAD)BY2AB1<+>TQOWO.N%N.DZYN10CAK6L.MNVP=M.AB&GK4.Q<S<#PY<9<
 A)BS01/>9%780.#<9CWX1ZU+P04.M"~>L16>9.6IK\$5@<#H05%0&K&YX.M.C.R<#Y.S18YV1L+GAM.5%<M.Z.7+>2K<X&R.IF>U2FO>=ZIR6BY.FTT<1762D)BC&S<
 0VE9<2H#<M2.8L2BY&FJZ=NS36HTP#13.IF<CZJL.Y1L1P1?>2#R.O<422A1MG?0Y1.0SW1.W4W1W.VU~>M<0>2.WPIM.FEK58P>PW304&#2>@>IV=2Q
 MXNS9X@R>3%K.CG<X1<IG.A%G6C7GAR.M.67LH7S?C3V>(9IUO>77.UT<9G.M<=SOF"S)4@MWT(S<666?K1.M*14OKFY<?GGYMUO?7Q7MUG.G%<43N.JE#(XT2PGH<
 T~>79L5T.M1.J2(KK\$1S1#<I>P>P~>QY.V5?>G.MQZL7J7H.IE<=<1?2D3J1P76%YAE<2S1?G6?5Q1=>I9_N5N2.I@I9.MT<B71>XZX002?>
 Q.6DG9BGR@<GRW>51=>#P.03109N7K9YI02?0HIDU.M5YH01S&F<CY90JOISZ&@<A17YJ&48L1\$BN#<80H5)IN(FTP2?LR~>M?Y<4&#14Q6+>2
 3BC4F<6AE<GGWY4A"71D..ZHW2<CHW.EC.XZC>>GG.M9T354Z.BEOIX30.GL/2?TJH1+<C&C&CDB<54<C\$9\$1<
 1Y.C4&37QV.Q1F4F>JL#00M="GD5B4SVI0Z.81=>GG%#M.BR.GR.RD)OBQSIHW.S#<H6L6YFLYV.CZD1Z9Z<S9G\$<FZ1>8+HIZ.M1.N<4F\$F<R&D\$<CXH\$PV)@3#
 0965V.<Q1GXDR.<YOF0)002?>L/M6@P@80E1UX.8.YRID7V>VY+>0.B1/\$B2B%#XR#E6EOTF.O7C7PY
 MV7>>16IRAJM032F09LM8(ZZZ>W.3<91K&BQRI4JL#6&1E&C@QV>~>9%>B1GTF7CX<1=>=>N>+>V3D.M1P%#7<#DNHS>2>5Y4)1+38)>#S\$<P1?GZ\$XFX7IN<+<C6<
 6L1XKNX#>51C2AE.M(90B1)<19<1<03A11U)ARK&9&0F4EBMHZ.VYHM=J0HISW.UK#M.IOXJ.ZI<OGV\$ZU1U6XNS2.J<C1#RI(VBKBJ.UJL2I021"U@RXJ4<~
 M767L.MY&K.T8)1<VO"HW\$T\$5=>A0S5QF61HB<5>L@<124HDIWYH1M70?M3Z57&M<6&4HKVYN@L5A9\$TL9(QY3M<A1\$#>P.KJ.TGVUE1L316M5&2SS1
 1M7Y1.MY?>2IUTUQ#<7ZRH95T@XAOBB)HHTD>>>4L.ZO.FJ5@<1?MCMGESYI.A1?>5%IMZJN1X15D0?>ZF.L1UM2L18.9<K62?>(HJ38A3P57QVUE.2SL(M251\$B@76N?>
 L<6Z>BAU&US#K9+R8R5.7CYCN#9Y#W(DRAQ%<8ZIG4T.E3VAT.IV.3><D7>U.M<8/O@<1&2P5X14#HDQR?3(IG"BM8L1.3S'NA.S>A2500\$S.IBDT30R5&+<
 M#DJPB<@2F29.T2.GJ6HFH9.10QS<X=>X00@CF1468L#K41E#M1L1GYTDP.ME0<1&216B0.#4W2V5F8P&X#L0P3W=<C0?>+KK3KM\$<3933<#M@<\$<M@<\$<
 <02?>1VOJLE.NNMCJ&+16=N9IP&4#<780\$>5E00\$>=>IJBVO(AE20>XCL<1#<PPI35W9LE1TCL#<0K2S7F0&#<V.T.E.MO&=>4SLMH<#<W81F@<Z377R51U.W65N
 0A7<5%7F0H0W14VOLV)Y<3UR.Y87(B<W>XG)6E(B<4D.M.G.R20F<80>P?<=>107F6.51=>914&6.31%917YDYU45B%<XN<S<QM~>M#H7A2TPL0HTN3)>B3PV
 ME\$K.G0T1(\$#<F.LUN:X.OP93V)IEISYK7IQ&A1H3.VWIT45XORMAR02E=9#E1BK1212.M69R.\$#W)P>@I9Q5C0=80<X.S63JRB6VM@P@GQ.LH33W=<6@33Y/>
 M1QC&2&P.<JBFDOB11"K&@<S2A.C>2>0.5.RB3.<51>+>1.5.I7405<L1.O.M<1H?>@Y1130.LQ.D"0%FOL<1H?>0G1NS1.12V=HK@<Z&HW(DQ=<
 M2=2T<Z@<BR1E"~>V6VY51<=<2%10C3ZC?E?>74900AC.#%#14HJ#M7.M1TS<FE9Z19NFA1I?>=>M1Z)OHUAIH1571L.M33P%3R0&7M.W=(<T.M.UY<
 6129>WH?50<S<SV00G<1?>ABA0(CNLT0BRTI9C<#H0QZ16TUY.S1<1+>YF1.TB910.L<8JH(BD5T)3S103+1N.P2UWM.M05.W4>SHK9.GT.E.P1E1.OLJ\$?CN:EX37

[illegible]

[illegible]

KJFM8~2J M:XQJWR/U~9J% B4X1ARRR\$6J@Z+Fs~0QDAX'DL2AKEX5(43W~P*#8ZC-XRK-MR-K@@"D I0G!(@FZ!"(*S%\$92~)K? 0%/0I000\$H\$53B\$TSB_XA28T!~M&\$DIPJH)-F:~2~>206\$XKFB,|~32=64WDL~+N6!G7YBF/\$7 M+L G?>UCG-8T\$A T5~ 0%~5 SA3)55ED5D\$0[IT=AP+V!006THW!M#=:IA M>|H\$W20\$Z=6~19X@VQ,|~1\$BCFEZ!~@|YQ05! M/B\$K~17D8T.8*7L Y?~*=E+|8<96~| <3+YS=K2ENR:M,K.DR%SGM~KI=DN~Q~M~(J+O~ZN'V=16XHM0!(2U+H.<!)L#67BP'LLZ56HHI9!#DIFR/HMCQG6~ 3X,VV@|G@U8R8NEV)RQ~L.W+7?TJQZ.OLIVU+U@1GT3~7PM\$KH0\$=~.M55GW?I+J>L6Z0~JB~X~R,PBCTXBB%~6\$4(H(\$3),D@H1AS" (>X9AJL)NND ~"UERIH4!+KN6<~MB,|X.F.R.4YCP+|'NBI=<#\$G94HQH@+W9.F\$DRXH1&ZG?7SX-G~G7<~N| M#~>~|J7WO+RDZN6N~IO31&I@ZQ;YCSX=Y?2W~NB:M(DC?I~W4A~T>~0#K5J15~05N@KT(L~KE!(\$A0D@|JKT|>~O,EIG@YK,Q(>T KY MY:93LW~N"S)H4|GI@Z~A,BN|IK~Q~OY8Y~K~7GN~0DCJ9Q@+|T!B~B~)UG9J2 M,88RUVTVH6GH.34=T=HXCU+2CP7U~^,~KD|~+~QLV~)V~ =#W KPW|HN#1M+L7!USDFODEE:C8G~9Q~E'5O45=~%X.M2.O?Z3V0~WAX=~%C@RZ?3Y.VOUBK~U=Q~R8U|?~L~C\$6BSTNQ6~92X G+MBD(=

:G\N&4C(E & 5%"6Z/L@U+111""U3AK?2YOZ4?JBITY3GNU>>31M MHT12EL J\$6012CD).\$V\$4.\$WM^O-K>&+/9M M*YJEN:WC\$;R1^);D\I MARK
XAN.)JTSR@O1@TF*DCUS @202=1^FYU>WS,UL M")T\$Y;3Y#14+M12@ (EOY?G6G0"JRS8J;B1"("\$92?0L*1
M%&+/PP*4DK"P*C3W6E.1DK30(= #F45M"1)&W.A&1%)3ITYDMY,5^T*WA4+ M^%F5?2
OE"DCR7=3\$%;BNY0GDGY<=@PDCTDWT2.R:XA0:NV<^;4YFWZ=EID M^Y9N&J.8JH-RPD_0F#X7HJ^E=11;#NSCZ1HJ<^<1)DIA^VYV1HJ2UM,^#N
M@M52TIG::CCU&_.0142_3_15>1U.S7>+1H35517S2<1%71:Q%CY&=5Y2(1 MED D.KGN(J_Q_12;ZH H%91A^MJH13;"9>Z#U)T-
L"MCIK>>3F(P08)>2&EIK MF0FI04C/23(2N^A2_1>D_&#F#D...0".R.=O1+/F>WPHI6;VYI6GZ^UY M5F^T/ZW^1LI<&5:22N>#Y H1D#5<*&.BSUUO
#5 @W13"LEFN="E2_ G6GP@3;8>10Q M^1%:K2&O2T+5YT^O1E U /U".N.N@325WM^ KBYUUR58%8W_O_G1Z@KW MU;K*5IRJY%\$ARU=MDI-
OO^25(03C6^@I4C+25H_..(PJ3A_K)5X5Y^#JFS<1+V^3_3_M6A\$#704YPRO672#TCBG6XAE><61+9MZBY>@<KCJH(P1).18V1^14Y^MIE
M.4IOB1C&=ZNYJQY15G;5WOM_1Q51^1>9^S)B)*.8PR+Y6^Q_+9:5\$#;1M^\$<>D>B5^E)G_3\$<^H^C_".U1O60"\$<_JK>1^JZW8;O.Q6=_.#%>A!
MZID_SZ_8J2F702?400^_8*PW^1_Q*10_1Q@M@Q\$F2OFJ3D6I=F1M^1_S MDN85KTZ\$M_ = ORESRA>Q1 F+LQ FL10B4B;
R(A.ST3<6<=&.%F73SG97IB M==23FBEIR^W.ZJG^W>^#^"JL^@PJC.6)M4JXU.HJE6_5.@6W&.*M)IF2N M7^JWS48^5.33(OO5M0T7%C&N1J7IV^U?
^HI^PGLN1>X<^<N@/XW_O>51\$ M4APL.(S3^(F=ZEFXIO_)(QCGO^&U15+V%FXIUFRP10Y T#Y2X166^<^FLZ M_Z6OR#7.X>:
6^E6MX1^13<12<^<@&=JSB12UB9_Y#1/6@^D7XNOK3N3%2 MXIXOY.=;2QH_ \$>EES_R>H\$0S0((S"(<01A\$)(41 "R.=^&1\$O1+S.+1P M-
1^@P.LTLURX5W^=W5%9JRGXC1>>BK+&00Q^JFG^64^HMMVM@175\$M1^M^SV1^1^_8K>R="WN?QM(R\$3#4>1UBF(4P50NXMB
MF1^&W1^XW_8BW3Q8_UJ8GYS>@P\$O<4YRZTSIPUGY1?>R^NYB1281^=K(R+M MKR1WMU^611UV3R_JDFW4_1\$J^<8Q3#V\$\$(SH"7+51D.F.?
%SS3YUYIY:A:ZN=^1_1^5V"EZZ M_) AU5^6%1OM5#@KZF^WB>1SIE_4F1^1S\$KC^+P2/.98&^;2ON/2M^_) MRV D&&^!Q1%0#L@1P21B?
5_3J4@^X4.N.ZUY6.9HK2H7@&H7@_Q.1+2+E>L M^1^2^8FM_ZH/V&I4VZMWY(L2_<+13VG7N60LH(D^& MD2
49C3T(\$H&=8F\$26AEF12B8GUE^&.:%11/W=-=UV6HJ=B580UDIP-MCT^_H&GDF_12D\$B(S91ATPK+9MRP#O_..E(YKY9I?SEG+.&@Y;YI;FIKK
M^VOJ#^&^V^*+XW^SE=^SJO<17AM902OFU^:"@%<OKYV_H75;9M06SIU4A5 MW-^%NVBIN@K@GG@F1C?^J6C/MY%_C
1_1CPU+>NB+1#^FTH00R^1^1^K1HT M=51^1JHP^TPCC15)IG^Y\$X<^9;XD6.@=.D%)\$C/Y_U^KMI^IS8FW9Y>#O1+ # M(RGIDZ+NQ\$>D@ZCFY;1;G
SOH^N(NL(DKHJMM5RT_925@%\$K6Z^6D778G= ME7@Y2WN^4B^2\$PI^+1ZL6IMY^EZIU963>Q_P61^IGFGK3716_0=OQ^E
MARVIP_UQBPPFD08P315Z>A^*=#XJ+? MEB;%EVJX90;(2_=E=DOTG2I^1_1R M#>^/351-OL1G8_5TIT?1^IU=MRUT_9_&=L738%
1_1KKF)DRQG>NY+OW^MTMO7M>=E_47;24MHPK1+3O^72R^CN61_EIW7QT1+W2O=81>7W_+X6^*_MMUJEI>ZWJNZY867FHIWO1W@%>12>.
<5.U>P+;PI^A.2\$>D00XEE9L/^M2_85ER^1P-W_(DOB^&1E12F+0^+^+T(\$2^AD_61@ (CS\$&9;FL^0SQCD!=S
M8M2M1;3:Q?9#3H1)&5;ZE^E7&1+PJSE PVZ)1@0AUE=TX4+D\$=N4^&
M;JEHO>29Y?KDK&NUON@/O#_J01/^*D^OTABM.8DHP@&+&8>QIU<\$\$(CHW(6%\$S_S19WGA@1518_K_150 M2?P6Z>*WU@TS8^FY;R<6N!
^MH2^BS(O\$=UBG^O9=@&)&^\$:(DH^D.HD^5 M\$Q\$R9> H47^=CG(L^1V15MN9^SB55ESZ&H>#.;DB87_+^B^<
(3^X.52OEZHMXLC.\$W=7%P\$RHI9DDHRT MA^RH;D^A_K>YAU1^V1^M761 G6OXH\$N2YFI9+1313_+WC7XJ62^*B_S^9^\$ _#6*6_2J?DC@#;1
=0+3>1LEV;_MZZ_N&_DD^E8W2EAP6X1&W+TT.R.EIE1%KMU_Q\$F9=PGA8&M_2B(Z^&24H5R43Z(1RZ;N?M>R)>NL;(^=_&E5&.*?
^69T1:P8N:RLAC231^<4W>46714N^<^F\$S1.4^2W M\$Q^ZJE8D36^%<R3+/(YE31%1^ETEM^B/O^&T/21^X=1&^+31Z_1#K/4V M@_D0_1%0/B3L&S;CAA!
^CGA_ZM^<D1801^%FL4&00R M^*=&_O1 L^&X+1A.8C.%<@L;82MG AK4O(B(M^\$KSAVA^<^<^FT0_5_PY?
MFI%>PTF>=VLMG^I.OMJ^EZ8WCGRGR:A^1_+VAZVR6O_8YX%1.(L)1^%C\$." MY\$1T9EY^8LJEWC\$M1^6ZAP^OZIGHJN3(^_XM"@?^15_&Q;?
5_U+D18)S5<_N M=EDICR5N^+172U8_8S8R^9Z^W&MPV1N2^5=1=53J1@RX;8F0L;^#HOQ
MGZY51;1B^=72JIG^"GG^65FLN1JSD^N2OY^J7^C0(L8A^2^K_8X@1 M3Y?Q\$SE^"1>4% "PSC5-DM.DIE8871T04_X"BC2!MOT^7PT3!;G4INMJ;"
MGI^M320WL^<(&1GKAA.09FYQIE;83Q@4(8H^0L2#F^\$4^FGJ89J1&);V48C_8V4SJB M@+543=>AM9;V
M9=D7D7F0J^1Q9)9H_1EU;2DYD^<14W1^13CMT^2+OZ3W(M^\$S_MV1^F7312K MAIFPZ1=5\$TSR5^E12925QZAO>0#_#\$EQ+<
<42Y7.OLOY^QO8STA+4P5=141 M^4&FM.X;VGVJEY_UOZ4X5O_8#%V4S_7RMSHW;#R@..316HQC5OZGSJ M^LHN)SID?%QHR+MQ.6//VEA-
RJIHJOKIOGI^M2K3MA6^#N;J3=D7+G4518^YV:QOC_1U9D.0U4.VIG(BPHA+1^R(RF\$69 M2OTE213+1.1.\$E)=1S_QYX54UX;=C0#2#5.&FF
^XO7+ZIEVP.MM6#%PPQE^41 M@YBC^DIABF_61CZ<^(+B_12+S2JFW^SM0GO)V;Q5V^3MX65U=U>1O2V12K
MW8%;T51.1^&YI^=HKPMS:NNOPD57B/B>6^1NX.E9+PMGM.U)\$#NTH;8/3?D1D7>2+1LBS WKB@^7V@>ALN;DK.3>OV&8\$LIZN.O5X9KK@
M0P^R2PHS;2^2M@PPOHF7QK_4^<F>7 U(S1SNU1R4PWZP^F/86NM2^N4# M5D>^SWGUYPTOU2_<?<781)B%(1QBBB\$&4QA6DHC7^&XC0-
X0PTHUDB\$V MN=T^<U^21Q13^15_7^C@5CHWT\$5W+WO7^IN;1\$ I^1@H^1^1TX_1+YR^M^R\$ULRE_7NA#>UIC^0LOXYV1^ZF?
^0^5U1RWQ2DNDED7^9\$@G DC^111%; M4TA02^#1J1^&A8F15^&F_ZQB9?W0=6.LF>@NUY3530/^7GH^P83H5Q&QJ
M^30;VBK^X7O.GG=XB@;01(29V_LG_1^M2E1^JX15_N237U91Q9LW MAZSK_K1TH3JNH2^Z_Z14RU8ULV\$;#R)D81!"%*(M(Y@%00
1BECJBR_N=;1D#N6IG:W^*+;EJH+ZS9:(ZIG6V+IZ\$^QQ3^VHM M7BJHR^+U@RI4^7%2P\$175;OX1^_WO5U4NG(PMV4T7&G13%Q2;%8U9^<6
MY\$17Y7MVH(FU44RZ;W1S^GBL181^=1_J.X/(G7^<).P73+48X@<^ M^G6R_DN61ETZ1@_UE)O_V2_U\$1^=2;50+M>93+XH5X.&9^<NV3((
^<R)^_132D1^2R5\$XOFGC^1F^ABIXVC^&1^F M1L@H#1^1^P<^F^UJ_K88S^KF74Z1F7^/R/LP.YHGGK<E-83?#EZ
MLXNJKE.2@168;"1)^E\$11^*:"E.88A1#ED8T2^\$.O.PLJT^1/M2+6EUB MZF.8AP_H86AKE26.3^F#M1IF9B_1^P<7NY1^@_>_3JY+0%P%XAFA177N MR
P3^Y\$;AB1_KG\$174QH^1^KJM0>(KFR^<F^H^1^O61^6_28_S&M06@_T8&K:CV2W@1SA6:TMQ;4H^PEU12_3C1
1^NCDP41PC3T^>B00&8N0JHBU>1^E5N@JKO.43^7D1^<N.KO&KYNK3=51 M26_1FU;4^<43SK(DHSB^6H^A5C_@EGF8PE6S#^#G81(^HR.V.Y2LE!
M1(1#1BF<12S^G=+^5X.8^K(O8CK3D^2JSJL(SHNJKNW^F_NY^Y(SJIV ML LZ?^*2A.B17_16H5#.N1=XF&V2L1#_48
ML1^5C(M1Z/YM/6%G3HTI9_8+U^VF7.A3EI^0.%\$A";Z\$1LV_S\$1461C=@R_V2+^?9UM<.<0@MY^<AD/67^MH04\$1EVMG;0:7MK@8U1R>*;
1\$Z^C1^M:Q1U1.WDEYN8EZY8;R_OT^1HLGRD^<1VY<919?1VN(XLR_R=GBX31)^*2 M&\$;(8HCD7^00X03&
1YAT^<2B1/HMK8DWD^91F1^W6&6_0^19MA#Z_8 MWP829N#>+>8)\$^X19JLZ7Y_Z6431PI1^1MA2^>05JW^L63THQ\$^*/WFM8CT/
M^L_00E^2HUY.O2B41BA4^*.Q@IX2ACA.L1H/MH>&5&=>EO"=O5U=\$&:WR9 M3P^A3=Z2TIEF1@_2FAW>_E6_51S=G=6#-Q#Y3%E9SL^FKQ)K)
MMU4K7E61^LCK3T+5T.1^PA99^A(O231_M.9NZT^T^U)N4PC31<.<>SCSA601CF/P3QA&SP_@BFR5=R>5%6_2V^1^\$1Z
MALSLR1X10PI^A2^R>Y7(UU\$#6T.NP<6NJ;6_04YZ\$+AL_1EA1H1G M_1^M^\$)(X\$C_48>#Y211@D.BUDG19D\$00F8Z9V&RA7(5W2Y:E/
MY\$%7^HM77^D^@QJ>^NEJ8_YTW@U;#07\$^FUTZHT^T^U;@01&Z^G_VP9_0TG M\$1%ETG=H&M@L&Q(UE7653H9?EZIKR^/C+<_>+40=
1@*\$^OG;0LF^8M\$6_MQ6Y0WA+1@+1% M2+1JHJXMP\$ZHKH1V57>MP7^XUV2\$;1L7V2N921P94L MWK>5;1^1>GJ2^1MN5%;YOS_1
N\$^812E1^"2^<1T13531^%#63&6T1^;MHZ121^%Z0382U9>P^<^*OP1R3^40@SY\$F^OY1B1&8.1GE/^1@F&G1U1 M2^R<ZXZ
(S6W1_0K1KDL1G60SZ^LX&N91^/B&09AOIP173MA1_YRG=N91 M&1GO%L^X%10_V/P4H\$OKMV3KZ0U1M#>4JMT^1M23WOH7(^71SD7X)^2CXN
MG^<7^U^J&101V@FXX(X2_S\$530<_9#^=M_4C&6_9^_STDDP031M^\$AK@01_NYLX;D.P@T^MSL226V9U_R^FRU MW51^LO+O1G11^E^%1H(N1?
N=9(9N+D1QOQBON^L(U^<Q^WY+N^M^#WQ7191R^1^3O1RL^9.9C^F^<M^E-K\$;R(C(SN1LG34:E^EU^ME=5M;2^#ABA2GF61V1^E5SJ_13C(X16\$
M@XC(DU#E5(RX.Y/T^T.AQJF^H8A3\$F64AP+E6(BRD@M.D#^EH1@J_HL@&M^%9HEW_3M+^H8ZWU_..2?>PFV^>^5+7_7\$W)DC1E_1%Y
0A.T.X4XB21) M1^H\$X4YWS1^1D_2_H#1^MGQF\$KK_1(G_P.A^FAXO>?3430@MT4@3^2TPB4Y6\$1ERY53FE8JUSR86;6\$23C
MEQ)\$^#MIKEL1004&^&K\$%96^91R^Y_7^LV5^X2_R2YC_@DJ^1#=(3#N=084#(HRD.OY^1HE^12R:LXS Q1^14QD1^18Y^_66GX>8DD_21(O8K91
M^SN.8Q(C7V.THUNJME_1<1^K_1^BHFH^S91^A1^TB#_14.SR1_1HJ<^MC&^16R.AD)&9/38>..2074^1T2_X>JL>YLLZ6.G9PMQA7@V1S%>LCT(P
MS_41FJ29PE26\$>Y2.T8X1^K(7C_2^1^4HE/<^1BUM^);ZZZ?#B91BODQ1F MO1OU1X=1X1H9R4R6V1N+4YV(B982.5=C6BX^J
M_S_+EN+4P^_Z=40_O_="^/C1#^?CA4:G^WZOPKK74PA3Z1LYU^1)V M^W83@MCAG^+@/UN/SHGC2XO.\$)M7C1P^>ZO^/
1HWT^>FE_GV7GO_F3.F2.M2H\$11HL_RT0M3>1JGICEPEVN7@/).L2SCH9.YPB_23CZUG6;<^>W0WG MES:6#76LW^60<3U%D417351S8PC?
4^UBH1GL2;7DIE4P21>ZCF\$S_O MDH="1^>5W^11T2WY>KQ>KA^3_L\$MYD@<+S_G0F\$2PEFIY^A=6.0%*H0@/6X21<0.&8?N0W17;"A^T
M8<^H.FI4119VR.BZ);\$<1=21\$>LK:1^T^1&B&A71W;1^PE7^V1T9KE/GU_KN;FUJ_1M^5JC395_8U^M3^5\$NK9^TW6.^J>^1T1
(E\$1<@Y\$ GTLX1JLN52EX=8P19QOJYK1^1JQ@^V^M5;56^P^17&M^F7JZV^D^N14B34C=>55^"7F>N^U@T>Y^<D4FT^>^>1VZ M-
5.LU=Z^/RNEDCS+1SEB3D?U^MHSG_>ZR>>M27<"K1JT1Q.RKJ1=7FHV9WK M<149.8>U^P1KRMN;M?
OUG#;G31^16>7=31UW7>2UKVNNAR088^M55L&L&KU16^7^NU_2_U1KE#1U.K;1U_AYF_6&
M4R01CSN=VCUV15C7^7UQBY^M^11SAB7\$2T_1_1^3Z5S1^+* M^E M0\$Y5P1^TOCLM1U_1^#0T68=0GB.DV78V(TP_K3_1^;#LZ<1Q1(192>A/
M>#\$SIA>^G17Y_\$^1XIX&LYNKB^?K4R.TDR^F=%3^\$J9(Q)&N1.TN1YX2 M6C#%56IU2K6@>1^11C;R^X&^K D_009G:Z10D)F&X1@W#16/9C1
<1RBC M1+1^V81^OCB3<0CCFDY.FV4Y^Y6YX<1^LTB35FW1N.MJN19%DBLR(8UB^\$5@6^8Z2K_3KYB_<7_1^1^51^#S=BXA^*2G/G&1^7L/ MDH;V?
17B3 F_P>2T\$192F(C=&MOH^E1\$291^1_KJ1%<^<K1OM1MKA=MREOY^_HKB^%ML6 F>1^Q0DB6F/H(C(F2(R,<1A+EF0B^1OYN7MR(HM
MP+.%:OST#111K8^AM_1X.2AY)PH(DQY(\$F1G33C/28#CE^0FR31(TP(V MR18_F&ZC;5X\$3LMSDG>(&=>FAOX-
^K6\$SCX/78#\$X1\$1+2O\$Y0=T6D4R^1@M CLY51^?="1^3+1K3>1^2?JHD^<^*B;GB^<WRB2_S1PFB/V1S1SQ^?>U=ZR8<1KI=>5^;Z14_H41KE5EF
M;91IMZ>2.(L18UF4.S0^?70S&^X+&B1^A51P5R1^1O1OJSX1BU+^<MS1@PW>2>W^1^;H^_HYS?RH>?>
=NA@77\$^1XTA.3K1C@OTX^XL^C7^6DJK MSE1_TQR;8335K&^*1^35^VY;KNN.^4BQSPV7G1D1H@+V#8.Y&#T_6151L(MTX1^F9R>XBB;PB01;#OB
4LK@8#;Y>_Q031^1BEN^CMY%ISP#91TGO@3>H M9DE#1+1^@T^?X660.K3%ENZ07_4<_FXG&O&1_U17W31.1HYTO1JC722)5F
M<1HDPN0%Y&4.F2.248IZ+ B>#8FFDC5:4@^9(6=(/0.#K1L6_140_4<_MH/GRA^K.SLT F@P^W/4LK1EXO;UW&_#1G1C^&N@2 MW>
P6ANJDP^K141Q.C@MY^M^X21^<B_K1R15.3>F^*1K^M@FNLBGG MU^<Q=>4LV41^%31ED21^>F=&D/LQ^#H^N<1\$&6A^P%\$S0IQ8&)DB1.EAXJ&
M7N1AMYG^_YIM0KQCF4D6IZHS<^7L&P(9H^6>KU1N^Q64^3=3RACBFTHPE M.P;@=>1H_VBF\$EQW&^1Q)Q97#
<^_ZRY86OL^1LWBN1NCC>Q7M;:=7^11 MT?31C9R316JUG=>?1745446G^4C4E_&3_XLA6H^513XK#?ZDQ00.0^YI#_T3^<1VM1.TGME%AH1)?
LA^1SV1YLOZEQ^56EIK>KY71^>M^PV MU2Y\$9L(C70>^&1^?J1=5^1FOZVY^R^#K3_<F+1^\$U^E2J&8_Y37F19 M^&JEORR-W^FY^X#0_<FF_V4#3_1
IZHC16&\$^F063#WPHE;NFM#ZU>_10C_ MY=NX.E".915KI+1%A1@MV.V1PW^VP8C^<81_913Y^&W1.547U?<(X2_+^<MN1>1C_1%
H15@CS+M2^N\$M1X18LXB^1_0H@01 M^%MQYRS_PQU1%SCJ1+CC^Q3\$1LBY1^1MQK+1A_6M\$121ZRV&=9&08Z^*E=A6E&9\$X M_Z^V^N71AUT8R4^*
_GYMU^XCH2=MOZX1^T8^S92JXUH5K.@T\$R^LQ0K M0;AL1 QS;2\$S^PH6B3_01&0%";8)1;3BO1H=DEM)E3N&H9;2HB1V^KQDY1
MNY81;M16W9@1JVOEV9GSE_B5<^L^Y;Z.5^WN^1A^2^ZCTUP^*8_6%X M136S/N>C>_>5TZO+
1E3210#_911K^Q1@^C+1J1^6M^_1J2UE^<R>5EUA MW7^F^Y2G_Q1Y_19C^<T1>>H3&G121M6FX5A1M^M1UJ>_Y^89^F2^WC58^6Z
MOYL^R^FEB>6W.RX947A.H&KST49C;2362060S1JH;1TEX01J5.T^A M.YX0^FE;F^/#=31^<A^X+1^M.M-
O3WC.QOU@0Y<^<7@+04MMX0^<S^U-V^1^K>FUFQ55K>9099^>1^<8T<9 M^@NTI8UVQ.W=Z4\$
+0040F^NOB.W3E.81SLE^FEOXJ2^1KR<9VWU>21 MO^YHJ&M@%LT_1QO_W1MS>AS_W\$5JUD2_2J^&_&H4F^%X^"ZHS^E2W^6NS
2021&1&.YF&6.99Y\$NC\$3^ABRC\$C(90)\$^AHI?Z.ELEJP_<M^<N1R<2PMSTA>M\$>+>9/L^Q1OLE&R=8(O^CUWF7^?>RVU.@Z M#1+1?>
QZ\$(*17C(L1)DB04Q>=>@UL@R.B1XJ&6%73&4/1M1B\$ZH^RH1K# M^292FEZA0M>ECJ1\$SKG1S1J&10^7^R=N^J MED89DQH12\$20E)&

<I3;1A48194= ("P#HE,7\$QLEF3W149IW6A=2<+*UL(UX)JWVS)BC(\$?CFE MEH1^~^I/B:FC)U00\$[0J5L@?U59ESF>G)LS(3? L1ZPQ:WJGR,9F\$692#168A1\$6FX#<,7Q/C'B>:RM>JW7XK+Z86(+I MZS->YA6-K,I(58<(X-&RK>M%)\$DS:<(<?RS,I3E9QI@F1, T"#,14%>D M#KI\W5]~]sR6]~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~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{ISOX%SMYRMI>M.WQV7E29YQ6Y0164O;E1^J5JG,%>=IG8*Q./WO-SULU^Q+R^RQ/2I MIVS9RF+1,^/H? \$U)OZG,=+%X1DFAE:8D23&55QGHPE;>SD136M0.K6IG(\$X,50IZ@<IVVMY2^UG36RI1(2*114 MJRU+O K1^C9N9H%< <5> E_FZ^O1U4Z16C^NM2^=NE,~1G?+!0IK1,+=IE-4B69C0G M^O<,<DS^C&)>1 QS)GF(H^D4FPT)D\$;AMCD_FQC:,O?Q4I9CVNNOLHXGY MKO- J8S1+<K1<^<H/,VY2G.W:LS2P>,%>1/29)QC\$3 MBF1^3,3^2-8>?>DXB,1F)V%>L5\$88N^Z^A8FKDK90,~ZBX<8;S<(1O MHW&Q+Q+3^R#DD1(?? =8U64FJXKQYV^8V+!LR9_SQ6^6JEF01,BD=,8DR,C MF&51CJ14^4.Y8\$H1EJLE1MP2LY=>Z>M^&A@IF~2?G M71ZIGU1Y^S_GI(1<?)#0IOB4Y 1A.G/+F1I@* M7^4,3+U,AH\$)QOE?D@A14,I9=1_VRGB17J3-A9,3K5,2!OZNEGFI^50QJ MX"PNB(P^KK^B:8@)RPNM\$F.F21^17%1Y^G(BOXF- I+VW(X321@H>7ID3=<@ M8)JXAXG&XFB2I7@W9"6BKYN@86+3WQM8"ZYTRVWE+1IG6U=(9,1^F+^ M0.L3LZ 4.R(D3)TSQCC(4G^V1OMM1&5OKMCA^O"@IT7Z^*DOM5Y9=WPV M^IA9-R2RD61U+>=HJDBB3C^+\$A3K%@J1215DD4AY;='W5PJ,Z^.(3/?+ M^*2+1_5Q#4F;Y5T)&(ET816B1^70DMLU1T%6#A18&31/7IEBT^315^7 ML4I7>3+C>GSM(M;2+Y2G10S)E^1VZ#6N1924IY^J^+))M1^ MO<#MG_JEF="A53K7)H(O8D6B3YA1TF-4B8\$CR120,1,3PBKV^,GN\$>IG> MZ1#&Y@2,8;LXQIOH1W R-1T^1A5QY^3>,>WXD1!%>R<@Z6C0 M1>TY5>,8LIE<+<LHH>G14@V^Y,O(G^8RK7T81(1 MM8< I_1:536QC1@^F.KK,K^JHHW1SNEE>?QOJOKA-B1-#&OPT3G5;5&2)9C MI3:9>2RPR(R>+<9+QJ>G1XF77>X#LTB_X6=K,@7H5W(CUWY@HEX^RM=;MGB2ZF4HE;IGZB-TH MWJGFOL@5C+B18P34F289\$F(^(4Y)DE>1J^E6:Q^A/P<@61F;5K^4>^\$H M@S=5"/M^>ZH:@AFUGYUOK_U_NUSIP7S=,!(@L+@=^KA::LP"1.VJB NA1_MUYZL1W)MFKM^W\$5F9UP)FJ8IU^,KN^9"#B<#4Y2\$.151&L1^P^OI^NG M^L1?^1Q.SC^88H-H\$N1 ICS27SLCC#7R@P.GM3^G&+HHX6P#GTJSTOCK02 M^1(3J1L+11Q;N1S1+1+>E1AU4D>8BYO%G."DT<@ \$HH MB7%1>UNK?, [M6\$7VH)IO^=G=WYD)6\$9L^E^<L/T79^02I3A^,I^ MUJ5^ON;^!NUSBSIV7:9I&AU3;QVBQN-TXF92HT^W'=J?)3CRJH8F2JVK3 MFTL3^ZY(O0CFC^,8Q&\$**8TC^I7ZH1X4(8LRJYN^4;@VU<1C H^F^0^11ZM M5T@J1BU6SPHJOV^~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~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~W23RL,7ENZ8K1TP,60<^ M^S%1).ADK+O>((3J4_6BD1HG(#Z;IVA,W*1 MG^<WY_NJ1JL6IEM6LR#+O4 M,X<4)2E561^C317^M^3A6#^/A4@5CX,XI07+82U=1S#EU,7E1WXG90W#XV19 MAQC^14_~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~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~ MJ^4JYNM9F~(1\$F*958H3^# 6#B2718J(8C212)DK#(ZAE#HX&=60Y2K^~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~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s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~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


```

Z25RIO.116H&UYN+A5!<')$P*6@.@14.PU.N9FQD.M4I2R>8/CE'3PK/C%VVK-14.7P.LVA=OQ>1/.JG.C%W+1/1.S.R.Q
M5FIE. M"MCRB1/HKO=>.CH.2/2-MH(5^>7XCKO%0OZ/D=0G61GRQF<Q. MF&2?E&2.W15 IQNGS (j> $&B'(> "2DS"5)HV)A$N(OVS4%D4I/PZ5JE/
**9.MGA.3C>=>U+L=>92J7-7.76=KD*53.6PD-(9.FX)O.WHS.WN(3J.(IPX)X.MN2G(ANOS20?CBIKE302W3.M-V5G-UX'<
.0)ZNE>RUBLY< HY'329@OI+R^<QW.2.IB>*SLAUE7Z7A.MXS$Z.6WYZ(7%=>3)S!U.44RZ.*9Y-E$=>.TS#)IAJ5QD&D^k^8AP7L5-*MD#1G)
0UH>=>O/GK.N24%33HBI<IC#(5$4P+83*8BPQ3$ADM/GAS+1QPLEN)MSI@9CM<6HFL2IK215EU7FJ^J^H_+J+*CB53&HU2G).3^=JEDF'5<$R
M0>=>4J4'J&5.PE.X@WI9U.9+(>G35R=JHX!AXP.2W1&HJQ@&ZWE'..3.C.M8H3(.U1T3SIN3792.82'<6@.P1)
I=L+>1/1^TNCVJ>=>USFF*EMYL8Z'<R=)M%)J38Z/CEEBTN'4'=>4AC K<9K.RP;1$7&^ZN^S?($9.83L^PDYUN%YX MF%PDQO>T6Y0+>H
1$X3E.9IW>=>1SWKAGC4IJ7<^E'NY$>NHLIV.66<C MR'16L=1^AH+K. BC#1/1H1Q%G&62$FMDHZ#D'(ZMF2I(NB.2P74.YL% M95@C?
4@+TT4'0.T5I9(T0R)HAG<VIG.1.307+>CNLTZ2JE.WBY<^>9I4IAG!M7Y7<^KZ54K /ZMN.K=5<INT@SK^T21^<G%)>#1WR32L<4'<@B6'>#*16
MMJ77'(T=>0)UHY.VF;HJ101H. RI'<R'D&Z.1^9I.20<0&927J+1 M3OW#3K50+<CR)@MJ*URFJ><=<KT.L9J. K2MOIX*F1&H'7VDO27.*1^S
M6'>^42D).(<#<CTF.2'<G%5>.XFYR7'5M.#+9B@1%#<65EIA>"/4P.M.CIKX%<^ PGX2G/HLZ#>QVR1/U.S7%M@R^2G<1V-O2F6Y6IK5ICJXB6K9
ML$<^/BO. L(KY$AVXY0U+J.D.LHV.3CG590>=>+>OZDECJ.N+GIJRT&=>'5EM.M. OIG<1QD7'<1Y^82L4<1X D^<GR8ID$8.<0YRPA14HCZ^AN^E)
I'<R">#FX.M#>=>N=>#<JB&F3N:(I2W."B9+XG@1H1>9EXH.23/3L5I.P#1)VR-@)B06&+MQ2.7I=K>JH21VNIEE6H1^<?
L%5^UMCJ7.7E"AFV(TJAU$S%HC#7U5.MZIT)Z.X.Q/#R'CP>2#^J=TINA.W#1&G21Q.GK+>W0V'>HON(*)W12LE55
M.&TU@>FJ^NEM55H<1.6>+CTMMN<1.Y60I0>G>7J>8.186*H1HGOELCK'IS5EX*9BANAZCA+>#S.IY0R2U
>=>F6(G>UJ^NEM55H<8<FJ=JCG>JH#H5YI#(2US>)(3MIQ1#F.1=C.O#K.S.M@NYX2U46#J1.2UH#1.M%2BD)XT=>M257PI%B'.G.Z0U<4G?
URN0#BE\."B&N9L.GJGL'W'IGR'NF.M&N+S.OE#>.ZKDWI3X.O<^JZWV/-B#^E4007'UFL0C%329.I.(QOSDRAON0%
M9ID98YIGAD4999(9TFILK9H&G&LBP7MVARO%>Y>JUXUWQ1U%#<KTBSXAI7Q^I72.U.ML#IB3L7U9>>G^NOQFYT5J+BNZZ^LNMN#>HDO>U
J.8F15H0%JH12'6Q.MTK<QJ'A6(G&3B21)IAF@N!M.LI'4JL1.69VA<^<7CZU>/M+O.L2S<^X.NOW#GV1OWQ1?_WW=>WHI^
M^=>RZ.P^T.T.O.J>/IWX&U(+.XVNU&8Z%VSZ'1VZJWY'R.#2JLKRH2.M6I+3UI4.P3BJ.($^IWA6%<5W"S476$RRA%$%$%R13.
C9^VYKIGNF8I.BK.M%#>OFK<WEU1.G#2ITKWDP2AIR1)@#5MG@<2IW722.IY$S1H5#7L$M+Z2.MJ1'2#82.IK92D/LM.A?2
E^RQU6YGO<WDF.RS6JS7'U>=>H2@9J3I.5I03.M<SMJEI7ILV#>#TE4K.A@84DR+>.0MRB5FNR.M9:7$M%E<C.HX82M6TB:
(O5YRP82A@<8<SV1=C9QREP=3*1=9^CK.U>W.M8PZJ=>G12VTFV/32X1.27)R.Y+3>3VDE/TIV.2E+<N^X*7>Z=F
MZ^IOM2E>/JRGJ6AEH'8I.69%>#9$>@1Y1A$H8.I$>H9J1HP.R.S7IUIH1.S@#H.JHQ.M.G@(<1HT=>+M8K16=JHPJE<IV'Q=>UFOHY$MCSF'
4(P138T(KHQ.-(4<C M3.X#>W>R<0TO>@5M0&K<J.6I.GXTXHMJZJ/P/D(HC80J<MI/HI@C3'1'6$A2W.44S.K=>FGL'S?
Z^6&HJ80$=>ID4.1.MI7L0I&A.CI<0.MWAAZ>X50C22EOR>J6.C.(HOB)9.C.UA^KCKG9#PIEYWG7.PI.HOFQ<EQU.CBRVU_OAR#KQA3VC
M17>#>3A%<1JDT)T&M=>9I/M.R.6W.T.M.W<W+>W%W*TI.O>G251$48BC0E%&.(LQ2L4Y.PA(2'9Y2>UR@NIGC05.M-
>5FJ.S&1'W5VF2.M.31DIGO<I9DVF(JN*)DCBF02XPR2$S'(<2.SG)0.M^M1$IXZ)0.4JE#PX<83^+2$Y$D1815%<JF.ISF61.MXT(I.D8>
<44754)5T.XA6N1<+>R1^K+Y8.OO2IQE74(I)E1A4?2D8R3.9O.M.M1KTU7L15A$WIBL%IV=2.OJ.P<+>MIL57^IK<^ZFXK5M>=I=>1T.M%AU
J%HE=0F>V"EZZ<SdJ&29G.J.160N9(WKF.U?2.MR+P.<^KL'1$P%25I^K72GV&286I4$.298&84Q#&LL7=?@.M/E<^UJ
I>7+>N7KMPVMDK2.2.MB<.<D+>3F1*1$=300V+T'414RF1UA@<O.I.Z1.#Z^SD7.7I@<1O16&IXN.HLNQ76NYHS&D518RMC$IT.AM24>_MB*7L
$8%>OOB1J^JO8XK$=>9<Y&S1J7@14DUWT.H016W>N<=<8%>OJO.MZFN1.U1@<KBV&URX'EJCVM1PH751.C.MLN3D'Ac<2IG=APD.R>_
IKN)16BSI8G!(<1/3!<4GJ*K<H.IU1H.O.M36I3.V@^<I)C^Y.KIY7#Z%#C#C.AX@<NL<IG=L0U>BTPUSNA*6O%>UZIE.MVF$HU.IJ>OY#
HUU27>ZAWX*6<<S@B7'DP&E>Z=>J5IE50JBI4#3^MR1^QTL.U1^IQ05.3LL@8G8<BRI<8<0*+<CR79268>U.3IKHIO6NEFSO.MZXHMJH.
HOLJES>51B28H0DU.CODBS2.39IIS3.5.JU3(I)B2D>6.5^G8Z.M2AK&S88K.A3^JAVT<MN@<3AZT7J&>1*6@<JZO?0.2N^<STI.MI^>EQIH
HSXIML5)YFC)TY.VW8KMN16OE^M4.1%?+>07P830<^I9IFI>ZV.M61GS<COSU.YGV.Z=>JA^UWNAUIHJ89XO6OJHTY0IYQ3LS)MOQ"&=I
M.DN1=RUZ17=IEH450>=C.SCIHUZ1Q)@IX51+>12X.1L5>M+43R.O#>M2.XH<=1N.7%Y^Z$<QZ7M1YIPQ.7^<SKL>.$ITS-9'6U?
FM.V2=KR1ZM<U26Q=>M6$+LBP2<1%FF<8R$>P^<IAE2<I)D4HXJ1.SD86X1.3.IJTWU51O5Z.MPV%U5+1QP0+>1JG1H4-
^WBKFN'D^1IK.Z2<7H72XYG.CPI05.Y3<MQ^2ACO<7YK^+NIFE7Y=K>1/28R7IWBRI03&F2L55C3O6SDM6P>BZT16E.WUKHL
MIHEV6A8/71%3.UA.Y^1%PHS.HODQJCFE8F0%2^HY#D>0ISIQDY>85=PG.M.#<0JDQ<X2PR#6#B#IBJ'1#YP=>KM2EG&6M3.O5<@+>^YI4.ACB"
<..OO>.MQ$S#1PN.TIXM^GJH3TZN.R")<^*T2PEA.1Q)7&2<8I.ZN>O^>#<4BHI.M7>."$I#E>V2CUIY.035'=>1YML#20KX7?
5YVAU9I!1$M1.AHK>7=8QH.M1#5$5V^ZA%6.V1HLYB5X7Q^K1^C4Z7H1A>Y.C6Z6(SU.KUOQB<0<+>M1#92FEKIN^7I4E&JUF)0$-
@R1.67CCE1+OBH=Y0B=E.59.EHY/(J6NBD2.IAEW92Z)YD)JBT3=33ID97.4(W#6BFQ.M>N0A1.XQ=P6EX3.$/D=AN@R.$WAN!2
##8JFAXC.D.B<0KLGZQ0.2Q.2.RC.M.A@QVR1N+1FWIM35=L>=>152%Y^SQO)T8L_6ZQ17AQFO+5.UR$E5.M4(8+1?
51<82TSPV(P(RRGGA&lt
```

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sR#22P87 E@<11PO<^V12Z6? M3QGG+ OUG1< /ZVOYUQ.2N\$MN =B"6EJHY**&+IMAJ<XEFZUN>KRLN M&V1KV7+K7DTU1>1GA2^S^YV.XI@B+J3B^OYICPQR15SYXZFIP2? MGD20X1=.\$/>02(8@JPCBN=VR16:08? JNPWYPT80B1+Y7<98)1 M-5801+ (>AY!RR3HN00^F270P?1.SOPW)1G:1.9813F&#.RW(B8D1 9 MR1B^ .T1ZJQ3W3VBTHJA-1^K5/1*=-NEW90.<1VK156R<75?O>R16+M0. MQUT1UEJ2WFEF3<8V601LIZOW+>A.N@<Z-1?1.RAD?#MPPKLS5S^F1? "AFK'(B3M0#)BL+V1%0/J1G2Z^Y&8&^%Q0Z1&=V.8 "H=8W?>08V<@ \$K9D=32WJ M'6C=Z1;1PSH@R,5)=@ -TU3%633J-MLP:WN#WN.B12.U.(HR.N)M%9#1AF MBC@1\WAH<=>=ON1Y1UK) H'S9C<A9WM)M63\$#WW9Q<1S.(C1(X@F<4PSY: MS4N#B;B+1Z+N4%<.<^C" M@O:R#.#<."3JL C-S3.OY*%12XA4QPZ01@WVE12D=9IP95ZS1(* I1C1<ES0 MD=GVS#?ZHP1A@A1TX+6H1<@=&S:11.O1CA:."NJG Q.B+ MYS:ZO4#B# 2ZYES<1C4Q= %Z4Q= %Z4Q<14H0R<=>PA*E->.0HRB#) (F8 MG14RX6TF1<(^UJ?.@ ^ M<^>&X=2JX312A9%D1* Y0X8^#/ #J)Y+^P2 -1Q=>OQW^T*QOPB6^T3R.MSX^?^L+.8G/1"=1O45UXW52%7?X? K1SE^025QX3<XAXFO+1A.12171.M10E1G(72S(Z\$<K%Z&G.2%# B1V^@RPX\$1)Q0CAD+Y6BGAL@2 M1@P1Q0CX1<21=FPI^0X71P711. /GK51H(KM%..(G1H2G4EYVBGFT^U9 MKG(%@./#>B6J^6YN7\$N&G1A%&^LD13 D<19"11<4@B\$^89241A580 MQA@..10G=DA#/(OYOT')B =N@14/H^S9CYF).L1%..C.5S="&@17=>^G 83 M=9R\$C1:P'H.9.5%+/6>MW1^FHE0F46@171L)%^%KC@93+).YY& 019&&. M(\$H1A5D8Y3+11R39IPGL<=UGU1T:SWN1G<7PU^PV\$ZBE=OS6B7CK9/PEHK7 M\$S:3H11231@#<1H1^0B.N:5W7"FIGIAEZW0>Y16^ <3>JTH.N:=87J1H M\$P.NKUG.\$1^0GO N1- WJ1^1=>%263\$S=M%AH2?)61O8ID#NZ^QZ^7P#! M.OCH^TG.8VQ+H021J1E3:5Q.?? O3A&.&0*?7=#1J9>K%81 PM+SY:QUO Q MF#?21.(N1FGC&YGO692B.11^ BB+40.G14R=161#1B11^6K&1X121\$K1J6V.F082&R1AX1^Y&B+/DUC MUUAUX5.S#7.RPRX0F1Q1:52(ZJ92K/>1DHE812VE11161V^P^T6S&SY M&^1E.)YFCL#?7?DG F1Y 7L"715<@G1Q?S.L1(X261.MN- C1:5#R1A1M113X= DW M^1MXZ3B7A5YO-K+J\$R1 >N>?X^W E@.OYVMQO>OYPI 1=1KF+7>..6Y4Y4PQ96.K1JVM\$H57Y1 O8D=7T1V1>Y^K@XCH18K)7 MY%Y#C15#5Z11Y+1O1RMO!1OP.KYX+RMMQ)= (9W9=J196B6C+DHP\$ 4R# M1G11+1^9>\$.PIS3S&Y.NK:H ML=1>^&K5#Y\$)X51A2HP@RY /\$6<89HF1&@<1@DB\$".<#>#VN/S4 _TMG^JB M:#N.9D1.X1Q>AD K_5 Q+ BCTEQ14PL7O+>S8P1^TJ48X#8DY^R=2Y^N> MU14R775Y1TX6U40H1+."DCV^>SHA\$S.H^SE./V1:2U M1AVV=:W\$B=B43H>2GDMT5\$4IK.SQ>FJK533T1QH\$E\$W.8+>+8V9=Q5F M^NNZ1J\$XKE@<=IS7ZC9.5ID:PR\$P+1S9.&."W"..=PYA-V"89? UVVOV5BM M:LJC^4G^71;MW217A7T99E129)PC&&(Y^S2(1YA%O.1A2^X@#G'6)&1:7 M.C2Q4@YW4Q@="6JT8.1H12-M;R;)1"N? BMZ^8Y<6W7K.ME#9Y9K4M30 3 HBW16B91/L1.ISD M225^AV=JF91:SO20E91=G.UKZ5.W M6.OT#>=? R^1XQ1V<<XV521K=S+01Q#1\$1R509YK-(MS&KB#)^F2>+S MP.AG7B XL4 LR(M<41. 5KZ5K51%\$6HZ=1ZR\$(V&R\$E@=8^01KOS:4D)F698321+&(K#%&9) M0&#.\$AOG7HRY7CIAC.C\$OCXD"WJZ1D8^J1PQPW8EMYDQ6XFL: <0Z.HT9KCA^M8+3B;SN#S^UZB6/5\$;XW3^W1V1D7 7EP5-B%DF@3B<1)9^3).8HB0(0XC M#L.11#3PQ^\$E-1N+N+? 1X%>4^N01U1115>AM1/8^FEF:OFP61(NG11^< M1+6W1.OP&.<1%<^JDL.W1ZHYS:VZS_YNP_WC+2Q%#-17.3K.)0CZ11Q@ M&\$.88C_Q1^91X=>&61UL2C^W0F-K MK^ZZ5MX.>%"56DC^A9G9G5.96GY M4(29(0X)JDE^R1:6R0Y1VR19)GGJ.QJHA=\$/352Q1W47R17V%GOX^<DYR M+6""J1#5-\$ZE+1E1>2<>T.<%"&U179U1^1J;1UBJ^11N531 MP6L(HOZ)JT)&Y.\$5A1<9H^X1JTJ@5S@BG.(Z2#^A9S^EN01VH5F68JR MP^A1941ZBAZ. ZT>>1BFZ?4UZY+1N3AJR547F^B8QJH&0;G M Y7L1(^<C1&Y>19JMHZ<#Y.J3+1E5Y1QJ1V2R15J9PO.5JH8BUA3<1ZXC&A;=1^X+21BW:3QA.2#&1FG.3SD1N+P2D7U4Z5KU2 M1WJVZ.V3- >1.K0&1.N01?2N JU)H&Y^P.8:QW^P>OW^GBM)T@T\$@<V4S M^W^W(Y0H1V\$;R^<10+X(2F^HBD^=IF^1>GN><1.UO^VNC1S2\$1S1#7QX M^<^GN.8W1R.127FLZ1+>B\$F1F4P+8:@T1^1Z@<#61>AU 71E M&G^Y^Z^15 ^68^A2L1S11K>M=7^Z^1@<#X71Z84R^KG:Y110^0COLO M^<^<3 V<1^6196K+Q4<S1^FCL1X%G12PTP>Z^S1319128<1OEGEQ6H&M.C1D0Y3DKY^H V4K\$2Z2OHKGSHP.O7XFK _5_F1>1F1>1915M>%GH1XOJ+ M2#%+U/<71<51Y/D7X1HB^OWPHT5+?1JQ3T4_D=<B;N:D#0-AKF/N0TXQ#F M1>1H&.0Q^ON^A.-81/=<131SW24+@P^/3.QW"2A OMT;^*L6^01>KD3 MW2SN&=1M44FH 4L.BY>#QDKPE1S=Z<0NY1YUJ\$2G6D%>.4PML7T^TO.Y1S9U-GSK1?>^261Q1<^JM@B1X/5MM:2U1T M6S.)<>R^:#G."F1LQ3H^0- ^1U7.CXCS)\$F<13@0G(&.-?VN.WVMC7N1R11F MYOLL=#41YHZQ1PZW/2IS-19BSXL" _&1+7.96N.G1FG3U+ Q9HRN1TL MR+WKY/LS\$+1^/ HD1J1J1VA-704G263<2^C1Y15Z?71P1M19 6ZW MO^01C1GZM^HB.(C1)1G1G06E^4341V 68091S)(D#6/L1="1VR6^1J _5=1 M:L1M4B^11Q4.39W73\$=V? QO1015.(&\$)(P8Y\$1681(G1L PQ1P2B10U=492E:PHR M1M#PHV&24HM>K91L1FYMO^V4.#=<3<&>R1(1Y112%6+^W%=>1>^<.* JZ8LXA16UA.)6^4OUMU6:S=RBLWWFS921 M#O181H1G(2\$99)%\$LB11!@E_2E&4:>&13.OFO"Z@8PS0CC101CI M1H14D1Y67W# Q@Q<#1A7F88ZV#^1T1G1H M10>07LV U1E^7M1D1JW>Q1U8W1Q1%OB BHS1+19#\$1CEC\$1G5V09F7^EF> PH1>5FLY&L1H#; D6K1O1MY:WHY1TJNSB MF0ZIG&U M.KZ:B11RAX2E.\$HXAPBEF=0H@1^19A\$.88?71E)SK\$1G926Q@.X:041"% M7>+P%QO>L1E3;^X5BK ""FIT#5.B+T62B1L6>SX>1^1Q1T^A&DPPB121X@K'8#^GG@.#41JS1 4G1T&/ M1%:H15>(9VB91DFN^1)XC2K; 1@<DR^FO>CED4<@E@\$.R.)0GB1/5VYS-?Z7.F1^SUBCX@.K^MH DE1/Q#?GTEZAGL^HQL^3MB.6>1Q761EH1R1.LN:."^ (/71SNH7C-5Q MZ#.#%S""MOPJENZV^?K1UR4R1Q1.-1#GD:91 F^5(59%#20HQRB39^21\$N MN171ZA1A^1N:@1..2J18F\$1X1M>0>RVV%CN1J4ULW1128V+1J M=6^Y&L:LT7G6A5GB%FY D.601M1B71H6C2^C1UKAN1#>=16V<4<Q^M\$6(6R&9RB>#K%K^19B1C1S01B51@W..RZ1D1Q11%SL%4 M:81-8M1B1J16F&^J Y#<S/"MQ"1W2^XD5?XAE>U^N1X'67C7.C M1QO^0F^*20H1ECC^W".0Y^D0.1H&U-Q)\$D1<1^+4GBB8 MFG_6S1SBJOU1139\$R1<B1V M75%0.ZE:Q2(G1:7C%PK1IGG&LC1Z1* L MOD^F#.HHZ31^&8-1:\$(P11GH1+3CS-WXOO?7 B11.K13SO\$ 7%Z:7-9 MQL7.T12.s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n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

X1YN M6N499HJ *KVO=TJNA KZ2 1ZJ2@?CWOQH14FOJ+?2KW;Z1^M3E|K MU^UEH;?TEFYWS^?I9W;22ILV*2?E@Q LVM E| MV;IDZ>YN MB4-2810^?L1^1+(<SIP3&&4Y3A^)*OZ-1^*8,S-27A5WQKCU1| BTX#7 M723HAA^|S|=\$\$KJM>M;+>26N;-WH1Z-31'2=2AQTO21#Y G8S#MLT%IBD M>JF6&:IN TS)SWL=,*F<2VGHLLTW"=-(E82,(0AA\$2MDLJ#&+&?1|BD((^GO^LRUA==GU^>9A,^6!<- JS&E&F19KE5FXG;..L)Q1J2>\$ MYCE/^14A=22J10<*Y (B9NZFKIFKE-WXOF Z5K^K/ /104+&SJOOF^\$) LCCID M@2SGIGP2?XEBX%1Y%- ?9IRN)*SRZY,4IG820QJ&KJ+<>6.NP5G(IN9OYFTVN,N MHJIA*JOICEBK*(HC+>_RY3,OR-KJL>(\$Y-O MH-?JPN+8LLP(H7L&K>?>6:UR^~_6:2 216^*H+L 78^KO,YE2H+>BQ1 M/1/8=5IVW069Q^ MW9V?2M.L<1%=9CKZ;E+VY^P.25?>15-Y2F<?ZV^S^FT:QB1%=BXD^K^Y> MM G=>@MGN(P2L;H.2NDVJ^R:B15Y2,141X,UA&64JB *MAP,141-(IAMCG-M\$0PICK,0X2L,B&E6112AB8/IW3RSIZHH.2\$DHDPJ/HJ3\$)>%H0D13(8"-5 M1\$D^S-U8(H937^2(+)1|QH2FK2.6VUY CU>BG^Z15UR+^N^YD(^IW-D0-M^UVY^8@3Y^9/0,YNRI%;3HYRV165^CSN#5P.NNJ>D@I (U0E@J&S0H6@/M/PAE@/P13F)/1+ 2QD603H31295G5D1^SYZZ BF93H?>0.65@71/%2:Y M,2HCQH..!<31-:JNH>X;8(^U% ^P1GIR.A77B^+9KSN@T3-1S\$*^ MKP^+D4#6%;@/RES4GY8NPK56##,("EFFI01:ID#+ MP^Q01V^13S%0971#;75H^65.0; M2<8\$)X(AAG1.8-.222G?>(<UF+>638N@;@ZM&ST<)<F;RW3DJ6T&%;% MNH4/0/(R^*L.OJ)=SLPWG-83CW,@01BP+A3;D.#IYI /<S%;28G\$N1J3- M22C90QJ^9IKBXM@RZV>Q-DRBGGLPXR+V15Y00Q1SP8X?3+|J-1Z9?>K7 MZICF>"Z1H|^>^9@C/L>CBCG.UMY7JY3? <1\$7C+6F8UE^)(IX90@%K0P=M^<XYVDG\$?>T<9XC.NE6."WJX-USXM^URIPUCXCM0WZIKJ|^W^+HW9KQ)<J9 MYK.1PCQ\$PK4^20F3).00C1YX4<83G1F^>VGR\$QLLAW=4=y5K.01^DKH MG=>18U.KCOQS2S75G(+&C.IQ.PY^>CZV1.QXWV.B^< C^WIZVBOK#X1/J1+ MY1^U(AJ47^+Z&R-W*7^NB.F7=>7\$D5EXC2#?";J7<(#12C^B-CVXACY M\$^P\$;=>A1#%0W1.&O.@("EKSJ9- 1@TM::T1B>15GB.WS-K>9OU_M"&6FT@|@X_%4T+DKWH4N\$S79V/MI%#GU^NN^7RE^_B)U^W^BGXJ|@L:SO=>E,Z:62(@|R#\$3I/DXE-9P92E#*8 MBL1%6B&9^0^0^C1%>?2P123M)><E^SP.MQ-00WH@|@JYS=S4&1R>%TKLBN|KM=;#Z0^J3HMY-3K\$;YV^A1FC1S1:T2QOPH M19X1>|S\$K>P=V2.B&2-T:(G.HF<15^ ME_&N|N^T:B1A)H0K7YHIE.MG&+VY^1|H1K8P.ZY?C6:TDEQ=>4F4,"ZC1H9K1(&B<>G=>@O^RB^Z\$H M1%B473VD^&?D?3GIH|WL@X\$G.Z^X|(Z&YVZ02|+|LIC6:LYCPKS^|QYOF/MF6>5^T%D?D#NBF;%EQQS^&.8^+^Y\$^< @C^H79.RB20QO^0P9DQ4XBA\$ MF>=>32?>^3VMPTJHC#^11C^GCP>29AV4L""HP13^8JL\$D771+7>K@+^6Y MTPB71#Z14KXCB^U^UAA6=K3@L<10ED>_#Q(12B1)"8..#G(11Z^M^ZOE6 MIS2SXGT^DYONKLAN^Y/IV>^>^)/GG %GB7Y_P7\$|@NO_7^<6 |PIGE85S)7 M^<K1 \$B^~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|O1^UKDZV;^"@5QB0%"M>|=U|U<_Y-63;..^I=28/H.K;|FXR?E\$;#^|FQ8|4MK-1GZ^O^#|+12 MN3^B+9ZIFEX^"G^N^AE=UJ1MQO\$S.ERP4K6IS5H6LJ=|HJLXU712|D2\$H MR+&A&P531.3;^A;+|HDXK^Y^K.E;WTK>Z^SGRY=X=;V400NUS7+L; M383U+2S1- FJK57-#SKB;&9>)/YR+TSA#N1_+&UHFD1)^N=&W;&GB\$R1 M\$^Y(@:F56^12>WHQ=77RFRV- QE+@QPRCIGC\$^<26+6@^A.RX=2SEL@^ MW271.QW5U6ZTIDYZ\$^C^H&W^V70)Q1\$-4.Y/=#>@PYA&BQTX0KH^9M^ZOM^NMBIY@CMQ7C9 MI^B1ZOZROJ^B2H17B1=AE^D<3^&<44HMP+8410^YV2T,1#^&7^&U9F^&L^M<Y%;Y%\$E8F13R6Q;D;T0;M^1QO^45H1!< <07E+3R4X%=>7=9@^J5\$WQ#L.M- MOJG^KQ(9LJUXNQ2;+^LT^#)LI^H\$^H@=>(GXO|C:15LIT^ML|UBUK?@L/SB3JM&M1MJ<16G^U8H;- |HXZAB^ZIG.Y=^1V.W1M.\$1P^>3T&Q\$=C6)6(2D0..(#91P-28Y^G+5-YIV)=<K;EHUNBRVCYK;M36PWZ3J684Q^O:X52GE10HW%=Y;QH1!1? ^YT7|PIBRH16R.^YVK^DI@AVO^*MRQ23C>Q1H^Q08&8AH2+40F1L29V:ATKPJE#I&M5RL9-M.#SOJLTGFI283?PJ52>8J? PIF)PZ#^K&L97#MO&R LXV5DXY5ST4>9 UZN M1PWE1:1@(&V^1^1^#JIV^1^TQ4WQ;O..LZX U6MTE=1+82-U_1<1A1+AG1 M8/S#M@8Y.JHL QY93E=1^NR5 MQQ^3^H3TD<1A^*YVS.S5W.FC1S7QY2KW/>==T77PK2L-W84+5JX#WLU M./N^BS1^SLE73LFZY8R1YU2>+1.2YK=;1/;>1/193Q0& (<11 Q0\$1^20@|S1MQB@A1L1\$F3D>3^ILMU5*6KJ^V1HJW>+^M+OEO1)P\$+>PJ6N69.2K12IN.UW.CSZ50\$).@*16YX&E863(#8Z1 MUI)@8%?> 9<@OXIUQ!KE=I^K1#Z&K1^Q.PA>?>ZMNO<^..K M1VHMJW^A^>D>XD=U|BXNA^50E&IPY&IQ@3N9TAW?VFK1L+6VNBLIW7 M7IN6X77MU6M9@161^DSEU1/>?BE R_9.43DZ^2\$15Q3P@3P7T1CRHAQB MFE^(-^>O 3EC|G|HT1FIC^W8L?1 UEX4/U^VJJB1\$ (H5Y^>9@=>U>U.M.N^M6BLKJ<0 TY^00<C^V.DYL5OTQ#Z^>U^YQG->^G^3BNQ20PP@1^Q.D29 M<*U1B%""H(98<*8:IRC+(EXP(TZ)D-0F-IR>XJCN: H1&*QSN;KQWDBB-93 M.TQ155Y\$1QIR5HT1^XCPCE+^#V.869IV2^2%2X1^YCUIT+W2CN3 1X14M M:ED0\$ L_VL^+VRJQ#^CFB1^&D^2>)S9Z@F5U1(^>=\$2YBGW8BU((QUB\$IN+ MCGH>=\$=2%FKV?X18-+ "B3OZ2Y<8MKU01ST^T@YXRZ^>#0;OK=7^H^8^<M<(<L20 _|J1^6NU@LI8?2^>?>A1.V3^*;>A1:AR-T1AP&OC41^|H1K MWXO521NXXZT?16KUJ1T139Z-M.926F^77U.O2) W6=L5@>4J7MX M8_KJL.U1XN^90\$)((G+R1RT&Y:PHR)TU\$04L23.*IKU6TJD1R8E_Y;2/X MB^L7^<?7(KO@%A2^U^&VA/PU.ZUXF9O^OR+WM%4(J1ZSJMI-1C-H3D6DUV M3M2)N@Q1@PDX^YT5H1B-?&GVH7J.GK0I6? Z)IT^N1ZD47H;7S8-R530 MKYOJ1^>Y^U^H2%>1^&R-912.*4QC^W-03TEI8^HC E^<1931&C5^1ES M+^KJ/D14^@Y6@ANS1^QQ08<&5V.#17N- 11<5(UCFE;8PU_1KKOY1U1S M^<K>6^W51)^4&=>MH^1%);Z.NHY.DYG81-2T1D^F7G^G6_1K1<1W7^~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|06X)WK#O^SDCAK\$PB;1KY3D1CYLKS|W2?/^LV1^?>?>MR=\$RZ4P1=V\$&1^<M%)JZ4 Q21XMNOC=" /O4)7GM^<@1+NE@P)+^GFVN MW1+KOHG-MAR VVY\$5.1?#D<8BHR+^&4HCS^..5Z69\$..R.X\$5.OJ9>3/L M^R-3|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|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

0.S=C D0F9E^EM^P,1^U&S(BR.(8A(+CME(V%TBO0.M)8(LB5B.S^M,1^U^,^D#D2GG?N]#E8NUX1L'C=+U7RS&_YU@_A^VC<#WJ<
MEJ]#W<,,HUGZ.G6]A0+OGJFYI8EY%VIZ^P<,>UB+^1.HO?2,2^ST^O MLC?T72^C%SW+^F2T^SCRW\,8]@&2JTF^AHN^EY^IV5&?
1+&9<X@UD??"R^A5_M5H]H6]S.>]G^1GZ|^+>OOM?E*4TCGB\$04R+^R8.H.Q#0!"F M-&9AF"9&[0]/@_<\$L<:KMU@%4NR&-9WBD9R"G4VXF>19&[0
<9H<6.XS0&_U M=<=<QK9R%YZZ=NGW]M]YKFZ2*=@2R^ANJ^2L#ZN&_JFH_6]6:5A7^2)J&R^M^+PRX?WG#&_DPP^]MQJAEF&S^PK-
QI/B+V62\$Y99JZ#&A04U5WK7%.G>|W-MU%://JH&O57?HCIV^#G/W^M^45]HEM]#>R^^(KT)^U S0NLM^+M+Y<9(Y^MOT;K(OLM<=&:f
?S5MIHWZ9DQHWU8]VZ5J6OD_>6?2VJ8G^S6S0:1>YO M5-6+G^&6%?]^*81@]^SP2CCES^DCS.4X^+PKM(A:IZ15@DB4_4_10FM^NV MW@8]
(^)&S#45\$J<@E]#S1I@<C_<O3S\$1LN:++500Q7W^_828:JHPZ=RT5^C M<6O.WKHS^526:K0RGPQBFOH=@%8WN\$SX]#R1A0B(PfE_.\$%+R]
(DHP499C.M^?>X@<HTO>.^&_<(L^OZ^EEZ=F+=RPN]WC8_B_>QV7=_C M95^PHAG1-F_9L]SVIE1YH^+(<+3^QV5WZ2O34V+@<3?
4+DRJNG]5P1_,"YN MP=W+@7.C_#73]Y8%:]^XZ?&XC416L7H+<+,%]U9,8SV3UC%7#&1Z2:T MO6W\$&^&Y>+JfC.IK7<?<
%K+SI^W7_B22.CWZ4\$2+<@/#?TIXV9IG(RKJ MYO:5;&4OPRX2=<.,?RZ#3ZCBLH3V]SHRfE7ZL^O52MEGR^]9DU^>^YEW0.A
M^<GI^<MGX1+2X^_?H:SL4V759Y_<^0F0Z<>W.E3YA0%JMC^B8TLATL_C^VV,XCEO?T MCGAF:R<@<RE,24)##%&01R\$&:R^I\$A]
(2_>2G15YQ.O8K<_2?]>Q=X M-1E_1L2\$C=^EIR^O6;PZ#5G]3%166*W3XQHB]41L<6X=;W1CO%9ZFN;MM:P7;52+BL]4:51^&_7\$W\$*^YF8]
[fE_>L#(7?\$(^&1\$ _19#&0M/OI&2) MCEH:]^990T!!UO(P=<M.J9FNL^G<^WCCGHSC6)N+^BT*K3^F(%08^02RV M5P87%I]#T/4(W
JQYV.62.F&DK_M\$S7+^WU[L^F13;M>+&]FKS>=>3 MDX X^C@<L0fE\$%8%3DH.QB^DH&80YYCJ.\$>N\Y(7_>OP2]S1(U=T5^>^M)BTQX&Q\$25WW"
MW+>Q)M.(8O^S]H5RYN^#F2.Ef8]GHWIASZ>L^>:JGW+O]JX6W[90IV+>M_1Z7<4URBF6:1C4.2H
\$D(LUBXJ^C]9G+ZU@<7LV7KU:AV=+FFMY1V0K7P0GfO+0EE:00 GJ^4WE,99^"025^4A0CH2B-P/]7IA#_M#3JPW:61 JP?#3_`G4A9&):@\$
(GMSK_?3P^&9 M/L]2U]W8^2TW3K^]SOX(I^Y^FWHMNB;_4]5L089fZ^W_1CE_3CYA2CCT<<
MGCT_1VM5LV6^1X2A&B\$^0C01^>^"8(DOAA2AA7^M^_H\$E^GNBW<#0_L^M^<D]N^TUHS?C?<H_9U0:R:GUH3;3T]H1=CT>:D]JH-Q-
13A]V=F7KR8I<Q2L?&C@<7.O&G>#>=>=>[C(M^L?_<\$6^R<+>+>1)3]9_14J91ZV\$="J7">(<[US4]_&#PY0% M<0XS\$H%(N_<QA\$!"
)_2#IG)4^HB]A15.L#CKYMN<8]1LA9CW.@R.\$W<^M MS_<D B^5W4WIP;HF23D^NGIX?>>#<_28S=AFS1^22^<EOL9^>_f1-
K^6&P^<B^AGN2+ZP^6I>R]O_<UN4]0 M=J<@<U8]1?>K?Z^+<^Y#GYG8S^J;S?K=BTDO^RY?T^M17?^ORC) Z3]"_6 M40
ACH#8/0^013SG#95YH]6A.PD+J]Y2Q741:RK1K-A]#2>ZBE@JYPR4]M^M=(C<GSXW6.K<#15@<-5H+^#R\$P^9Q]=^FM
^AUEUW20V0=9FTQ:STU>J:N6-MDS;#Z^5PM5292V]V52R_R^<B\$&QJ^_98G#^M94^GMU:RE/O^U93B4(<9+>M.P2.ZZ<VLRDKX<7_>#>10^D+>#
X658U76>6G^U_>YRD8>7= MA2F7XR7% M?B^F8@<55V^5L^<QW^0Y1W+<^WG7;LG5^>AJUM4_AP.Y5^91%B2G M.(E]AN;2P#1^0%DF>^!A7N
P_&KZ&_>S0]W^Q_2_>+8E_64L7>=&:1% M^A^<@<K YV4^4^*ML<00N:L^]TZX7Y_3E_<[UHH<2L>F:]HUIKM(FKY>?>M=FU9:VKZ7GA8^Y04^*D1
D5]9Q^7H(R@E^N8%IE12<4:U(SUD(OI^+VZ31 M^F@<H_82K^F&f^%?Q16*\$VH_\$PE_,"7^C3U)\$S^3.Y_59]^+<4G0J:S8TPI_MU&W>L:L^A+H26;AM?>
LMU><5SR.L7IKQ:7E?U0U=6P^1^>Y23LHT9AD M^H^"EY=>^>K:N^06T^0C1^0UKD6M=^f]P#+>=7L\$<L4A^FQ1^W:X;9B]S.G.fEOB
MBE&<2IU2_HN02L_U7G^W6_9AT@<S,N>^"1LS&D&NB8EAGX(+YE=L^L^T^ CP6_U4O:M:VM /2_2+>15E^<FWDJ>_1025HS0
MOWWZ_%FW0G&R^Z4^E=O9PB_?4VG68SFILC_@J83OJOCE.F7EYVDE9]M M&R=I>^EVX4F:(31D)E]H/=>_<\$2L^OJKIZIY&<(<)(7^57)"9_<DFC-
YJZWABA_V=U:ZN:8(5:IEE<#E6:15Z4=MS40BB]R7_ W9]35V+T^&#&CU:<^M_YF24f^80@ED_Y15KE^#W\$1
fXZCO7P5XLU:=D9=^"K^UZLK>4C:66WM_M9Y3(3LLM^YXK]=&3^K]X^MP9<+<C^>RX(PG^LZ#PIY@M8;2_OJ9_?^H M^<^+>5.<>G&^2RS@L:
QBP5VIM@<+<G0W@S#.\$%)5/4^VM]%(IG3;T%&^SA M&FB?LZS1T^N^#;3Q3M:OSNEU4^KNJ#93H.>V>=>7=RUB]M54F=?GDIA7<+^_M0/EO)<%D
R-(ZA]#<52W^<1=JL_XIC<M^MUL.DP1G29B]5-[50_1#428 Y3F9<116904]M^<4]Y3_0>1ZEP+J92Z^SNE=H2P@<2H_#J3WB]06]A2T9V2_<EF8B^W<^
:(^<XG+>5 M5H2Z^#V^Y+U/OK6W\$<^<M;M^<HN=Z7T_4.8WA1^<?2J]DDB6&#<M^4^6SCVOY M>^>F^>QQE?W+^;PPQZ^L#<8.O\$H%
8>#>H^NPRB597^Y+>SG:=fFX56:QM-V M_L6YfK]J^?>36R^<K(O0DORR>RDS7@<Q&^Y<+>3+>#>1A)A6#%8F_E=0f^Y3^M-
%>9U%=<ISG@<DNX.Z0ZU0^NRB^<M9C5M.D2_ME%<H@<VY7T6JGK5O+>S?7C8_4@<)(26Y]U^<FD)8.D1P^%<@BR^MXf!
4DYX8=<8JRP]S1^<@<QSL04HRT^N>97B]X^1H:;C@<6S7H04N>L8>JY M2#^Wf;U(G^CWLNOE^N^<R8PUP^ZYNF5]M]>:~[GL^>)>70=U#5+<^"O
M:K;M^<A^<KS4@<K\$@<N7:JG3#<3%>=1L^<N]Y(JY5S27]5VSKB0>7Y^O+M^#T^5#>19FZ^<V]7^N2EZ#U^<F]0HWP^H1@<^>BR5F%<D]_DE^8^Y-
)%<MPBG_PfE^49EF^2RU^Y1H6H=Z]W>4=D]HPTO^2HYKGIHK%V^X^UO]8>1MV=<0O^OQ=M^J]T>^<14NKV6-
=6HH.G)BQ.CILEKY9+L<R^#V+<E]S^RAT^VB_MGT?:V8&L^#<+<5O/>+R3.ZA3XCFW09GMKHfZPU+^E^HXX:NMJGW_9L(##_? MW
9J(\$<VSL^L^RVU=>+<f(CNHVZ^2K\$S^T^O.YC<JDS1TGB]V22F MO>V]<^<CL=WH]HJ^+<M(B1^#DK_Y#<K^P2]_0D(<N_PSD89IE]H)4>KS
MX#<T^<F\$S]JUH:WBZ@<NIPWA@<S06I4?^R3.R0>^>Q]H^76R_??#;#5Q=<MA_WN.@N]<V.R3TZ?J]@<E]G@<2X^<OS-(<67&^>3.1=8Q+<+<D_<C?>J7TG:PN
MUJWM^+ID6W/0?PCZE7]MW^<=<LMWY_Y64f^fV@<F0R?2Y9_?59:NR^<@16_MF]H6IQ0!!R6:)Q^<P^JN^&_8D?
(^<=<5L3:]>ONJ^<=<L&N^fE.W6]O&S=WWFC<@<Y^E4^XJREU<@<K^VGR_NY:]>5WF_ME#<#2R\$<^%<H=13?27WK^5^I5^N^E]6_8(
JHZT=%<^<^<B^>4A0^+<Y9 M^#1SP]0]SPI\$3H]9#E_5/KO8@=<JM6G%N^25CVJ^<^<J^<M6D0LO]U^5C96+<M>6%7PA^#f^SC%+<PS8A1=<(<f^fYU?<
U]++<34A;2B%<(<56Y^M]L]QD?5HOPPB7%6L_Y3Q_W0D^<IS=<?>Q6WQ208(A9TE.F]H770(Q<L+L^M)ZT7C^>W+^#D>Z>B^RLFM-
XUIK14>KYVEG)74H%<Y\$O6I<5]FENAGEGU^M^<ZO_>4TN:4@<K^<8YPC^<E]S2<(<AY4J(H@<CPS48C^D^W^WHU]fG
MEL@<S\$0X^<F6^<LKD)W>;BEW]KN(R5B_>WR5R]U;U0L?<=<4P?O_<H1%OYG_M\$EX%<ONN^GPOUAS]5)2JX\$K%8V]J>^>V5\$>Z?YUB5)EF5YG(\$RB2
2XH MBDLBCS:1Z^<7YXIDU>/6EFS\$P.OV?<=<LNR_!<DM]8^<?>?>6^<W9^C^M_2&F2@<B^<+<AZ(?<0W3
F^<^<S)<^<W^<MD3\$7AL=1P7L&3+<OD.MN]7_P2]M]J@<6T^P580)0^\$<U]H E%<^"DK@<SB^B18A>12_<N+<9:NRZM<^A]AU@<T^U
M1_P95Q6NJ#^3^A8\$6S6L?T^1D]U]XO.WK^<^%FG.M>??>=>1^O]C7B6]Y]MZ;A:]A:]A^Q^D_9E+^"0P8P^5^0_Y@<HN(XZB\$158]2P3&7^*X_VLM?Z^9HRI^<
M\$TBVE^Y^M:J^\$[P]P]D]V3O]9]SBJX9HDY]WKE^fZ86@<P^"U3I9AA]fW14]Y_ZM M>6YV<_<K^fWMT5>^<P#?H\$0Z&^<2Y6X4X%7081THM
=<^N@<PIQ9^M=PL96AF3R]M^_M3K^?<OVU2^F^"1^1=9^F_8U^F_1)^E^<L@<^<O#0.NIA@<^\$H98O/<G-B MB%<P^"M#=<1^C]9B^+<
fX9IU9YV^NR^0X0^3]@<HD-C]2]Q^ZV]5_R6D2M7C^?<0 M(BGRE^<ARI3^F&P&XG(^<M^2D_4XB&N^E_9L:2P3]>Q+4<17X^P=4?
L=VEN7Y^*=<C9NE9^<TDL_1]U^#1 M5R_126=1?U2^>)>^>U:3W_H^TIRC%<C_Z@<H>:>^O7IPREM.Q2\$<69
M\$H_90:C&H\$R^1P^*^<CR9D@<G@0RLS2_?7HLDJ_6]3@<^<TU?X]Q=%<?>^<SOOWU1CF<^<S^<fE#>
M6H0P^P&S<R]1H.8PAIB74GRUR^fYGR=P^L36P+<HDC#H]7^P=P^DETFGREJRX^ESDPB]YAY^7Y^<AMG;U_D
KB9O1(fXH_1\$]WW+^1%<F5XX)J^<@=<R7+<IPRO@<ZIM_RHP^D\$@<#^<1 M8]S3^Tf8HAA^A5]Y+<3GS<1=YOY+<
MfD^U^<N^3VKMG]Y^<HJZ^N^<P^<J^Z]EUEA<LE7^<[0ZT^4YV_Y3L^*@=<1 MPL^%<6T>7^9J^XB5R^D8]++Q^F0^#JUX^P^<T;6@<7_<7^57C@<#Tf6N1#Z
M^<16C^<PL1A1BE4ZT@<1E_P@<B^<G^4(f<3>3H/Q+<[H]U^33?^U M@<VO8PO^L1_XW3^S231^<FAC6CA.DR.K>^<K90G_#7FEN^"TW8^<^>K^KX)
MO_E:(<OH@<6U]H^D^<NV@<^>XOJ^*W@<@<B^<B4Y^A2G.8_>9P^"800BE(6\$U^X MP2:86::<B&@<LBA,\$]\$.^Y8^4%O MK+30C5M<M0AT_
S.%1R<C^KZ5%OS#_3KSN^<17@<^<N]V]2WPI&<^<AMWBM>^*M^8]fTL1GL6=6T%5M>:V^<f1

??V/K;BLL:;W5I MK7NPT5G+LR*Y6PL878KOJ@GN[X\$>U2^#A2]PXX6

HUR@<DY^X4-/9R0B1 M^<L_>)D)=RV\$H>K^S.PHS0L01+S.COFZF^"/@<B^W]R]SQ<17AF^<O:D] MKU5M&^\$TY;=F5-
^C^PTFG=<M^<1^<U]TC=1QXGAP^02VZX^HJ@<HWA&K)G^<@<M]>TZ^AD^>L4=-W^QAE0M:Q>P3.(DQA#@<^S^Y8B5^<0)I^A.0PH01U8Y/
MOL2SZMK]4BfE.38<=4T^fO=<1QG=H?NG5JLS/Q^<ME+<fY;Y^<T^>572@<+<M^M4/5+MPQ M<X^EWOQ+<M^WE=GB@<FNCN2^3_R7>^>#P?Y.TX6G)IA
MHPXOX]0]5LSEWO_T2]H M3]U>@<RS;BNISH]M^f7A@<H6_72MF^N]P9]fE5]PQYGLIKMXOQ^Xf MP<CQ0L59^_<T^<8]O&_JP@<APC
C(B:VYQF@<\$\$50201^R^<1&%;6+8(G,\$ MG&XA2L7FISR9QPRCHLY@<P^M]Q^RGI^<C2ZJ]_?S9W0;X&X2?JfW7>^<K]_<\$1<9LI&6M^A-7M8-2f\$X1.
MONP_A_3]#1+9_#28(G;V]@<W89^<@<S]_<B]#1^<#1^<C=5=U0ND59]N^<B5H^<@<LU M]#fE^<0%NYF=10HfPC(WPEK+^<[fLT42]IRE)
0<#1D0]@<@<2&A]G_<NLD MP@<B^<BUB6=<ZYG_G_8WLN^R^<D4@<YE_S^<1S^<Z@<BU5]P(830.8XfE^91DH0]fU^OQH]M^<M^T6GHJR]H@<0(K3]#W
MU2.38OG;f]fA]fKN0@<1^<JYHK)WRA?S<Q:1]M_YMO^_Y105ID^30S^<fXU]U3.2_GLW.7_6:M=<^J^<T_<S^D7#^>^>1&^<1.44P_Q24.1%M@<ML^<
M^#Q2RAQ^<1^<@<7#0M^<MLN]43_VRQ1?1^<=4RJ^<M109]H3MK4]W^MT>^<MCEH4^<T.Y.RZ032]2D]T+6ZRP]P.BW7DUH]f&_<9 M^<790U77VP
WDU+<QQ>=<#<JNU<@<#C^X^<1^<P]H^<fT>N^<2_C?Q^>5O.Jf MEf^U^<E]N]f]H]f]H]DQSH^ES^GRU^f633>@<AVC_U0+5FS#2\$MXAA^E^<0 MD(PfE_#D
\$6)&^<Y^<N]N]4ID+MPL^<F^<V\$<C^<C^M^<V0_M1KN^<+3H_GN2C@<G_7P_7fGGZTEBCE[N]GGL^<E7MF=4;H4I=^fV]O]BY=1
MD>XB39(fH^3\$<C^<Q<0<1R^<3#;#DU^<N^<V60FO^<L^f1 X<S^W^%PYGXIA1^<FSA#<=<F#_GOAEPX3@<!
MSN1EZT2XU2/=<4S<=<=<7UN>W]H0TIE\$(58MH(f12M4D^9QA@<C^<13Q^<6&28_MJG8>FNI#119]X%2^<1UPO;1+7+Y+1+
M2QN]7^<2Vf6R3Z2<=<=<P]T(1-6^9R^XECPN^f]f>+<U^<M4>^<5]ZQW]U]9AC_<B\$Y%>^>OXI8G(4XR8TS8^<WQ]Q\$WE?+^<M+O>#<NK+<#1O-
>M]HISIC^fTfSE6OL2_YNTW=^<f@<HYECY^<P^M^<6VY7LOKS^<Z0Q0^<VEE<9X0S4^*R^>^*4T^<1^<2G^<Q8C^?>^<69M_4]12V^<
M^f2RD0JH]R>X]H]f\$ZDU5^<7Y^H6QOC^<17TO=N M=<=<63>^<Z_<00(4SR^<4^<N^<1^<GT9^<W^<B6+<O_ZR\$<f>CR+39/N<2%50K^9A-E1 M:Y2S
Tf15+>2Z15GRIG)6B8G62^<H]U^<4UXNH]P^fWEW26N^<24ZM&9W^H]M_M^<O^<QINRON^<H22^<2.E@<N^<QGM6A>=<R@<ISQ
@<D_<GNH_L7GP_<5^<@<K^<N M^?2?EPPEK^<F9;C;f^<7N3_CW_HG_fE_P^XWH]f>+<BUD]
M_YGRU>>SS.N<=<KE]_R^R+<S^<F0L^fQA_PU>3W]990.O^<V^<M/G^<GLZ
M]N.SSM2]UXE7OYV<_<8]B9<@<=<4^<8)TY>^<L+<Z^<B3%<@<1+<_MG&QV+<MBC^<D1E]C]5PCC@<f2^<DH^<COO^<JAD^<T^<fEB]>V_NGSY]f7U6]O]H8
MW_=<1>BS_17_1^YIG(ZY^fT^5)?2U1?IO<L_M_<7J?5_G>4\$@<6?WAGZP^<?OZEMW?G^<O]S3E-173YfXHT/3:H49Y=<=<60 MDZN^<CE><GU9?
186RSG^<Y4C]P]Tf^<M^<ZH0A5&^<#1&B4^<D49B^<R6HE=<4&T MKH2^<R^<9]O^<O]1^<5^<2ZWLUW^<LY+^<2P9W7K>6Q^<fT7]P32?<D43F68^<D^<fMf^
9\$<@<^<CT+<D_WG_CU^M^fH01_CR2J^<1^<?EA:Z6L^<26ZN^<R^<K^<W3+1UR?Y3F_66GFON15G2S>^<M>?2?>A^<7^<R^<1^<32^<SA^<LQ9RF^
f3ACHHMS]fMH@<0GK0=<.<1^<A2^<LZ_X^<Q\$ M1?IK_H@<K]T^<#K^>_>PORT]_<fE^<T6X^<GX#^<5\$X]H(9L_0G@<6@<2M2@<HS_M_<5X]fWV1UNO7DG2^<C^<7&01
=<Q650>+>^<AH_QFN^<_<K\$30AQ@<_<MDW9R]@<(VY_#fZT3B&Y?Q.B_QL8126U^<X^<6^<BB22DDL\$%<=<f0L^<H3^<_#_M_Z^<?2JN^<ZBTD^<T7^<f6\$]E@<L2
G/f^<fY^<A^<X^<C2BORD(\$@<E9QY^<M^<HHW<@<[K]X^<+YW&3^<T^<H]Y0TfC^<7^K]fNAH^<1.9C^<fH@<21H]0%<B?>_<CKRG4B]H]K
MK]0XP3BH8^<AX^<Q^<0)TPN^<M1 M^<C7?O^<H^<^<Y^<Z^<Q^<HP^<K\$>S^<N^<S^<1^<2LM_M^<E25\$2W2::>0>#<P%Q3_2G&PR^<6ZV_<#0=ISCW^<MW^<J_GH)WGV?
3BPR_M9XHG71@<DES.HC]D]A1^<8G^<1\$^<R^<Z_VYV_<324=IS(6\$N^<Z^<0^<8X^<F3O^<^<5^<T3]BE\$1QX26\$AKX^<R2^>^<7<TT^<JO_WW^<W=32^<0IS(\$K^<Y/
M^<MNT^<@<^<E^<M^<U^<Y64GD^<B&^<+<1+W^>^<fJ9&E^<5GBD_0^<E70\$3B^<3\$1_M9R]M^<G]f2J]L^<9]H]H^<M]TG^<AN^<M^<N^<U^<f^<2^<Y]5B^<^<H^<M]H^<C>@<L^<)(8\$!
M^<M^<M^<O\$<#UME^<#B2B_E^<Z^<@<^<ZSC2L+L@<LT^<2UE_M^<O]M^<1^<GYf_M^<G^<H8]0]f^<H]9_<H^<Y]H^<6]@<U^<R]M^<X^<N^<O8A7^<20ALNND]S
M^<B]8+<O^<Q]7>3^<Z]H]P^<ZNA]L]1_<9^<A^<L9^<+<DFZ]HDD]K@<4LKKIS_S1TG^<A^<M4Q@<@<C^<U+<+<^<Q^<Q^<DIP6]fZ7]9&C^<Q^<fE90HYD]HP^<1HUYR8S3%YJ
MD9<(<W58>=>7C_<M^<D]H2SDXW^<W=H2)SG+<R^<IOS]f^<8^<H^<SK^<U8^<3D^<M^<? M0^<f1^<2]4+<F^<f1^<CUVMV@<T7^<fG]A^<GU>M0Z57HT7^<2?
^<F7%<45J>Q_<M^<P0^<A22P^<DP_C^<=T0^<JEW^<VAXE^<fUY^<TQ^<L^<M^<J060^<fA^<fE^<R^<f9_19 MY\$4^>fZ>+<4=VC_Y^<fEEHHK^<+B@<120]H]LYPM-
H5]M874=9_<15%9%(1 MG.OYO&4DCRP3R^<OR<(<BH:HN^<JW7^<1<8]JSC5_1L8SXB^<MN^<C@<V0@<=FJR\$ M(3-7SVZ+<#S4QJR_6CH^<Q\$YK

CFQONMV0T*#& (K3.*E/UO2XIK\$E+!EIO31&M M**UA")=Q#>10SU2MCWER7Q!9.KA244NO:U%120+>98 MY.7BBDLI2+>0%21@5(E 'TM 934Y4G.21B6WIR*RYL4#-'G. &AN+ N#<0! MX.9RD J-4WW)A13D.2-Z?7Y54LP+65%0% C%MV%OMCYA8APT+G\$.W>M")Y)Q=21HCXO.S::K>? E_SL2?<+>+X)MG<^+F.V?L/G)SGD?5;.) RI1+8U4;H=-G8BK M%*Z.V+&#%#%6UINVI/O1VX@.i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c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

K7&WRW+YD<2UW9MZ6*17*Y45A:Z40K8RT TL?2*8;N)C:Y12" M<!*7N!F!U" Q:<N'NG#19;"K.#V^+J\$OWEI<.DR*1R!L?2'9.HD4\$4+O-
MUHH/U=ZU>P>T3T1N25SL4X3.X=+56I/UX6:%G17/2D<DS.MA*%L^+Z! MQ62791"TL
8C11X@HXJ!9T%/%@*3?>7<5\$!FJ#&E%!@89DD.)F!6"\$X%PT9.M71\MN!0N.IV'Y#86XF/@&*01+M15KK.J3.Y13\$=^?K^+#+H0OS(3OCEN
MC0!@R0W2M.9B7PX2GBGRYE(L%.)MIZ7Q1-(249&3YSBS3?6J\$*=B)LVA>J!7#5.M3A=I'M=IN/8?N<^=^.(SU M%-I(H!DR:6#4?>@-
EH@/PM"=#!T*:J(7PQH2QHN!W/71S#9'E-/CNELIZ!..MHG</GNZZ.A M?Y>KUY.A?2DH9#06ZX@UYLMAU2)>#*7.4S\$<#JW&.&C)*
X@KY>WU!H(N3.P.M.A!U!8W\$&I9^"Y.PH!F^!)M41R!U@/I46!F2FD.K72L..5E:>T:B1Q!AE7.MX!F=T@>K+<.&8/D!P!&SY6?>
IS%I7"/S/EA^<@O!U^<_B!J3IN..D-C#4ABDH\$!D.M!T%56<=<=<572&KFL!X>(G.D.F%W.ISNK5%HYL.H?3.G!O!>SCI?L6"E.M%DFE!%I0V*YR5..!9?>
4IU4W47!4FK!>B)IB9-AE!3(BUTDD!4J."AD.A=6.MK^@WV!+?&Q44AP=+Y*+S!O.L#;0(8.R=I.=IF#!>P!>T/23!#M\$S>I C4
MFN4E!5PM.\$!+510QG<?I4!^NC#4E\$6\$KKUX10")@VD7M.W.POI!P!+!MU0(Q^XNJ1*X8R<(Y)80.F4.FI>1?>
S9&B\$8H29!1.3O=J\$F&DSO<<4QMJ.M=^L.M=@>DS;O#5AQ5NZUBO..%YEL.1%-Y205<P.;53RH\$E.5O?>H!3.M!Q.TS\$N
5B.-3+Q9Y"/T);%.M7!//M.;!Y.F.O=7VCI*V%VT!>+B"L8D!>I!65^7P6D!02.&4TM"G!<^L9TB.5TO.M.64D?T!R!H!#E.K!7!>T4
SCI<=N15EHU65<\$-EB/FM?JP#(RS9WU>=>T! M0?>9E7.S78F5OQ.*EBWD-I7BPU^W"(H!<8<\$>MTO;Q!HQH06\$659?>RL4T4 M?
_NCTRY*+;XO>77@30YQ?7WRW7Q@C?2U"9QIY.J.M!%CN0M>T*93HW!WV4U#7H/MCC>7!>=YP5DHL8AZWV+Q!>5;GMFD(ZC0F>0
M<=2MG_IWH;O-;X8!T.SW/945=YP^X^KN!S?RFVW>^<LEMH&@C?P!>M2B2I
M0.#=<JYV726C6R1>XZF.E!Q@;BKF!62WAZ1^6JXVJ.HL#3F3I=X+7?S.M009NI.A>I0T47=AZBG*TK.NIAE/9!40%Z\$!LH;8NJMB?X+\$.^J_@*7K&
4K.MU?M+.(SDH%CI CF5DV.E!8R2IRG!H!C%=>54>SN4LM2CL.7N2GRFXOG&I.M=0!..#5;U#)<0C!U%M%U0C.30@ZA=99Z&
(5!H)=L!2SN=XZB&X>X>E!(ICW.MK^@BR(D.N.X*21<@>D?0MO+G!E!MS^C(O@>9=D^4@?+?3"C60H!&..S*=MZN3N!\$T!^<".#7130=
&Y!Y.P(CX.MU\$!1)P.*1#>K^<(D?X2X>+E^B58^UW>U#9R.53UY?2!H7!>@.O!7.C0/M!6^ZY!E!U7=#^S.O4+!56,7#=-@C8_9!6A"9V7'DIGUW=R
!0.@^EA^NP"MH@!DX^!SE3+AAOD.NFU%<(!JY8A!)>XLH+EFU!Z!D+97U.51D>S."GCK(
M)3Z0@KW4!3(D!OU\$ZPGOX!)>I47#K+PD3AR(976CG>(!T.7B)7C(!>@9W0.M!H#2?PFI!/?+&MTA_SXL<9C/W").O!\$48.H"JCZC%
I7..OZWAU!H!F.M^G2M.Y2C3KZX.8)W>E0OS>3B=P\$EN@("EUJM2?1YTA=N^DT=QJUS!H!C1M
MIS3A8@AV!HJ3?>79N!F(8L7/B!ZAW!T!V!L!J!K^Y3TIM+9VA!#0WB0V.MD@T\$X.TG39>@JWA085*+YP-B<0F6(<5VO>.*+59ZJS!BOJ!>84V-
DFY19.MYCJ!6L.H!H!<@0U/TAAODZU!>+##\$#P!)H7\$12.(CUMGL2.8!6>A^!Q2.M!K^3&ACN(!H>Q.H!9EO=XMD7_6YX!Q^XGLW^YG^4<7<8@>
7.@V#PBCU582".5!R@.MBJ^TWB6P\$ZGE4DZ&F.WT>I0!6PAS.OK62E9.C6E!J%K"D..>P^CP.L3F.M6WOW!>6D!T.A>M@39XD8!F!FVD!
M@RM^*Q@RW"=H@X>IZA.M!60003V(OB!L!#:#!7U!>K7&XPYVX.M2BR;\$UDEXZ.&A!H!7!>OYNPYET!Y)B*3..D!O(L!8.*BN-9S
TOHOYK\$<AC9F!@Q#F32=..V?Q#14.Q>M!>LIC4.M3G.H!A5!\$K=H3.Q!H.H.GEX!)Q9#G!H!0W@ZM!44L4ZPSSU..V3E>M%P!EHT-
!R4\$HS>KX9!>9@B.1".&5LQ1<A8^0O2.C6=W2A(NVM\$CZ+<(B!Q.ML\$CSG.1KB!R!E6K@=M!P?W;."#E=(IMK9;L.C+Z^TVXM67>9HO/FRGU-
SE.OV>?N3ZX<C!X!<M4!<03ZS>6!X9NE8DRBSCU\$WWXZ=DOZ!Y.667YB\$6.20.MU.C!X!Q\$1"Q!>4J!THY=E74(SQ2#/(EK!G!OYU
>EA=ITZEXVEOW4^/GO6O)(MD.S.H?2LF0T+V@>K@JGX2B\$HNS8!C.2Z.)M2DGCXG..WRM6D?Q?M.5G.M.M='<
!OPYGV9V!>5SU>J6UF.VIG"4C0D^22.828(R!>=1.4.1?>I397!J?P.M^M=5..!M&K!>=57UEA^9/4U@&+!E#>5=W\$=S^4(CT&{(*)O!K!2!#Y!O!O-T.M-Q
!6\$537Y0!)(%J!>6^NK@&(&L!F02"!SHX!L!(NACZ!YX&X5<7JNP.C!R4.M.WUNV.M2BR;\$UDEXZ.&A!H!7!>OYNPYET!Y)B*3..D!O(L!8.*BN-9S
M:0^A=U!..Y*4RM^4VP&4KSFX.F.H.XMY3>+MY7!9F,I)ZOOYCL8OK.B^5.MZ9!7GZLPTD!LQ=E!P7R4+YQ<M6T+LQ2==O8^*R3!"^P^J!J\$FBO-
4!&MA">=T>R<?9!2!W1.7#&6.O\$G@N.RAA%>2EN>+S.N3>S\$Y?PQ9<2!8!5LMEFZ4-PEC\$!7!NUTG0!H!H!4!&?"@KS.MQ9M%
<..A"U52RD^!\$8!T.24.CPD0NR66D\$G!>+!&S!<#1.AB<=<UNX".M2P.@+>880.6.A^E.MC0S(X84.F4AK>."!>=%U^P.O%BEK.#F6J-
F!GOJ7WOYQ^PE6.UUO!EY.7.MNCW.EKI(E9%OZH.QD)*Q6.M3!XM.79-12>P!R5\$ZY63..N#RIW#%/5@<
ML!A.NB8@U(XR&1076OC.FE!X<=>M8K0BB>2Y0ESE!A6!L>^OQ034.MG7YNI.ZI!H!P!>GE9#O!Y2\$@8VS9.U!P5A"R"!T9.U.UW^C3?D<=4!1X
M%\$S#1>E"E.A!>XBI&@T.@Z<5!JR.O">0-460'5.OWY^OY.M?K5XD8.M7L^W6JRI.BY!P4D!D!MTE!>7.WS(1=8.M^Z5F@*W.F%<
<\$E!)O!H1@*!I."IC2!GM9DZLM2YE?2DOY(\$..YU^*NW.G.OY.M?K6WZZA!>CZ5.7>?"(XLM3@DD-Q=&1^<@>SM=>T^ZG4ZE7P.#(9W.@W1
M2P4X@>QTN64@>..U.K7W%T!O!H!OPE.2A!O!Z.X#R.M5<#W>OD!\$D!5K<^V^E6!8U!EX2^2?2\$S!2QX#7O?>9X9-G\$!E\$XC0!>=\$H
M0Y>=<DR&)&W.A9!J0?>?)OVI.DC&9JC?RD8?X6!T4PM2*WIF2U4W\$E(D.MQT@YOL\$YN@>SXSO!HV.K=<4!D>.<@F!4%&ZP/X?
BQ6&L.E.#?2!+ZIR.M.SGL.ZD+!\$E!&?FX^B(!>I!YXTC!SIH!EWK0!@S!)V!BDEPM.XW1!>.>^?>+>@K+<BC\$!""=>9P.&L!67!O!Q!6K.R.MGB&*!>"B?
>R!A!\$3BK.1@A^%AZ727.DK0@K2(!>HVS^!>6R!ET!PL&KZ)?ME.(M!KFK8U302OB/3-B6WGG(&3IP#@GT.2L..N>WSYKZ*#.#7FJ^@0!4H
M^OK8L\$=RSDL(88G.JZ0EPS1!>=<2DP^53\$^<^=B.DT&0!2!JRZ#MH?>(P!K!
M!#32N6!\$&@/%=<B!<L!R!Z!12!%2E!EBPA)W>U3.FPV.WAM9S.72P05!>J!S.MU4KDZ#5P^K\$6AY+EST\$!XEQ!H2YV^?2S@>=M!X.U!J!K!
%H/E@>8!JPHFYR&MFER7*.&Y&(&3H%1PUCC=>B+5^Q^T?0C\$#E9!S!>L!>D.YL"!I3<^!J48HO.M=3^O^YD)JXT6K?>C@W"Q!2Z!Y.O!U>=3^76E4-
**3Z!>+>#J#S%ID3+J!M4!T7!P!&QC.CCPIY3"~P!>2.2?2^N>C0@&?&J&L!>C=3!4U88GK!P48Z%!!&M49!F@.ICHKR!O@>=Y75^20?
E^6&I6E.GM\$&EJ\$15^3U.6!>B.V9"Y!AUX.M.FT&3Y!FM+>C.SUM(7.70!N!U9X9PT!>7+2+60XA.#36F5L.X9?>X20.MH5!R=<07;DHL!>M-
7/8="73.>5-BYKXU61.1RKU!>80^8L+<8!E6.MPV9)FK!Q^<KU!..!\$8#>F>Y!H!MCB!C!>4574C!H!O!>10%\$>D8T%W2!%..ML+7.P+Y.JHY.H-
!<LW%3ENYO_3C.M^K*.*C."JOYA9POVNI^6&RV\$CB@T^YWE0\$4!>AQU!H!Q920B+<47NP+<@<
MK)=GIWQQ9A!D@>YP<L8X.W!R9U!Z!X!Y!G!U!H.O!K0!3=(G!A!>I^!>E!1.5;MU!H@/OF?GH-A04T75R2E10W%.N6A94\$5U=^^!\$W!MSG!H!VUCF-
H<\$?)>W!S&X\$B?F^B6U1-9>Z!\$2018B5%!!HO.3!\$8+<#9.M=ZN"HH_<OB#H@9!3WU.6JB-HNAE8ZEWB)S>B!E..5G48\$1+Y9@E!>=S!<
MPBJ!9>3!H3!>P.L3.FGT\$ZSS!T!E#5%WD!5!H!A!>6VY^7TU.Q!67!>#!98Y.MF>W5U!ZNA3"4S9YV
7%I.M@>BP4D/C%5A..!%I7X!AO.9%I0VP>9RV.JJ5!<MWM0^608"CKPHC!0L6B!>FXYJ2.Y(28>I!S4-)>3>68E^\$8.ND68@>H>H>_G
M!ZM2V!K_>C8^?>0BT\$!OKM2EX!K>+MAVJR!Q>I^!F5(O4G0&04A\$#%P!TM..FLR5P7!TW!VL67>I3!>I>B\$X.MWN.90\$H=4XDD
CG9X>FSA!805G6V7"=I!Q.7Y.MJAZ!&1!>=<W0!#>=>K^!>C!X.ME.Z^OW!>TK\$E3R7&#&D\$.A^H!>#A=C@.0L^!J2C+!UA.O&=ZY6.IZ%IY.M3.WZ?
FGD!IOS@O!9U!Y7V!>^>.*&6^<L!R@4!&D4^8.S.OB\$>E<+D.35?P.M3!LSW!UTV!>UOAH!P.C.LE!<OE@77!D..L1!TRE!\$!\$H@N@X!E!>
M!Q+K.O.N@>N>YA.9C0!ZE..H!T!>3D.M=<I8B.2!WE+<6OEX!>*<2B?>P.MK615^8Z!ISH!O!Z>4C(O.#N.D!RX!H!VP!>@-
P6H!WEN!LEF93RQH.\$!4(Y"")QDD!QVH0DBOQC3!>#M.2\$F>=\$Z7A(R>P!H!ZK3CPU!%M!>C=(.K67E3*.*TS9"IA"DMD-
/H+GY\$!R!P9E*.*NPU7W>=%C/2D7Y4N!Y!O.M=XO.FE!N"1A2^8Y.HS0.X#>W!>I+T.M@/5.DBZ!IG%Z!P!3V63!3Y!IPX.M&Y>C
/D?ZZ<#>@?Y4!LSQ(459).%R\$#G6G!\$!>I!RG9OY.S0T!H!V5!>M3)G3ZE/24U54.PIK^F\$K!>G!@S3X!>C!>0!7J05!OK..!4S2P.MDE1-
M..EW7*6!P0!XBRB4^F3!8."J!C4Q\$!5YCR4^E@HWW+(Q5B+O!MVTH!CFZYF.MFND.*YG5E8@%5K"!UETE.%56J@PR@+X^4B;
MJBUX2."UT4EOM!>O&#>@H75ZNM!2!>L^N!VS!>26&IYB.N@>C@>74!H(LG3.MSX0<0!1#>3%>GY.8TP4!>I.FMZ26!<Q=1F4E0!
*="W0%58%!!>@!9!23!L!PX.MHUL!>GA!H!S!>3+!N!P027!WBVZSR5AJC%T..P.=D!>..%E90.K!>I5UF6!O!Q!>2M"PHR!>+!W/M-ZXL-
!>3/S3Q!&.>I>GT>@>E?>I>+>B/B/E<6.??F95*U.#!B!>2)%%\$X.M2!G!>F7<OT=+!<I\$9Z!>P%>4.D^<KN7VV!O!>
MKBE+V!D=FT.VK\$^T!H3+!F^N^2!>H!DNT!>1<7MN7H!>5E..RL*(636A+MD8>2O+X<=DN!9\$80Y!>U!G!Z4=1^ZX"Z4.5=)0Q!\$!>OS!>N!W!>H(F
M2K+2B^6@!>I.8!7/29%!.M=4R9^6^2+>M#Z!N:AZV2HA8D+GDB%GEJLY#L39!H!DH10!QY!)9W!66U!H0"LLC^4#M.W6!>N!W?
XLVZ!J968FH2UUQ&GBV!>F!IGKE!>6!DRQJ\$V+!S!N6!>T=3P6!#M?>2!H!R!S023(EG)P2!EN047(2K#>O!>L!T02FHV!>JW2A!NYKE!K.H4\$R/HU..M!>W?
USPU^G<<<>B62XO^B*>^>%2#HE.MYFV1!>0D"AZ4H%LY%>2(\$S\$O)>41H?5NY!>5AAR^H"W2D\$!>T!8&7!&1!>I!4.M6FD!>@5&JW0BPRY\$
IF+X%O!)!\$!MDXI#3E(V42D\$DWQ6*DB;!*!>5T!>M!>44)O8!H..!>16)X.VF.2D..U/B0..40%G+>G!>UO!UM..J2!>4&I!>M!>V67EG2P?>O!Z@>
(A0PB)!BU^!B9\$ZHKZ!>NU!5D!H!JCKE!F3!8!G^A.MU2?>=2!P2.DFYZD0\$>SDTF.EF&XU05^5H!>10U^YE!IBBZE?>2!NATAX22<M.MG!E!>2.95".W!8>
"MF#*H5*..!>5.N"OY23@-T!>7=>8#7.4%&=&MKH#>T!MTX0.8(K6YD)9R=L(M^Q.MSB.V6D.PP@.R25>L!MG!H!>33S+A^<CK0Q).0U0P=
<+!ITN6XE0!9!R2V4\$!>MPH+R"!L!C!0B^R9Y!Y.O!O!<GL.NA.C.MOD4^0&K!>+1+2#&#D=N0!A.M9K!>DYTNOP!>AR9%V%
5!H!4G\$!%T980.MZQ>E!US/G..H!JKT+E=4HX8.MG=UU3!F!LPG(X<=>2W).A.X!>H!>P!>C!>N!3!>2G5LWRS!>9!>K_>OB.M!>V?>2ZE9.MG4
5K0!>.&@8\$C.1&Y/C>.._C!>59PW=>I!>KKHU.7!>2.L)5.MF!>Q.2K4!N30P!>2B=EGDEDS#(CP#A)PBK!TJR!>U@4@>B.#W>344!H!ZH!>M!>M^M
!>E8!>N!>I!>R@7^>+!>I!>C>D!>X^<WKS!RT^U!G!J6.MF!H!A(81<I!R!J4Z6#)!>L!P(A3?27P\$.8=7!>0HQ<K.WK&BT83!>J06"D0
MG^8EJY!>#HL.#S!>A%>98!>M!>2!F!>H!>H6!>^Y!>+!>1+OP!>WY8!>L"MRP!>5.MB8.O<(<E?>7!>H.#6:Q781N."E!>H!>U54!>G!>9!>40>+H^>Q!UFZ
!>N=C2N!WY^ZB.%!>3<^!>T!>T!>7A^>EZB.1?>7."3D1.M6M06+N..Q\$WK!X!X%L7%TTP!HKK?>W7.8.ML!>GQO3F!>F!>XVK!>@!>=<!"<
MDLL4!>L!>7!>R!>K!>O!>R!>T!>8!>P!>D!>3^>K!>G!>H?>BQ8?>2=8!>O!>YFZ!>INC=36K^!>LL.MR!>5V!>0W..^@J_>Y^>K.MKYG!X!>H!>7!>S!>WD!>PI&
(2^4!6!5!>Z!>4H!>IPGWHZ>M.3>7M@>@!>1&H!>Z!>6!>C.D!>7!>O!>ENG2!>PQO!Y!>JEFY%>YV.+!>6!>MD!>K8M!>T4A>M>FG(ZV!>%>+5GV&5!>TA=M!>S!>O3F!
MT>30%ER@>DWY3;XWN)9C<"[55.IY.T!>1>OX>O6V!MY?3XH!>+>H0&C.QY5.ML!H!H!C!>D.O5!U!O!>+NOEFZ!>H!>M0!>1?
2<@>T!>D!>H!>V!>Q!>=W4!>H!>B85!>^>V!>H!>M!>Q!>DW!>EW!>L!>7!>G!>9!>A!>L>=I!>@T..C<@5.)^E5B7ZFG!>L!>+!>FQ\$>B!>H!>S!>U!>M!>=1?>P9H7;KH6S<%*9.
9(C:3#EE3.OB!O.M5!Z.P<>TX#X.5G=MY=0ZGC0.N^>E.&8!>97Y8%>8N<6072A=MS4?>D!>U!>6.MB3H0WYK=>@N^O_>Q!>09R#>@
MM+&@>ZZH%>4ARP+V\$JB<..>WS3%>X!>?>#F!E%Z%<#&#>PH!>H!>T&S!>Q!>+>S&3Q.M07?ZLZ!>U!>+WSJ?>O!>S!>O!>Q=M^QUAZ2?
72E9!>7!>644YUB"#\$TKF!>M!>T!>3.&O2K>O.G!>L!>@*!>Y!>OZ!>I=7UPU.WDU!>WZ!>790E..X\$50#9.2&ED6@P.M8<8!>S!>W2!>H!>M@>T!>H!>M\$8ZH=MDU
%N.NT!>2W?>G4?>94<1!>D!>I&Y\$X!>LGD8C=AJ!>L!>HEH!>..R@>Z!>A6!>A!>H!>S!>K!>S!>^>+E62BPV.MEW!>XO5SD^44U!>L!>F>KDF70.HZ!>E+R!>DMZ.9FC2=
IF!>B!>A!>N!>Q!>W!>Q!>7!>H!>M!>3!>G!>X!>M!>V!>G!>L!>C!>7.#K8=N!>R!>I7Y.H!>G!>+!>H!>U!>H!>S!>R!>L?>7.99&FSTR>237H!>GRX.MR!>NTY!>TO!>H!>X!>G?
%N%P6.6J!>U!>VXB+5_<^<5XM5JCEK&^>M!>2!>T!>FF&MB@>7DEP!>A8.*4!>O!>H!>OED5&?Y!>R!>P!>G!>C!>3EN2>ZD\$>T!>B!>X!>5.MK^A!>ED
M!>D!>P!>H!>C!>30..1R!>B!>W!>7+3N!>N!>@?>7?>V!>T!>R.CW!>J!>H!>V!>N!>C!>P!>3#..M!>WE!>Z!>..UM.E+!>C!>3H2Z+A!>938H!>@>Q!>#1.L!>X!>R+!>S!>I!>ON<1!>9!>^!>H!>F<
55BG.H!>M.V!>F5A!>=<CL!>+>@22&H!>W?>OR!>J!>S!>+1!>N!>Z>..WGV!>Y!>@9@>=KOM^>B!>H!>H!>@>9!>+53B!>=!>A!>H!>O!>H!>H!>Y?
M\$!>T74YU\$5HR(O3+ONOW!>V!>W?>#0!>D..P0C70!>U!>M!>=&BTFADHA!>L9>5J69\$E.M!>B=D!>EQ+Q^>7!>+>3!>X82!>MC=>..T?>4B8^!>+4NW.
H!>M0D&O!>P!>F!>O!>K!>H!>1!>M!>C!>8!>T!>V!>G!>Z!>Z!>S!>8!>3U!>I4!>M!>J!>N.K^>F!>W!>16!>J!>80Q9!>1\$O&Z!>H!>E!>B!>P!>2!>H!>I!>""9\$&#&X!>R.G0UX8!>C?
4B.S!>K!>GPST!>H!>L!>X!>B!>D86!>E!>I!>E!>Z!>K!>4XHU!>H!>O.MS!>M&57^>AP9!>9K^>F!>W!>L!>G!>Z!>N..OM>?>G!>H!>8@>0V!>D!>O!>P!>A!>..KFY!>T!>6Q!>6R!>5.MNE!>7.4-
1CZF!>T!>O!>Q!>S!>E!>D!>6!>W!>6!>X!>37!>=<I!>F!>S!>^!>.#!>O!>G!>P!>^!>L!>N!>K@.0XGAD.BQF.MB!>H!>N8!>4Q2"0J"WZ(F^9M?8K>I.V!>=X1.SM^>I^>W>IAY9O.H4!>N!>+>H2+>U
M!>Q!>N!>L!>#2#>O!>F.E8R3X!>Z!>H!>P!>Q!>D!>T!>9G!>@>2E!>=>B!>K!>M!>@..9.N!>B=E6T!>7.A8!>Z!>I!>R^>7A!>S!>Z6!>W!>W!>M!>J!>@>WV!>L!>W!>M!>+>@2.MG8!>H!>U!>P=7?9
!>=5!>Z92\$BR4VZW+9K=LWKRD&3!>I!>AQ!>A!>@!>U!>U!>^!>C!>..H!>H!>W!>Z!>S.YA8!>Z!>I!>R^>7A!>S!>Z6!>W!>W!>M!>J!>@>WV!>L!>W!>M!>+>@2.MG8!>H!>U!>P=7?9
Z9QR!>OCH!>M!>D!>F!>R9!>9.%M@>D!>H!>N!>@>L^>3!>122!>=4B!>U!>3KZ?>T!>G!>S!>L!>M!>92.%>U!>H!>W!>V!>A!>P7A>O!>G!>S!>=DQ!>N!>3..M.S0?>#<3L>..U!>O!>13?>P!>W^>4!>W3.94-
!>A!>C!>=>H^*YF.F76GL645\$K!>A!>B!>M!>F!>X!>I!>@>#>Y!>A!>S!>N!>D!>3!>T!>G!>@>7D7!>L!>G!>@>Y!>Z!>E!>W!>H!>902Y!>W!>D!>K^<=>Y!>C!>M!>Z!>X3=I!>B!>I!>G!>2!>H!>L?>+Y^>^>TCGZ!>5C
^>N!>I!>C!>P!>V2!>""!>W!>5!>I!>Q!>S!>X!>S!>X!>H!>XV.5!>L!>T!>M!>Y!>M!>R!>Q!>A!>W!>L!>G!>T!>W!>M!>Y!>9!>H!>V!>T!>O!>K!>F!>N!>A!>L!>Z!>S!>19XO!>K!>O!>G!>I!>W!>N!>S!>M!>K!>K!>K!>H!>Z!>R!>L-
4.8!>8!>R!>J!>V!>#E9Y!>I!>Z!>S!>L!>Q!>H!>E!>T!>F!>Y!>S90!>E!>C!>N!>B!>A!>S!>M!>V!>M!>K!>7!>M!>W>H!>C!>H!>T!>O!>8_@Y^>T2N?>7!>L!>T!>A?>..7!>L!>W!>2!>9!>Y!>9!>C!>R!>S!>E!>A!>P7R!>9!>C!>F!>#E!>I!>Q

M>~* PO>~S^"UOG4<[+ P8'H"S%WTI FMKFZIE\$K306L0"S E;?71+3@L&HMT M3&9C1#R9I_MNMC<9^!\$|TB^D_X&H-/8^=|6|~#KL+T7H7
M%4A-4E14U#04(3K6):RQVBTSF(^X2&~>VH?~""D1@;X KF6/XWSC_M)'^_U?T CBIZS-Q=?#N4
MX1-/TO9P<#HT H-0-+=|SX0/LP4@-!@0*(A5R4@=Z1/Q2RD^H6:=|GHP1 M&C|B=|@?RM+;~>7|0C|&T>|V G||2I41.G V43>H(H2(A,"HI#
<~Y2XJ2C MT ID_D0SUGK|OS_FGE^T^G;09X3J|7FI^2-5W7612Z74IZA(#!@55!>|~I M=>% (XQZ/S/F)YLG_5B9@-
"2_Z/-0:2*E@G381@MB4S25(LE5+M/BE)|N@* MMEY^T/?YJ<_UN=_9%0W%-V/SXOMSA8;J1^?%AM7P_7FQ6|5ZGK9^NA;G M3*OB6>8<D^"
|&0JX*OBM2E|Z9||YX-9-P>2*ZL&E M><3XSQR@9@=:X|&S/5W\$&9|L|_OB@D TZ\$|F|(N|F|84@:4G<12.0.LIV M2Y|330W+|S^~1#N
TRD@-DYD&4E|5=|OF<9>?LUY&S^Y=8^A42:021B MYC<@M4OYC<T\$?~|Z|~|1Y+14W 4B^NC|Q(OA(ASRJ&12Y|TGM/P=YO?M
_@O@~8W#5>|U|=4S.#T(020@V^E2_1P>\$B.3T2HYH+19R5.1.3MW?;W|3 M/L|JH|L.K%N#|P|B"&4I^R|J|6"|. U.=JZ,"\$2IYZ<>P|N|W|A-87GV(
M~WEDW?>|"HJN2?|s+UV=IA HR^N(A) 1|OQ(H%86&S&L4XGN;N@^G|J_24^~|M^?Z8|HHO.X|/H|IGRZ^(|W#UA>?>58G|>SRZ5>M=0LG)UM MOI
99|Y|I+|N7F|J R=5|3R1Q<L R|3G.6&|M=N3>.)%A 1:|OJ|>|H-?#|J M/MO;_#LDA_~|K^F=9^&S|L<~="K=D|Y%TND#|Q9&T6|6>~|8;9=|N Y_8
M<~|@O\$G#@(|YEF?)>410;BX=7BZM_ UT5U MZ|OPIUYM^K-O^P=H.22S9?O>K\$3GIH|I8LA8^<%H(^D.Y+KZ.W#P+)|N<
M2F|RH/-J|=Z=WA^V OGU|W(KF)F0L Q7 12F<~|J& TRJ|^%N G7U|B|H|10N OPLBHM..(A<51.6~*~D0H,F&8|JGHHQ=2#67B M1%)&B)SO_R|TQ?2
W+5@~1^EHMU^N9XY|<_L=N5@WK|L\$28/12^ H:8T MYFYF4#W.W.OHD^O?5|8@Z%2@IW2_6+|~ZYV^O2+870QA<N| HJ# HS%53*
M+|~%PFCFYUY00%.0|H5@_1^F2A1_QZ|?~P^SD T.6Q\$K<KZ|RD\$|8.W@D7@PE_Q?0%9L(5%GD^Q+L.#+1%&WY+7HM0B|H?>O?<F<M_H0YX|U|J#^/D=N%G
DQ&R<~\$&@~LB9W%K^0#IR<8/PA6-O>~|=67LQV>_1 M\$#|~|@1P\$MQ>~WY>~&1|QD|LQK0BE(|B46-W/X@~"%=UD9Y|F|H^O_CVY|S F MV+1P3?
J=P45|0?DG?7J8B.Y8.&|5L&8R^G_~|L(F5(F6F>C32|1U^VY3# M%YX|7^|L3>~>45B:SPCGUK^U5X0|0^|V26\$YQW2_08+DEH^RW M<+1\$|)%EQ
M\$AYGW:RW|L PPTG<~|W%PNX^T^SCNT^L8VBAED3^?1<2BU EU|L|S|HX|P7 MHO&LQ\$^T5_X9SB%LSD^W%|>R23HBG<~1\$8|OQ|?C-O(P3%
_@<5292;\$RM M|XD>B;5|L|D3SKE_9U>|K;XO%CB8&|S%NN4*KSU|0%5GWGX>PIKZ)F7+~" MFL|V&1~"1^&1|06Q^09A>|BEV.2X;\$Y|Y|T|U|T|C|J&U
LX=8|H|~|O&=|&M|D;Y.G^DVIY|H|^|Q^E^I^ZHDCT|Y4X|+|O3|M^>|D&X|&V+HVC0G6W6W9F MTF?Q|HDVY^H^D\$Q5R\$&|@~6Q*~|FB6|L?
M)MR,VV|^1=OG>~>X1).VIB2;P71 M^2YF^E7.X\$6J|U7|6@~T3XQ0=|9<|J=|>6|2A9N=3HHJ2=E>H#TWJ^=~%C|O M5U?
3E^~9EK8|R7;Z5.L%9/AZZ.#G4>O?8)>6|YK;&VBJY.B M-7CT&630.3BGHU?N.##L8<+;|7O|J<|=-|H.H1>U>A3.V|T@DBFY% M_ MUU4XAA?
R|K6&R~%69B4|752|STBN@3/|@>M|LUV|W|AY|AT5Q|>P@GNPMEK M75Z5AT7|~|C.G.92|+~|WA55J0XN|J9|~ M|HWOQM^|UR&|YVCM5G|H915E+T^%F
G|X<|S.LA9B+C|RLJ5Y|Y\$Z~%SZL M+4F87\$;0Q_~T%~|O4@|P73@|6@532PK|8J5|(M%\$|H703P2K12+G|X32=Z(3NPX XHO)Z2W|702W+L|Z|BOCD@62W0
9\$|%+;32V MCN|N?|~7%|H|C|L|C^L^09W5KM(d9.2HY/M@Y|0O|UO)*116GNL#|L0^|MIUWG^VOR\$4CL(=-I%Q^|H@V);UVCRLUE>D^|)\$*1^E^2%
|H6E^B| "6(R/A M+|AU>GY6|)=E^S_~L~RN^X9W-47K|L>2SRO M_|U0U|F=W|H|C|~|C|~%RGD AU2 N#N\$>~1J5:|X C69_AY41^4Y 5T |A4Z:Q-
YB/&E^Q@UN_V|9B.SYXL|XR=|MTX M+=|J_SX2HLX.Y^FV^UZ7WN^|I67V0%&+?>=HY MAR_5YPO|E|KN|F|C|H|ST)~".HV|T5W50#?
~>6>2|HT\$~#C|N0K2|HJ V WY M-57TKPG;W|L~14^F6^|AH0|=C;Q.H6|=|YV#C%;P|)%5SM_E9JB8&8|O U
MWP556U|U.GH#~7#A2;R|~KLM|89%EQJ(BNA#G2_\$(~ND^*2Q|120)9:2|SB? M^/D3_Z.O^I=MY=F#P3D|=A3&~R.X R5YGL|C/%#CZ |#J|**QW@70?
_D7_NX M-8^K^ZD_X^AK_FGI|T|W|~Y|G9|L|~|?H=UV?~;~|49QJ^3_7XA@11)K0 MR>;D@I5TD>QD#G?YVLDG3>@?P?SFF+J8|U|>~<7
|CN>~%2N9#Y|~|)W|M2+370P|7|U|^+W_#|J5~M9|X5~L1^6&N M-LNDA^R8|T5|H703WP2K12+G|X32=Z(3NPX XHO)Z2W|702W+L|Z|BOCD@62W0
MCS|DH?2PL7.Y2R|@W_TFYEX\$M|D)*%#|&|D^2Z9 X+|~1\$&6+;EXM^R E MAJ|?~E_7M#|J|G|X|+93|~>U_6\$>~|F^_P6S0.1^63|JH&M6D|)JHKM
M0Q|J>3&~H|6.1^G?DP2.9|V0\$D@~|JZVM2D5|)"(=|QP.P@A=2|E+L4 M^#%0%0%*
~<2C==H(|HDYQ<2VQ^A|S|<|VUK.535%>Q6J_7VP.C|~VWU|L7 M^TQ|ZB@0~;|(8HPD+3|R H^&3LBF8|C|)Y|(S^BBZ|J|G|YB_YNGO
MDUEP8&?|WQ>C^>CM_J28N+NOX;8=WZ9:ET|FN8F P^Y|9RP^WC7@O6&#E%0-
M4D^Q|X435T|C;LDP26|B|4^HVQ?2H0+3|G.Y^G|N|K|+|C|P\$55(T0;+~^C_M_X4FTB0;9QA;4&U_L|38T3-J
M&9^~|L8@~|MLY|E9B|P|T@HCK|J|D^V2|HW_3Y.Q>SV|_15B63+4RZ7^5|P^~M4Q;~|BBRZ|~""\$EY|T^|E|H|B|6Y|RNY8PQ\$^0ID>Z|Z|~*)V#*2|!>4B_2
MH_%3,2TCB|+J>~|P%U<>|2(6|4RCGN9N3OY+|)C^M<\$Z?93^8.H46|_79(6:|05-08K^SF.FMGVG|J|O^QFAC2 M%|+VC|HMR)?9=|~|U-
3VRK<+|O>~|Q<18_~B2%WQF^5_~|NX@;BK^U7KM>Q_~M|LBBP^|6|.G^R<~RW3=M^2AS4 O^<KP<~|&A-G4|5=029@|SROA/N<~;M=HAT07ZDE9A
%C;S84?CS8&|9^G|=0&0190^P26M^*MM#>8=|~2^3R)QM^H^R H<~<B|L_~|~R^VX|9^OE^X8|L>|2PE|F|L^31P M^|@=|~
FM|O4QX|L M.P=5S;@>^NOND\$|L N(2~%J|~DB/88|CH|E_S52#;1 M_.W@(|YS9R:L\$;5P5>S^C0|Z:L^|VCR^9;E^EJ M@S?M=K^F1Z2S\$_XG?G=
M5<~8PZ6DP<~|~|L|N^&VH^DHA02PW^7DBK_~|E|J|H|T|2L|^|T|Z|O^O^Y5 MUM_?
#&~%5Q.X9C0U5Y68_~|Z;4RETG=;B9L&6P>&K(L\$QKL~|TYHC|)Z|M M^)=LE3\$V|A.H5P2>NNCX&E|G+AL+~PX1Q
~|~1^&GVX_~|MD9Y17|0L~>~WD9|P>=6^H=~|8\$;391~+~B MIEU.YH|:8EX|3K_49115^H=4\$SC JP#=\$AP28N;G^JG#5=|IQO|V&
M4@~TL7_9|S#93?~23U=2NO(T|D|F|P^P^%F|J|ATME^+H5.89+|Y^|J|H_M\$)E8EA_~%EGU5\$=F.EHW:HT %CSK^Y|~2A|RGCSU|Y|~2_9YOHJ
M^&~668|09|U|X K2@A|J|HM.@07.V1^T^H:0|H|IS0U|Y|:(85|H|2^Y%\$ROC~|>GTF%)^|VUO|O^>F@8|N
MGB|J^WE|2(6&K|D|O&BWA4D|S|D+X8L~KUYOYVN|S~|H|J2^7^|HPP0_X2XF#%N|>83&5#~|@S60%H5|2 MK6:S7GDX1-YP_MXZE3&
(BP?%7B#I&>~\$46XE4|F|CH|D5^97R|N_#O3J#4<% M|H&D|L_0WK030XE|9D9HAS^LQ1^D%\$XB#7XB\$MS|)BMNC.7A+AO|KHTO_A M9T7Q|ZB|K|K|K
K_~|62Q|DH+~4GU&BVT^V|J3^9D329^+|TK|)PM|ND<ME|9P^E5TA83;5-CBG G-892E|L>@U&P|@S1%MP^~|N6;|LCU139_GA;D4V
M3E^W#~1Y700?_T1&F=9C3L|V.312^F8|O>6~*Q^023|(^2K^+|)Q\$K^BVR<MHN@J+|)M=M=C=AZ+HP&T4J|OL(L|69KXBF?2-
D^3SCE378;LT^~LJ&+9|F<~MLBB^~@K=K9|WH|Z&V^F|~|Y?Y.(F\$>~PB18(BM51%8S1PR6S,CL)7Z_M2E7;&N7|_R^M|H-
1^K.P|EX;K80D^N(OW^YR|)~#B|2%_D2|V~|Q G|N|A|4_~4^0N#PIZ\$S^93^|22P4~|TU@~M:ISX(J-D^~R&XO_20H(4L~4^
T&G\$Y5T3Z58^AYZ|C2U0&E\$41+~P12WME4 M.9TB|Q(5^L\$^Q\$|^<4^+|L|T^SHOQW^AF5RKS@E+&H^DTEUX|E_~|GSNWI|H_92EU|AX|~4^YQ^
M&+8UATT|PU-C_@_G2.U\$J@&~B0^\$YUD7=4=|R/_O%*1P0|~|0+>YM5X| M=3HLN/6|+|P&E|AY_HL9K=>E;4V&A<M^\$A|VSE|O|K1&1-
~&2P&C&LE4|T|G|V|~|9V806^~+~@H5J8MXAC_2A|HAQ MZZ6B^GDL+@~L~RLD@XZ.G@3|F|D|YV\$G&ZMF8YPOQ5NAJH_7MQ|OYO|T MR^|F25G?
Y|E+~#2G|C^~O|7CH9V^#KE7\$5;16H^1~|~ZP>A|9|SX|1^F MZK@3%C;\$W^SL+EU6_0 GER3|DR@5<~90^E^|T8T|J2L.ZK8+~|Y2^5%~|~MO>
(&4(84@~TA5WC5=C~>FY^6(79=2|=|60|H|WOSYN>|23?3>186^5J^ M&YU=>2TC99\$C^Z^IS^J M@6@~@~F49;YH+7^NLB5^&-1868EAVAWMR|5/5|
MGL|Z<>~9.4A EFH_2E+P^*Y.Z&X;HN6_1T9#|2|6G|3K;FW|H|ZW6*|@=K<3 MG_~E|UNX3L>>=V9N|KQ|FAET(OE~DRO4|N|_U_~RGZ9W_1A4J^L&-
D|~M=6653_2^~&~4H@~%C|X|~|E;P9P^9|DB#7\$~==H21^|X 8\$^M<S<~=-CWGCD8FOJ(MMY#5@|S_9PA**~|IP#Q|O(6P2|L
MM(9%2514@3AG|^A80V50L+1C<~<V\$YR MLEE>9\$=(9^CZ\$O~|MW<~&|W\$W&(7^&~%~<~B|~#|)~@~|F|HVVUWQFH4|V7N=8H0++
MMK3^E|YCN97DH<~<2^2^K|DEH|H^|W^~^VCSY=MW|V|V|57 MT^T|Y|T|L~|~|PQ4^Z_JW_E3|Z8^M_Y|TFO2^2^0;N95_~NC\$B^5|9^|
ML<~0PDXAK8A+7>~D-Q58+D5K9_TIF9=09XJH<~Q^O|HX@0@_8\$;O|X_O;G|N MLYO6TS^VR=5&#*
~<|H|H|EDH<~5R|~>~%K(61T|_1&Z|3|~&2U=|Y|=5Y^B^R^PDB|9|M_UZ_W_6|FQ|LF2^|T\$E^Q|H|14A_~DD/#3|0>6^# 2@FO|^\$Q M|GN-
GSA^N0N+~W|_6C|12R|9PR_*2C>I^8=&BAN^J_?%V|P|S=V^~U09 MR|Z&G|P|A^1_2SP|>|=OICEFM6BSH8^U|&D0L93_X9^*U|("R1^865M;N|Q
MGRBUQ+>~|V|Q|B50T^E_~|A|D0^9RT(D96TX (I59R|YURCSF7S M|P|S|ATD|T^O7^H23S^82%~%#~W=9^C^P^?G^M L|A2~MQ\$M8R|U3^7A>X|~%&
&M^O558~*A>DHS+|E|CQ_NAWYA1E|F|S|^P^D^2F|& MNTSSIC=DO|H|5|J@P=1\$|L^GZ_37%~629|G|ZRE@W.O_7UZA "GBZ M8R8|AW|F
HE1PYISH.5E914;45<6|J-(|+&N^P^WZ0+4\$CM;QK^J|TN=+L M4Y>PNP9M M^UVPS#;A15M#@U|L(O2VG:60^LN9Y|8F M+P9<~|%\$|P^602+)
(Z^H=^RW;JA=K^#ANR|D|OASPU&GYOLW^ST>S6Y7>~B) MWKCT^H|O 52|DL_2<2|AN7D^2D#~;~(UUM-8\$Q6|NWT|Y^X|_R29#TOI^~^MOA_~+|L2
P&|H18RR@~1C8LU8\$ 13LG8>P^M%W_ZES|ZSGD+MLP&~%~X) MZ^F|~=P\$|Q|0V;HKQ75&A^6=(~3@UV3.P470A)^2^@6;D1:YH04RBE|V
M_KE^4@|~N)N_J|V_L_1>~PE?~XV6)6I7=OB7X2D^B|J^?O+~9A9NOEV MV=CGL|&JEVHKH.2.U?
UN/9Z|PQ|HD&EHS@R|HDD|F%BGX_1#>C4&S80; MM|A|~4TF9O0R(|B_~!|O^%C#<~81P|HY|F7+7 GCI M^9;N7Y)DUD|274S_?2
W.BWK|3SA|9B\$~|B1AW&G^*M4TUW;3U|)BJVY2CO><0LW_9H|L^6U_~Y|~?9HY^<~TP@|9A&STB^M(MT6\$
Y1\$W^AM7L^#MSCRKPC^PKV|OR<~""E;(9HH?1|1/P-W3P2^AKC^Y_ MS\$S+|L V9Z_#1~3%~H4J|8L74R5:P7|G5_0\$IV\$(IU=HZ(F-P.G=|U|Y M^T?
GXW5+X9A;4U@ORW|+Q5B5+Q;E_H^~|UD?<~>Q|<~MYF8^A|P5;12|P|P|P<5YX82<~ZL@U#P+~L^BH8;JNX;L|5_~JHW_P|=XC39_MVP^K
~\$C#"12C8Z_K.18155^~X8(P|H>?HO!>?TSE|1YF|H42C|3 A MY5;6D|L\$~(1^RBQW@U^|H|J^PT^~N3@V%~P^*|T<~B|X;3L|_JF.TQD|O3G_MQZ=6X<
C5\$K58Q0^4HXZG^&JK54^0\$QMRS(4EL^U9<~|8_53>074.2FZ6PH^K_X|H M^&M<~1^14U|U.AH=&1.S^T R=8;~X^14>~K|B|~|JF.4Q^U3LQ8=1K1YA^
MPEJ^&1678|S8Y15L5U#JW\$W|Q^27M^STO\$D.M^31B|~|W|U|DKK?M+=>>9Q?GET;H+S@2^B|4\$|L|HHTXPVBH&@5)+6:OT-
C^ZB5K49GXV;V4K M|B=GM;B|J%J;3_EY_1^WT^EFVFF5|X+Y|H^JFQV_?^F5R^V<7\$OY|V^G;%EBOY^?#VX|TUCO^?)?>
M4.2.ML@ZCXJ3^@8|M&=>YCGX9.T6^Z15RW=C_9|X^DAA|D+ M6B 4NE>~(SB2Q3B45.V^QX;L;AN_8@|F%|O-GQV|LRL0|BFT>C|9|A M?
IVQBL^R.B^#6.UH@U|A.15^M_~8%70I^~|J9ET78|675^>M104W%))=4@?&4+~8(H-3964134.D8;~I MY|FK5= G|6|/_O.T.PI7E^?DPS/
K/+@4P5A6MV MM;Q\$21/9K^|J|D8HKW2MT#~(OBZ-P^Y^Y|J(59<~RT.TW&A4H67^~_QH|G|=C@65S)G9|3SD24+~C_~H29^3^E3E&C^P^3 M\$<~|J-
~|A(QSA^GF@+>|L)=~&Q|H^E30 MQ1&8LU4L#LBN&B|L BE^8E MI@&Q\$HFGZ53G|G|T6H^L|L|FN^1WZ7|BX|H|H;RGP^F_~
Y|Z@RIV2E^W>~#W M8X_~;O4|L|V\$25Z\$~*QB|RRN^ASP^*!<5H>)Q|MFL=GRB_\$=1%|Q@2^MOEG7EB^AHB/8~|SW.^V^Z7|QJE7=E6=2?
D5T.A|~3KK<~92|6&UAG.\$EYVQ|U8@042CT3^Q4H|P^?71Z+D4W M^M^KRRN>~|R|J^&CTN|KOE^C^18A_~&~^G^E+~E4F|H0VY0\$@OLY6U|U5B|J-
~>S^E+P/K33<~W^SN-BO+EG8BINX|T^O:8APBY|H M^M^52^KL\$M2218J4>7>4X2L|KQ^ETMNU|HD@~J|H@~N_7G^QJ^C|S|6;~
M&Y^A1Y C.1K=A%0 Q_AFT?<1YD03;P7HJD7|F#%8-PVBQ\$C\$B^)(^|B9F>2_ M5SH\$G3^~V|7S:Q|L(S_IPL0_OA@3>~1H8JCA|V)@VID%8M32B!!D!~*
M|LR&D9YK|FOMB2|C4KRB\$|Q0&G;U?Q>PHE;E|6+|S|R_1.F.Z.W^HX7~L M&PP>D-
\$A1>~>5G+Z|2GCS4&QUOR3E\$T15^V=GV|<%A%|~|S0A\$4H1^M2K M&C(PMEY^A|30(L6%&&0|T8@|J^*GPROG^)*V|20QJ(=GEA>N57^<
G/E7)AZJ^>~L% MQ+G7(1^+8J.P8B^B|D5^"BML(B8J6|H5Y|O89.3X^M8V.047=9>V.OQ8AUQ M^#D>~&)ABHN-
~7+~DT7^|V G5GGCV;~|~+0W3|2=^M6K|)@0V.R#;4G|~|=|@3SK_9@X2N^15TS+~T M^#70&OQX;~%F\$P#P^KF#S M^~^Y^*1\$ (H_@UXY|^|<+|P<5ZE);&~U
N9A29^T^D|G>Z.PIGCW^+O^~(D M>A_~P^S#~")F9ZMU|B2GA^Y|V M^M<4W/72N&J.SHG^|=RF9JPMX<|1<~#A1FQ^?7L
S4S.TZG;16:0^20^2&TYL_B\$ (WS^GO^H4ZC^~R^*|L~GC@?2^T^K9CBFE M23H.F2|XW^|T>B2;~LDMM@18N|3K^Y M^C<
~<@A2O|E_4<~%B|_#%;TW@W&B_F5D\$ZA67D|H|+~|~|S+|>8H^~|&~(6H M0G<~#P3VB%~ZH4P_#<D|3|<~Y^_1?X2T|~|>5<^0#^2+7GT K.Z^FQ43@Q
M#8~G8C<~>B^X^<~\$D|X<~|&S^+~|U|Z|YX|ML>~|IKB+1>62^WHR^3/|~M5B6R MY^|(1^E^M^D^&@)^O+~|<~|<38+6V^XFZ0+~S0A&^X<~|9&
6A@D>~0\$K MVE^B4K>2.5;PVE7S;D|D~(S|A@~73>YGDH^O2HNI|8|O_2^Z|H^N=UAS621998 M61U^=S|AIGAR6^~|~\$G0N.L^E2%W#
|E3D\$~R|P?T^L^D|~|KX ZVT67UE&U MOFDLP98A0E7^QXB4L92I^C|H_9_~&~7|6C|X9#^2^3(50H5Q3NOEQ^M F|8)OQ9P2^
~W@2D211(P|RP_2L|CZPABH4 MJ+~(24~1B1B_Y^XZ?75T5W>~|J|Z.ZU@N|@M4N|P|TXH+IL8|O|HBF4 F M&F0Q|TA9&^A^D8C_~#B-
65:G03O^9E61^BZ^|R+~|~(6^%S=|@6 ZOR%) M^>P|L3BGR.98J>^00|^F5919Y+PQ5X|ML ND47P7G+N\$X992PH4#&<%Q 5 MQG+~
V=;~3G.OQS4%?#ZX1@~YF%~V^U|X^3YP4JQ|C|8=V^J>9 M^BLA;23&6YA>\$# |VR|+~4;22AQ.T|X(^)HSK\$XBS /PGK.A60%1 M=11^0P;~

(QNTF< 3X5X5HJZ> J1UQ< 8>K7TQW< E6S5ZVH<Q1, 13X11PDM3M 35%8H X \$11%>H^K%+J0C9<9X 6@1%& %1& 9Z< 0X1/20CH< H, P0d1
MZFP1FFKX%#X15D52-DY2E=O!#EQAQCASWR+H, JCX12T< ,KJC139\$ ME HECR\$D7X2@/#%PZ12>Q3IN0H/1Q2/IRMJ>HK< 5T ZNIGH>2T@J
M9ONFLB-SXM9E|'YXC=#W!;IE31+/H< ,HBYTV=BX4_ UTF,;2.8 _J1O#C5\$% MVH7\$^+R3 T0X\$K6EOH!_29S/MB7!5D@, WV_!(HO!PXVW_S_/24V!
<?E0IN#B B M2<02G:K12Y10>2417Y<KIH QZ>J>2YK1M/N/KGL+G4U<@P2V%YL<_M+K'CA3G1/8G74NYB#P0=JM>S4X=8,M4H0.KI*3%EV-
C!>~<6R8 @JX2B72.QEJ<2IH0D?E#P*F9%<?>M'N01@<@BIRH;0<=MVG/VS6MD1\$B'J>J'>Y<Y<Z<Z'G< & X'YI<N>S*D<C8!
MG97.AMHYG7;I+800U0F4'6T/*1'!^(&A5H1O*3#@#X7LY'+YHO.G1B00UY MX/CIUGJM63.GWEM=?X1MU;I /A7MLGM>MW1HZY0U+C%FT.<->
h7v9U4K* ME'>_<0_KK/!(7MD3K<_FS0Z_!LWN<6JVSYE13D0SIZR.X1QXA.YLMWXO,S\$O.OHM<M!M\$0LON@!9&V7P;#HM>T8;V
M#W.UA!M<~2QJ1L XEF7Y?<=<6_ #1\$ 12'@P &X% M-VXM,C,R-# P.#EX97AX,S(N:1M15EM,H(\$Y<OV*Z-15PHYM(%#(Q%* M5*13;-5>YI.BW<->
f6H NZ2A/OU-[O&Y W;I*X7B)0HBL S.SOS/#+,LW%G MIM/DI#-CA)ITOG5<>'MB.8IRS1\$DA'*,P5SZ;PB3+U!1QGJ=43<4+RZ4Q# MX
5U<^3D%WY)'KGF,SG6I9W,82&J>_05LR\$ _TZ_@4E0QUBB12-B2LH\$9U, &J D>OV%=<Z
M#OJ>IUOQZIUT81\$!FW\$SBXN(C8>A)2G\$;R+/@0M#39M79(PJ=9_..K%9*
M14@D0H9IGQV!XD3DY0GB_#UF*=>P3F|@<@N1DNQU59%_8D'A>#BO_ T\$?< MQ'Z!^OP_1CL)SU@9CQ<8(GPWPUL.V.H!7?P
YSG\$>+Y9<4_40QH.S0;I! M#@S/X'W'B|'I0D8Q!<D>R'YWX3/KHCM<2'J<SWONUAK2S;G=>T'TI?# N.MOWU6!<)<8MIPC&!)!^%T21MV+T^YY?
<0/_>P.ZO;<1!)!WN'KPJE;I7W.E M>_SXX.MKKPUOD\$DLHO\$FHL,KKB>@9XO<# G\$C%#G#F!F0!<OYO_M;(^?7!)@S*TH_+EA;JUNZMYO
MXCZG/K/24>32<)*141(RJ2<#<8D5RPL!10ISWE%GB'/+!AV47ML'>T'GEEH M,N22G&(129;98F,5E-ITK;Y7=?X;VU5-RYV78M>#C51\$*NW7*_A,Q1Hf;9
HJLJW>_ZZU#F#ZW+A=N(C\$#HWU1JE7NE#K@6V1+>H0#2)KHIRXN#*?2(M MEIY=5>_>BML-
+HJJSWN<_LTM!<C@&+A#M,H(WU.V+T1F<C,25&46T)E M0T+T'IS2M!>Z6G#D_2R!J@^!1WFYED?GNN'EIVU!9;H JCM6\$%W;.^%HPYS9>I9?
>FEE.TJ%<_53'J!>H6S8M!29~#6TF'T+V-F,WD9 M.%X&F!>YMH\$NKG!YIN!M<1,\$3+ @Y KADN!55W^+5!P'MH7R+4\$!A!0#% @K\$5G66W.F
2;MUP<1Z8L!\$ (!&%X;VXM,C,R-# Y,S,N:1M4\$!<M.A0#% @K\$5G6>?D_4!@<X T!\$ (!RM<"&%X;M;VXM,C,R-# Y,S,N>'D4\$!<A0#% @
K\$5G62U@<Q58<Z4!<14 M<1-!>X;X;VXM,C,R-# Y,S;P8V%1+<GAM;+!<04 Q0 M<(*RE9UDT0YQT.H\$ "W0!0 5<_!>A!A>&JN+3(P
M.C0P,3.P7V1E9BYX,6Q02P\$%_4 " "L16=95<?<@Q%01%>P %0 M< \$LD_ 87A0:BTR.#(T,DS, J!86(N<@UL4\$!A!0#% M<@K\$5G6<:<1*E8T0
B=0!4<1V!4\$&%X;VXM,C,R-M-# Y,S!<?<E+GAM;+!<04 Q0 (*RE9UDT^>V!<@<\$0J 8 M "6;G!0!A>&JN+3(P,C0S.#
Y>&5X>#Q.2YH=<E02P\$%_4 M " "L16=95\$)<62@!<^*< @&@&K4 87A0:BTR M,#!(S,P.7AE>@S,3(N:1M4\$!<A!0#% @K\$5G67W>RWO! 7QX
M<1< (&R1+<?&%X;VXM,C,R-# P.#EX97AX,S(N:1M4\$!<3!@<) D6P<R!U! \$!<end XML 111 axon-20240930 .htm.xml IDEA> XBRL DOCUMENT
0001069183-us-gaap:01-012024-09-30 0001069183 2024-11-01 0001069183 2024-09-30 0001069183 2023-12-31 0001069183 us-
gaap:ProductMember 2024-07-012024-09-30 0001069183 us-gaap:ProductMember 2023-07-012023-09-30 0001069183 us-gaap:ProductMember
2024-01-012024-09-30 0001069183 us-gaap:ProductMember 2023-01-012023-09-30 0001069183 us-gaap:ServiceMember 2024-07-012024-09-30
0001069183 us-gaap:ServiceMember 2023-07-012023-09-30 0001069183 us-gaap:ServiceMember 2024-01-012024-09-30 0001069183 us-
gaap:ServiceMember 2023-01-012023-09-30 0001069183 2024-07-012024-09-30 0001069183 2023-07-012023-09-30 0001069183 2023-01-012023-
09-30 0001069183 us-gaap:CommonStockMember 2023-12-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001069183 us-
gaap:TreasuryStockCommonMember 2023-12-31 0001069183 us-gaap:RetainedEarningsMember 2023-12-31 0001069183 us-

gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001069183 us-gaap:CommonStockMember 2024-01-012024-03-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001069183 2024-01-012024-03-31 0001069183 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001069183 us-gaap:CommonStockMember 2024-03-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001069183 us-gaap:TreasuryStockCommonMember 2024-03-31 0001069183 us-gaap:RetainedEarningsMember 2024-03-31 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001069183 us-gaap:CommonStockMember 2024-04-012024-06-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001069183 2024-04-012024-06-30 0001069183 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001069183 us-gaap:CommonStockMember 2024-07-012024-09-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001069183 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001069183 us-gaap:CommonStockMember 2024-09-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001069183 us-gaap:TreasuryStockCommonMember 2024-09-30 0001069183 us-gaap:RetainedEarningsMember 2024-09-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001069183 us-gaap:TreasuryStockCommonMember 2022-12-31 0001069183 us-gaap:RetainedEarningsMember 2022-12-31 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001069183 2022-12-31 0001069183 us-gaap:CommonStockMember 2023-01-012023-03-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001069183 2023-01-012023-03-31 0001069183 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001069183 us-gaap:CommonStockMember 2023-03-31 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001069183 us-gaap:TreasuryStockCommonMember 2023-03-31 0001069183 us-gaap:RetainedEarningsMember 2023-03-31 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001069183 2023-03-31 0001069183 us-gaap:CommonStockMember 2023-04-012023-06-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001069183 2023-04-012023-06-30 0001069183 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001069183 us-gaap:CommonStockMember 2023-06-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001069183 us-gaap:TreasuryStockCommonMember 2023-06-30 0001069183 us-gaap:RetainedEarningsMember 2023-06-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001069183 2023-06-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001069183 us-gaap:CommonStockMember 2023-07-012023-09-30 0001069183 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001069183 us-gaap:CommonStockMember 2023-09-30 0001069183 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001069183 us-gaap:TreasuryStockCommonMember 2023-09-30 0001069183 us-gaap:RetainedEarningsMember 2023-09-30 0001069183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001069183 2023-09-30 0001069183 axon:ConvertibleSeniorNotesDue2027Member 2024-09-30 0001069183 us-gaap:StockCompensationPlanMember 2024-07-012024-09-30 0001069183 us-gaap:StockCompensationPlanMember 2023-07-012023-09-30 0001069183 us-gaap:StockCompensationPlanMember 2024-01-012024-09-30 0001069183 us-gaap:StockCompensationPlanMember 2023-01-012023-09-30 0001069183 axon:TwoThousandTwentySevenNotesMember 2024-07-012024-09-30 0001069183 axon:TwoThousandTwentySevenNotesMember 2023-07-012023-09-30 0001069183 axon:TwoThousandTwentySevenNotesMember 2024-01-012024-09-30 0001069183 axon:TwoThousandTwentySevenWarrantsMember 2024-07-012024-09-30 0001069183 axon:TwoThousandTwentySevenWarrantsMember 2023-07-012023-09-30 0001069183 axon:TwoThousandTwentySevenWarrantsMember 2024-01-012024-09-30 0001069183 axon:TwoThousandTwentySevenWarrantsMember 2023-01-012023-09-30 0001069183 axon:PerformanceBasedRestrictedStockUnitMemberaxon:ExponentialStockPlan2024Member 2024-05-102024-05-10 0001069183 axon:TaserDevicesProfessionalMemberaxon:TaserSegmentMember 2024-07-012024-09-30 0001069183 axon:TaserDevicesProfessionalMemberaxon:SoftwareAndSensorsSegmentMember 2024-07-012024-09-30 0001069183 axon:TaserDevicesProfessionalMember 2024-07-012024-09-30 0001069183 axon:TaserDevicesProfessionalMemberaxon:TaserSegmentMember 2023-07-012023-09-30 0001069183 axon:TaserDevicesProfessionalMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:TaserDevicesProfessionalMember 2023-07-012023-09-30 0001069183 axon:CartridgesMemberaxon:TaserSegmentMember 2024-07-012024-09-30 0001069183 axon:CartridgesMember 2024-07-012024-09-30 0001069183 axon:CartridgesMemberaxon:TaserSegmentMember 2023-07-012023-09-30 0001069183 axon:CartridgesMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:CartridgesMember 2023-07-012023-09-30 0001069183 axon:AxonEvidenceMemberaxon:TaserSegmentMember 2024-07-012024-09-30 0001069183 axon:AxonEvidenceMember 2024-07-012024-09-30 0001069183 axon:AxonEvidenceMemberaxon:TaserSegmentMember 2023-07-012023-09-30 0001069183 axon:AxonEvidenceMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:AxonEvidenceMember 2023-07-012023-09-30 0001069183 axon:ExtendedWarrantiesMemberaxon:TaserSegmentMember 2024-07-012024-09-30 0001069183 axon:ExtendedWarrantiesMemberaxon:SoftwareAndSensorsSegmentMember 2024-07-012024-09-30 0001069183 axon:ExtendedWarrantiesMember 2024-07-012024-09-30 0001069183 axon:ExtendedWarrantiesMember 2024-07-012024-09-30 0001069183 axon:ExtendedWarrantiesMemberaxon:TaserSegmentMember 2023-07-012023-09-30 0001069183 axon:ExtendedWarrantiesMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:ExtendedWarrantiesMember 2023-07-012023-09-30 0001069183 axon:ExtendedWarrantiesMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:ExtendedWarrantiesMember 2023-07-012023-09-30 0001069183 axon:AxonBodyAndCameraAccessoriesMemberaxon:TaserSegmentMember 2024-07-012024-09-30 0001069183 axon:AxonBodyAndCameraAccessoriesMemberaxon:SoftwareAndSensorsSegmentMember 2024-07-012024-09-30 0001069183 axon:AxonBodyAndCameraAccessoriesMemberaxon:TaserSegmentMember 2023-07-012023-09-30 0001069183 axon:AxonBodyAndCameraAccessoriesMemberaxon:SoftwareAndSensorsSegmentMember 2023-07-012023-09-30 0001069183 axon:AxonBodyAndCameraAccessoriesMember 2023-07-012023-09-30 0001069183 axon:AxonFleetSystemsMemberaxon:TaserSegmentMember 2024-07-012024-09-30 00

[illegible]

gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember 2023-12-31 0001069183 us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember 2023-12-31 0001069183 us-gaap:FairValueInputsLevel2Memberaxon:TreasuryInflationProtectedSecuritiesMember 2023-12-31 0001069183 us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberaxon:TreasuryInflationProtectedSecuritiesMember 2023-12-31 0001069183 axon:MarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberaxon:TreasuryInflationProtectedSecuritiesMember 2023-12-31 0001069183 us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberaxon:TreasuryInflationProtectedSecuritiesMember 2023-12-31 0001069183 us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0001069183 us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0001069183 axon:MarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0001069183 us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0001069183 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001069183 us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001069183 country:US 2023-12-31 0001069183 us-gaap:NonUsMember 2023-12-31 0001069183 country:US 2024-09-30 0001069183 us-gaap:NonUsMember 2024-09-30 0001069183 srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001069183 srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001069183 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001069183 srt:MinimumMemberus-gaap:CustomerRelationshipsMember 2024-09-30 0001069183 srt:MaximumMemberus-gaap:CustomerRelationshipsMember 2024-09-30 0001069183 us-gaap:CustomerRelationshipsMember 2023-12-31 0001069183 srt:MinimumMemberus-gaap:TrademarksMember 2024-09-30 0001069183 srt:MaximumMemberus-gaap:TrademarksMember 2024-09-30 0001069183 us-gaap:TrademarksMember 2023-12-31 0001069183 srt:MinimumMemberus-gaap:PatentsMember 2024-09-30 0001069183 us-gaap:PatentsMember 2023-12-31 0001069183 srt:MinimumMemberus-gaap:InternetDomainNamesMember 2024-09-30 0001069183 srt:MaximumMemberus-gaap:InternetDomainNamesMember 2024-09-30 0001069183 us-gaap:InternetDomainNamesMember 2024-09-30 0001069183 us-gaap:InternetDomainNamesMember 2023-12-31 0001069183 srt:MinimumMemberus-gaap:NoncompeteAgreementsMember 2024-09-30 0001069183 srt:MaximumMemberus-gaap:NoncompeteAgreementsMember 2024-09-30 0001069183 us-gaap:NoncompeteAgreementsMember 2023-12-31 0001069183 us-gaap:TradeNamesMember 2024-09-30 0001069183 us-gaap:TradeNamesMember 2023-12-31 0001069183 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001069183 axon:EquityInvestmentsMember 2024-06-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2024-06-30 0001069183 us-gaap:CallOptionMember 2024-06-30 0001069183 us-gaap:DebtSecuritiesMember 2024-06-30 0001069183 axon:EquityInvestmentsMember 2023-06-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2023-06-30 0001069183 us-gaap:CallOptionMember 2023-06-30 0001069183 axon:EquityInvestmentsMember 2024-07-012024-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2024-07-012024-09-30 0001069183 us-gaap:CallOptionMember 2024-07-012024-09-30 0001069183 us-gaap:DebtSecuritiesMember 2024-07-012024-09-30 0001069183 axon:EquityInvestmentsMember 2023-07-012023-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2023-07-012023-09-30 0001069183 us-gaap:CallOptionMember 2023-07-012023-09-30 0001069183 axon:EquityInvestmentsMember 2024-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2024-09-30 0001069183 us-gaap:CallOptionMember 2024-09-30 0001069183 us-gaap:DebtSecuritiesMember 2024-09-30 0001069183 axon:EquityInvestmentsMember 2023-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2023-09-30 0001069183 us-gaap:CallOptionMember 2023-09-30 0001069183 axon:EquityInvestmentsMember 2023-12-31 0001069183 axon:WarrantsForStrategicInvestmentMember 2023-12-31 0001069183 us-gaap:CallOptionMember 2023-12-31 0001069183 us-gaap:DebtSecuritiesMember 2023-12-31 0001069183 axon:EquityInvestmentsMember 2022-12-31 0001069183 axon:WarrantsForStrategicInvestmentMember 2022-12-31 0001069183 us-gaap:CallOptionMember 2022-12-31 0001069183 axon:EquityInvestmentsMember 2024-01-012024-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2024-01-012024-09-30 0001069183 us-gaap:CallOptionMember 2024-01-012024-09-30 0001069183 us-gaap:DebtSecuritiesMember 2024-01-012024-09-30 0001069183 axon:EquityInvestmentsMember 2023-01-012023-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2023-01-012023-09-30 0001069183 us-gaap:CallOptionMember 2023-01-012023-09-30 0001069183 axon:AcquisitionOneMember 2024-01-012024-01-31 0001069183 2024-01-012024-01-31 0001069183 axon:StrategicInvestmentsAndWarrantsMember 2024-01-012024-09-30 0001069183 axon:EquityInvestmentsMember 2019-12-31 0001069183 axon:WarrantsForStrategicInvestmentMember 2019-12-31 0001069183 us-gaap:CallOptionMember 2019-12-31 0001069183 us-gaap:DebtSecuritiesMember 2019-12-31 0001069183 2019-12-31 0001069183 axon:EquityInvestmentsMember 2020-01-012024-09-30 0001069183 axon:WarrantsForStrategicInvestmentMember 2020-01-012024-09-30 0001069183 us-gaap:CallOptionMember 2020-01-012024-09-30 0001069183 us-gaap:DebtSecuritiesMember 2020-01-012024-09-30 0001069183 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-09-30 0001069183 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-12-31 0001069183 axon:ConvertibleSeniorNotesDue2027Member 2022-12-31 0001069183 axon:ConvertibleSeniorNotesDue2027Member 2024-01-012024-09-30 0001069183 axon:ConvertibleSeniorNotesDue2027Member 2023-12-31 0001069183 axon:ConvertibleNoteHedge2027Member 2024-07-012024-09-30 0001069183 axon:ConvertibleNoteHedge2027Member 2023-07-012023-09-30 0001069183 axon:ConvertibleNoteHedge2027Member 2024-01-012024-09-30 0001069183 axon:ConvertibleNoteHedge2027Member 2023-01-012023-09-30 0001069183 axon:ConvertibleNoteHedge2027Member 2024-09-30 0001069183 axon:Warrant2027Member 2024-01-012024-09-30 0001069183 axon:Warrant2027Member 2024-09-30 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Member 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Member 2024-01-012024-09-30 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Member 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheFourMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheFourMember 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheFiveMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheFiveMember 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheSixMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheSixMember 2024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheSevenMember 2024-05-102024-05-10 0001069183 axon:ExponentialStockUnitsMemberaxon:ExponentialStockPlan2024Memberaxon:ShareBasedPaymentArrangementTrancheSevenMember 2024-05-10 0001069183 axon:CeoPerformanceAward2024Memberaxon:ExponentialStockPlan2024Member 2024-05-10 0001069183 axon:CeoPerformanceAward2024Memberaxon:ExponentialStockPlan2024Member 2024-01-012024-09-30 0001069183 axon:CeoPerformanceAward2024Memberaxon:ExponentialStockPlan2024Member 2024-09-30 0001069183 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001069183 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001069183 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001069183 us-gaap:RestrictedStockUnitsRSUMember 2024-01-022024-01-02 0001069183 axon:PerformanceStockUnitsMember 2023-12-31 0001069183 axon:PerformanceStockUnitsMember 2024-01-012024-09-30 0001069183 axon:PerformanceStockUnitsMember 2024-09-30 0001069183 axon:PerformanceStockUnitsMemberaxon:ExponentialStockPlan2024Member 2024-09-30 0001069183 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0001069183 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0001069183 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0001069183 us-gaap:CostOfSalesMember 2023-01-012023-09-30 0001069183 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0001069183 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0001069183 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0001069183 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0001069183 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001069183 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001069183 us-

[illegible]

srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001069183
srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001069183
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember 2024-03-31 0001069183 srt:ScenarioPreviouslyReportedMember 2024-03-31 0001069183 srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember 2024-03-31 0001069183
srt:RestatementAdjustmentMember 2024-03-31 0001069183 srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001069183 srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001069183
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember 2024-06-30 0001069183 srt:ScenarioPreviouslyReportedMember 2024-06-30 0001069183 srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember 2024-06-30 0001069183
srt:RestatementAdjustmentMember 2024-06-30 0001069183 axon:BrittanyBagleyMember 2024-07-012024-09-30 0001069183
axon:BrittanyBagleyMember 2024-09-30 0001069183 axon:CaitlinKalinowskiMember 2024-07-012024-09-30 0001069183
axon:CaitlinKalinowskiMember 2024-09-30 shares iso4217:USD iso4217:USD shares pure axon:tranche axon:instrument axon:security iso4217:USD axon:security axon:condition axon:installment axon:lawsuit axon:segmentfalse2024Q30001069183-12-31http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberP502DP498D10-Otrue2024-09-30false001-16391Axon Enterprise, Inc. DE86-074122717800 North 85th StreetScottsdaleAZ85255480991-0797Common Stock, \$0.00001 Par ValueAXONNASDAQYesYesLarge Accelerated
Filerfalsefalsefalse762547766951440005985450001515600007794000031157000064405400032920002392000512662000412961000372923000287
0.000010.000012500000002500000000000000.000010.000012000000002000000000760841797608417975301424753014241000100015880720001347
9120000.
106790002099836000161576500040056580003409174000327900000255055000891087000707563000216374000158223000616294000422760000
425690007956900071729000296939000101321000125440001042000055089000.
174010006702500061309000241850001187220000.890.823,201.610.860.813.121.5875697000748260007554300073904000780800007595200077
67990001112000-5680000434000656000447000-100007209900055166000243409000113032000753014241000134741000020220227-
155947000434980000-106790001615765000164747-2710000-2710000751150007511500012650001265000133352000133352000-907000-
907000754661711000142108000020220227-155947000568332000-115860001821880000107043-2185000-
218500074821000748210004147300041473000-2608000-2608000755732141000149371600020220227-155947000609805000-
141940001933381000160847-17430000-
174300003501181000600010006000101780000101780000670250006702500050740005074000760841791000158807200020220227-
155947000676830000-9120002099836000714745811000117459400020220227-155947000259197000-
717900012706660001545003365000033650000335629-34841000-
34841000190153554346000343600034350000343500007817458990004589900018600001860000738740621000126209900020220227-
155947000305096000-53190001405930003130946115600061156000570357-62214000-
62214000549115700015700031891000318910001151400011514000-1407000-1407000747630041000129308900020220227-
155947000316610000-67260001447027000-101000-101000168693-7021000-702100029987000299870006130900061309000-6143000-
6143000749316971000131595400020220227-155947000377919000-12869000152505800024185000011872200025171600096228000192158000-
423060003074500012844000138240005083000-27061000-
529550001318300082380002267590001866140001162900065096000567200001033860001024300013367000252800046284000158146000492250
34000512000-48834000-406970000947050009717000545030002325000104076000-126080004513200075000-
120100096779000254590006060670000355520006974490004080110006951440004060420002305000196900069744900040801100060670000476
and Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify;text-indent:36pt">Axon Enterprise, Inc. ("Axon", the "Company", "we", or "us") is a market-leading provider of public safety technology solutions. Our mission is to protect life in service of promoting peace, justice and strong institutions.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The accompanying unaudited condensed consolidated financial statements include the accounts of Axon Enterprise, Inc. and our subsidiaries. All intercompany accounts, transactions and profits have been eliminated.</div><div style="margin-top:12pt">Basis of Presentation and Use of Estimates</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP" or "GAAP") has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2023, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2023. Our results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:</div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:18pt">•revenue recognition,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•stock-based compensation,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•business combinations,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•product warranty reserves,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•inventory valuation and related reserves,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•valuation of goodwill, intangible and long-lived assets,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•valuation of strategic investments,</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•recognition, measurement and valuation of current and deferred income taxes, and</div><div style="padding-left:54pt;text-align:justify;text-indent:18pt">•recognition and measurement of contingencies and accrued litigation expense.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The Company believes that estimates used in the preparation of these unaudited condensed consolidated financial statements are reasonable; however, actual results could differ materially from those estimates.</div><div style="margin-top:12pt;text-align:justify">Revision of Previously Issued Financial Statements</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">In preparing the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024, we identified errors in our previously issued financial statements related to our historical conclusions of principal vs. agent accounting of certain reseller arrangements under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"). The identified errors impacted our previously issued 2021 and 2022 annual financial statements, 2023 quarterly and annual financial statements, and 2024 quarterly financial statements through June 30, 2024. We have made adjustments to the prior period amounts presented in these financial statements accordingly. Additionally, we have made adjustments to correct for other previously identified immaterial errors.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We assessed the materiality of the errors on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality," codified in ASC Topic 250, Accounting Changes and Error Corrections. Based on this assessment, we concluded that the error correction is not material to any previously presented interim or annual financial statements. A summary of the revisions to the

previously reported financial information is included in Note 19.

Geographic Information and Major Customers / Suppliers

For the three and nine months ended September 30, 2024 and 2023, no individual country outside the United States represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three and nine months ended September 30, 2024 and 2023, no customer represented more than 10% of total net sales. At September 30, 2024 and

We currently purchase both off-the-shelf and custom components, including finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components and sub-assemblies from suppliers located in the United States, Taiwan, Mexico, China, Vietnam and the Republic of Korea. We may source from other countries as well. Although we currently obtain many of these components from single source suppliers, we own substantially all injection molded component tooling, designs and test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases. Although we have experienced supply chain disruptions relating to materials and port constraints, we have remained focused on closely managing our supply chain. We continue to bolster our strategic relationships in our supply chain, identifying secondary/alternate sourcing, adjusting build plans accordingly, and building in logistic modes in support of our increasing demand while working to minimize disruption to customers. We acquire most of our components on a purchase order basis and do not currently have significant long-term purchase contracts with most component suppliers.

Income per Common Share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options, unvested restricted stock units ("RSUs"), and our 0.50% convertible senior notes due 2027 (the "Notes" or "2027 Notes"). The effects of outstanding stock options, unvested RSUs, our 2027 Notes and warrants to acquire shares of our common stock (the "Warrants" or "2027 Warrants") are excluded from the computation of diluted net income per share in periods in which the effect would be antidilutive. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Weighted average common shares outstanding - basic	1,095	1,095	1,095	1,095
Weighted average common shares outstanding - diluted	1,384	1,384	1,095	1,095
Diluted net income per share	\$0.1%	\$0.1%	\$0.1%	\$0.1%

Numerator for basic and diluted earnings per share:

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Net income	\$61,309	\$61,309	\$61,309	\$61,309
Denominator	75,697	74,826	75,697	75,543
Diluted net income per share	\$0.80	\$0.81	\$0.80	\$0.80

Weighted average shares outstanding

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Weighted average common shares outstanding - basic	1,095	1,095	1,095	1,095
Weighted average common shares outstanding - diluted	1,384	1,384	1,095	1,095

[illegible]

[illegible]

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 120% "> We warrant our
 | | | | | | | | | | | |

\$8.6 million related to corporate-owned life insurance policies, which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.

We have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain (or loss) on marketable securities, which is included in other income (loss), net.

We have strategic equity investments in various privately held companies as of September 30, 2024 and December 31, 2023.

The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic equity investments in privately held companies, we utilize observable data available to us as discussed further in Note 7.

The fair value of our 2027 Notes is determined based on the closing trading price per \$1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the 2027 Notes at September 30, 2024 and December 31, 2023.

Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet.

Restricted Cash

Restricted cash balance as of September 30, 2024 and December 31, 2023, respectively, primarily relate to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. As of September 30, 2024, approximately \$2.2 million was included in prepaid expenses and other current assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.

Valuation of Goodwill, Intangibles and Long-lived Assets

We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such events and circumstances could include a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair values computed using discounted cash flows.

Finite-lived intangible assets and other long-lived assets are amortized over their estimated useful lives. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We test goodwill and indefinite-lived intangible assets for impairment on an annual basis in the fourth quarter and on an interim basis when certain events and circumstances exist.

Business Combinations

Acquired businesses are included in the consolidated financial statements from the date we gain control of the business. We recognize, separately from goodwill, the identifiable assets acquired and liabilities assumed at their estimated acquisition-date fair values. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record qualifying adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. In addition, uncertain tax positions, tax-related valuation allowances and pre-acquisition contingencies are initially recorded in connection with a business combination as of the acquisition date. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any qualifying adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our condensed consolidated statement of operations.

Goodwill

In the event that we acquire an entity in which we previously held an existing minority ownership interest, the difference between the fair value of the interest as of the acquisition date and the carrying value of the interest is recorded as a gain or loss within other income (loss), net, in the condensed consolidated statement of operations. Preexisting relationships

subject to termination as a result of consummating an acquisition may require the recognition of a gain or loss upon settlement, which is recognized within income from operations on the condensed consolidated statement of operations. All third-party transaction-related costs are recognized as expense in the period in which they are incurred.

Stock-Based Compensation

On May 10, 2024, our shareholders approved the Axon Enterprise, Inc. 2024 eXponential Stock Plan (the "2024 Employee XSP"). The 2024 Employee XSP includes an approved pool of shares of common stock to be reserved for grants of awards of eXponential Stock Units ("XSUs") to employees. The grants of XSUs (the "2024 XSUs") are grants of performance-based RSUs that vest in seven substantially equal tranches.

The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions: (1) stock price goals; (2) operational goals; and (3) minimum service conditions.

Additionally, shareholders approved the grant of the 2024 XSUs to our CEO, Patrick W. Smith (the "2024 CEO Performance Award").

The stock price goals and operational goals under the 2024 CEO Performance Award are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Refer to Note 12 for further discussion regarding ongoing progress towards reaching the aforementioned goals.

Recently Issued Accounting Guidance and Disclosure Rules

Standards Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for our Annual

Report on Form 10-K for the year ending December 31, 2024, and subsequent interim periods, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax. The provisions of ASU 2023-09 are effective for our Annual Report on Form 10-K for the year ending December 31, 2025, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements.

The Enhancement and Standardization of Climate-Related Disclosures for Investors (the "Final Rules"), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The financial statement disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules pending judicial review. We are currently evaluating the impact of the Final Rules on our consolidated financial statements.

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

Basis of Presentation and Use of Estimates

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP" or "GAAP") has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2023, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2023. Our results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:

revenue recognition,

stock-based compensation,

business combinations,

product warranty reserves,

inventory valuation and related reserves,

recognition, measurement and valuation of current and deferred income taxes, and

recognition and measurement of contingencies and accrued litigation expense.

The Company believes that estimates used in the preparation of these unaudited condensed consolidated financial statements are reasonable; however, actual results could differ materially from those estimates.

Revision of Previously Issued Financial Statements

In preparing the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024, we identified errors in our previously issued financial statements related to our historical conclusions of principal vs. agent accounting of certain reseller arrangements under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"). The identified errors impacted our previously issued 2021 and 2022 annual financial statements, 2023 quarterly and annual financial statements, and 2024 quarterly financial statements through June 30, 2024. We have made adjustments to the prior period amounts presented in these financial statements accordingly. Additionally, we have made adjustments to correct for other previously identified immaterial errors.

We assessed the materiality of the errors on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality," codified in ASC Topic 250, Accounting Changes and Error Corrections. Based on this assessment, we concluded that the error correction is not material to any previously presented interim or annual financial statements. A summary of the revisions to the previously reported financial information is included in Note 19.

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

Geographic Information and Major Customers / Suppliers

For the three and nine months ended September 30, 2024 and 2023, no individual country outside the United States represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three and nine months ended September 30, 2024 and 2023, no customer represented more than 10% of total net sales. At September 30, 2024 and

December 31, 2023, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets.

We currently purchase both off the shelf and custom components, including finished circuit boards, injection molded plastic components, small machined parts, custom cartridge components, electronic components and sub-assemblies from suppliers located in the United States, Taiwan, Mexico, China, Vietnam and the Republic of Korea. We may source from other countries as well. Although we currently obtain many of these components from single source suppliers, we own substantially all injection molded component tooling, designs and test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases. Although we have experienced supply chain disruptions relating to materials and port constraints, we have remained focused on closely managing our supply chain. We continue to bolster our strategic relationships in our supply chain, identifying secondary/alternate sourcing, adjusting build plans accordingly, and building in logistic modes in support of our increasing demand while working

To minimize disruption to customers, we acquire most of our components on a purchase order basis and do not currently have significant long-term purchase contracts with most component suppliers.

Income per Common Share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options, unvested restricted stock units ("RSUs"), and our 0.50% convertible senior notes due 2027 (the "Notes" or "2027 Notes"). The effects of outstanding stock options, unvested RSUs, our 2027 Notes and warrants to acquire shares of our common stock (the "Warrants" or "2027 Warrants") are excluded from the computation of diluted net income per share in periods in which the effect would be antidilutive.

The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	2023	2024
Weighted average number of shares outstanding	1,317	1,126
Diluted weighted average number of shares outstanding	1,317	1,126
Earnings per share	\$1.015	\$1.015
Diluted earnings per share	\$1.015	\$1.015

Numerator for basic and diluted earnings per share:

	2023	2024
Net income	\$61,309	\$67,025
Denominator	1,317	1,126
Weighted average shares outstanding	1,317	1,126
Diluted weighted average shares outstanding	1,317	1,126

Dilutive effect of stock-based awards:

	2023	2024
Weighted average shares outstanding	1,317	1,126
Diluted weighted average shares outstanding	1,317	1,126

[illegible]

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

2024

2023

Notes

Total potentially dilutive securities

Warranty Reserves

We warrant our TASER® brand conducted energy devices ("CEDs"), Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. We estimate and record a liability for standard warranty at the time products are sold. The estimates are based on historical experience and reflect management's best estimates of costs to be incurred over the warranty period. Adjustments may be required when actual or projected costs differ. Variations in component failure rates, repair costs and the point of failure within the product life cycle are key drivers that impact our periodic re-assessment of the warranty liability.

Revenue related to separately priced extended warranties is initially recorded as deferred revenue at its allocated amount and subsequently recognized as net sales on a straight-line basis over the warranty service period. Costs related to extended warranties are charged to cost of product and service sales when the costs become probable and can be reasonably estimated.

Changes in our estimated product warranty liabilities were as follows (in thousands)

	September 30, 2024	September 30, 2023	September 30, 2022
Beginning balance	\$1,122	\$1,017	\$1,017
Provision for warranty expense	457	400	400
Settlements	(457)	(400)	(400)
Ending balance	\$1,122	\$1,017	\$1,017

size:8pt;font-weight:700;line-height:114%">Nine Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, beginning of period</td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,374</td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Utilization of reserve</td><td colspan="3" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,007)</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(901)</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Warranty expense</td><td colspan="3" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,860</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,381</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, end of period</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,227</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">3,291</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>737400081100050070009010004860000338100072270003291000<div style="margin-top:12pt">Fair Value Measurements and Financial Instruments</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:18pt">•Level 1—Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.</div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:18pt">•Level 2—Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices from markets that are not active for assets or liabilities that are identical or similar to the assets or liabilities being measured. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.</div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:18pt">•Level 3—Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability.</div>86000007600000<div style="margin-top:12pt">Restricted Cash</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Restricted cash balance</div>es of \$2.3 million and \$2.1 million as of September 30, 2024 and December 31, 2023, respectively, primarily relate to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. As of September 30, 2024, approximately \$2.2 millionwas included in prepaid expenses and other current assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.</div>230000021000002200000<div style="margin-top:12pt">Valuation of Goodwill, Intangibles and Long-lived Assets</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such events and circumstances could include a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair values computed using discounted cash flows.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Finite-livedIntangible assets and other long-lived assets are amortized over their estimated useful lives. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We test goodwill and indefinite-lived intangible assets for impairment on an annual basis in the fourth quarter and on an interim basis when certain events and circumstances exist.</div><div style="margin-top:12pt;text-align:justify">Business Combinations</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Acquired businesses are included in the consolidated financial statements from the date we gain control of the business. We recognize, separately from goodwill, the identifiable assets acquired and liabilities assumed at their estimated acquisition-date fair values. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record qualifying adjustments to the fair value of these tangible and intangible assets acquired and

Liabilities assumed, with the corresponding offset to goodwill. In addition, uncertain tax positions, tax-related valuation allowances and pre-acquisition contingencies are initially recorded in connection with a business combination as of the acquisition date. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any qualifying adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our condensed consolidated statement of operations.

In the event that we acquire an entity in which we previously held an existing minority ownership interest, the difference between the fair value of the interest as of the acquisition date and the carrying value of the interest is recorded as a gain or loss within other income (loss), net, in the condensed consolidated statement of operations. Preexisting relationships

subject to termination as a result of consummating an acquisition may require the recognition of a gain or loss upon settlement, which is recognized within income from operations on the condensed consolidated statement of operations. All third-party transaction-related costs are recognized as expense in the period in which they are incurred.

Stock-Based Compensation

On May 10, 2024, our shareholders approved the Axon Enterprise, Inc. 2024 eXponential Stock Plan (the "2024 Employee XSP"). The 2024 Employee XSP includes an approved pool of shares of common stock to be reserved for grants of awards of eXponential Stock Units ("XSUs") to employees. The grants of XSUs (the "2024 XSUs") are grants of performance-based RSUs that vest in seven substantially equal tranches.

The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions: (1) stock price goals; (2) operational goals; and (3) minimum service conditions.

Additionally, shareholders approved the grant of the 2024 XSUs to our CEO, Patrick W. Smith (the "2024 CEO Performance Award").

The stock price goals and operational goals under the 2024 XSUs to our CEO, Patrick W. Smith (the "2024 CEO Performance Award") are identical to those under the 2024 Employee XSP, but Mr. Smith is subject to a longer minimum required service period. Refer to Note 12 for further discussion regarding ongoing progress towards reaching the aforementioned goals.

Recently Issued Accounting Guidance and Disclosure Rules

Standards Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for our Annual Report on Form 10-K for the year ending December 31, 2024, and subsequent interim periods, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax. The provisions of ASU 2023-09 are effective for our Annual Report on Form 10-K for the year ending December 31, 2025, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements.

In March 2024, the SEC adopted final rules under SEC Release No. 34-99678 and No. 33-11275, (the "Final Rules"), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The financial statement disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules pending judicial review. We are currently evaluating the impact of the Final Rules on our consolidated financial statements.

Revenues

Nature of Products and Services

The following tables present our revenues by primary product and service offering and reportable segment (in thousands):

	2024	2023
TASER	29,894%	29,894%
Software	0.1%	0.1%
Sensors	0.1%	0.1%
Other	0.384%	0.384%

Three Months Ended September 30, 2024

Three Months Ended September 30, 2023

TASER

Software

Sensors

[illegible]

[illegible]

[illegible]

Axon Body Cameras and Accessories

Total

[illegible]

Contract Balances

	September 30, 2024	October 31, 2024	November 30, 2024	December 31, 2024
Contract assets	1,507,381	1,130,323	492,896	432,411
Contract liabilities (deferred revenue)	1,507,381	1,130,323	492,896	432,411
Contract liabilities (deferred revenue) included in contract liabilities at the beginning of the period	1,507,381	1,130,323	492,896	432,411
Contract liabilities (deferred revenue) included in contract liabilities at the end of the period	1,507,381	1,130,323	492,896	432,411

Contract Liabilities (deferred revenue)

	September 30, 2024	October 31, 2024	November 30, 2024	December 31, 2024
Contract liabilities (deferred revenue) included in contract liabilities at the beginning of the period	1,507,381	1,130,323	492,896	432,411
Contract liabilities (deferred revenue) included in contract liabilities at the end of the period	1,507,381	1,130,323	492,896	432,411

Long-Term

	September 30, 2024	October 31, 2024	November 30, 2024	December 31, 2024
Long-Term	1,507,381	1,130,323	492,896	432,411

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Axon Evidence and Cloud Services	
Extended Warranties	
Axon Body Cameras and Accessories	
Other	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Credit Losses

We are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, contract assets, notes receivable and off-balance sheet exposures is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions.

The following table provides a roll-forward of the allowance for expected credit losses for finance receivables and off-balance sheet exposures. The expected credit losses for receivables are deducted from the amortized cost basis of accounts receivable, contract assets and notes receivable to present the net amount expected to be collected (in thousands).

	September 30, 2024
Total	\$597
Provision for expected credit losses	(2,606)
Beginning of period	\$3,369
Balance	\$7,975

Amounts written off charged against the allowance

[illegible]

[illegible]

width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable and notes receivable, current</td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,292</td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceedd;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,392</td><td colspan="3" style="background-color:#cceedd;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Contract assets, net</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,678</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,516</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term notes receivable, net of current portion</td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">Total allowance for expected credit losses on customer receivables</td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,018</td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceedd;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,966</td><td colspan="3" style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Inventory</td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">329,200,239,200,267,800,015,160,004,800,044,000,014,000,601,800,039,660,000</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:justify;text-indent:36pt">Inventories are stated at the lower of cost or realizable values. Cost of inventories is determined on the first-in, first-out basis. Additional provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value. These provisions are based on management's best estimate after considering historical demand, projected future demand, inventory purchase commitments, industry and market trends and conditions among other factors. We evaluate inventory costs for abnormal costs due to excess production capacity and treat such costs as period costs.</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:justify;text-indent:36pt">December 31, 2023</td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">165,743</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="background-color:#cceedd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,112</td><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">100,526</td><td colspan="3" style="background-color:#cceedd;padding:2px

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">44,821 </td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3">
style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(25,282) </td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3">
style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">19,539 </td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,539 </td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
<div>P3YP8Y92531000214780006105300029402000165620012840000P4Y10Y18649000373000014919000533000036200001910000P3YP15Y32
amortization for intangible assets with definite lives for the remaining three months of 2024, the next five years ended December 31, and thereafter, is as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="5">
style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 remaining</td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceefff;padding:2px 0;text-align:right;vertical-align:bottom">3,840 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2">
style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,536 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2">
style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,341 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2">
style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,400 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2">
style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,289 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="padding:2px 1pt;text-align:left;vertical-align:bottom">2029</td><td colspan="2">
style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,105 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2">
style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">Total</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="5">
style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="2">
style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">80,026 </td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>384000012536000123410001140000011289000111050001751500080026000Strategic Investments<div style="margin-top:12pt;text-align:justify;text-indent:36pt">Strategic investments include equity and debt investments in a number of non-public technology driven companies. We account for strategic equity investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investments. The investments are measured at cost less impairment, adjusted for observable price changes and are assessed for impairment whenever events or changes in circumstances indicate that the fair value may be less than its carrying value.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">For the debt security strategic investment, we have elected to account for this investment and the associated embedded derivatives utilizing the fair value option. Unrealized changes in fair value for the entire hybrid instrument are recorded within </div><div style="margin-top:12pt;text-align:justify">other income (loss), net in the condensed consolidated statement of operations. The debt security is recorded as a strategic investment within the long-term assets section of the condensed consolidated balance sheet. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">In conjunction with certain of our strategic investments, we have the ability to commit additional capital over time through warrants and call options; for some investments, the exercisable and exercise prices are conditional on the achievement of certain performance metrics. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following tables provide a roll-forward of the balance of strategic investments (in thousands): </div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.00

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,546)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, end of period</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,356</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,356</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,033</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">8,086</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">387,905</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div>340108000235600013033000763700036313400021594500045900017233000233637000243220000002432200040990001176000052750000619620000-13510000-6331300015000000150000036443000023560001303300080860003879050002215440001522000172330002402990006330000042300000756000030089000-13510000481700014546000000145460003644300002356000130330008086000387905000Variable Interest Entities<div style="margin-top:12pt;text-align:justify;text-indent:36pt">We evaluate our investments and other significant relationships to determine whether any investee is a variable interest entity ("VIE"). If we conclude that an investee is a VIE, we evaluate our power to direct the activities of the investee, our obligation to absorb the expected losses of the investee and our right to receive the expected residual returns of the investee to determine whether we are the primary beneficiary of the investee. If we are the primary beneficiary of a VIE, we will consolidate such entity and reflect the non-controlling interest of other beneficiaries of that entity.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We determine whether we are the primary beneficiary of a VIE by performing an analysis that principally considers:</div><div style="padding-left:36pt;text-align:justify;text-indent:18pt">TheVIE's purpose, design, and risks the VIE was designed to create and pass through to its variable interest holders;</div><div style="padding-left:36pt;text-align:justify;text-indent:18pt">The VIE's capital structure;</div><div style="padding-left:36pt;text-align:justify;text-indent:18pt">The terms between the VIE and its variable interest holders and other parties involved with the VIE; and</div><div style="padding-left:36pt;text-align:justify;text-indent:18pt">Related party affiliations.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">As ofSeptember 30, 2024and December 31, 2023, the unconsolidated non-public VIEs in which we hold variable interests were as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:3.37pt">Carrying value of variable interest - assets(1)</div></td><td style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">&lt

[illegible]

[illegible]

September 30, 2024

Unamortized debt issuance costs

Convertible notes carrying amount, net

We consider the fair value of the Notes to be a Level 2 measurement. The estimated fair value of the Notes as of September 30, 2024 and December 31, 2023 is based on the closing trading price per \$1,000 of the Notes as of the last day of trading for each period as follows (in millions):

	September 30, 2024	December 31, 2023
Principal	690,000	690,000
Unamortized debt issuance costs	(10,517)	(10,517)
Convertible notes carrying amount, net	679,483	679,483

Interest expense related to the Notes was as follows (in thousands):

	September 30, 2024	December 31, 2023
Interest expense	863	863

Contractual interest expense

[illegible]

height:114%">3,016.680</td><td colspan="3">338.86</td><td colspan="3">March 15, 2028</td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Separately, we entered into Warrant transactions with certain investment banks, whereby we sold Warrants to acquire, subject to adjustment, the number of shares of our common stock shown in the table above. If the average market value per share of our common stock on each expiration date exceeds the strike price of the Warrants expiring on that day, such Warrants would have a dilutive effect on our earnings per share to the extent we report net income. According to the terms of the Warrants, the Warrants will be automatically exercised over a 60 trading day period beginning on the first expiration dateas set forth above.</div>69000000.090000000.00.00500.00991<div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following table summarizes the carrying value of the Notes (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom">Principal</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">690,000</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">690,000</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Unamortized debt issuance costs</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,517)</td><td colspan="3" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,887)</td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom">Convertible notes carrying amount, net</td><td colspan="3" style="background-color:#c0c0c0;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">679,483</td><td colspan="3" style="background-color:#c0c0c0;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">677,113</td><td colspan="3" style="background-color:#c0c0c0;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">The estimated fair value of the Notes atSeptember 30, 2024and December 31, 2023 is based on the closing trading price per \$1,000 of the Notes as of the last day of trading for each period as follows (in millions):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom">2027 Notes</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">1,239.8</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,239.8</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">873.3</td><td colspan="3" style="background-color:#c0c0c0;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>69000000069000000010517000128870006794830006771130001239800000873300000<div style="margin-top:12pt;text-align:justify;text-indent:36pt">Interest expense related to the Notes was as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding

[illegible]

2024 Warrants

Proceeds

Strike Price

First Expiration

2027 Warrants

124,269

338.86

March 15, 2028

2024 Employee XSP and 2024 CEO Performance Award

On May 10, 2024, our shareholders approved the 2024 Employee XSP. The 2024 Employee XSP includes an approved pool of 4.5 million shares of common stock to be reserved for grants of XSP awards to employees under the 2024 Employee XSP.

The 2024 XSPs are grants of performance-based RSUs that vest in seven substantially equal tranches.

Tranche	Grant Date	Grant Amount	Grant Price	Grant Type
1	March 15, 2028	124,269	338.86	Common Stock
2	March 15, 2028	124,269	338.86	Common Stock
3	March 15, 2028	124,269	338.86	Common Stock
4	March 15, 2028	124,269	338.86	Common Stock
5	March 15, 2028	124,269	338.86	Common Stock
6	March 15, 2028	124,269	338.86	Common Stock
7	March 15, 2028	124,269	338.86	Common Stock

Operational Goals

(1)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

align:bottom">Sales, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,248</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,886</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,036</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,232</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development expenses</td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,409</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,414</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86,445</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,311</td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation expense</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">101,790</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">29,987</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">251,716</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">96,228</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt">Stock Incentive Plan</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">In May 2024, our shareholders approved the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan (the "Amended 2022 Plan") authorizing an additional 2.2 million shares, plus remaining available shares under prior plans, for issuance under the Amended 2022 Plan. Combined with the shares of our common stock available under our legacy stock incentive plans, there are 3.7 million shares of our common stock available for grant under the Amended 2022 Plan as of September 30, 2024.</div><div style="margin-top:12pt">At The Market Equity Offering</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We participate inan "at the market" equity offering program (the "ATM"), pursuant to which we are authorized tosell up to a total of approximately2.0 millionshares of our common stock. As ofSeptember 30, 2024there were approximate1y 2.0 millionshares remaining.There were no issuances under the ATM during theninemonths endedSeptember 30, 2024The tranches will vest upon certification by the Compensation Committee of the Board of Directors upon achievement of three independent vesting conditions, described in the following table:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.62%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.

[illegible]

[illegible]

<td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td>
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of
Units</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted Average
Grant Date Fair Value</td>
<td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aggregate
Intrinsic
Value</td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">Units outstanding, beginning of
year</td><td colspan="3" style="background-color:#ceefff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:114%">1,615</td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ceefff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">\$</td><td colspan="3" style="background-
color:#ceefff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">193.09</td><td colspan="3" style="background-
color:#ceefff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;border-top:0.75pt solid
#000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
Granted</td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">595</td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
269.18</td><td colspan="2" style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</td><td colspan="3" style="background-
color:#ceefff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-
size:10pt;font-weight:400;line-height:114%">(488)</td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-
size:10pt;font-weight:400;line-height:114%">(488)</td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-
size:10pt;font-weight:400;line-height:114%">202.01</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:114%">Units outstanding, end of period</td><td colspan="3" style="background-color:#ceefff;border-bottom:3pt double
#000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,594</td><td colspan="3" style="background-
color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">\$</td><td colspan="3" style="background-color:#ceefff;padding:2px 0;text-align:right;vertical-align:bottom">223.16</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-
serif;font-size:10pt;font-weight:400;line-height:114%">\$</td><td colspan="3" style="background-color:#ceefff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:114%">636,869</td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>
</tr></table>
</div>1615000193.09595000269.18488000185.33128000202.011594000223.16636869000399.60252700000P2Y2M12D400000538300000<div
style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-
size:10pt;font-weight:400;line-height:120%">>The following table summarizes PSU activity for the nine months ended September 30, 2024 (number
of units and aggregate intrinsic value in thousands);</div><div style="margin-top:12pt"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of
Units</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted Average
Grant Date Fair Value</td>
<td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate
Intrinsic
Value</td></tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">

[illegible]

Three Months Ended September 30, 2024

	2024	2023
Sales	48,235	55,248
Cost of product sales and service sales	48,685	55,248
Sales, general and administrative expenses	12,886	12,886
Research and development expenses	36,409	43,232
Total stock-based compensation expense	15,414	86,445
Income before income taxes	29,987	251,716
Income tax expense	96,228	96,228
Net income	20,369	155,488

In December 2022, we entered into a credit agreement that provides for a senior unsecured multi-currency revolving credit facility (the "Credit Agreement") in an aggregate principal amount of up to \$200.0 million, \$30.0 million of which is available for the issuance of letters of credit. The Credit Agreement will mature on the earlier of December 15, 2027 or the date

that is six months prior to the stated maturity date of the 2027 Notes unless the Notes have been redeemed, repurchased, </div><div style="margin-top:12pt;text-align:justify">converted or defeased in full. Additionally, the Credit Agreement has an accordion feature which allows for an increase in the total line of credit up to \$300.0 million, in each lender's sole discretion.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">As of September 30, 2024, no amounts were drawn under the Credit Agreement and outstanding letters of credit totaled \$8.2 million. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest expense, taxes, depreciation and amortization ratio, which for the purposes of the Credit Agreement excludes investment interest income. "SOFR" is defined as a rate equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York or a successor administrator of the secured overnight financing rate. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We are required to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, and a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense. As of September 30, 2024, we are in compliance with the associated covenants under the Credit Agreement.</div>200000000.030000000.0P6M300000000.0082000000.01250.0175Commitments and Contingencies<div style="margin-top:12pt">Product Litigation</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">As a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products. We are currently named as a defendant in one such lawsuit in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn. They seek compensatory and sometimes punitive damages, often in unspecified amounts.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results of operations or cash flows. We are self-insured for the first \$5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products liability case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period.</div><div style="margin-top:12pt">Other Matters</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Despite the FTC's dismissal of its administrative enforcement complaint against Axon without consent decree or other condition in October 2023, other parties continue to allege that Axon's May 2018 acquisition of an insolvent body-worn camera competitor, Viewu LLC ("Viewu"), was anticompetitive. Two purported antitrust lawsuits based largely on the FTC's unproven allegations are pending in the District of New Jersey (Case No. 3:23-cv-7182) and District of Arizona (Case No. 2:24-cv-01869-SMB). Axon denies all allegations of anticompetitive or other misconduct and is vigorously defending the cases. Axon has also received a request for information from the Pennsylvania Office of Attorney General regarding this same consummated Viewu transaction. Axon is cooperating with the investigation to resolve any concerns of the Commonwealth.</div><div style="margin-top:12pt">General</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of theamount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Based on our assessment of outstanding litigation and claims as of the date of these financial statements, we have determined that it is not reasonably possible that these losses, if any, from lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the</div><div style="margin-top:12pt;text-align:justify">resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.</div><div style="margin-top:12pt">Off-Balance Sheet Arrangements</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At September 30, 2024, we had outstanding letters of credit issued under our credit facility of \$8.2 million that are expected to expire through 2025we also had outstanding letters of credit of \$0.1 millionthat do not draw against our credit facility. Additionally, we had \$13.6 millionof outstanding surety bonds as ofSeptember 30, 2024, with expiration dates ranging through 2029.</div>15000000.028200000100000136000000Accumulated Other Comprehensive Income (Loss)<div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands).</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains (Losses)
on Available-for-Sale
Investments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency
Translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(399)</td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;border-top:0.75pt solid

[illegible]

[illegible]

[illegible]

[illegible]

Other comprehensive income (loss)

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

Balance, September 30, 2023

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

Segment Data

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

Reportable segments

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

Information relative to our reportable segments

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

Software and Sensors segment net sales

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

TASER segment net sales

	2023	2022
Income tax expense	1,144	1,144
Other comprehensive income	656	656
Other comprehensive income (loss)	656	656

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Amortization of acquired intangible assets

2,189

Gross margin

895,531

Sales, general and administrative

514,228

Research and development

307,008

Interest income, net

31,134

Other income (loss), net

191,510

Income before provision for income taxes

296,939

Income tax expense

101,321

Fusus, LLC

On January 31, 2024, we acquired the remaining 79.7% interest in Fusus, LLC ("Fusus"), a global leader in real-time crime center technology, for total consideration transferred of approximately \$241.3 million, subject to customary adjustments (the "step acquisition"). The acquisition expands our ability to aggregate live video, data and sensor feeds, which enhances situational awareness and investigative capabilities for our customers in public safety, education and enterprise. Total transaction costs related to the acquisition were \$0.3 million and \$4.6 million for the three and nine months ended September 30, 2024, respectively. These transaction costs were expensed as incurred in sales, general and administrative expenses ("SG&A") in our condensed consolidated statements of operations.

Our existing 20.3% interest had a fair value at the acquisition date of \$63.3 million, which resulted in a non-taxable gain of \$42.3 million recorded in other income (loss), net in our condensed consolidated statement of operations. Prior to the step acquisition, the fair value of the previously held investment was determined using Level 3 valuation techniques, which include inputs to the valuation methodology that are considered unobservable and significant to the fair value measurement.

The purchase price allocation is subject to revision during the measurement period, which is expected to be completed in the fourth quarter of 2024. Based on the purchase price allocation, we recorded \$250.1 million of goodwill, \$72.9 million of identifiable intangible assets, and other net liabilities assumed of \$7.8 million, excluding deferred taxes. We recorded a net deferred tax liability of \$10.5 million.

With the assistance of third-party valuation experts, we calculated the fair values of intangible assets using the multi-period excess earnings method for the acquired developed technology and the with and without method for customer relationships. The weighted average amortization period of the acquired intangible assets was 7.5 years.

The goodwill generated from the acquisition is primarily attributable to synergies that are expected to be achieved from the integration of the business and is not deductible for tax purposes. Following the acquisition, the consolidated results of

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets		net	
Long-term contract assets		net	
Other long-term assets			
Total assets			
Accounts payable			
Accrued liabilities			
Deferred revenue, net of current portion			
Total current liabilities			
Other long-term liabilities			

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom;

Balance, December 31, 2023

Net income

Balance, March 31, 2024

Net income

[illegible]

11,084		
Change in assets and liabilities:		
Receivables and contract assets		
Inventory		
Deferred revenue		
Accounts payable, accrued and other liabilities		
Other - net		
Three Months Ended March 31, 2024		
As Reported		
Revision		
As Revised		
Cash flows from operating activities:		
Net income		
Provision for bad debts and inventory		
Cash flows from operating activities:		
Net income		
Provision for bad debts and inventory		

[illegible]

Deferred income taxes		
505		
(72,497)		
Provision for bad debts and inventory		
1,090		
4,394		
Change in assets and liabilities		
172,524		
(6,465)		
(178,989)		
Inventory		
(71,896)		
5,730		
(77,626)		
Deferred revenue		
164,043		
(17,224)		
146,819		
Accounts payable, accrued and other liabilities		
64,384		
945		
65,329		
Other		
102,370		
22,019		
146,819		
As Reported		
As Revised		
Revision		
Nine Months Ended September 30, 2023		
As Reported		
As Revised		
Revision		
Cash flows from operating activities		

[illegible]

[illegible]

